{"title": "enfermedades autoinmunes asociadas: Topics by Science.gov", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "1995-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "[Enfermedad diarreica aguda por Escherichia coli pat\u00f3genas en Colombia](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4469391)\nG\u00f3mez-Duarte, Oscar G.\n2014-01-01\nResumen Las cepas de E. coli pat\u00f3genas intestinales son causas importantes de la enfermedad diarreica aguda (EDA) en ni\u00f1os menores de 5 a\u00f1os en Am\u00e9rica Latina, \u00c1frica y Asia y est\u00e1n asociadas a alta mortalidad en ni\u00f1os en las comunidades m\u00e1s pobres de \u00c1frica y el Sudeste Asi\u00e1tico. Estudios sobre el papel de las E. coli pat\u00f3genas intestinales en la EDA infantil en Colombia y otros pa\u00edses de Am\u00e9rica Latina son limitados debido a la carencia de ensayos para detecci\u00f3n de estos pat\u00f3genos en los laboratorios cl\u00ednicos de centros de salud. Estudios recientes han reportado la detecci\u00f3n de E. coli pat\u00f3genas intestinales en Colombia, siendo la E. coli enterotoxig\u00e9nica la cepa m\u00e1s frecuentemente asociada a diarrea en ni\u00f1os menores de 5 a\u00f1os. Otros pat\u00f3genos detectados en estos pacientes incluyen las E. coli enteroagregativa, enteropat\u00f3gena, productora de toxina Shiga, y de adherencia difusa. Con base en estudios que reportan la presencia de E. coli productora de toxina Shiga y E. coli enteroagregativa en carnes y vegetales en supermercados, se cree que productos alimentarios contaminados contribuyen a la transmisi\u00f3n de estos pat\u00f3genos y a la infecci\u00f3n del hu\u00e9sped susceptible. M\u00e1s estudios son necesarios para evaluar los mecanismos de transmisi\u00f3n, el impacto en la epidemiologia de la EDA, y las pautas de manejo y prevenci\u00f3n de estos pat\u00f3genos que afectan la poblaci\u00f3n pedi\u00e1trica en Colombia. PMID:25491457\n[TUBERCULOSIS COMO ENFERMEDAD OCUPACIONAL](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4114320)\nMendoza-Ticona, Alberto\n2014-01-01\nExiste evidencia suficiente para declarar a la tuberculosis como enfermedad ocupacional en diversos profesionales especialmente entre los trabajadores de salud. En el Per\u00fa est\u00e1n normados y reglamentados los derechos laborales inherentes a la tuberculosis como enfermedad ocupacional, como la cobertura por discapacidad temporal o permanente. Sin embargo, estos derechos a\u00fan no han sido suficientemente socializados. En este trabajo se presenta informaci\u00f3n sobre el riesgo de adquirir tuberculosis en el lugar de trabajo, se revisan las evidencias para declarar a la tuberculosis como enfermedad ocupacional en trabajadores de salud y se presenta la legislaci\u00f3n peruana vigente al respecto. PMID:22858771\n[Sobre la terapia g\u00e9nica para enfermedades de la retina.](https://www.ncbi.nlm.nih.gov/pubmed/28693021)\nFischer, M Dominik\n2017-07-11\nLas mutaciones en un gran n\u00famero de genes provocan degeneraci\u00f3n de la retina y ceguera sin que exista actualmente cura alguna. En las \u00faltimas d\u00e9cadas, la terapia g\u00e9nica para enfermedades de la retina ha evolucionado y se ha convertido en un nuevo y prometedor paradigma terap\u00e9utico para estas enfermedades poco comunes. Este art\u00edculo refleja las ideas y los conceptos que parten de la ciencia b\u00e1sica hacia la aplicabilidad de la terapia g\u00e9nica en el \u00e1mbito cl\u00ednico. Se describen los avances y las reflexiones actuales sobre la eficacia de los ensayos cl\u00ednicos en la actualidad y se discuten los posibles obst\u00e1culos y soluciones de cara al futuro de la terapia g\u00e9nica para enfermedades de la retina. \u00a9 2017 S. Karger AG, Basel.\n[Neuroimagen en la enfermedad de Alzheimer: nuevas perspectivas](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3325789)\nBecker, James T.\n2012-01-01\nIntroducci\u00f3n y desarrollo En los pr\u00f3ximos 50 a\u00f1os vamos a presenciar un incremento significativo de la poblaci\u00f3n mayor de 65 a\u00f1os y por lo tanto va a aumentar, considerablemente, el n\u00famero de individuos con riesgo de desarrollar demencias neurodegenerativas, especialmente la enfermedad de Alzheimer (EA). Las estrategias actuales de tratamiento farmacol\u00f3gico y no farmacol\u00f3gico se han centrado en las fases sintom\u00e1ticas de esta enfermedad y, gradualmente, vamos teniendo una mayor comprensi\u00f3n de los posibles factores de riesgo del s\u00edndrome cl\u00ednico. Conclusiones Los estudios de neuroimagen han sido muy \u00fatiles para mostrar los cambios estructurales del envejecimiento normal y patol\u00f3gico, as\u00ed como tambi\u00e9n los factores de riesgo para la EA. Los tratamientos apropiados de los factores de riesgo y su posible combinaci\u00f3n con tratamientos espec\u00edficos para la EA podr\u00edan prolongar el per\u00edodo presintom\u00e1tico de la EA y, por tanto, mejorar la calidad de vida y disminuir la carga para el paciente, la familia y la sociedad. PMID:20517866\n[An\u00e1lisis de costo de la enfermedad, del tratamiento, las complicaciones e intervenciones de la hipercolesterolemia en M\u00e9xico en 2016.](https://www.ncbi.nlm.nih.gov/pubmed/29684901)\nBaeza-Cruz, German; Peniche-Otero, Gustavo; Alva-Esqueda, M\u00f3nica E; Naranjo-Muedano, Mariana; Soria-Su\u00e1rez, No\u00e9; Morales-Flores, H\u00e9ctor J\n2018-04-20\nDescribir los costos y el impacto econ\u00f3mico de la atenci\u00f3n de pacientes diagnosticados con hipercolesterolemia en M\u00e9xico en el a\u00f1o 2016. METODOLOG\u00edA: Se desarrolla una evaluaci\u00f3n econ\u00f3mica del tipo an\u00e1lisis de costo de la enfermedad donde se cuantifican los recursos m\u00e9dicos utilizados para el tratamiento de la hipercolesterolemia as\u00ed como para sus complicaciones. Los costos de los recursos m\u00e9dicos utilizados son obtenidos de los costos unitarios por nivel de atenci\u00f3n del Instituto Mexicano del Seguro Social (IMSS) as\u00ed como de las licitaciones publicadas en el portal de compras del IMSS. El uso de recursos se obtiene mediante un panel de expertos y para el porcentaje de presencia de las complicaciones se efect\u00faa una revisi\u00f3n de literatura. Los costos m\u00e9dicos directos son estimados multiplicando la frecuencia de uso por el costo unitario, agrup\u00e1ndolos y obteniendo as\u00ed los costos individuales de cada recurso m\u00e9dico. Los casos de hipercolesterolemia en prevenci\u00f3n secundaria con enfermedad coronaria y enfermedad cardiovascular representan un mayor costo promedio anual ($111,835.19, D.E. $84,276.37), seguido de la hipercolesterolemia en prevenci\u00f3n secundaria con enfermedad coronaria sin enfermedad cardiovascular ($56,352.13, D.E. $29,004.04), los cuales no incluyen los costos generados por las complicaciones. El resto de los grupos de hipercolesterolemia representan una carga econ\u00f3mica menor. La carga econ\u00f3mica de la hipercolesterolemia representa en promedio por caso al a\u00f1o $258,761.37, esto traducido a los aproximadamente 445,075 de casos diagnosticados y tratados al a\u00f1o representar\u00eda un impacto econ\u00f3mico en el sistema de salud de m\u00e1s de ciento quince mil millones ($115,168,331,355.11). Copyright \u00a9 2018. Published by Elsevier Inc.\n[Consensus on updating immunizations in patients with primary immunodeficiencies](https://www.ncbi.nlm.nih.gov/pubmed/29775036)\n2018-04-01\nLas inmunodeficiencias primarias (IDP) constituyen un grupo de enfermedades hereditarias que afectan el n\u00famero y/o la funci\u00f3n de los distintos componentes del sistema inmune. Su prevalencia es de 1:1000-2000 nacimientos. Comprenden defectos de la inmunidad adaptativa, defectos de la inmunidad innata, inmunodeficiencias con fenotipos caracter\u00edsticos, trastornos de la regulaci\u00f3n inmune, s\u00edndromes autoinflamatorios, defectos de los fagocitos y del sistema del complemento y defectos considerados fenocopias de IDP. La vacunaci\u00f3n con vacunas inactivadas es segura y puede ser efectiva en muchas inmunodeficiencias; las vacunas vivas atenuadas pueden no ser protectoras en ciertas IDP o presentarse como enfermedad vacunal asociada a la inmunizaci\u00f3n, lo que conlleva una alta morbimortalidad. Con el objetivo de actualizar las recomendaciones de vacunas en pacientes con IDP, el Comit\u00e9 Nacional de Infectolog\u00eda y el Grupo de Trabajo de Inmunolog\u00eda trabajaron sobre las vacunas que pod\u00edan indicarse a estos pacientes, convivientes y el equipo de salud.\n[Poblacion estelar joven embebida en la nube molecular galactica asociada a la fuente IRAS 18236-1205](http://adsabs.harvard.edu/abs/2008MsT..........1R) [NASA Astrophysics Data System (ADS)](http://adsabs.harvard.edu/abstract_service.html)\nRomero, Ricardo Retes\n2008-06-01\nEn esta tesis presento una metodolog\u00eda de seleccion y estudio de la poblaci\u00f3n estelar embebida en la nube molecular galactica asociada a la fuente IRAS 18236-1205. La fuente IRAS posee colores de region Ultra Compacta HII (UCHII) y tiene detecci\u00f3on en monosulfuro de carbono (CS), trazador molecular de alta densidad, lo cual da la posibilidad de definir la nube molecular asociada hacia esta region. Lo anterior muestra que esta es buena candidata a regi\u00f3n de formaci\u00f3n estelar masiva. La metodolog\u00eda de seleccion de la poblaci\u00f3n embebida, est \u00e0 basada por una parte, en la distribuci\u00f3n del gas molecular monoxido de carbono (13CO) asociado a la fuente IRAS, nube molecular seleccionada del mapeo Galactic Ring Survey (GRS) realizado en 13CO. Otros pasos de la seleccion, se basan en los diagramas color-color y color-magnitud con datos del cercano infrarrrojo de 2MASS. Para el estudio de la componente estelar se usaron los catalogos de fuentes puntuales en el cercano, medio y lejano infrarrojo de 2MASS, SPITZER e IRAS, respectivamente. De los diagramas color-color y color-magnitud, usando datos de 2MASS, se construyo un criterio fotom\u00e9trico para identificar los objetos estelares j ovenes embebidos en la region molecular. Aplicando modelos a la distribuci\u00f3n espectral de energ\u00eda (SED) de algunos ellos, se encontraron parametros estelares de objetos estelares j ovenes embebidos de masa intermedia y alta. Adicionalmente, se encontro un objeto de masa \u00c2\u00b4 intermedia no identifiado por el catalogo de 2MASS y su efecto sobre el medio interestelar, emision en la banda de [4.5] \u03bcm de IRAC-Spitzer asociado a un outflow. Dos de los objetos seleccionados por el criterio fotometrico resultaron ser objetos estelares jovenes de alta e intermedia masa (B1V/B2V y B8V/A0V respectivamente), los cuales deben estar asociados a la emision radiativa responsable de los colores de regi\u00f3n UC HII. Otro objeto estelar joven de baja masa (F0V/F5V) fue encontrado en la region de estudio\n[Editorial quality, diffusion and bibliometric indicators of the Revista Espa\u00e3nola de Enfermedades Digestivas.](https://www.ncbi.nlm.nih.gov/pubmed/10089785)\nL\u00f3pez-C\u00f3zar, E D; Ruiz-P\u00e9rez, R; Jim\u00e9nez-Contreras, E\n1999-01-01\nTo evaluate the editorial quality, diffusion, relevance of the scientific content, and the publication practices of the specialised journal Revista Espa\u00f1ola de Enfermedades Digestivas. We checked 136 parameters based on ISO standards, the recommendations of scientific and editorial organisations, and studies of scientific editing and international publishing practices for biomedical journals. Diffusion was calculated using national and international databases, specialised libraries in Spain, and Internet sources. The analysis of the scientific content and publication practices was based on bibliometric indicators for the journal, authorship, and contributions. The sample for this study comprised six alternate issues of volume number 88 (1996), the last issue of this volume, and the first issue of volume 89 (1997). The samples used for the bibliometric analysis varied depending on the characteristics of specific indicators and the availability of information. The overall mean value for compliance with standards was 46.1%, while the real mean was calculated at 72.21%. The editorial procedures at the journal are similar to those of analogous international journals. The Revista Espa\u00f1ola de Enfermedades Digestivas is included in international databases of biomedical journals, and in the interdisciplinary international database SCI. It was found to be present in 70% of the medical libraries of Spanish universities, and in 73% of the hospital libraries studied. Bibliometric indicators showed co-authorship to be 5.5%; the origin of the authors grouped by province and by type of institutional affiliations showed 27.8% of all authors to be from Madrid, and that more were affiliated with general hospitals than with university hospitals. The mean delay between initial receipt of a manuscript and its publication was 300 days. Cocitation analysis gave the journal a central position amongst the 38 Spanish biomedical journals considered representative of the field. The journal\n[[Scientific productivity, collaboration and research areas in Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (2003-2007)].](https://www.ncbi.nlm.nih.gov/pubmed/20381210)\nGonz\u00e1lez-Alcaide, Gregorio; Valderrama-Zuri\u00e1n, Juan Carlos; Ramos-Rinc\u00f3n, Jos\u00e9 Manuel\n2010-10-01\nCollaboration is essential for biomedical research. The Carlos III Health Institute (the Spanish national public organization responsible for promoting biomedical research) has encouraged scientific collaboration by promoting Thematic Networks and Cooperative Research Centres. Scientific collaboration in Enfermedades Infecciosas y Microbiolog\u00eda Clinica journal is investigated. Papers published in Enfermedades Infecciosas y Microbiolog\u00eda Clinica in the period 2002-2007 have been identified. Bibliometrics and Social Network Analysis methods have been carried out in order to quantify and characterise scientific collaboration and research areas. A total of 805 papers generated by 2,289 authors and 326 institutions have been analysed. There were 36 research groups involving 138 authors identified. The Collaboration Index for articles was 5.5. Institutional collaboration was determined in 75% of articles. The collaboration between departments or units of the same institution prevails (43%), followed by intra-regional domestic collaboration (41%) and inter-regional domestic collaboration (14%). Hospital centres were the main institutional sector responsible of research (88% of papers), with 68% of articles cited. Sida/VIH (AIDS/HIV) is the main research area (n=114), followed by Staphylococcal Infections (n=33). Notable collaboration and citation rates have been observed. Research is focused on diseases with the highest mortality rates caused by infectious diseases in Spain. Copyright \u00a9 2009 Elsevier Espa\u00f1a, S.L. All rights reserved.\n[Instituto Nacional de Enfermedades Neopl\u00e1sicas: past and present.](https://www.ncbi.nlm.nih.gov/pubmed/2389103)\nPinillos, L\n1990-01-01\nThe Instituto Nacional de Enfermedades Neopl\u00e1sicas was established by the government of Peru as an institution for the treatment of cancer patients in 1939; it has existed under different names until the current title was adopted in 1952. Between 1980 and 1987, attendance increased by 70% and a new and larger facility came into use at the beginning of 1988. This institution has national responsibility for cancer prevention, detection, treatment, education, and research and is currently organizing satellite treatment centers in other parts of the country. More than 80% of the medical staff has been trained in the institute's residency program, the majority of whom received additional postgraduate training in the United States and Europe; 90% of the medical staff hold academic appointments in medical schools. In 1952 the Institute became the first hospital in Peru with a formal postgraduate training system for various medical disciplines, including surgical oncology and medical oncology. So far we have trained about 500 surgical oncologists who are working in all parts of Peru. The Maes-Heller Institute for Cancer Research forms part of the National Cancer Institute complex. Research will be directed mainly toward new diagnostic and therapeutic approaches, multidisciplinary tumor therapy, and large-scale cancer screening. The Institute focuses on early detection and prevention of cancer and is active in breast self-examination education and antismoking campaigns. It enjoys community support evidenced in the women's organization, Adainen, involved in fundraising; 460 women volunteers give at least 4 hr service per week to the Institute. The Institute has grown from 9,000 patients seen per year in its early days to 215,000 attendances in 1986.\n[[Krukenberg ovary tumor pathological clinical study of 56 cases in the Instituto Nacional de Enfermedades Neoplasicas (National Cancer Institute)].](https://www.ncbi.nlm.nih.gov/pubmed/19898592)\nS\u00e1nchez Lih\u00f3n, Juvenal\n2009-01-01\nWe report 56 cases of ovary Krukenberg tumor at Instituto Nacional de Enfermedades NeoplAsicas en relation to microscopic diagnosis, primary origin and clinicopathologic correlation. The patients ranged from 18 to 84 years. The most frecuent primary tumor was stomach 33 (58.9%) cases. Abdominal swelling and pain usually accounted for the clinical presentation. Ascitis, abnormal vaginal bleeding. 21 patients had frozen section.11(52.3%) cases the primary carcinoma was found during an operation for the ovary tumor and the most frecuent was stomach 9/21. 35 cases the tumor was bilateral the largest dimension was 30 x 20 cm microscopic examination showed variety of patterns.the survival data, follow up and prognosis is bad. It is important the correct diagnosis of Krukenberg tumor. We recommended frozen section. The prognosis is very poor.\n[[Bibliographic errors in Revista Espa\u00f1ola de Enfermedades Digestivas. A retrospective study of the year 1995].](https://www.ncbi.nlm.nih.gov/pubmed/9198479)\nAcea Nebril, B; G\u00f3mez Freijoso, C\n1997-03-01\nTo determine the accuracy of bibliographic citation in Revista Espa\u00f1ola de Enfermedades Digestivas (REED) and compare it with other Spanish and international journals. We reviewed all 1995 volumes of the REED and randomly selected 100 references from these volumes. Nine citations of non-journal articles were excluded and the remaining 91 citations were carefully scrutinized. Each original article was compared for author's name, title of article, name of journal, volume number, year of publication and pages. Some type of error was detected in 61.6% of the references and on 3 occasions (3.3%) impeded finding to the original article. Errors were found in authors (37.3%); article title (16.4%), pages (6.6%), journal title (4.4%), volume (2.2%) and year (1%). A single error was found in 42 citations, 2 were found in 13 and 3 were found in 1. REED's rate of error in references is comparable to the rates of other spanish and international journals. Authors should exercise more care in preparing bibliographies and should invest more effort in verification of quoted references.\n[[Eccrine Porocarcinoma: clinical-pathological study of 19 cases in the Instituto Nacional de Enfermedades Neopl\u00e1sicas, Lima - Peru].](https://www.ncbi.nlm.nih.gov/pubmed/24100819)\nCasavilca, Sandro; Lama, Anny; Guerrero, Melvy; Essary, Lydia R; Mantilla, Ra\u00fal; Cano, Luis; Barrionuevo, Carlos\n2013-07-01\nIn order to describe the clinical-pathological characteristics of the cases of Eccrine Porocarcinoma (EP) found in the Instituto Nacional de Enfermedades Neopl\u00e1sicas (INEN), a cross-sectional study was carried out, including all EP cases recorded between 1998 and 2009. A revision of the clinical-pathological records indentified and a new reading of the pathology slides of the cases found were performed. 19 EP cases were found, the median age of which was 64 years (range: 37-98). EP was primarily found on male patients (57.9%) and was most commonly located on the foot (21.1%), followed by the head, thorax and thigh (15.8%, respectively). In one case, EP was located on the gluteal region, and showed an unusually invasive behavior and rectal involvement. We conclude that EP is a rather uncommon entity in Peru. Its most common location is on the foot and it affects mostly male patients for the most part.\nValero Ch\u00e1vez, Francisco Javier; Luengo P\u00e9rez, Luis Miguel; Cubero Ju\u00e1nez, Javier\n2016-09-20\nIntroducci\u00f3n: ante las nuevas implicaciones atribuidas a la vitamina D y la asociaci\u00f3n con enfermedades tales como el c\u00e1ncer, diabetes, enfermedades cardiovasculares, autoinmunes y mortalidad, no es de extra\u00f1ar que se haya defendido la medici\u00f3n de los niveles de vitamina D en la poblaci\u00f3n general. Sin embargo, no existen datos experimentales que demuestren la viabilidad y rentabilidad de la estrategia de cribado en la poblaci\u00f3n y tampoco se ha comprobado la existencia de beneficios para la salud, por lo que en la actualidad solo es aconsejable la medida de 25 (OH) vitamina D en los grupos de personas de alto riesgo como indican las gu\u00edas cl\u00ednicas internacionales.Objetivos: analizar las peticiones de vitamina D comprobando si se adecuan a las gu\u00edas cl\u00ednicas.M\u00e9todos: realizamos un estudio descriptivo transversal en el \u00c1rea de Salud de Badajoz (Espa\u00f1a) estudiando las peticiones de determinaci\u00f3n de vitamina D durante 12 meses consecutivos (n = 3.907). En dicho estudio revisamos el diagn\u00f3stico de petici\u00f3n y la historia cl\u00ednica del paciente para discriminar entre peticiones que se adecuaban a las gu\u00edas cl\u00ednicas y peticiones injustificadas. Por \u00faltimo, realizamos el estudio econ\u00f3mico.Resultados: en nuestros resultados encontramos que casi un tercio de peticiones no se adecuaban a las gu\u00edas cl\u00ednicas, en patolog\u00edas tales como diabetes, dislipemias e hipertensi\u00f3n en las que no est\u00e1 recomendada la medici\u00f3n de los niveles de vitamina D, por lo que supon\u00eda un exceso de gasto para el sistema sanitario. Gasto que se incrementa cada a\u00f1o, tanto es as\u00ed que se ha producido un aumento en las peticiones de m\u00e1s del 1.000% en los \u00faltimos 6 a\u00f1os.Conclusiones: concluimos la necesidad de crear protocolos de petici\u00f3n de vitamina D que se ajusten a las gu\u00edas cl\u00ednicas hasta que existan m\u00e1s estudios experimentales sobre las nuevas implicaciones de la vitamina D y as\u00ed conseguir una correcta utilizaci\u00f3n de los recursos econ\u00f3micos del hospital.\n[Experiencias at\u00edpicas psic\u00f3ticas y cuasi-psic\u00f3ticas en adolescentes puertorrique\u00f1os/as deprimidos/as: Prevalencia y factores asociados1](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6018019)\nL\u00f3pez Robledo, Yaritza M.; Cumba-Avil\u00e9s, Eduardo; Bernal, Guillermo\n2018-01-01\nSe examin\u00f3 la prevalencia de experiencias at\u00edpicas psic\u00f3ticas y cuasi-psic\u00f3ticas y se identificaron factores asociados a \u00e9stas en 162 j\u00f3venes puertorrique\u00f1os/as entre 13 y 17.5 a\u00f1os. Se evalu\u00f3 la sintomatolog\u00eda depresiva, la ideaci\u00f3n suicida, as\u00ed como la presencia o historia de experiencias at\u00edpicas, eventos traum\u00e1ticos y maltrato o abuso. Las experiencias at\u00edpicas estuvieron asociadas (p<.05) a ser f\u00e9mina, a tener enfermedades f\u00edsicas, a experimentar eventos traum\u00e1ticos, a haber recibido tratamiento para la depresi\u00f3n, y a una sintomatolog\u00eda depresiva e ideaci\u00f3n suicida elevada. Los eventos traum\u00e1ticos, el tratamiento farmacol\u00f3gico para la depresi\u00f3n y la severidad de la ideaci\u00f3n suicida fueron predictores significativos del n\u00famero de experiencias reportadas. Los resultados confirman que la mayor\u00eda de las experiencias no son psic\u00f3ticas. Se discuten las implicaciones para la evaluaci\u00f3n y el tratamiento de j\u00f3venes deprimidos/as.\n[[Methods for evaluating diagnostic tests in Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica].](https://www.ncbi.nlm.nih.gov/pubmed/9646562)\nRamos, J M; Hern\u00e1ndez, I\n1998-04-01\nIn the field of infectious diseases and clinical microbiology, the evaluation of diagnostic tests (DT) is an important research area. The specific difficulties of this type of research has motivated that have not caught the severity methodological of others areas of clinical research. This article try to asses and characterize the methodology of articles about DT published in Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (EIMC) journal. Forty-five articles was selected in the EIMC journal during the 1990-1996 period, because of determinate the sensitivity and specificity of different DT. Methodological standards, extensively accepted was used. In all of articles, except one (98%) the gold standard was specified yours use, however in 4 studies (9%) include the DT in the gold standard (incorporation bias). The correct description of DT was reported in 75% of cases, but only in 11% cases the reproducibility of test was evaluated. The description of source of reference population, standard of inclusion and spectrum of composition was described in 58, 33 and 40% of articles, respectively. In 33% of studies presented workup bias, only 6% commented blind-analysis of results, and 11% presented indeterminate test results. Half of the studies reported test indexes for clinical subgroups, only one article (2%) provided numerical precision for test indexes, and only 7% reported receiver operating characteristics curves. The methodological quality of DT research in the EIMC journal may improve in different aspects of design and presentation of results.\n[Cirug\u00eda transnasal endosc\u00f3pica para tumores de hip\u00f3fisis](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3627816)\nAjler, Pablo; Hem, Santiago; Goldschmidt, Ezequiel; Landriel, Federico; Campero, Alvaro; Yampolsky, Claudio; Carrizo, Antonio\n2012-01-01\nIntroducci\u00f3n: Exponer la t\u00e9cnica utilizada y los resultados obtenidos en los primeros 52 pacientes portadores de tumores hipofisarios tratados por la v\u00eda endosc\u00f3pica transnasal en el Hospital Italiano de Buenos Aires M\u00e9todos: Se llev\u00f3 a cabo un an\u00e1lisis retrospectivo de 52 cirug\u00edas endosc\u00f3picas transnasales utilizadas en el tratamiento de tumores hipofis\u00e1rios. Las mismas fueron realizadas en el Hospital Italiano de Buenos Aires durante el per\u00edodo junio del 2011 a junio del 2012. Se analizaron las caracter\u00edsticas demogr\u00e1ficas de los pacientes, la patolog\u00eda de base y la morbimortalidad asociada a la cirug\u00eda. Resultados: La edad media de los pacientes fue de 41,52 a\u00f1os con un rango de 18-79. La distribuci\u00f3n fue similar entre hombres y mujeres. Las patolog\u00edas m\u00e1s frecuentes fueron: adenomas no funcionantes (40.4%), tumores productores de GH/Acromegalia (25%) y tumores productores de ACTH/Enfermedad de Cushing (23.1%). Aproximadamente el 70 % correspondieron a macroadenomas. S\u00f3lo un paciente present\u00f3 complicaciones. No se registro ning\u00fan \u00f3bito. Conclusi\u00f3n: Si bien podremos objetivar fehacientemente resultados m\u00e1s concluyentes en futuros trabajos, podemos decir a priori que, en la endoscop\u00eda el detalle anat\u00f3mico es claramente superior al microsc\u00f3pico y que la posibilidad de la introducci\u00f3n del endoscopio en la silla turca permite la visualizaci\u00f3n directa de remanentes tumorales, de sitios de f\u00edstula y como as\u00ed tambi\u00e9n de la gl\u00e1ndula normal, ventajas que potencialmente podr\u00edan permitir obtener mejores resultados quir\u00fargicos, en t\u00e9rminos de control de la enfermedad y tasa de complicaciones. PMID:23596553\n[[Gender analysis among articles published in Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (2001-2005)].](https://www.ncbi.nlm.nih.gov/pubmed/18053472)\nAleixandre-Benavent, Rafael; Gonz\u00e1lez-Alcaide, Gregorio; Alonso-Arroyo, Adolfo; Castellano-G\u00f3mez, Miguel; Valderrama-Zuri\u00e1n, Juan Carlos\n2007-12-01\nThere is growing concern for promoting equality between sexes and full integration of women in research activities. The purpose of this study is to identify the bibliometric characteristics of articles published during the 2001-2005 period in Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (EIMC) from the perspective of gender. EIMC records for 2001-2005 were obtained from the Science Citation Index database and differences according to sex were calculated for the following indicators: year of publication, type of document, number and order of author signatures, number of collaborators, and the signature/article index at the institutional and geographical level. A total of 2,163 authors were identified, 1,220 (56.4%) men and 943 (43.6%) women. The greatest of contribution from women was in original articles (42.32% of signatures). Excluding the Centro Nacional de Microbiolog\u00eda (Spanish National Center for Microbiology), the participation of women was lower than men in the most productive institutions. There were significant differences regarding the number of papers published and the number of collaborators; with greater productivity for men and a higher rate of collaboration for women. Studies on scientific activity according to gender provide essential information to establish the basis for a policy of equality in this regard. A yearly increase of almost 1% was seen in the number of female authors contributing articles to the EIMC, which, if the trend continues, will result in parity in coming years. Nevertheless, the presence of women in positions of high productivity remains low. The causes of this difference should be identified and corrected.\n[Papiloma invertido sinunasal con invasi\u00f3n intracraneal: Reporte de caso y revisi\u00f3n bibliogr\u00e1fica](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5799940)\nDi Pietrantonio, Andr\u00e9s; Asmus, Humberto; Ingratta, Christian; Brennan, Walter; Schulz, Javier; Carballo, Leandro\n2018-01-01\nResumen Introducci\u00d3n: El papiloma invertido es una neoplasia benigna de los senos paranasales localmente agresiva con alto potencial de recurrencia y de malignizaci\u00f3n. La extensi\u00f3n intracraneal es infrecuente y m\u00e1s a\u00fan, la penetraci\u00f3n dural, asoci\u00e1ndose a menudo a la recurrencia de la enfermedad o a su degeneraci\u00f3n en carcinoma de c\u00e9lulas escamosas. Caso cl\u00ednico: Presentamos el caso de una paciente de 32 a\u00f1os que consult\u00f3 por lesi\u00f3n exof\u00edtica en fosa nasal derecha y exoftalmos, asociada a cefalea, anosmia y disgeusia. Se estudi\u00f3 con TC cerebro, macizo facial y RM de enc\u00e9falo que evidencian lesi\u00f3n en fosa nasal derecha con ocupaci\u00f3n de senos a\u00e9reos, oste\u00f3lisis de pared medial orbitaria y base de cr\u00e1neo anterior e invasi\u00f3n intracraneal frontal derecha, con efecto de masa y compresi\u00f3n del par\u00e9nquima encef\u00e1lico adyacente. Intervenci\u00f3n: Se realiz\u00f3 una nasofibroscop\u00eda en primer tiempo con diagn\u00f3stico anatomopatol\u00f3gico de papiloma invertido y posteriormente resecci\u00f3n de la lesi\u00f3n mediante doble abordaje m\u00e1s reconstrucci\u00f3n de la fosa craneal anterior. Se obtuvo diagn\u00f3stico definitivo de papiloma invertido de tipo Schneideriano con \u00e1reas de transformaci\u00f3n at\u00edpica in situ. La paciente evolucion\u00f3 de forma favorable y sin complicaciones, con permeabilidad de v\u00eda a\u00e9rea superior, sin signos de recidiva lesional luego de 4 a\u00f1os de seguimiento. Conclusi\u00f3n: La invasi\u00f3n intracraneal de esta patolog\u00eda es sumamente infrecuente. Cuando existe, es indicador de agresividad y potencial recidiva, por lo que la ex\u00e9resis completa de la misma define el pron\u00f3stico de la enfermedad. PMID:29430328\n1983-05-05\nMecanicas Asociadas, headquartered in Madrid. The group includes other members, say workers, such as Mecanica La Pena, Boetticher y Navarro, and...Moreda report that the company is not now linked to any group, because in 1980 Mecanicas Asociadas sold the stock it held. Sources at Mecanicas\n[Original articles published in Revista Espa\u00f1ola de Enfermedades Digestivas (1993-1998): authorship, interval between acceptance and publication, and bibliographic references.](https://www.ncbi.nlm.nih.gov/pubmed/11138239)\nAcea Nebril, B; Figueira Moure, A; G\u00f3mez Freijoso, C\n2000-09-01\nTo study changes in authorship, interval between acceptance and publication, and bibliographic references of original articles published in Revista Espa\u00f1ola de Enfermedades Digestivas (REED) between 1993 and 1998. This was a descriptive retrospective study of 359 original research articles published in REED between 1993 and 1998. The variables assessed were: number of authors (author/article index), interval between acceptance of the manuscript and publication in the journal, and degree of obsolescence of articles based on the age of the references cited (Burton-Kleber and Price indexes). The author/article index was 6.1, and increased from 5.9 in 1993 to 6.5 in 1998. The interval between acceptance and publication increased from 251 days to 436 days in this period (p < 0.0001). English was the language of publication used most commonly, followed by Spanish (10.7%). Citations to Spanish references decreased from 12.5% in 1993 to 8.7% in 1998. The half-life of articles was 7 years, and Price index was 41.5%. REED's bibliometric characteristics are similar to those of other national journals, but this study shows changes in bibliographic indicators from 1993 to 1998; increases in the number of authors per article, the interval to publication, the use of foreign references and the degree of obsolescence.\n[Transmission scenarios of major vector-borne diseases in Colombia, 1990-2016.](https://www.ncbi.nlm.nih.gov/pubmed/29165933)\nPadilla, Julio C\u00e9sar; Lizarazo, Fredy Eberto; Murillo, Olga Luc\u00eda; Mendiga\u00f1a, Fernando Antonio; Pach\u00f3n, Edwin; Vera, Mauricio Javier\n2017-03-29\nIntroducci\u00f3n. Las enfermedades transmitidas por vectores representan m\u00e1s de 17 % de todas las enfermedades infecciosas y causan anualmente un mill\u00f3n de defunciones a nivel mundial. En Colombia, la malaria, el dengue, la enfermedad de Chagas y las leishmaniasis son condiciones endemoepid\u00e9micas persistentes.Objetivo. Determinar el comportamiento epidemiol\u00f3gico de las enfermedades transmitidas por vectores en zonas urbanas y rurales de Colombia entre 1990 y 2016.Materiales y m\u00e9todos. Se hizo un estudio descriptivo del comportamiento epidemiol\u00f3gico de las principales enfermedades transmitidas por vectores en zonas urbanas y rurales de Colombia entre 1990 y 2016, con la informaci\u00f3n proveniente de fuentes oficiales secundarias.Resultados. En el periodo estudiado se registraron 5'360.134 casos de enfermedades transmitidas por vectores, de los cuales 54,7 % fueron de malaria y 24,9 % de dengue. Estos casos concentraron el 80 % de la carga acumulada de casos de enfermedades transmitidas por vectores. Las medianas de las tasas de incidencia fueron 1.371 y 188 por 100.00 habitantes para malaria y dengue, respectivamente. Adem\u00e1s, los casos de chikungunya fueron 774.831 desde su introducci\u00f3n en el 2014 y, los de Zika, 117.674 desde su aparici\u00f3n en 2015. En las zonas rurales predominaron las enfermedades parasitarias transmitidas por vectores como la malaria, las leishmaniasis y la enfermedad de Chagas. A nivel urbano, predominaron el dengue, el chikungunya y el Zika.Conclusiones. La transmisi\u00f3n en Colombia de estas enfermedades es persistente en las zonas urbanas y en las rurales, y de tipo endemoepid\u00e9mico en los casos de malaria, dengue, leishmaniasis y enfermedad de Chagas. Dicha transmisi\u00f3n se ha dado de manera focalizada y con patrones variables de intensidad. Asimismo, se mantienen las condiciones que han favorecido la transmisi\u00f3n emergente de nuevas arbovirosis.\n[[Clinical-pathological features and survival in young women with cervical cancer: a retrospective analysis from the instituto nacional de enfermedades neopl\u00e1sicas].](https://www.ncbi.nlm.nih.gov/pubmed/29177379)\nRuiz, Rossana; Serrano, Mariana; Ruiz, Eloy F; Mantilla, Raul; Valdivieso, Natalia; Olivera, Mivael; \u00c1lvarez, Manuel; Mas, Luis; Gomez, Henry L\n2017-01-01\nTo determine the clinical and histological characteristics and prognostic factors of cervical cancer (CC) in young Peruvian patients. Retrospective analysis of patients younger than 35 years old diagnosed with CC between 2008 and 2012 in the Instituto Nacional de Enfermedades Neopl\u00e1sicas. 449 patients had epithelial neoplasms. The main histological types were: squamous cell carcinoma (84.9%), adenocarcinoma (11.0%) and adenosquamous carcinoma (2.4%). The average tumor size was 4.98 cm. Anemia (55.7%), elevated creatinine (21.2%) and hydronephrosis (13.8%) were also identified. 82.3% of the patients presented locally advanced disease. Stages IIB (47.4%) and IIIB (25.8%) were the most common. Overall 5-year survival was 59.5% (I, 90.9%; II, 57.5%; III, 42.7% and IV, 13.3%). Elevated creatinine, anemia, tumor size, parametrial involvement and hydronephrosis were factors that affected survival. No significant relation was found between histological type and survival. The presence of anemia (adjusted hazard ratio [aHR]: 2.5; 95% confidence interval [CI 95%]: 1.6-4.0) and hydronephrosis (aHR: 1.6; CI 95%: 1.0-4.0) were independently associated with survival; likewise, the parametrial commitment with (aHR: 3.3; CI 95%: 1.5-7.2) or without (aRH: 2.6; CI 95%: 1.3-5.3) extension to the pelvic bone. Cervical cancer in young Peruvians is diagnosed in advanced stages. Overall survival in each stage is similar to the reported in older patients. The importance of conventional prognosis- related factors was confirmed. Anemia was an important independent prognostic factor requiring further investigations.\n[Medical Civic Action Programs (MEDCAPS) and Medical Readiness Training Exercises (MEDRETES) as Instruments of Foreign Policy](http://www.dtic.mil/docs/citations/ADA195304)\n1988-05-24\nterm for their program, namely GUARDE, which stands for Guiar de Assistancia Resistancia De Enfermedades (Guided Assistance to Resistance to Sickness...Measles, Tetanus, Toxoid,- BCG). 2. Tuberculosis 3. C.E.D. (Control de Enfermedades Diarreicas) Control of Diarrhea (Oral Rehidration) 4. I.R.A...Infecciones Respiratorias Agudas) Acute Respiratory Infections ,. 5. Rabia . Rabies -control \" 6.. .T. S.-.( Enfermedades de Transmisi6n Sexual) S \", -T\n... del Instituto Nacional de la Diabetes y las Enfermedades Digestivas y Renales (NIDDK, por sus siglas en ... para incrementar el conocimiento de salud y las enfermedades entre pacientes, profesionales de la salud y el ...\n[Detection of Bartonella bacilliformis by Real-Time PCR in Naturally Infected Sand Flies](http://www.dtic.mil/docs/citations/ADA434804)\n2004-03-04\npp 231-298. 81 Magui\u00f1a, C. 1998. Bartonellosis o Enfermedad de...Carrion, nuevos aspectos de una vieja enfermedad . A.F.A. Editores Importadores. Lima, Peru Malqui, V., Speelmon, E., Verastegui, M., Maguina, C\n[Regarding Critical Care of the Burn Patient: The First 48 Hours](http://www.dtic.mil/docs/citations/ADA629410)\n2010-01-01\ntal, University Rovira & Virgili, Institut Pere Virgili, CIBER Enfermedades Res- piratorias (CIBERES), Tarragona. Spain; and Critical Care Department...University Hospital, University Rovira & Virgili, In- stitut Pere Virgili, CIBER Enfermedades Respiratorias (CIBERES), Tarragona. Spain REFERENCES 1\n[Biliary Tract Disorders, Gallbladder Disorders, and Gallstone Pancreatitis](http://patients.gi.org/topics/biliary-tract-disorders-gallbladder-disorders-and-gallstone-pancreatitis/)\n... biliary disorders? What is the biliary tract? Enfermedades de la Vesicula y de la Via Biliar, Pancreatitis Biliar - Ricardo Morgenstern, MD and Ruben Acosta, MD Enfermedades de la Vesicula y de la Via Biliar, Pancreatitis ...\n[Beliefs About Children\u2019s Illness Among Rural Guatemalan Women.](http://www.dtic.mil/docs/citations/ADA317354)\n1996-07-01\na neighboring community. \"The question was: \"i,Por que cree que le dio esta enfermedad a su hijo(a)?\" or \"Why do you think your child got sick...began: \"Ya hablamos de los asientos. Ahora quisiera que me dijera ^que enfermedades del pecho o los pulmones les dan a los ninos aquf en (la communidad...Bronchitis {Bronquitisl Enfermedad de bronquios) 3 0 8 11 22 Cough (Jos) 13 20 6 6 45 Cold/pulmonary cold (catarrol catarro pulmonar) 1 3 4\n... riesgo m\u00e1s alto de tener diabetes tipo 2, enfermedades del coraz\u00f3n, accidentes cerebrovasculares y otros problemas de ... del Instituto Nacional de la Diabetes y las Enfermedades Digestivas y Renales (NIDDK, por sus siglas en ...\n[Differential Dengue Tropism & Neutralization: Potential Mechanisms of Pathogenesis](http://www.dtic.mil/docs/citations/ADA476452)\n2006-01-04\nDr. Guillermo Comach and Dr. Daria Camacho, Laboratorio Regional de Diagnostico e Investigacion del Dengue y otras Enfermedades Virales, Centro de... Enfermedades Virales, Centro de Investigaciones Biomedicas de la Universidad de Carabobo (LARDIDEV/BIOMED- UC), Maracay, Venezuela. 4Naval Medical Research\n[Chemotherapeutic Studies on Schistosomiasis and Clinical, Epidemiological and Immunological Studies on Malaria in Amazonas, Brazil, along the Ituxi River.](http://www.dtic.mil/docs/citations/ADA158674)\n1982-09-01\nenfermedades infecciosas en zonas colindantes con la Carretera Transamazonica en Brasil. II. Epidemiologia de las infecciones por arbovirus. Bol. Of...F.P. 1981. Programa multidisciplinario de vigilancia de las enfermedades , infecciosas en zonas colindantes con la Carretera Transamazonica en Brasil\n[National Biocontainment Training Center](http://www.dtic.mil/docs/citations/ADA567639)\n2012-08-01\npast reporting year, the training facility\u2019s engineering and maintenance team welcomed trainees from the Institutio Nacional de Enfermedades Virales... Enfermedades Virales Humanas \u201cDr. Julio Maiztegui\u201d and the Universidad Technologica Nacional attended the NBTC\u2019s Biocontainment Engineering Training Program\n[An Epidemic of Oroya Fever in the Peruvian Andes](http://www.dtic.mil/docs/citations/ADA223527)\n1990-01-01\notras Enfermedads MAmisiero de Salud. Lima. Peru. Naval Medical Research Instaitue. Bethesda. Af: Naval Medical Research Institsaae Derachmeint. Dma. Peru...review of the manuscript. tibastonella en la enfermedad de carrion o bar- trhe outstanding field work of Enrique Morales. Jaime tonelosis humana\nBl\u00e1zquez, Ferr\u00e1n Padr\u00f3s; Navarro Contreras, Gabriela; Garcidue\u00f1as Gallegos, Diana; Fulgencio Ju\u00e1rez, M\u00f3nica\n2016-03-25\nIntroducci\u00f3n: la obesidad es una enfermedad asociada a diferentes trastornos f\u00edsicos y emocionales que inciden en la calidad de vida y que representan un problema de elevada prevalencia en el mundo. La etiolog\u00eda es m\u00faltiple y compleja; se ha se\u00f1alado la culpa como consecuencia del sobrepeso y, al mismo tiempo, como factor asociado al aumento de peso. En M\u00e9xico no existen instrumentos para evaluar la culpa por obesidad y sobrepeso en ni\u00f1os y adolescentes. Objetivos: analizar la fiabilidad y validez de la Escala de Culpa por Obesidad o Sobrepeso para Ni\u00f1os y Adolescentes (ECOSNA) en poblaci\u00f3n de Morelia (M\u00e9xico). Material y m\u00e9todos: se elabor\u00f3 una versi\u00f3n preliminar basada en la bibliograf\u00eda que se someti\u00f3 a la revisi\u00f3n de jueces expertos. La escala obtenida de 6 \u00edtems se aplic\u00f3 a una muestra de 1.418 estudiantes de educaci\u00f3n b\u00e1sica de 7 a 15 a\u00f1os. Se realiz\u00f3 un an\u00e1lisis factorial confir- matorio y se estudi\u00f3 la relaci\u00f3n de la escala con otras variables como autoestima, sintomatolog\u00eda depresiva y ansiedad. Resultados: la escala result\u00f3 unifactorial, se obtuvo un \u00edndice alfa de Cronbach de 0,853. La escala ECOSNA mostr\u00f3 una correlaci\u00f3n moderada e inversa con la escala de autoestima, y directa y baja con la sintomatolog\u00eda depresiva y la ansiedad cl\u00ednica. Conclusi\u00f3n: los datos emp\u00edricos indican que la escala presenta una validez y confiabilidad satisfactorias.\n[Familial recurrent hypersomnia: two siblings with Kleine-Levin syndrome and menstrual-related hypersomnia.](https://www.ncbi.nlm.nih.gov/pubmed/20404354)\nRocamora, Rodrigo; Gil-Nagel, Antonio; Franch, Oriol; Vela-Bueno, Antonio\n2010-11-01\nKleine-Levin syndrome and menstrual-related hypersomnia are rare idiopathic sleep disorders occurring primarily in adolescence. They are characterized by intermittent periods of excessive sleepiness, cognitive disturbances, and behavioral abnormalities. In both, the etiology remains unknown but autoinmune, hormonal, infectious, and inflammatory mechanisms have been proposed. The authors describe, for the first time, the association of Kleine-Levin syndrome and menstrual-related hypersomnia in 2 adolescent siblings who shared the human leukocyte antigen (HLA) loci DQB1*0501. The same haplotype has been associated with sleepwalking and with rapid eye movement (REM) sleep behavior disorder. This gender differences in the manifestation of a probably genetic influenced sleep disorder suggests that hormonal mechanisms could be implicated in the phenotypical expression of this sleep disorder. The male sibling with Kleine-Levin syndrome was easily controlled with carbamazepine in low doses, but his sister could be only efficaciously treated with oral contraceptives.\n[[Visceral leishmaniasis. Pediatric case report].](https://www.ncbi.nlm.nih.gov/pubmed/28737879)\nGomila H, Andr\u00e9s; Vanzo, Carolina; Garnero, Anal\u00eda; Peruzzo, Luisina; Badalotti, M\u00f3nica\n2017-08-01\nLa leishmaniasis es una enfermedad causada por par\u00e1sitos obligados intracelulares pertenecientes al g\u00e9nero Leishmania y que reconoce tres formas cl\u00ednicas principales: cut\u00e1nea, visceral y mucocut\u00e1nea. Es una patolog\u00eda del grupo de las \"enfermedades desatendidas\". Es la \u00fanica enfermedad tropical transmitida a trav\u00e9s de vectores que se ha mantenido end\u00e9mica por d\u00e9cadas en el sur de Europa. La leishmaniasis visceral representa la forma m\u00e1s grave. Se caracteriza por fiebre, p\u00e9rdida de peso, anemia y hepatoesplenomegalia. Su per\u00edodo de incubaci\u00f3n oscila entre 2 semanas y 18 meses. La leishmaniasis se considera una enfermedad reemergente a nivel mundial. Algunos de los factores que favorecen esta situaci\u00f3n son los cambios en las condiciones clim\u00e1ticas, migraciones y urbanizaciones deficitarias en saneamiento ambiental. Se presenta el caso de un ni\u00f1o europeo que estaba vacacionando en C\u00f3rdoba y fue derivado a nuestro Hospital por fiebre y pancitopenia, lo que gener\u00f3 un abordaje multidisciplinario con resoluci\u00f3n cl\u00ednica favorable. Sociedad Argentina de Pediatr\u00eda.\nReal Delor, Ra\u00fal Emilio\n2018-04-23\nSe presenta caso de paciente obesa a quien se le realiza endoscop\u00eda digestiva alta por disfagia tras ingesta accidental de hueso de pollo. Se constata leve esofagitis de reflujo y atrofia duodenal. La biopsia intestinal informa atrofia intestinal con infiltrado inflamatorio. Los autoanticuerpos para enfermedad celiaca resultan positivos. La paciente nunca present\u00f3 s\u00edntomas digestivos. Se confirma enfermedad celiaca silente e inicia dieta sin gluten.\n[Culture and Illness (Cultura y Enfermedad)](https://eric.ed.gov/?q=cultura&pg=4&id=EJ116172) [ERIC Educational Resources Information Center](http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced)\nMartinez, Pedro Daniel\n1975-01-01\nEvery culture has unique attitudes and values toward health and sickness. This article explores Mexican medical culture on native, folk and scientific levels, and its effect on national health and medical practice. (In Spanish). (CK)\nGerm\u00e1n D\u00edaz, Marta; Moreno Villares, Jos\u00e9 Manuel; Gomis Mu\u00f1oz, Pilar\n2016-07-19\nIntroducci\u00f3n: la nutrici\u00f3n parenteral domiciliaria se ha convertido en un punto clave en el tratamiento de pacientes con fracaso intestinal cr\u00f3nico. A pesar de los importantes avances que se han producido en las \u00faltimas d\u00e9cadas, tanto en los accesos vasculares, como en las soluciones empleadas, las infecciones asociadas a cat\u00e9ter venoso central siguen constituyendo una de las complicaciones m\u00e1s importantes. Dentro de las estrategias para la prevenci\u00f3n o el tratamiento de estas infecciones se encuentra el empleo de sellados con antis\u00e9pticos, como el etanol o la taurolidina, o de antibi\u00f3ticos.Objetivo: el objetivo de este art\u00edculo es revisar la evidencia disponible sobre el empleo de sellados con antis\u00e9pticos o antibi\u00f3ticos en el manejo de pacientes pedi\u00e1tricos con nutrici\u00f3n parenteral domiciliaria.Material y m\u00e9todos: el uso de sellados con etanol o taurolidina para prevenir el desarrollo de infecciones asociadas a cat\u00e9ter central estar\u00eda indicado en pacientes con nutrici\u00f3n parenteral domiciliaria que hayan tenido m\u00e1s de una infecci\u00f3n en el a\u00f1o anterior o que se consideren pacientes de riesgo. Los sellados con antibi\u00f3ticos est\u00e1n indicados en el tratamiento de bacteriemias asociadas a cat\u00e9ter central producidas por S. coagulasa-negativo o gramnegativos, asociados a un tratamiento sist\u00e9mico, siempre que sea posible, con el fin de salvar el cat\u00e9ter. Se deber\u00eda llevar a cabo la retirada del mismo cuando existan signos de infecci\u00f3n del punto de entrada o del trayecto subcut\u00e1neo, o cuando el germen responsable de la infecci\u00f3n sea S. aureus o C\u00e1ndida.Conclusi\u00f3n: a pesar de que la fuerza de la evidencia sobre la eficacia del sellado en la prevenci\u00f3n o el tratamiento de infecciones asociadas al cat\u00e9ter es limitada, tanto en el ni\u00f1o como en el adulto, cada vez existen m\u00e1s datos a usar esta alternativa en pacientes con nutrici\u00f3n parenteral domiciliaria en los que la atenci\u00f3n y salvaguarda de los cat\u00e9teres es primordial.\n[Medicinal ethnobotany in Huacareta (Chuquisaca, Bolivia)](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3484016)\n2012-01-01\nused as a base for subsequent work related to traditional medicine and its contribution to allopathic medicine in San Pablo de Huacareta. Resumen Introducci\u00f3n El objetivo del presente estudio fue documentar los tipos de enfermedades tratadas mediante el uso de plantas medicinales, sus aplicaciones principales y tambi\u00e9n tener un reporte de las enfermedades mayormente atendidas en el Hospital de San Pablo de Huacareta (Chuquisaca, Bolivia). M\u00e9todos Se realizaron encuestas semiestructuradas a 10 informantes locales anotando los usos atribuidos a sus plantas medicinales, se agruparon las plantas por categor\u00edas de enfermedades tratadas en la medicina tradicional. Se obtuvieron reportes de casos tratados en el Hospital de Huacareta para poder relacionar el tratamiento de enfermedades recurrentes en la zona entre la medicina tradicional y la medicina occidental. Resultados Se reportaron 91 especies nativas y ex\u00f3ticas, adem\u00e1s de un esp\u00e9cimen indeterminado ex\u00f3tico que intervienen en un total de 258 aplicaciones medicinales, las cuales son empleadas en un total de 13 categor\u00edas de enfermedades. Los des\u00f3rdenes gastrointestinales (55%) son mayormente tratados mediante plantas medicinales, seguidas de las afecciones al sistema esqueleto-muscular (25%) y enfermedades dermatol\u00f3gicas (24%). La informaci\u00f3n del Hospital indica que las enfermedades m\u00e1s frecuentes son Infecciones Respiratorias Agudas (47%) y Enfermedades Diarreicas Agudas (37%). Los remedios vegetales se emplean en forma de infusiones y cocciones principalmente. Se emplean mayormente plantas nativas, tambi\u00e9n se introdujo en la farmacopea m\u00e9dica el uso de plantas ex\u00f3ticas al lugar. Conclusiones El tratamiento de trastornos gastrointestinales constituye el objetivo primordial de la etnobot\u00e1nica m\u00e9dica de los habitantes de Huacareta, las enfermedades del sistema respiratorio, son mayormente tratadas en el Hospital. Observando los datos del libro de consultas del Hospital, se puede inferir que los des\nAngulo, Daniela; Bustos, Edson; S\u00e1nchez, Andr\u00e9s; Barja, Salesa\n2016-07-19\nIntroducci\u00f3n: la rehabilitaci\u00f3n de la alimentaci\u00f3n por v\u00eda oral (RVO) es compleja en pacientes que han recibido nutrici\u00f3n enteral (NE) prolongada. Objetivo: describir este proceso en ni\u00f1os con enfermedades respiratorias cr\u00f3nicas y sonda nasoenteral (SNE) o gastrostom\u00eda (GT).Pacientes y m\u00e9todos: estudio retrospectivo con revisi\u00f3n de registros cl\u00ednicos de ni\u00f1os con NE mayor a dos meses, ingresados entre 2005 y 2014 al Hospital Josefina Mart\u00ednez.Resultados: Se incluyeron 116 pacientes, con mediana de edad 10 meses (Rango: 3 a 101), 56% hombres. Diagn\u00f3stico: 34,5% Da\u00f1o pulmonar cr\u00f3nico postinfeccioso (DPC), 29,3% Insuficiencia respiratoria por enfermedad neuromuscular, 19% Displasia broncopulmonar y 17,2% enfermedad de la v\u00eda a\u00e9rea. Con traqueostom\u00eda: 82,8%. Eran usuarios de GT 89,7% y de SNG 10,3%, instaladas con mediana de edad 6 meses (0 a 74), por ingesta insuficiente (6,6%) o trastorno de degluci\u00f3n (92,4%). Del grupo total, 36,2% (42/116) ten\u00eda indicaci\u00f3n de RVO, los cuales hab\u00edan recibido NE durante 12,2 meses (2 a 41); de estos 50% (21/42) logr\u00f3 alimentarse exclusivamente por v\u00eda oral (91% SNG y 35,4% GT, Chi2 p = 0,023), 14% parcialmente y 36% no lo logr\u00f3. El tiempo para lograr la v\u00eda oral exclusiva fue de 9,75 meses (0,5 a 47), sin diferencia por edad, sexo, v\u00eda de acceso, duraci\u00f3n NE ni presencia de enfermedad neurol\u00f3gica.Conclusi\u00f3n: en pacientes con enfermedades respiratorias cr\u00f3nicas graves y NE prolongada, la RVO es un proceso lento pero posible: 64% lo logra de modo completo o parcial.\n[Estrellas asociadas con planetas extrasolares vs. estrellas de tipo \u03b2 Pictoris](http://adsabs.harvard.edu/abs/2002BAAA...45...26C) [NASA Astrophysics Data System (ADS)](http://adsabs.harvard.edu/abstract_service.html)\nChavero, C.; G\u00f3mez, M.\nIn this contribution we initially confront physical properties of two groups of stars: the Planet Host Stars and the Vega-like objects. The Planet Host Star group has one or more planet mass object associated and the Vega-like stars have circumstellar disks. We have compiled magnitudes, colors, parallaxes, spectral types, etc. for these objects from the literature and analyzed the distribution of both groups. We find that the samples are very similar in metallicities, ages, and spatial distributions. Our analysis suggests that the circumstellar environments are probably different while the central objects have similar physical properties. This difference may explain, at least in part, why the Planet Host Stars form extra-solar planetary objects such as those detected by the Doppler effect while the Vega-like objects are not commonly associated with these planet-mass bodies.\nCorella Aznar, Elena Guadalupe; Ayerza Casas, Ariadna; Samper Villagrasa, Pilar; Rodr\u00edguez Vigil, Carmen; Jim\u00e9nez Monta\u00f1\u00e9s, Lorenzo; Calvo Escribano, Carlota; Labarta Aizpun, Jos\u00e9 Ignacio\n2016-06-30\nIntroducci\u00f3n: los supervivientes de leucemia aguda (LA) infantil presentan un riesgo incrementado de alteraciones metab\u00f3licas y cardiovasculares que aumentan su morbimortalidad a largo plazo.Objetivo: estimar la prevalencia de obesidad, resistencia a la insulina, dislipemia e hipertensi\u00f3n arterial como factores de riesgo cardiometab\u00f3lico (FRCM) en un grupo de supervivientes de LA infantil, y analizar las posibles causas asociadas a su desarrollo.Material y m\u00e9todos: estudio observacional retrospectivo en 47 supervivientes de LA tratados en un periodo de 4 a\u00f1os, que recibieron seguimiento durante 10 a\u00f1os.Resultados: el 40% de los participantes presentaron al menos un FRCM durante el seguimiento, siendo la dislipemia (aumento LDL) el m\u00e1s frecuente (38,3%), seguido de obesidad/sobrepeso (31,9%) y HTA sist\u00f3lica (23,4%). El sexo femenino se estableci\u00f3 como factor de riesgo parael desarrollo de todos ellos (RR 1,6; RR 3,16; RR 1,69; p < 0,05). Ning\u00fan superviviente desarroll\u00f3 diabetes mellitus, pero s\u00ed resistencia a la insulina el 19,4%. Los pacientes con leucemias de peor pron\u00f3stico presentaron mayor riesgo de desarrollar obesidad, resistencia a la insulina y aumento de LDL (RR 3,56; RR 4,08; RR 2,53; p < 0,05). Los pacientes tratados con trasplante de progenitores hematopoy\u00e9ticos presentaron mayor riesgo de obesidad, aumento de LDL e HTA sist\u00f3lica (RR 2,86; RR 2,39; RR 3,12; p<0,05). La radioterapia se asoci\u00f3 de igual modo con un incremento de resistencia a la insulina e hipertensi\u00f3n arterial sist\u00f3lica (RR 2,47; RR 2,53; p < 0,05).Conclusiones: existe un aumento en la prevalencia de obesidad/sobrepeso, dislipemia, resistencia a la insulina y alteraci\u00f3n de la tensi\u00f3n arterial sist\u00f3lica en supervivientes de leucemia aguda infantil a lo largo del tiempo, especialmente en aquellos con enfermedades y tratamientos m\u00e1s agresivos.\nTorrado, Julio; Piazuelo, Mar\u00eda Blanca; Ruiz, Irune; Izarzugaza, Mar\u00eda Isabel; Camargo, Mar\u00eda Constanza; Delgado, Alberto; Abdirad, Afshin; Correa, Pelayo\n2010-01-01\nANTECEDENTES: El es\u00f3fago de Barrett es una reconocida lesi\u00f3n precursora de adenocarcinoma esof\u00e1gico. Aunque generalmente asociada al reflujo gastroesof\u00e1gico, los mecanismos patog\u00e9nicos de la enfermedad no son bien conocidos. El objetivo del presente estudio es explorar la historia natural e identificar marcadores de progreso del proceso precanceroso. MATERIAL Y M#ENTITYSTARTX000E9;TODOS: Se utilizaron cortes histol\u00f3gicos de 67 espec\u00edmenes de es\u00f3fago correspondientes a 14 pacientes con es\u00f3fago de Barrett, a los que se sigui\u00f3 entre 1 - 9 a\u00f1os. Se clasificaron las lesiones en: es\u00f3fago de Barrett sin displasia, indefinido para displasia o con displasia. Se evalu\u00f3 la expresi\u00f3n de diferentes mucinas en las c\u00e9lulas caliciformes y en las columnares usando t\u00e9cnicas de histoqu\u00edmica e inmunohistoqu\u00edmica. RESULTADOS: En todos los casos se comprob\u00f3 la presencia de metaplasia intestinal incompleta. Las c\u00e9lulas columnares dentro del epitelio metapl\u00e1sico conten\u00edan mucinas neutras. A mayor severidad de la lesi\u00f3n se encontr\u00f3 significativamente menor expresi\u00f3n de sialomucinas en las c\u00e9lulas columnares (p de tendencia igual a 0,03). En sujetos con lesiones indefinidas para displasia se observ\u00f3 un mayor contenido de sulfomucinas en las c\u00e9lulas caliciformes (p=0,034) y de MUC2 en las c\u00e9lulas columnares (p=0,029) que en sujetos con es\u00f3fago de Barrett sin displasia. Se observ\u00f3 expresi\u00f3n de la mucina intestinal MUC2 y de la mucina g\u00e1strica MUC5AC en todas las muestras. MUC6, una mucina de las gl\u00e1ndulas profundas g\u00e1stricas, se present\u00f3 ocasionalmente. CONCLUSI#ENTITYSTARTX000F3;N: La evaluaci\u00f3n de los perfiles de mucinas en el es\u00f3fago de Barrett sugiere una transici\u00f3n gradual del fenotipo del epitelio metapl\u00e1sico a medida que la lesi\u00f3n avanza en el tiempo.\n[El fenotipo de las mucinas en el es\u00f3fago de Barrett](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3144548)\nTorrado, Julio; Piazuelo, Mar\u00eda Blanca; Ruiz, Irune; Izarzugaza, Mar\u00eda Isabel; Camargo, Mar\u00eda Constanza; Delgado, Alberto; Abdirad, Afshin; Correa, Pelayo\n2011-01-01\nAntecedentes El es\u00f3fago de Barrett es una reconocida lesi\u00f3n precursora de adenocarcinoma esof\u00e1gico. Aunque generalmente asociada al reflujo gastroesof\u00e1gico, los mecanismos patog\u00e9nicos de la enfermedad no son bien conocidos. El objetivo del presente estudio es explorar la historia natural e identificar marcadores de progreso del proceso precanceroso. Material y m\u00e9todos Se utilizaron cortes histol\u00f3gicos de 67 espec\u00edmenes de es\u00f3fago correspondientes a 14 pacientes con es\u00f3fago de Barrett, a los que se sigui\u00f3 entre 1 \u2013 9 a\u00f1os. Se clasificaron las lesiones en: es\u00f3fago de Barrett sin displasia, indefinido para displasia o con displasia. Se evalu\u00f3 la expresi\u00f3n de diferentes mucinas en las c\u00e9lulas caliciformes y en las columnares usando t\u00e9cnicas de histoqu\u00edmica e inmunohistoqu\u00edmica. Resultados En todos los casos se comprob\u00f3 la presencia de metaplasia intestinal incompleta. Las c\u00e9lulas columnares dentro del epitelio metapl\u00e1sico conten\u00edan mucinas neutras. A mayor severidad de la lesi\u00f3n se encontr\u00f3 significativamente menor expresi\u00f3n de sialomucinas en las c\u00e9lulas columnares (p de tendencia igual a 0,03). En sujetos con lesiones indefinidas para displasia se observ\u00f3 un mayor contenido de sulfomucinas en las c\u00e9lulas caliciformes (p=0,034) y de MUC2 en las c\u00e9lulas columnares (p=0,029) que en sujetos con es\u00f3fago de Barrett sin displasia. Se observ\u00f3 expresi\u00f3n de la mucina intestinal MUC2 y de la mucina g\u00e1strica MUC5AC en todas las muestras. MUC6, una mucina de las gl\u00e1ndulas profundas g\u00e1stricas, se present\u00f3 ocasionalmente. Conclusi\u00f3n La evaluaci\u00f3n de los perfiles de mucinas en el es\u00f3fago de Barrett sugiere una transici\u00f3n gradual del fenotipo del epitelio metapl\u00e1sico a medida que la lesi\u00f3n avanza en el tiempo. PMID:21804831\n[A quantitative synthesis of the medicinal ethnobotany of the Malink\u00e9 of Mali and the Ash\u00e1ninka of Peru, with a new theoretical framework](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2248176)\nBletter, Nathaniel\n2007-01-01\nsignificativamente mayor a la similitud de las floras generales, solamente cuando las enfermedades analizadas se agruparon en las categor\u00edas de enfermedades parasitarias y enfermedades autoinmunes. Si se demostrara que las otras partes de esta hip\u00f3tesis son ciertas, se podr\u00eda sintetizar la informaci\u00f3n sobre plantas medicinales alrededor del mundo, para establecer as\u00ed las plantas potencialmente m\u00e1s eficaces para llevarlas al laboratorio y analizarlas m\u00e1s profundamente. French abstract Par rapport aux recherches men\u00e9es de fa\u00e7on al\u00e9atoire, les recherches effectu\u00e9es par des crit\u00e8res ethnobotaniques et taxonomiques ont de meilleures chances \u00e0 d\u00e9couvrir de nouvelles plantes m\u00e9dicinales \u00e0 produit chimique actifs. Pendant les derni\u00e8res d\u00e9cennies pourtant, l'ethnobotanique a r\u00e9alis\u00e9 peu de ces promesses \u00e0 r\u00e9v\u00e9ler un grand nombre de plantes m\u00e9dicinales et de nouveaux produits chimiques, test\u00e9s au laboratoire. Avec les ressources limit\u00e9es pour la recherche au laboratoire et le co\u00fbt \u00e9lev\u00e9 des \u00e9preuves cliniques pour trouver de nouveaux candidats aux m\u00e9dicaments, il est difficile d'\u00e9tudier, d'isoler et d'\u00e9lucider la structure et le m\u00e9canisme des produits chimiques de chacune des nombreuses plantes m\u00e9dicinales (et les utilisations de ces plantes) d\u00e9crites chaque ann\u00e9e. Nous proposons une nouvelle technique th\u00e9orique et quantitative pour pr\u00e9ciser la recherche de nouvelles plantes m\u00e9dicinales; elle est bas\u00e9e sur l'hypoth\u00e8se que les plantes \u00e9troitement apparent\u00e9es, employ\u00e9es pour traiter les maladies \u00e9troitement apparent\u00e9es dans les cultures tr\u00e8s \u00e9loign\u00e9es les unes des autres, ont une potentialit\u00e9 d'efficacit\u00e9 sup\u00e9rieure parce qu'elles repr\u00e9sentent la d\u00e9couverte ind\u00e9pendante des propri\u00e9t\u00e9s chimiques semblables des plantes. Une partie de cette hypoth\u00e8se-qui d\u00e9montre que la s\u00e9lection des plantes m\u00e9dicinales semblables est un choix rationnel et qu'il y a davantage de ressemblance dans la flore m\u00e9dicinale de deux cultures \u00e9loign\u00e9es que\n[Anxiety, depression, resilience and self-esteem in individuals with cardiovascular diseases.](https://www.ncbi.nlm.nih.gov/pubmed/27901221)\nCarvalho, Isabela Gonzales; Bertolli, Eduarda Dos Santos; Paiva, Luciana; Rossi, Lidia Aparecida; Dantas, Rosana Aparecida Spadoti; Pompeo, Daniele Alcal\u00e1\n2016-11-28\n\u00edstica foi constitu\u00edda por 120 pacientes. As vari\u00e1veis de interesse foram avaliadas pela Escala Hospitalar de Ansiedade e Depress\u00e3o, Escala de Resili\u00eancia e Escala de Autoestima de Rosenberg. os sintomas de ansiedade e depress\u00e3o estavam presentes em 32,5% e 17,5% dos pacientes, respectivamente e foram associados ao sexo feminino (p = 0,002; p = 0,022). As manifesta\u00e7\u00f5es de depress\u00e3o foram associadas \u00e0 presen\u00e7a de comorbidades (p = 0,020). Pacientes mais resilientes n\u00e3o apresentaram sintomas depressivos (p < 0,001) e, as mulheres ansiosas, foram menos resilientes (p = 0,042). Os maiores escores de autoestima estiveram presentes em pacientes com ansiedade e depress\u00e3o. Os homens apresentaram maior resili\u00eancia e menor autoestima quando comparados \u00e0s mulheres. pacientes com ansiedade e depress\u00e3o foram menos resilientes e apresentaram maior autoestima. analizar las relaciones entre los s\u00edntomas ansiedad y depresi\u00f3n, resiliencia y autoestima, con las caracter\u00edsticas sociodemogr\u00e1ficas y cl\u00ednicas; correlacionar la resiliencia y autoestima con la edad y el tiempo de la enfermedad; analizar asociaciones entre ansiedad y depresi\u00f3n con las medidas de resiliencia y autoestima en individuos con enfermedades cardiovasculares. estudio de correlaci\u00f3n, realizado en un Hospital de Ense\u00f1anza de gran porte del interior del estado de Sao Paulo. La poblaci\u00f3n estuvo constituida por pacientes adultos internados con enfermedades cardiovasculares. Una muestra consecutiva y no probabil\u00edstica fue constituida por 120 pacientes. Las variables de inter\u00e9s fueron evaluadas por la Escala Hospitalaria de Ansiedad y Depresi\u00f3n, la Escala de Resiliencia y la Escala de Autoestima de Rosenberg. los s\u00edntomas de ansiedad y depresi\u00f3n estaban presentes en 32,5% y 17,5% de los pacientes, respectivamente y fueron asociados al sexo femenino (p = 0,002; p = 0,022). Las manifestaciones de depresi\u00f3n fueron asociadas a la presencia de comorbilidades (p = 0,020). Pacientes m\u00e1s resilientes no\n[El medio interestelar alrededor de estrellas Of: HD 108](http://adsabs.harvard.edu/abs/1998BAAA...42Q..51C) [NASA Astrophysics Data System (ADS)](http://adsabs.harvard.edu/abstract_service.html)\nCappa, C.; Testori, J. C.\nHemos analizado la distribuci\u00f3n del hidr\u00f3geno neutro interestelar en la vecindad de la estrella Of HD 108 en base a perfiles de la l\u00ednea de 21 cm. Estos datos nos han permitido encontrar una probable burbuja interestelar asociada a la estrella. Comparamos estos resultados con la emisi\u00f3n en otros rangos espectrales y estimamos los principales par\u00e1metros f\u00edsicos de la estructura.\n[Autoimmunity-related neutrophilic dermatosis: a newly described entity that is not exclusive of systemic lupus erythematosus.](https://www.ncbi.nlm.nih.gov/pubmed/23518639)\nSaeb-Lima, Marcela; Charli-Joseph, Yann; Rodr\u00edguez-Acosta, Elva Dalia; Dom\u00ednguez-Cherit, Judith\n2013-08-01\nNeutrophilic dermatoses have long been known to be associated with autoinmune systemic diseases. Recently, a small number of cases of a disorder distinct from Sweet syndrome or bullous lupus erythematosus (LE) have been described as specifically related to systemic LE under diverse terms, including nonbullous neutrophilic dermatosis, nonbullous neutrophilic LE, and Sweet-like neutrophilic dermatosis. We describe 7 patients that developed urticarial lesions in the context of a known or concurrently diagnosed autoimmune connective tissue disease. Of a total of 7 patients, 6 were afflicted by systemic LE and 1 by rheumatoid arthritis and secondary Sj\u00f6gren syndrome. Histological findings in all patients included an interstitial and perivascular neutrophilic infiltrate with leukocytoclasia, vacuolar alteration along the dermal-edidermal junction, and no vasculitis. Most patients had active systemic disease at the time of the cutaneous eruption. Skin lesions resolved rapidly after the administration of immunomodulating agents. In conclusion, we provide additional evidence of the existence of a recently defined nonbullous neutrophilic dermatosis in the context of autoimmune connective tissue diseases and propose the term autoimmunity-related neutrophilic dermatosis as an appropriate designation. Furthermore, we believe that this entity should prompt physicians to screen the presence of an active systemic disorder in afflicted patients.\n[[Orofacial clinical manifestations in adult patients with variable common immunodeficiency].](https://www.ncbi.nlm.nih.gov/pubmed/25958373)\nCh\u00e1vez-Garc\u00eda, Aurora Alejandra; Moreno-Alba, Miguel \u00c1ngel; Elizalde-Monroy, Mart\u00edn; Segura-M\u00e9ndez, Nora Hilda; Romero-Flores, Jovita; Cambray-Guti\u00e9rrez, Julio C\u00e9sar; L\u00f3pez-P\u00e9rez, Patricia; Del Rivero-Hern\u00e1ndez, Leonel Gerardo\n2015-01-01\nCommon variable immunodeficiency is the primary immunodeficiency (CVID) frequently found in adults. Its prevalence is estimated from 1:25,000 to 75,000 alive newborns; there are variations by ethnic groups, it is estimated about 50-70% in Caucasian patients. Oral cavity lesions are rarely found in adult patients with CVID, there are reports about lesions on pediatric patients mostly caused by infections. To describe the orofacial lesions (oral, maxillofacial and neck area) affecting adults with CVID. A transversal, prospective study was done in patients with CVID attended at Specialties Hospital, CMN SXXI, Mexico City. Patients where examined by the oral and maxillofacial surgeon and clinical findings were reported, then the descriptive analysis of the lesions was done. We evaluated 26 patients, 16 female and 10 males, average age of 38.6 years. In 18/26 patients we found oral lesions on 7 different types. The most frequent was minor salivary glands hiperplasia (19/26),petechiae (12/26) and herpetic ulcers (7/26). In head and neck, we found 4 different lesions, the most common was lymphadenopathy <2cm (4/26). The immunologic alterations associated to CVID favors the development of lesions mainly of infectious and probably autoinmune origin that affects the oral cavity and head and neck area.\n[S\u00edntesis del estado del conocimiento del ciclo de carbono en ecosistemas boscosos de los Estados Unidos](https://www.fs.usda.gov/treesearch/pubs/39130)\nMichael G. Ryan; Mark E. Harmon; Richard A. Birdsey; Christian P. Giardina; Linda S. Heath; Richard A. Houghton; Robert B. Jackson; Duncan C. McKinley; James F. Morrison; Brian C. Murray; Diane E. Pataki; Kenneth E. Skog\n2010-01-01\nLos bosques juegan un papel central en el ciclo de carbono de los Estados Unidos y global. El secuestro de carbono de los bosques de los Estados Unidos, a trav\u00c3\u00a9s de su crecimiento y la cosecha de productos madereros, compensa en la actualidad entre un 12 y un 19% de las emisiones de carbono asociadas al uso de combustible f\u00c3\u00b3sil de dicho pa\u00c3s. El ciclo natural de un...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[Genetics and Rheumatic Disease](https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Living-Well-with-Rheumatic-Disease/Genetics-and-Rheumatic-Disease)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[Pregnancy and Rheumatic Disease](https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Living-Well-with-Rheumatic-Disease/Pregnancy-Rheumatic-Disease)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[Immune System and Its Link to Rheumatic Diseases](https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Living-Well-with-Rheumatic-Disease/The-Immune-System-Its-Link-to-Rheumatic-Disease)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[NSAIDs (Nonsteroidal Anti-inflammatory Drugs)](https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/NSAIDs)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[Osteonecrosis of the Jaw (ONJ)](https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Osteonecrosis-of-the-Jaw-ONJ)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[American College of Rheumatology](https://www.rheumatology.org/)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[Granulomatosis with Polyangiitis (Wegener's)](https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Granulomatosis-with-Polyangitis-Wegners)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[Calcium Pyrophosphate Deposition (CPPD)](https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Calcium-Pyrophosphate-Deposition-CPPD)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[Cryopyrin-Associated Autoinflammatory Syndromes (CAPS) - Juvenile](https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Cryopyrin-Associated-Autoinflammatory-Syndrome-CAPS-Juvenile)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\n[Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis Syndrome (PFAPA)](https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Periodic-Fever-Aphthous-Stomatitis-Pharyngitis-Adenitis-Syndrome-Juvenile)\n... Keep me signed in Passwords are Case Sensitive. Ex. Enter smith as follows: Smith Forgot Username/Password? ... Erythematosus (Juvenile) Takayasu's Arteritis Tendinitis & Bursitis Tumor Necrosis Factor Receptor Associated Periodic Syndrome (Juvenile) Vasculitis Enfermedades y ...\nMolina Villaverde, Raquel\n2016-06-03\nEl c\u00e1ncer es un problema sanitario de primera magnitud a escala mundial. Su tratamiento es uno de los mayores campos de innovaci\u00f3n y desarrollo en medicina. La visi\u00f3n del c\u00e1ncer como una enfermedad sist\u00e9mica, heterog\u00e9nea y de una elevada complejidad hace que los enfermos deban recibir una atenci\u00f3n oncol\u00f3gica de calidad, proporcionada por equipos multidisciplinares altamente cualificados. Adem\u00e1s de la gran incidencia de malnutrici\u00f3n en estos pacientes, la intervenci\u00f3n nutricional precoz puede mejorar su pron\u00f3stico, aumentar la calidad de vida y disminuir la tasa de complicaciones de la enfermedad. Por ello, es necesaria una estrecha colaboraci\u00f3n entre el onc\u00f3logo y el experto en nutrici\u00f3n.\nEl humo de los incendios puede tener un efecto adverso en la salud de las personas, especialmente en aquellas que padecen de enfermedades card\u00edacas y pulmonares. Vea c\u00f3mo minimizar su exposici\u00f3n al humo.\n[Informaci\u00f3n general sobre los mosquitos](https://espanol.epa.gov/control-de-plagas/informacion-general-sobre-los-mosquitos)\nUna consecuencia m\u00e1s importante de algunas picaduras de mosquitos es la trasmisi\u00f3n de ciertas enfermedades graves como el paludismo, la fiebre del dengue y varias formas de encefalitis, que incluyen el virus del Nilo occidental.\n... discapacidad intelectual puede ser la consecuencia de un problema que comienza antes de que el ni\u00f1o nazca ... causa puede ser una lesi\u00f3n, enfermedad o un problema en el cerebro. En muchos ni\u00f1os no se ...\n[Sickle Cell Disease (For Parents)](https://kidshealth.org/en/parents/sickle-cell-anemia.html)\n... Safe Videos for Educators Search English Espa\u00f1ol Sickle Cell Disease KidsHealth / For Parents / Sickle Cell Disease What's ... espa\u00f1ol Enfermedad de c\u00e9lulas falciformes What Is Sickle Cell Disease? Sickle cell disease is a condition in ...\n... de la \u201cEstrategia para la prevenci\u00f3n y el control de las enfermedades arbovirales\u201d en las Am\u00e9ricas. Informe del taller; 2018 (Spanish only) First Meeting of the Technical Advisory Group on Public Health Entomology; 2016 All Documents [ Search ...\n[Seguridad Laboral al Usar Pesticidas](https://espanol.epa.gov/seguridad-laboral-al-usar-pesticidas)\nPara proteger a la gente que trabaja con pesticidas y quienes laboran en \u00e1reas tratadas con pesticidas; para educar al personal m\u00e9dico y al p\u00fablico acerca de c\u00f3mo reconocer y tratar las enfermedades relacionadas a los pesticidas.\n[[A historical view of the specialty of clinical microbiology].](https://www.ncbi.nlm.nih.gov/pubmed/21129580)\nP\u00e9rez, Evelio Perea; \u00c1lvarez, Rogelio Mart\u00edn\n2010-10-01\nClinical microbiology today is a well established specialty in Spain whose development has necessarily been linked to improvements in the diagnosis, treatment and prevention of infectious diseases. Over time, clinical, teaching, and research structures have been organized around these diseases. In addition, a scientific society for specialists in infectious diseases (Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica) has been set up, which in turn, publishes the journal ENFERMEDADES INFECCIOSAS Y MICROBIOLOG\u00cdA CL\u00cdNICA, and organizes congresses, meetings, working groups and a quality control program, etc. Clinical microbiologists will continue to be needed to meet future challenges (identification of new pathogenic microorganisms, methodological changes, diagnostic quality and speed, nosocomial infections, the development of antimicrobial resistance, etc.), which constitute a well-defined area of knowledge specific to our specialty. Copyright \u00a9 2010 Elsevier Espa\u00f1a S.L. All rights reserved.\n[[An automated registry program for nosocomial infections].](https://www.ncbi.nlm.nih.gov/pubmed/25643679)\nCasta\u00f1\u00f3n-Gonz\u00e1lez, Jorge Alberto; Polanco-Gonz\u00e1lez, Carlos; Samaniego-Mendoza, Jos\u00e9 Lino; Buhse, Thomas\n2014-12-01\nLas infecciones nosocomiales presentan un gran reto para la medicina hospitalaria, en general, y para las Unidades de Cuidados Intensivos, en particular. Su elevada prevalencia, la gran morbilidad y mortalidad asociadas, el incremento de la estancia hospitalaria y, en consecuencia, los costos de la atenci\u00f3n m\u00e9dica han hecho que los programas de vigilancia, control y prevenci\u00f3n de infecciones nosocomiales sean una parte toral de los protocolos de seguridad para el paciente y un indicador de calidad de la atenci\u00f3n m\u00e9dica.\n... Is at Risk for Tay-Sachs? Screening Prenatal Diagnosis Signs and Symptoms Helping a Child With Tay-Sachs Print en espa\u00f1ol La enfermedad de Tay-Sachs Healthy babies develop vision, movement, hearing, and other vital functions in part because enzymes clear out fatty ...\n... ojo \u00a1Ojo con su Visi\u00f3n! Glosario Recursos adicionales de informaci\u00f3n El glaucoma El glaucoma \u00bfCu\u00e1nto sabe sobre ... un ser querido Ojos sanos Ojos sanos Problemas de visi\u00f3n comunes Enfermedades y condiciones de los ojos ...\n[Molecular Comparison of Topotypic Specimens Confirms Anopheles (Nyssorhynchus) dunhami Causey (Diptera: Culicidae) in the Colombian Amazon](http://www.dtic.mil/docs/citations/ADA550563)\n2010-11-01\nof Health, Albany, NY, USA 5Facultad de Medicina , Universidad Nacional de Colombia, Bogot\u00e1, Colombia 6Programa de Estudio y Control de Enfermedades...Tropicales, Facultad de Medicina , Universidad de Antioquia, Medell\u00edn, Colombia The presence of Anopheles (Nyssorhynchus) dunhami Causey in Colombia\n[Spanish Navy Up to Date Data in DCS](http://www.dtic.mil/docs/citations/ADP011068)\n2001-06-01\ntherapeutic measures. Final results are similar to another world navies diving centres Bibliography: 1.- Pujante, A.; Inoriza, J; Viqueira, A. Estudio de 121... casos de enfermedad descompresiva Medicina Clinica, vol . 94, n` 7, 1990 2.- Rivera, J.C. Decompression sickness among divers: An analysis of 935\n[Systematic review and meta-analysis of persistent left superior vena cava on prenatal ultrasound: associated anomalies, diagnostic accuracy and postnatal outcome.](https://www.ncbi.nlm.nih.gov/pubmed/26970258)\nGustapane, S; Leombroni, M; Khalil, A; Giacci, F; Marrone, L; Bascietto, F; Rizzo, G; Acharya, G; Liberati, M; D'Antonio, F\n2016-12-01\nhigh-risk pregnancies, the rate of associated abnormalities is likely to be higher than that in the general population of fetuses with PLSVC, for which more data are needed. Revisi\u00f3n sistem\u00e1tica y metaan\u00e1lisis de la persistencia de la vena cava superior izquierda en la ecograf\u00eda prenatal: anomal\u00edas asociadas, precisi\u00f3n del diagn\u00f3stico y resultado postnatal RESUMEN OBJETIVOS: Cuantificar la prevalencia de anomal\u00edas cromos\u00f3micas en fetos con vena cava superior izquierda persistente (VCSIP), evaluar la solidez de la asociaci\u00f3n entre la VCSIP y la coartaci\u00f3n a\u00f3rtica, y determinar la precisi\u00f3n del diagn\u00f3stico de la ecograf\u00eda prenatal como m\u00e9todo para identificar correctamente casos aislados de VCSIP. M\u00c9TODOS: Se busc\u00f3 en las bases de datos de MEDLINE, EMBASE, CINHAL y Cochrane art\u00edculos publicados desde el a\u00f1o 2000 en adelante, usando combinaciones de las palabras clave \"vena cava superior izquierda\" y \"resultado\". Dos de los autores revisaron de forma independiente todos los res\u00famenes encontrados. La evaluaci\u00f3n de calidad de los estudios incluidos se realiz\u00f3 mediante la escala Newcastle-Ottawa para estudios de cohortes. Se analizaron las tasas de los siguientes resultados: anomal\u00edas cromos\u00f3micas; anomal\u00edas intracard\u00edacas (AIC) y anomal\u00edas extracard\u00edacas (AEC) asociadas diagnosticadas prenatalmente; AIC y AEC adicionales detectadas s\u00f3lo en ecograf\u00edas postnatales o mediante evaluaci\u00f3n cl\u00ednica, pero no observadas en ecograf\u00edas prenatales; y la asociaci\u00f3n entre la VCSIP y la coartaci\u00f3n a\u00f3rtica. Se utiliz\u00f3 un meta-an\u00e1lisis de proporciones para combinar los datos. En total, se identificaron 2708 art\u00edculos y se incluyeron 13 (n = 501) en la revisi\u00f3n sistem\u00e1tica. En la ecograf\u00eda prenatal o en una revisi\u00f3n de seguimiento se detectaron AIC y AEC asociadas en el 60,7% (IC 95%, 44,2-75,9%) y el 37,8% (IC 95%, 31,0-44,8%) de los casos, respectivamente. Se produjeron anomal\u00edas cromos\u00f3micas en el 12,5% (IC 95%, 9,0-16,4%) de los casos en\n[Medical Problems Related to Altitude in: Human Performance Physiology and Environmental Medicine at Terrestrial Extremes. Chapter 14,](http://www.dtic.mil/docs/citations/ADA188340)\n1987-10-01\nfunction primarily to increase oxygen availability at the tissue level. The most significant changes occur in the cardiovascular and pulmonary systems...52. 40. Monge, M.C. La Enfermedad de Los Andes. Sindromes Eritremicos. Ann. Fac. Med. (Peru) 11:1, 1928. 41. Moore, L..G., G.L. Harrison, R.E\n[Tumores neonatales y malformaciones cong\u00e9nitas](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3635533)\nTornero, O. Berbel; Garc\u00eda, J.A. Ortega; Tortajada, J. Ferr\u00eds i; Castell, J. Garc\u00eda; Colomer, J. Donat i; Soldin, O.P.; Soler, J.L. Fuster\n2013-01-01\nIntroducci\u00f3n La asociaci\u00f3n entre tumores y malformaciones cong\u00e9nitas est\u00e1 bien establecida, pero no existen datos exclusivos en el per\u00edodo neonatal y se desconocen los mecanismos subyacentes que generan dicha relaci\u00f3n. Objetivos Este trabajo tiene dos objetivos: primero, analizar la frecuencia de los tumores neonatales asociados a malformaciones cong\u00e9nitas, y segundo, comentar las posibles hip\u00f3tesis etiopatog\u00e9nicas de la relaci\u00f3n entre ambas entidades. Materiales y m\u00e9todo Estudio retrospectivo de las historias cl\u00ednicas de los tumores neonatales, en el Hospital Universitario Materno- Infantil La Fe de Valencia, desde enero de 1990 hasta diciembre de 1999. Selecci\u00f3n y descripci\u00f3n de las variedades histol\u00f3gicas asociadas a malformaciones cong\u00e9nitas. \u00c9stas se han agrupado siguiendo los criterios de la Clasificaci\u00f3n Internacional de Enfermedades CIE-9, c\u00f3digos 740.0\u2013759.9. Revisi\u00f3n sistem\u00e1tica bibliogr\u00e1fica de los \u00faltimos 25 a\u00f1os, obtenida del Medline, Cancerlit, Index Citation Science y Embase. El perfil de b\u00fasqueda utilizado fue la combinaci\u00f3n de \u201cneonatal/congenital-tumors/cancer/neoplasms\u201d y \u201ccongenital malformations/birth defects\u201d. Resultados Se identificaron 72 tumores neonatales (2,8 % del total de tumores pedi\u00e1tricos diagnosticados en dichos a\u00f1os) y 15 de ellos (20,8 %) asociados a malformaciones cong\u00e9nitas, enfermedades o s\u00edndromes cong\u00e9nitos. Las asociaciones entre tumores neonatales y malformaciones cong\u00e9nitas fueron las siguientes: a) angioma en 3 pacientes: con dos cardiopat\u00edas cong\u00e9nitas y una atresia de coanas-laringomalacia; b) neuroblastoma en 2 pacientes: uno con ri\u00f1\u00f3n en herradura y anomal\u00edas vertebrales, y otro con cardiopat\u00eda cong\u00e9nita; c) teratoma en 2 pacientes: uno con fisura palatina y anomal\u00edas vertebrales, y otro con metatarso varo; d) tumor del sistema nervioso central en un paciente con hernia de Bochdaleck; e) tumor card\u00edaco en 4 pacientes con esclerosis tuberosa; f) leucemia aguda en un\n[Sociodemographic factors and health conditions associated with the resilience of people with chronic diseases: a cross sectional study.](https://www.ncbi.nlm.nih.gov/pubmed/27598377)\nB\u00f6ell, Julia Estela Willrich; Silva, Denise Maria Guerreiro Vieira da; Hegadoren, Kathleen Mary\n2016-09-01\nenfermedad renal cr\u00f3nica y/o diabetes mellitus tipo 2. estudio observacional transversal, realizado con 603 personas con diagn\u00f3stico de enfermedad renal cr\u00f3nica y/o diabetes mellitus tipo 2. Aplicaci\u00f3n de instrumento para recolectar datos sociodemogr\u00e1ficos y de salud y Escala de Resiliencia desarrollada por Connor y Davidson. Fue realizado an\u00e1lisis descriptivo y multivariado de los datos. los participantes del estudio pose\u00edan, en promedio, 61 a\u00f1os de edad (DE=13,2), con uni\u00f3n estable (52,24%), creencia religiosa (96,7%), jubilados (49,09%), con ense\u00f1anza fundamental (65%) y renta de hasta tres salarios m\u00ednimos. Los participantes con enfermedad renal presentaron menor resiliencia que personas con diabetes. el tipo de enfermedad cr\u00f3nica, el tiempo de enfermedad, el \u00edndice de masa corporal y la creencia religiosa influenciaron la resiliencia de los participantes del estudio.\n[Linfoma Nasal de C\u00e9lulas T/Natural Killer Extranodal Refractario Mal Diagnosticado, Tratado de Manera Exitosa: Informe de Caso.](https://www.ncbi.nlm.nih.gov/pubmed/29430232)\nSaavedra Ram\u00edrez, Jos\u00e9 Domingo\n2017-01-01\nEl linfoma de c\u00e9lulas T/natural killer extranodal (\"extranodal natural killer/T-cell lymphoma\", ENKL) nasal es un linfoma no Hodgkin (LNH) agresivo y poco com\u00fan para el cual no se ha establecido un tratamiento de referencia claro, especialmente en el escenario de la enfermedad recidivante/refractaria. Debido a su rareza, no se han llevado a cabo ensayos aleatorizados espec\u00edficamente en ENKL nasal; sin embargo, los informes de caso y las series de caso peque\u00f1as ofrecen un conocimiento importante sobre nuevos tratamientos potenciales. Presentamos el informe de caso de un paciente con ENKL nasal (previamente mal diagnosticado como una sinusitis cr\u00f3nica recidivante) en quien la enfermedad progres\u00f3 durante la quimioterapia con m\u00faltiples agentes pero respondi\u00f3 al tratamiento de segunda l\u00ednea con pralatrexato como agente \u00fanico. Analizamos opciones de tratamiento para el ENKL nasal recidivante/refractario y sugerimos que el pralatrexato se eval\u00fae m\u00e1s a fondo en este escenario cl\u00ednico.\n[Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016.](https://www.ncbi.nlm.nih.gov/pubmed/28236498)\nMoreno, Santiago; Antela, Antonio; Garc\u00eda, Felipe; Del Amo, Julia; Boix, Vicente; Coll, Pep; Fortuny, Claudia; Sirvent, Juan L G\u00f3mez; Guti\u00e9rrez, F\u00e9lix; Iribarren, Jos\u00e9 A; Llibre, Josep M; Quir\u00f3s, Juan C L\u00f3pez Bernaldo de; Losa, Juan Emilio; Lozano, Ana; Meulbroek, Michael; Olalla, Juli\u00e1n; Pujol, Ferran; Pulido, Federico; Crespo Casal, Manuel; Garc\u00eda, Juan Gonz\u00e1lez; Aldeguer, Jos\u00e9 L\u00f3pez; Molina, Jose A P\u00e9rez; Podzamczer Palter, Daniel; Rom\u00e1n, Antonio Rivero\nAdministration of antiretroviral drugs to individuals exposed to, but not infected by, HIV has been shown to reduce the risk of transmission. The efficacy of pre-exposure prophylaxis (PrEP) makes it obligatory to include it in an integral program of prevention of HIV transmission, together with other measures, such as use of the condom, training, counseling, and appropriate treatment of infected individuals. In this document, the AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica [SEIMC]) provides its views on this important subject. The available evidence on the usefulness of PrEP in the prevention of transmission of HIV is presented, and the components that should make up a PrEP program and whose development and implementation are feasible in Spain are set out. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Linfoma Nasal de C\u00e9lulas T/Natural Killer Extranodal Refractario Mal Diagnosticado, Tratado de Manera Exitosa: Informe de Caso](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5803716)\nSaavedra Ram\u00edrez, Jos\u00e9 Domingo\n2017-01-01\nEl linfoma de c\u00e9lulas T/natural killer extranodal (\u201cextranodal natural killer/T-cell lymphoma\u201d, ENKL) nasal es un linfoma no Hodgkin (LNH) agresivo y poco com\u00fan para el cual no se ha establecido un tratamiento de referencia claro, especialmente en el escenario de la enfermedad recidivante/refractaria. Debido a su rareza, no se han llevado a cabo ensayos aleatorizados espec\u00edficamente en ENKL nasal; sin embargo, los informes de caso y las series de caso peque\u00f1as ofrecen un conocimiento importante sobre nuevos tratamientos potenciales. Presentamos el informe de caso de un paciente con ENKL nasal (previamente mal diagnosticado como una sinusitis cr\u00f3nica recidivante) en quien la enfermedad progres\u00f3 durante la quimioterapia con m\u00faltiples agentes pero respondi\u00f3 al tratamiento de segunda l\u00ednea con pralatrexato como agente \u00fanico. Analizamos opciones de tratamiento para el ENKL nasal recidivante/refractario y sugerimos que el pralatrexato se eval\u00fae m\u00e1s a fondo en este escenario cl\u00ednico. PMID:29430232\n[Living arrangements of the elderly and the sociodemographic and health determinants: a longitudinal study.](https://www.ncbi.nlm.nih.gov/pubmed/27508909)\nBolina, Alisson Fernandes; Tavares, Darlene Mara Dos Santos\n2016-08-08\nde un salario m\u00ednimo disminuye las probabilidades de cambiar la acomodaci\u00f3n domiciliaria en relaci\u00f3n a los que ganan m\u00e1s de tres sueldos (p=0,034). los factores determinantes de la acomodaci\u00f3n domiciliaria fueron el sexo y la ingreso mensual, siendo que las variables capacidad funcional y n\u00famero de enfermedades concomitantes, no estuvieron asociadas al resultado analizado.\n[Musings on \"Densidades, Potenciales y Funciones Asociadas a una Galaxia Reducida\" by Poveda et al. (1960)](http://adsabs.harvard.edu/abs/2011RMxAC..39..100L) [NASA Astrophysics Data System (ADS)](http://adsabs.harvard.edu/abstract_service.html)\nL\u00f3pez-Cruz, O.; Aguilar, L. A.; A\u00f1orve, C.\n2011-04-01\nWe present a critical review on the paper \"Densities, Potentials and related functions for a spherical reduced galaxy\" by A. Poveda, R. Iturriaga, and I. Orozco published in 1960 in the Bolet\u00edn de los Observatorios de Tonantzintla y Tacubaya (BOTT), 2, 20, 3.\n[Breast Cancer Epidemiology in Puerto Rico](http://www.dtic.mil/docs/citations/ADA584895)\n2012-06-01\nestudio no fue disefiado para tratar sus problemas de salud. Sin embargo, su participacion en este estudio es muy importante porque nos ayudar<i a...cigarrillos, exposicion al sol, informacion demogratica, numero de seguro social , historial personal y familiar de enfermedades cronicas, direccion actual e...physical activity, weight history, smoking, sun exposure, demographic characteristics, social security number, personal and familial history of\nHern\u00e1ndez Mosqueira, Claudio; Hern\u00e1ndez Vasquez, Dagoberto; Caniuqueo Vargas, Alexis; Castillo Quezada, Humberto; Fernandes Da Silva, Sandro; Pavez-Adasme, Gustavo; Mart\u00ednez Salazar, Cristian; C\u00e1rcamo-Oyarz\u00fan, Jaime; Fernandes Filho, Jos\u00e9\n2016-11-29\nIntroducci\u00f3n: Chile en las \u00faltimas d\u00e9cadas ha experimentado un cambio en su perfil epidemiol\u00f3gico nutricional, pasando de una situaci\u00f3n caracterizada por una elevada prevalencia de desnutrici\u00f3n y enfermedades infecciosas/parasitarias a otro completamente distinto, en donde las enfermedades cr\u00f3nicas y degenerativas presentan una elevada prevalencia.Objetivo: el objetivo del estudio es elaborar tablas de referencia de aspectos antropom\u00e9tricos y de condici\u00f3n f\u00edsica en estudiantes varones de 10 a 14 a\u00f1os de la ciudad de Chill\u00e1n.M\u00e9todo: estudio descriptivo de corte transversal. La muestra se compone de 1250 varones con edades entre los 10 y 14 a\u00f1os. Para la confecci\u00f3n de las tablas de referencia se utiliz\u00f3 estad\u00edstica descriptiva y estas fueron divididas en cinco clasificaciones desde muy malo, malo, media, bueno y muy bueno, teniendo como par\u00e1metro la edad.Resultados: observamos niveles importantes de sobrepeso que se asociaron con bajo desempe\u00f1o f\u00edsico, lo que plantea la urgencia de realizar un seguimiento en el tiempo con herramientas de f\u00e1cil aplicaci\u00f3n como la presente bater\u00eda; con el fin de detectar a tiempo a los ni\u00f1os que tienen bajos niveles de condici\u00f3n f\u00edsica y tomar medidas orientadas a estimular o mejorar la capacidad f\u00edsica como factores protectores de promoci\u00f3n de la salud y como ayuda en la prevenci\u00f3n de enfermedades cr\u00f3nicas relacionadas con el sobrepeso u obesidad.Conclusi\u00f3n: en este trabajo se han establecido valores de referencia para posteriores estudios en cuanto a la condici\u00f3n f\u00edsica orientada a la salud en estudiantes varones de 10 a 14 a\u00f1os de la ciudad de Chill\u00e1n, que permitir\u00e1n evaluar e interpretar correctamente la condici\u00f3n f\u00edsica orientada a la salud de este grupo etario.\nVila Nova, Larissa Pessoa; Ara\u00fajo Tavares de S\u00e1, Cristiane Maria; Freire Clementino da Silva, Maria Cleide; Lustosa, Marinaldo Freire; Batista de Medeiros, Rafael Augusto; Calado Brito, Daniel; De Ara\u00fajo Burgos, Maria Goretti Pessoa\n2016-07-19\nIntroducci\u00f3n: en los \u00faltimos a\u00f1os la importancia de identificar la resistencia a la insulina (RI) en pacientes con enfermedades cardiovasculares isqu\u00e9micas viene siendo debatida. M\u00e9todos alternativos, como los indicadores antropom\u00e9tricos y de composici\u00f3n corporal, han sido se\u00f1alados como una buena opci\u00f3n y contribuyen para identificar anomal\u00edas metab\u00f3licas y prevenir complicaciones.Objetivo: asociar indicadores antropom\u00e9tricos y de composici\u00f3n corporal como predictores de la resistencia a la insulina (RI) en pacientes con enfermedad de las arterias coronarias.M\u00e9todos: estudio transversal realizado en el hospital de referencia cardiol\u00f3gica de Pernambuco, en el periodo de junio a septiembre de 2014, con pacientes adultos y ancianos hospitalizados, de ambos sexos. Se verificaron los siguientes par\u00e1metros: estilo de vida, la presencia del s\u00edndrome metab\u00f3lico (SM) y otras comorbilidades. Se analiz\u00f3 la RI por el c\u00e1lculo del HOMA-IR. Los pacientes se sometieron a la impedancia bioel\u00e9ctrica (BIA) y a las verificaciones antropom\u00e9tricas.Resultados: la muestra fue constituida por 75 pacientes con edad media de 63,75 \u00b1 12,43 a\u00f1os, con un 64% de ancianos. Se encontr\u00f3 el diagn\u00f3stico de SM en el 65,3% de los pacientes, el 81,3% de sedentarios y el 37,4% con exceso de peso. Se diagnostic\u00f3 la RI en el 28% de los pacientes. Se observ\u00f3 correlaci\u00f3n entre el HOMA-IR y el di\u00e1metro abdominal sagital (DAS) (r = 0,476; p = 0,016), el \u00edndice de masa corporal (r = 0,233; p = 0,040) y el porcentual de grasa corporal (r = 0,276; p = 0,016).Conclusi\u00f3n: el DAS fue el indicador antropom\u00e9trico que present\u00f3 mejor correlaci\u00f3n con la RI en pacientes con enfermedad de las arterias coronarias hospitalizados.\n[Stop Disease: Diapering Procedures = Alto a las Enfermedades: Procedimientos para Cambiar Panales.](http://files.eric.ed.gov/fulltext/ED469408.pdf) [ERIC Educational Resources Information Center](http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced)\nCalifornia Child Care Health Program, Oakland.\nIn order to prevent the occurrence and spread of disease in California child care programs, this set of laminated procedure pages, in English and Spanish versions, details infant and child care procedures for safe diapering. The document delineates important rules about diapering, gives directions for making a disinfecting solution, and provides\u2026\n[C\u00famulos globulares como trazadores de bimodalidad estelar en galaxias cD](http://adsabs.harvard.edu/abs/2002BAAA...45...76F) [NASA Astrophysics Data System (ADS)](http://adsabs.harvard.edu/abstract_service.html)\nForte, J. C.\nSe muestra que tanto la forma de los perfiles de brillo como de color observados en dos galaxias arquet\u00edpicas de tipo cD (NGC 1399 y NGC 4486) son compatibles con la presencia de poblaciones estelares bi-modales que comparten la misma distribuci\u00f3n espacial y composici\u00f3n qu\u00edmica de las familias dominantes de c\u00famulos globulares asociadas con ellas. El modelo resultante tambi\u00e9n predice una variaci\u00f3n de la frecuencia espec\u00edfica de los c\u00famulos como funci\u00f3n del radio galactoc\u00e9ntrico. Se discute este resultado en el contexto de una variedad de escenarios astrof\u00edsicos que intentan describir la formaci\u00f3n de galaxias cD.\nTorres D\u00edaz, Cristina V; Mart\u00edn Pe\u00f1a, Gonzalo; Ezquiaga, Elena; Navas Garc\u00eda, Marta; Garc\u00eda de Sola, Rafael\n2016-07-19\nGracias a los avances t\u00e9cnicos en t\u00e9cnicas neuroquir\u00fargicas, y debido a que el diagn\u00f3stico y la clasificaci\u00f3n de las enfermedades psiqui\u00e1tricas han evolucionado significativamente a lo largo de las \u00faltimas d\u00e9cadas, se est\u00e1n desarrollando tratamientos a nivel experimental para aquellos pacientes resistentes al manejo conservador.La anorexia nerviosa es una enfermedad de prevalencia creciente, con la tasa de mortalidad m\u00e1s elevada dentro de los trastornos psiqui\u00e1tricos, y con aproximadamente un 20% de pacientes que presentan una evoluci\u00f3n t\u00f3rpida. Para estos pacientes que no responden a manejo conservador, la estimulaci\u00f3n cerebral profunda ha surgido como una alternativa terap\u00e9utica, si bien la literatura especializada al respecto es escasa.A continuaci\u00f3n presentamos una revisi\u00f3n de la fisiopatolog\u00eda de la anorexia nerviosa, as\u00ed como de los distintos tratamientos neuroquir\u00fargicos realizados a lo largo de la historia. Se detalla la perspectiva de tratamiento quir\u00fargico actual, as\u00ed como los aspectos \u00e9ticos que se han de considerar en relaci\u00f3n con el surgimiento de estas nuevas terapias.\n[Men's health: non-communicable chronic diseases and social vulnerability.](https://www.ncbi.nlm.nih.gov/pubmed/27533266)\nBidinotto, Daniele Nat\u00e1lia Pacharone Bertolini; Simonetti, Janete Pessuto; Bocchi, Silvia Cristina Mangini\n2016-08-15\nDoen\u00e7as em homens solteiros. Obtiveram-se 21 casos geoestatisticamente significantes de intoler\u00e2ncia \u00e0 glicose na zona urbana. Desses, 62% moravam em regi\u00e3o com a classifica\u00e7\u00e3o de vulnerabilidade social Muito Baixa, 19% M\u00e9dia, 14% Baixa e 5% Alta. observou-se que quanto mais velhos os homens, maior \u00e9 o n\u00famero de doen\u00e7as cr\u00f4nicas instaladas e menos eles faltam em consultas agendadas. Quanto ao uso do geoprocessamento, obteve-se n\u00famero de casos significantes de intoler\u00e2ncia \u00e0 glicose na zona urbana, sendo a maioria classificada como vulnerabilidade social Muito Baixa. P\u00f4de-se relacionar a distribui\u00e7\u00e3o espacial dessas doen\u00e7as com a classifica\u00e7\u00e3o de vulnerabilidade social, por\u00e9m, n\u00e3o foi poss\u00edvel perceber uma rela\u00e7\u00e3o delas com \u00edndices mais elevados de vulnerabilidade social. evaluar la relaci\u00f3n entre las faltas en las citas programadas y el n\u00famero de enfermedades cr\u00f3nicas y para investigar la relaci\u00f3n entre la distribuci\u00f3n espacial de estas enfermedades y la vulnerabilidad social, utilizando geoprocesamiento. estudio cuantitativo de enfoque mixto secuencial y siendo analizadas 158 historias cl\u00ednicas de los usuarios masculinos para relacionar las faltas y 1250 registros de geoprocesamiento. cuanto mayor eran el n\u00famero de ausencias en las citas m\u00e9dicas programadas, menores fueron el n\u00famero, para los hombres solteiros, de enfermedades cr\u00f3nicas y de las inclu\u00eddas en la Clasificaci\u00f3n Internacional de Enfermedades. Se obtuvieron 21 casos de intolerancia a la glucosa geoestad\u00edsticamente significativos en el \u00e1rea urbana. De \u00e9stos, el 62% viven en una regi\u00f3n con calificaci\u00f3n de vulnerabilidad social muy baja 19%, media, 14% baja y 5% Alta. se observ\u00f3 que cuanta mayor la edad de los hombres, mayor es el n\u00famero de enfermedades cr\u00f3nicas instaladas y menos faltas en las citas programadas. Respecto al uso de geoprocesamiento, obtuvimos n\u00famero significativo de casos de intolerancia a la glucosa en las zonas urbanas, la mayor\u00eda clasificada\n[[Extrinsic allergic alveolitis. Clinical experience at the Instituto National de Enfermedades Respiratorias (INER)].](https://www.ncbi.nlm.nih.gov/pubmed/10605257)\nChapela-Mendoza, R; Selman-Lama, M\n1999-01-01\nExtrinsic allergic alveolitis is an interstitial lung disease caused by exposure to a variety of inhaled antigens. In Mexico, the most frequent form is due to the inhalation of avian antigens, markedly pigeon proteins. Depending on type and time exposure, the disease presents different clinical forms usually characterized by progressive dyspnea, ground glass or reticulonodular images on chest x rays, a restrictive functional pattern, rest hypoxemia worsening with exercise, and increase of T lymphocytes in bronchoalveolar lavage with an inversion in the helper/suppressor ratio. In this paper, we discuss a 15-year experience with this pathological problem in Mexico, emphasizing the differences with this disorder in Caucasian populations. Generally, our patients display a chronic form of the disease, which evolves to fibrosis in about one-half of the patients. In this sense, the diagnostic, prognostic, and therapeutic focusing exhibit different elements, and thus the development of clinical and basic research is strongly required.\n[Strengthening relations with Latin American countries through health diplomacy](https://www.cancer.gov/about-nci/organization/cgh/blog/2016/diplomacy)\nAmbassador of Peru to the United States, Luis Miguel Castilla, visited the Center for Global Health (CGH) at the National Cancer Institute a year ago with the objective of strengthening collaboration between US NCI and the Instituto Nacional de Enfermedades Neoplasicas of Peru and Ministry of Health of Peru. As part of this partnership, Ambassador Castilla convened a Roundtable dinner at the Peru Embassy to discuss \u201cThe need for creating and implementing comprehensive cancer control plans in the Latin America region\".\n[Mejoras en el apuntado del telescopio de 2,15 mts de CASLEO](http://adsabs.harvard.edu/abs/1996BAAA...40...44A) [NASA Astrophysics Data System (ADS)](http://adsabs.harvard.edu/abstract_service.html)\nAballay, J. L.; Casagrande, A. R.; Pereyra, P. F.; Mar\u00fan, A. H.\nCon el objeto de optimizar el funcionamiento del telescopio de 2,15 mts. de CASLEO, se est\u00e1n eliminando los motores de calar, de gu\u00eda y mec\u00e1nica asociada. Para \u00e9sto, se est\u00e1n dise\u00f1ando dos electr\u00f3nicas que gobernar\u00e1n, solamente, el motor de slew y el de tracking. Con el control del motor de slew se realizar\u00e1n las funciones de slew y calar, controlando desde una PC la placa que maneja las rampas de velocidad. De este modo, el movimiento ser\u00e1 programado y por lo tanto, m\u00e1s suave y preciso. Con el control del motor de tracking, a trav\u00e9s de un generador de frecuencias programable desde una PC, se proveer\u00e1 los movimientos necesarios para el tracking y gu\u00eda.\n[Executive summary: Diagnosis and Treatment of Catheter-Related Bloodstream Infection: Clinical Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) and the Spanish Society of Intensive Care Medicine and Coronary Units (SEMICYUC).](https://www.ncbi.nlm.nih.gov/pubmed/29412895)\nChaves, Fernando; Garnacho-Montero, Jos\u00e9; Del Pozo, Jos\u00e9 Luis; Bouza, Emilio; Capdevila, Jos\u00e9 Antonio; de Cueto, Marina; Dom\u00ednguez, M \u00c1ngeles; Esteban, Jaime; Fern\u00e1ndez-Hidalgo, Nuria; Fern\u00e1ndez Sampedro, Marta; Fort\u00fan, Jes\u00fas; Guembe, Mar\u00eda; Lorente, Leonardo; Pa\u00f1o, Jose Ram\u00f3n; Ram\u00edrez, Paula; Salavert, Miguel; S\u00e1nchez, Miguel; Vall\u00e9s, Jordi\n2018-02-01\nCatheter-related bloodstream infections (CRBSI) constitute an important cause of hospital-acquired infection associated with morbidity, mortality, and cost. The aim of these guidelines is to provide updated recommendations for the diagnosis and management of CRBSI in adults. Prevention of CRBSI is excluded. Experts in the field were designated by the two participating Societies (Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica and the Sociedad Espa\u00f1ola de Medicina Intensiva, Cr\u00edtica y Unidades Coronarias). Short-term peripheral venous catheters, non-tunneled and long-term central venous catheters, tunneled catheters and hemodialysis catheters are covered by these guidelines. The panel identified 39 key topics that were formulated in accordance with the PICO format. The strength of the recommendations and quality of the evidence were graded in accordance with ESCMID guidelines. Recommendations are made for the diagnosis of CRBSI with and without catheter removal and of tunnel infection. The document establishes the clinical situations in which a conservative diagnosis of CRBSI (diagnosis without catheter removal) is feasible. Recommendations are also made regarding empirical therapy, pathogen-specific treatment (coagulase-negative staphylococci, Sthaphylococcus aureus, Enterococcus spp, Gram-negative bacilli, and Candida spp), antibiotic lock therapy, diagnosis and management of suppurative thrombophlebitis and local complications. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Outbreak of Salmonella Typhimurium infections associated with consumption of chorizo in Bizkaia].](https://www.ncbi.nlm.nih.gov/pubmed/26211840)\nHern\u00e1ndez Arricibita, Esther; Santamaria Zuazua, Rosaura; Ramos L\u00f3pez, Gemma; Herrera-Le\u00f3n, Silvia; K\u00e1rkamo Zu\u00f1eda, Jos\u00e9 Antonio; Muniozguren Agirre, Nerea\n2016-11-01\nA report is presented on an outbreak of Salmonella enterica serovar Typhimurium infection that affected six people. The epidemiological and laboratory investigation associated the outbreak with the consumption of homemade chorizo purchased at a local street market. The vendor and producer were informed that the sale of meat products without sanitary authorization is prohibited, and the product was withdrawn from sale. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Community resilience and Chagas disease in a rural region of Mexico.](https://www.ncbi.nlm.nih.gov/pubmed/27509012)\nRangel, Jos\u00e9 Antonio Santana; Monreal, Luz Arenas; Ramsey, Janine M\n2016-08-04\nTo explore the pillars of community resilience in a region where Chagas disease is endemic, with the aim of promoting participatory processes to deal with this condition from the resilience of the population. Qualitative study using ethnographic record and six interviews of focus groups with young people, women and men. The research was carried out in a rural area of the state of Morelos, Mexico, between 2006 and 2007. We carried out educational sessions with the population in general, so that residents could identify the relationship between the vector Triatoma pallidipennis, the parasite (Trypanosoma cruzi), symptoms, and preventive actions for Chagas disease. The ethnographic record and groups were analyzed based on Taylor and Bogdan's modification, and the focus was to understand the socio-cultural meanings that guide the speeches and activities of residents in relation to the pillars of community resilience. The population felt proud of belonging to that location and three pillars of community resilience were clearly identified: collective self-esteem, cultural identity, and social honesty. Having these pillars as bases, we promoted the participation of the population concerning Chagas disease, and a Community Action Group was formed with young people, adult men and women, and social leaders. This Group initiated actions of epidemiological and entomological surveillance in the community to deal with this problem. It is necessary to create more experiences that deepen the understanding of the pillars of community resilience, and how they contribute to enhance participation in health to deal with Chagas disease. Explorar los pilares de la resiliencia comunitaria en una regi\u00f3n en la que la enfermedad de Chagas es end\u00e9mica, con la finalidad de partir de la resiliencia de la poblaci\u00f3n para impulsar procesos participativos para enfrentar este padecimiento. Estudio cualitativo que utiliz\u00f3 registro etnogr\u00e1fico y seis entrevistas de grupos focales con j\nMIj\u00e1n de la Torre, Alberto\n2016-06-03\nEl s\u00edndrome de caquexia cancerosa es responsable de la muerte de un n\u00famero significativo de pacientes con c\u00e1ncer. Se caracteriza por la presencia de una ingesta reducida, con inflamaci\u00f3n sist\u00e9mica y un metabolismo alterado. Los enfermos presentan caracter\u00edsticamente una progresiva p\u00e9rdida de peso y de masa muscular, junto a deterioro funcional. La p\u00e9rdida muscular se debe a la combinaci\u00f3n de reducci\u00f3n de la s\u00edntesis proteica con aumento de su degradaci\u00f3n. Ello conduce tanto a un acortamiento como a una reducci\u00f3n en el \u00e1rea de la fibra muscular. Asimismo, existen datos que apoyan que selectivamente algunos de los tipos de fibra muscular se ven m\u00e1s afectados. Es necesario definir bien los valores de corte de sarcopenia para diagnosticar la p\u00e9rdida muscular y existen diferentes m\u00e9todos. El sistema de la ubiquitina-proteasoma parece desempe\u00f1ar un papel predominante en la degradaci\u00f3n de la prote\u00edna miofibrilar. La tendencia a perder masa muscular en los pacientes con caquexia cancerosa parece estar asociada a la activaci\u00f3n de se\u00f1ales catab\u00f3licas por citoquinas proinflamatorias, as\u00ed como por productos tumorales del tipo factor inductor de prote\u00f3lisis. En referencia a los factores pron\u00f3sticos, el riesgo de muerte est\u00e1 bien documentado en pacientes con sarcopenia y, especialmente, en aquellos con obesidad asociada a la sarcopenia. Asimismo, se ha establecido una relaci\u00f3n directa entre la p\u00e9rdida intensa de masa muscular y la supervivencia en pacientes con diferentes tipos de tumores del tipo de c\u00e1ncer de p\u00e1ncreas, pulm\u00f3n, tracto biliar o c\u00e1ncer colorrectal. Respecto de la terapia en el s\u00edndrome de caquexia cancerosa, es factible que requiera tratamiento con varios grupos combinados que incluyan, junto al soporte nutricional, f\u00e1rmacos orex\u00edgenos, con efecto anab\u00f3lico y antinflamatorio, asociados a intervenciones que estimulen el ejercicio f\u00edsico.\n[Como Lo Hago Yo: Lipomas Medulares](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3987255)\nPortillo, Santiago\n2014-01-01\nBasados en la experiencia de 82 casos; en 5% se observaron anomal\u00edas p\u00e9lvicas asociadas. En los menores de 3 a\u00f1os el motivo de consulta (85%) fue la tumoraci\u00f3n. En los mayores de 3 a\u00f1os (42%) ten\u00eda problemas neurol\u00f3gicos. Solo el 24% preocupados por la tumoraci\u00f3n. El objetivo de la cirug\u00eda es desanclar la m\u00e9dula y no remover la totalidad del lipoma. El lipoma de filum es el que es mas simple para operar. A\u00fan cuando la escuela francesa propone operar solamente cuando hay s\u00edntomas favorezco cirug\u00eda preventiva. Favorezco una segunda cirug\u00eda si hay signos de anclaje postoperatorio, a\u00fan cuando observamos empeoramiento postoperatorio motor en 2.5% de los operados y urol\u00f3gico a largo plazo en 6% de los operados. PMID:24791218\nMart\u00ednez de Salazar, Pablo; Suy, Anna; S\u00e1nchez-Montalv\u00e1, Adri\u00e1n; Rod\u00f3, Carlota; Salvador, Fernando; Molina, Israel\n2016-04-01\nZika fever is an arboviral systemic disease that has recently become a public health challenge of global concern after its spread through the Americas. This review highlights the current understanding on Zika virus epidemiology, its routes of transmission, clinical manifestations, diagnostic tests, and the current management, prevention and control strategies. It also delves the association between Zika infection and complications, such as microencephaly or Guillem-Barr\u00e9 syndrome. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nBellido, Diego; Bellido, Virginia\n2016-09-20\nEl sobrepeso y la obesidad se definen como un dep\u00f3sito anormal o excesivo de grasa corporal. El aumento de su prevalencia en las \u00faltimas d\u00e9cadas lo convierte en uno de los principales problemas de salud p\u00fablica que afecta a 42 millones de ni\u00f1os menores de 5 a\u00f1os en el mundo. Su presencia durante la infancia puede ser causa de enfermedades metab\u00f3licas hasta ahora consideradas t\u00edpicas del adulto y mortalidad prematura, por lo que su correcto diagn\u00f3stico y tratamiento son fundamentales.\n[[Proteomics in infectious diseases].](https://www.ncbi.nlm.nih.gov/pubmed/25583331)\nQuero, Sara; P\u00e1rraga-Ni\u00f1o, Noem\u00ed; Garc\u00eda-N\u00fa\u00f1ez, Marian; Sabri\u00e0, Miquel\n2016-04-01\nInfectious diseases have a high incidence in the population, causing a major impact on global health. In vitro culture of microorganisms is the first technique applied for infection diagnosis which is laborious and time consuming. In recent decades, efforts have been focused on the applicability of \"Omics\" sciences, highlighting the progress provided by proteomic techniques in the field of infectious diseases. This review describes the management, processing and analysis of biological samples for proteomic research. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Health obligation or health fascism].](https://www.ncbi.nlm.nih.gov/pubmed/29206827)\nSandoval-Guti\u00e9rrez, Jos\u00e9 Luis\n2017-01-01\nEl Dr. Lifshitz presenta un editorial interesante sobre la campa\u00f1a de una regi\u00f3n de Italia que pretend\u00eda que la salud deb\u00eda ser obligatoria y que quien no la obedeciera tendr\u00eda pena de muerte. Esta pretensi\u00f3n, que de entrada resulta simp\u00e1tica, quiz\u00e1 muestra la desesperaci\u00f3n de un sistema de salud que se ve rebasado presupuestalmente con el incremento de la esperanza de vida y, por ende, de la presentaci\u00f3n de enfermedades cr\u00f3nicas degenerativas en la poblaci\u00f3n.\n[[Primary testicular lymphoma: experience at the Instituto Especializado de Enfermedades Neopl\u00e1sicas, Lima-Peru].](https://www.ncbi.nlm.nih.gov/pubmed/19418838)\nD\u00edaz P\u00e9rez, Gilmer A; Pow-Sang Godoy, Mariela; Morante Deza, Carlos; Meza Montoya, Luis; Destefano Urrutia, V\u00edctor\n2009-02-01\nTesticular lymphoma is a rare illness with peculiar characteristics but with a poor prognosis. We evaluated 32 patients retrospectively studying their epidemiologic characteristics, hematologic values, histologic type, metastasis sites, the treatment given and the survival. We compared our results with international reports and we think that prospective studies are needed for better conclusions. The average of age was 45-years-old, with more than the half of patients with clinical stage IV at the moment of the diagnosis, the histiocitic pathology was the most frequent, and the time of survival was 39,543 +/- 14,451 months and the time in which the 50% of the patients die is 15 +/- 7,025 months. This is a rare disease, with a very poor prognosis, with a time of survival of 39,543 +/- 14,451 months and the time in which the 50% of the patients die is 15 +/- 7,025 months.\n[Characterization of multidrug-resistant diabetic foot ulcer enterococci.](https://www.ncbi.nlm.nih.gov/pubmed/25704893)\nSemedo-Lemsaddek, Teresa; Mottola, Carla; Alves-Barroco, Cynthia; Cavaco-Silva, Patr\u00edcia; Tavares, Lu\u00eds; Oliveira, Manuela\n2016-02-01\nDiabetes mellitus is a highly prevalent chronic progressive disease with complications that include diabetic-foot ulcers. Enterococci isolated from diabetic-foot infections were identified, evaluated by macro-restriction analysis, and screened for virulence traits and antimicrobial resistance. All isolates were considered multidrug-resistant, cytolysin and gelatinase producers, and the majority also demonstrated the ability to produce biofilms. These results indicate the importance of enterococci in diabetic-foot infection development and persistence, especially regarding their biofilm-forming ability and resistance to clinically relevant antibiotics. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Comparison of clinical categories for Escherichia coli harboring specific qnr and chromosomal-mediated fluoroquinolone resistance determinants according to CLSI and EUCAST.](https://www.ncbi.nlm.nih.gov/pubmed/25772329)\nMachuca, Jes\u00fas; Briales, Alejandra; D\u00edaz-de-Alba, Paula; Mart\u00ednez-Mart\u00ednez, Luis; Rodr\u00edguez-Mart\u00ednez, Jos\u00e9-Manuel; Pascual, \u00c1lvaro\n2016-03-01\nEUCAST breakpoints are more restrictive than those defined by CLSI. This study highlights the discrepancies between CLSI and EUCAST in a well characterized isogenic Escherichia coli collection and their correlations with specific quinolone resistance mechanisms. The greatest number of discrepancies was observed in strains containing 2-4 resistance mechanisms (MIC values on the borderline of clinical resistance). Bearing in mind that quinolones are concentration dependent antimicrobial agents, small changes in MIC may have relevant consequences for treatment outcomes. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Executive summary. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI).](https://www.ncbi.nlm.nih.gov/pubmed/25976750)\nVidal, Elisa; Cervera, Carlos; Cordero, Elisa; Armi\u00f1anzas, Carlos; Carratal\u00e1, Jordi; Cisneros, Jos\u00e9 Miguel; Fari\u00f1as, M Carmen; L\u00f3pez-Medrano, Francisco; Moreno, Asunci\u00f3n; Mu\u00f1oz, Patricia; Orig\u00fcen, Julia; Sab\u00e9, N\u00faria; Valerio, Maricela; Torre-Cisneros, Juli\u00e1n\n2015-12-01\nUrinary tract infections (UTI) are one of the most common infections in solid organ transplant (SOT) recipients. A systematic review was performed to assess the management of UTI in SOT recipients. Recommendations are provided on the management of asymptomatic bacteriuria, and prophylaxis and treatment of UTI in SOT recipients. The diagnostic-therapeutic management of recurrent UTI and the role of infection in kidney graft rejection or dysfunction are reviewed. Finally, recommendations on antimicrobials and immunosuppressant interactions are also included. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Actitudes Haci la Enfermedad Mental: Revision Bibliografica (Attitudes toward Mental Illness: Revised Bibliography). Publication No. 40.](http://files.eric.ed.gov/fulltext/ED118646.pdf) [ERIC Educational Resources Information Center](http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced)\nStefani, Dorina\nIn this work, some of the most important instruments used to measure attitudes toward mental illness were analysed. A revision of different experimental investigations which studied attitudes toward mental illness among general public, mental health professionals and patients and their relatives was made. Some of the strategies applied to change\u2026\n[[Inherited colorectal cancer predisposition syndromes identified in the Instituto Nacional de Enfermedades Neoplasicas (INEN), Lima, Peru;].](https://www.ncbi.nlm.nih.gov/pubmed/25028899)\nCastro-Mujica, Mar\u00eda del Carmen; Sullcahuam\u00e1n-Allende, Yasser; Barreda-Bola\u00f1os, Fernando; Taxa-Rojas, Luis\n2014-04-01\nColorectal cancer (CRC) is the fourth most common cancer in the world and is classified according to their origin in sporadic CRC (~ 70%) and genetic CRC (~ 30%), this latter involves cases of familial aggregation and inherited s\u00edndromes that predispose to CRC. To describe inherited CRC predisposition syndromes, polyposic and non-polyposic, identified in the Oncogenetics Unit at National Institute of Cancer Disease (INEN). A descriptive observational record from the attentions of the Oncogenetics Unit at INEN during 2009 to 2013. We included patients with personal or familiar history of CRC and/or colonic polyposis who were referred for clinical assessment to the Oncogenetics Unitat INEN. 59.3 % were female, 40.7 % male, 69.8% under 50 years old, 60.5% had a single CRC, 23.2% had more than one CRC or CRC associated with other extracolonic neoplasia and 32.6% had a familiar history of cancer with autosomal dominant inheritance. According to the clinical genetic diagnosis, 93.1% of the included cases were inherited syndromes that predispose to CRC, with 33.8% of colonic polyposis syndromes, 23.3% of hereditary nonpolyposis CRC syndromes (HNPCC) and 36.0% of CCRHNP probable cases. Clinical genetic evaluation of patients with personal or familiar history of CRC and/or colonic polyposis can identify inherited colorectal cancer predisposition syndromes and provide an appropriategenetic counseling to patients and relatives at risk, establishing guidelines to follow-up and prevention strategies to prevent morbidity and mortality by cancer.\nM\u00fcller Vel\u00e1zquez, Luc\u00eda; Bobadilla, Fernando; Novosak, Marina; Cortese, Iliana; Laczeski, Margarita\n2018-03-20\nStreptococcus agalactiae (SGB) es causa de infecciones severas en menores de tres meses. Meningitis, neumon\u00eda y sepsis son los principales cuadros en estos ni\u00f1os. Estas infecciones se encuentran entre las m\u00e1s graves que puede sufrir un individuo en sus primeras doce horas de vida. El ni\u00f1o adquiere la infecci\u00f3n por transmisi\u00f3n vertical de la madre colonizada. Para prevenir la enfermedad neonatal se recomienda penicilina como droga de elecci\u00f3n en la profilaxis intraparto (PIP) en embarazadas colonizadas. Sin embargo, actualmente se han detectado cepas con sensibilidad disminuida a penicilina por lo que resulta importante realizar la vigilancia de la sensibilidad al mismo para asegurar su utilidad durante la profilaxis. El objetivo de este trabajo fue determinar la sensibilidad a penicilina en cepas de SGB recuperados de mujeres embarazadas de 35-37 semanas de gestaci\u00f3n. Se estudiaron 96 aislamientos y se determin\u00f3 la sensibilidad por m\u00e9todo epsilom\u00e9trico Etest\u00ae (LIOFILCHEM, Italia), siguiendo las recomendaciones del Clinical Laboratory Standards Institute (CLSI). Se obtuvo la Concentraci\u00f3n Inhibitoria M\u00ednima (CIM) para cada aislamiento bacteriano. El 100% (96) de las cepas estudiadas fue sensible a penicilina con valores de CIM comprendidos entre 0,012 y 0,094 \u00b5g mL-1. Estos resultados indican que penicilina sigue siendo el antimicrobiano de elecci\u00f3n durante la profilaxis intraparto, para la prevenci\u00f3n de la enfermedad neonatal causada por SGB en nuestra regi\u00f3n. Se destaca la importancia de la vigilancia epidemiol\u00f3gica de la sensibilidad a penicilina y a otros antimicrobianos para alertar sobre nuevos mecanismos de resistencia y adecuar estrategias de tratamiento.\n[CONTAMINACI\u00d3N AMBIENTAL, VARIABILIDAD CLIM\u00c1TICA Y CAMBIO CLIM\u00c1TICO: UNA REVISI\u00d3N DEL IMPACTO EN LA SALUD DE LA POBLACI\u00d3N PERUANA](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4351992)\nGonzales, Gustavo F.; Zevallos, Alisson; Gonzales-Casta\u00f1eda, Cynthia; Nu\u00f1ez, Denisse; Gasta\u00f1aga, Carmen; Cabezas, C\u00e9sar; Naeher, Luke; Levy, Karen; Steenland, Kyle\n2015-01-01\nRESUMEN El presente art\u00edculo es una revisi\u00f3n sobre la contaminaci\u00f3n del agua, el aire y el efecto del cambio clim\u00e1tico en la salud de la poblaci\u00f3n peruana. Uno de los principales contaminantes del aire es el material particulado menor de 2,5 \u03bc (PM 2,5), en la ciudad de Lima, anualmente 2300 muertes prematuras son atribuibles a este contaminante. Otro problema es la contaminaci\u00f3n del aire domiciliario por el uso de cocinas con combustible de biomasa, donde la exposici\u00f3n excesiva a PM 2,5 dentro de las casas es responsable de aproximadamente 3000 muertes prematuras anuales entre adultos, con otro n\u00famero desconocido de muertes entre ni\u00f1os debido a infecciones respiratorias. La contaminaci\u00f3n del agua tiene como principales causas los desag\u00fces vertidos directamente a los r\u00edos, minerales (ars\u00e9nico) de varias fuentes, y fallas de las plantas de tratamiento. En el Per\u00fa, el cambio clim\u00e1tico puede impactar en la frecuencia y severidad del fen\u00f3meno de El Ni\u00f1o oscilaci\u00f3n del sur (ENSO) que se ha asociado con un incremento en los casos de enfermedades como c\u00f3lera, malaria y dengue. El cambio clim\u00e1tico incrementa la temperatura y puede extender las \u00e1reas afectadas por enfermedades transmitidas por vectores, adem\u00e1s de tener efecto en la disponibilidad del agua y en la contaminaci\u00f3n del aire. En conclusi\u00f3n, el Per\u00fa, pasa por una transici\u00f3n de factores de riesgo ambientales, donde coexisten riesgos tradicionales y modernos, y persisten los problemas infecciosos y cr\u00f3nicos, algunos de los cuales se asocian con problemas de contaminaci\u00f3n de agua y de aire. PMID:25418656\nBeas, Renato; Anduaga-Beramendi, Alexander; Maticorena-Quevedo, Jesus; Mayta-Trist\u00e1n, Percy\n2018-03-26\nObjetivo: Identificar los factores asociados al S\u00edndrome de Burnout (SB) en trabajadores de salud del Per\u00fa en el a\u00f1o 2014.M\u00e9todos: Estudio transversal anal\u00edtico mediante un an\u00e1lisis secundario de la Encuesta Nacional de Usuarios de Salud del a\u00f1o 2014 en Per\u00fa. El SB fue medido mediante el Maslach Burnout Inventory - Human Services Survey (MBI-HSS). Se realiz\u00f3 un an\u00e1lisis descriptivo, tambi\u00e9n un an\u00e1lisis bivariado y multivariado calculando los valores de p y los OR crudos y ajustados mediante Regresi\u00f3n Log\u00edstica.Resultados: La prevalencia del SB en los profesionales de la salud fue 2,8%, encontr\u00e1ndose asociadas las variables: g\u00e9nero, tiempo en el sector salud, horas de trabajo e ingreso mensual total.Conclusiones: Se encontr\u00f3 que los factores asociados al SB en el personal de Per\u00fa en el a\u00f1o 2014 fueron el g\u00e9nero, el tiempo en el sector salud, las horas de trabajo y el ingreso mensual total.\nBurgos, Rosa\n2016-03-25\nLa desnutrici\u00f3n relacionada con la enfermedad (DRE) es un problema sanitario de elevada \u00edndole que impacta fuertemente en la morbilidad, mortalidad y calidad de vida de los pacientes ancianos ingresados en el hospital. Adem\u00e1s, incrementa enormemente el gasto sanitario, sobre todo a trav\u00e9s del aumento de la estancia hospitalaria, incremento de las complicaciones y necesidad de centro de convalecencia u otros recursos sanitarios al alta hospitalaria. Conjuntamente con la osteoporosis y la sarcopenia, contribuye de forma directa a la discapacidad y a la p\u00e9rdida de autonom\u00eda del anciano, con las repercusiones familiares y sociales que ello implica.\n[Publisher Correction: Reactive oxygen species regulate axonal regeneration through the release of exosomal NADPH oxidase 2 complexes into injured axons.](https://www.ncbi.nlm.nih.gov/pubmed/29520084)\nHervera, Arnau; De Virgiliis, Francesco; Palmisano, Ilaria; Zhou, Luming; Tantardini, Elena; Kong, Guiping; Hutson, Thomas; Danzi, Matt C; Perry, Rotem Ben-Tov; Santos, Celio X C; Kapustin, Alexander N; Fleck, Roland A; Del R\u00edo, Jos\u00e9 Antonio; Carroll, Thomas; Lemmon, Vance; Bixby, John L; Shah, Ajay M; Fainzilber, Mike; Di Giovanni, Simone\n2018-03-08\nIn the version of this Article originally published, the affiliations for Roland A. Fleck and Jos\u00e9 Antonio Del R\u00edo were incorrect due to a technical error that resulted in affiliations 8 and 9 being switched. The correct affiliations are: Roland A. Fleck: 8 Centre for Ultrastructural Imaging, Kings College London, London, UK. Jos\u00e9 Antonio Del R\u00edo: 2 Cellular and Molecular Neurobiotechnology, Institute for Bioengineering of Catalonia, Barcelona, Spain; 9 Department of Cell Biology, Physiology and Immunology, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain; 10 Centro de Investigaci\u00f3n Biom\u00e9dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain. This has now been amended in all online versions of the Article.\n[Postinfectious bronchiolitis obliterans](https://www.ncbi.nlm.nih.gov/pubmed/29775038)\n2018-06-01\nLa bronquiolitis obliterante es una enfermedad pulmonar cr\u00f3nica infrecuente y grave producto de una lesi\u00f3n del tracto respiratorio inferior. En nuestro pa\u00eds, es m\u00e1s frecuente observarla secundaria a una lesi\u00f3n viral grave, en especial, por adenovirus. La bronquiolitis obliterante se caracteriza por la oclusi\u00f3n parcial o total del lumen de los bronquiolos respiratorios y terminales por tejido inflamatorio y fibrosis, que produce la obstrucci\u00f3n cr\u00f3nica de la v\u00eda a\u00e9rea. Este consenso discute el estado actual del conocimiento en las diferentes \u00e1reas de la bronquiolitis obliterante secundaria a una lesi\u00f3n infecciosa.\n[Presence of quinolone resistance to qnrB1 genes and blaOXA-48 carbapenemase in clinical isolates of Klebsiella pneumoniae in Spain.](https://www.ncbi.nlm.nih.gov/pubmed/24746402)\nRodr\u00edguez Mart\u00ednez, J M; D\u00edaz-de Alba, P; Lopez-Cerero; Ruiz-Carrascoso, G; Gomez-Gil, R; Pascual, A\n2014-01-01\nA study is presented on the presence of quinolone resistance qnrB1 genes in clinical isolates belonging to the largest series of infections caused by OXA-48-producing Klebsiella pneumoniae in a single-centre outbreak in Spain. Evidence is also provided, according to in vitro results, that there is a possibility of co-transfer of plasmid harbouring blaOXA-48 with an other plasmid harbouring qnrB1 in presence of low antibiotic concentrations of fluoroquinolones, showing the risk of multi-resistance screening. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Tendencia de los egresos hospitalarios por enfermedades infecciosas intestinales en ni\u00f1os en Argentina, 2005-2013.](https://www.ncbi.nlm.nih.gov/pubmed/28737863)\nDegiuseppe, Juan I\n2017-08-01\nAcute diarrhea is one of the most serious public health problems in developing countries because it is generally associated with unfavorable living conditions. The objective of this study was to analyze trends in hospital discharges for intestinal infectious disease in children under age 5 recorded in official public hospitals from Argentina in the 2005-2013 period. This was an ecological, time-series study based on data provided by the Health Statistics and Information Department, at a national and regional level. Specific hospital discharge rates were estimated, and seasonal behavior and trends were analyzed in relation to this event. In Argentina, 2 521 729 patients under age 5 were discharged in this period; of these, 9.0% were diagnosed with intestinal infectious disease. Children under age 1 accounted for a third of hospitalizations; two annual peaks (summer and winter) were observed in the seasonality analysis. Overall, a downward trend was observed, with a mild increase in the 2007-2009 period. Rates were up to 3 or 4 times higher in Northwest and Northeast Argentina than in the Pampa region. Hospital discharges for intestinal infectious disease in the public subsector account for approximately 10% of all discharges of children under age 5. This event shows a seasonal pattern, with a slightly downward trend over the past years in spite of its heterogeneous distribution across the different Argentine regions. Sociedad Argentina de Pediatr\u00eda\n[Lesiones subcut\u00e1neas dolorosas en paciente con melanoma metast\u00e1sico: un caso de paniculitis linfoc\u00edtica asociado a vemurafenib.](https://www.ncbi.nlm.nih.gov/pubmed/29469793)\nBenavente-Villegas, Felipe; Ferrando-Roca, Francisco; Dolz-Gait\u00f3n, Raquel; Royo-Peir\u00f3, Mar\u00eda\n2017-10-15\nVemurafenib ha probado ser una herramienta \u00fatil en el tratamiento de melanoma metast\u00e1sico con mutaci\u00f3n BRAF-V600E. Los efectos adversos incluyen artralgias, fatiga y toxicidad cut\u00e1nea, siendo infrecuente la paniculitis. Presentamos el caso de una paciente de 43 a\u00f1os con melanoma metast\u00e1sico que desarrolla lesiones subcut\u00e1neas dolorosas en miembros inferiores y superiores, asociadas a cl\u00ednica sist\u00e9mica despu\u00e9s de 2 semanas de inicio de tratamiento con Vemurafenib + Cobimetinib. La histolog\u00eda demostr\u00f3 paniculitis linfocitaria septal y lobulillar. La paciente tuvo mala tolerancia al tratamiento anti diana a dosis plenas, requiriendo su ajuste, generando una corticodependencia para controlar sintomatolog\u00eda, y que finalmente oblig\u00f3 a la descontinuaci\u00f3n de la terapia dirigida contra melanoma. A la fecha, se han descrito 29 casos en la literatura de paniculitis asociada a vemurafenib, siendo la mayor\u00eda paniculitis neutrof\u00edlicas con adecuado control de sintomatolog\u00eda asociando antiinflamatorios no esteroidales y/o corticoides orales sin requerir en su mayor\u00eda modificaci\u00f3n de la terapia contra melanoma; sin embargo hay que tener presente que pueden haber casos con mala evoluci\u00f3n que obligan a la reducci\u00f3n de dosis de vemurafenib y descontinuar el tratamiento, como ha ocurrido en nuestro reporte.Vemurafenib has proven to be a useful tool in the treatment of metastatic melanoma with BRAF-V600E mutation. Adverse effects include arthralgia, fatigue, and skin toxicity; panniculitis is a rare complication. We present the case of a 43-year-old patient with metastatic melanoma who developed painful subcutaneous nodules of the lower and upper limbs and associated systemic clinical symptoms after 2 weeks of treatment with vemurafenib plus cobimetinib. Histology showed a septal and lobular lymphocytic panniculitis.The patient had poor tolerance of the full-dose treatment, requiring its adjustment. Systemic corticosteroids were required to control symptomatology\n[DESAF\u00cdOS \u00c9TICOS DE LA INVESTIGACI\u00d3N CON ANIMALES, MANIPULACI\u00d3N GEN\u00c9TICA](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3711750)\nYunta, Eduardo Rodr\u00edguez\n2012-01-01\nEn la investigaci\u00f3n con animales existen cuestionamientos \u00e9ticos tanto en el uso como modelos de enfermedades humanas y requisito previo para ensayos en humanos como en la introducci\u00f3n de modificaciones gen\u00e9ticas. Algunos de estos cuestionamientos son: no representar exactamente la condici\u00f3n humana como modelos, realizar pruebas de toxicidad con grave da\u00f1o para los animales, alterar su naturaleza mediante modificaciones gen\u00e9ticas, riesgos de la introducci\u00f3n de organismos gen\u00e9ticamente modificados. El uso de animales en investigaci\u00f3n para beneficio humano, impone al ser humano la responsabilidad moral de respetarlo, no haci\u00e9ndoles sufrir innecesariamente, al estar trabajando con seres vivientes y sentientes. PMID:23338641\n[Autochthonous Crimean-Congo Hemorrhagic Fever in Spain.](https://www.ncbi.nlm.nih.gov/pubmed/28700843)\nNegredo, Anabel; de la Calle-Prieto, Fernando; Palencia-Herrej\u00f3n, Eduardo; Mora-Rillo, Marta; Astray-Mochales, Jenaro; S\u00e1nchez-Seco, Mar\u00eda P; Bermejo Lopez, Esther; Men\u00e1rguez, Javier; Fern\u00e1ndez-Cruz, Ana; S\u00e1nchez-Artola, Beatriz; Keough-Delgado, Elena; Ram\u00edrez de Arellano, Eva; Lasala, F\u00e1tima; Milla, Jakob; Fraile, Jose L; Ordob\u00e1s Gav\u00edn, Maria; Martinez de la G\u00e1ndara, Amalia; L\u00f3pez Perez, Lorenzo; Diaz-Diaz, Domingo; L\u00f3pez-Garc\u00eda, M Aurora; Delgado-Jimenez, Pilar; Mart\u00edn-Quir\u00f3s, Alejandro; Trigo, Elena; Figueira, Juan C; Manzanares, Jes\u00fas; Rodriguez-Baena, Elena; Garcia-Comas, Luis; Rodr\u00edguez-Fraga, Olaia; Garc\u00eda-Arenzana, Nicol\u00e1s; Fern\u00e1ndez-D\u00edaz, Maria V; Cornejo, Victor M; Emmerich, Petra; Schmidt-Chanasit, Jonas; Arribas, Jose R\n2017-07-13\nCrimean-Congo hemorrhagic fever (CCHF) is a widely distributed, viral, tickborne disease. In Europe, cases have been reported only in the southeastern part of the continent. We report two autochthonous cases in Spain. The index patient acquired the disease through a tick bite in the province of \u00c1vila - 300 km away from the province of C\u00e1ceres, where viral RNA from ticks was amplified in 2010. The second patient was a nurse who became infected while caring for the index patient. Both were infected with the African 3 lineage of this virus. (Funded by Red de Investigaci\u00f3n Cooperativa en Enfermedades Tropicales [RICET] and Efficient Response to Highly Dangerous and Emerging Pathogens at EU [European Union] Level [EMERGE].).\n[Risk factors for antimicrobial-resistant Neisseria gonorrhoeae and characteristics of patients infected with gonorrhea.](https://www.ncbi.nlm.nih.gov/pubmed/28094065)\nFuertes de Vega, Irene; Baliu-Piqu\u00e9, Carola; Bosch Mestres, Jordi; Vergara G\u00f3mez, Andrea; Vall\u00e9s, Xavier; Alsina Gibert, Merc\u00e8\n2018-03-01\nThere are very few data available regarding risk factors associated with antibiotic resistant-Neisseria gonorrhoeae. A study was conducted on 110 samples from 101 patients with gonococcal infection, in order to describe their characteristics and compare them with the antimicrobial susceptibility profile of their samples. An association was observed between resistant infections and heterosexual men, older age, concurrent sexually transmitted infection, and unsafe sexual behaviors. There is a need for improved data on the risk factors associated with antibiotic resistant gonococcal infection in order to identify risk groups, and to propose public health strategies to control this infection. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Observaciones de la corona solar interior con un coron\u00f3grafo de espejo](http://adsabs.harvard.edu/abs/1999BAAA...43...22S) [NASA Astrophysics Data System (ADS)](http://adsabs.harvard.edu/abstract_service.html)\nStenborg, G.; Schwenn, R.; Francile, C.; Rovira, M.\nEl plasma de la corona solar es un buen indicador de las l\u00edneas de fuerza del campo magn\u00e9tico. Por lo tanto, el an\u00e1lisis de estructuras coronales cuasiestacionarias en la corona da importante informaci\u00f3n sobre el campo magn\u00e9tico y la actividad asociada. Se trata de poner l\u00edmites a los modelos te\u00f3ricos existentes mediante el estudio de distintas estructuras en la corona interior. En agosto de 1997 comenz\u00f3 a operar el coron\u00f3grafo solar (MICA) en El Leoncito como parte del Observatorio Solar Alem\u00e1n-Argentino. Desde su instalaci\u00f3n obtiene im\u00e1genes de la corona solar (1.05 a 2.0 radios solares) en 2 l\u00edneas espectrales correspondientes a la emisi\u00f3n de Fe XIV y Fe X. El instrumento puede obtener im\u00e1genes cada minuto por lo que es ideal para estudiar procesos r\u00e1pidos. Presentamos observaciones recientes que muestran la capacidad del coron\u00f3grafo as\u00ed como la evoluci\u00f3n de algunos eventos din\u00e1micos observados por MICA.\n[American woodcock (Scolopax minor) mortality associated with a reovirus](http://www.jstor.org/stable/1592132)\nDocherty, D.E.; Converse, K.A.; Hansen, W.R.; Norman, G.W.\n1994-01-01\nA virus isolate associated with a 1989-90 die-off in American woodcock (Scolopax minor) was identified as a reovirus. Emaciation was a consistent necropsy finding in the woodcock involved in this die-off. This reovirus infection appeared to be systemic, had the potential for fecal-oral virus transmission, and was associated with deterioration of body condition. To our knowledge this is the first report of a virus isolate from wild American woodcock. A survey conducted in 1990-92 indicated that this virus was not present at detectable levels in the woodcock breeding and wintering population. /// Un virus asociado con la mortalidad de becadas o perdices americanas (Scolopax minor) en 1989-1990-fue identificado como reovirus. La emaciaci??n fue un resultado com??n a la necropsia de las aves que murieron. Esta infecci??n por reovirus pareci?? ser sist??mica, ten?-a el potencial de transmisi??n fecal-oral y estuvo asociada con el deterioro del ave. Creemos que este sea el primer reporte de aislamiento viral a partir de becadas americanas. Una encuesta hecha entre 1990 y 1992 indic?? que este virus no estaba presente en los niveles detectables en los reproductores y en las aves invernales.\n[Guidelines for Clinical Practice: Hymenoptera sting allergy in children: 2017 update](https://www.ncbi.nlm.nih.gov/pubmed/29775033)\n2017-10-01\nLas picaduras por himen\u00f3pteros son frecuentes en la infancia. La mayor\u00eda producen reacciones locales, consecuencia de un mecanismo inflamatorio, no al\u00e9rgico, no tienen progresi\u00f3n y se resuelven con simples medidas terap\u00e9uticas. Las reacciones m\u00e1s extensas, generalmente, est\u00e1n asociadas a mecanismos al\u00e9rgicos, mediados por inmunoglobulina E. Su m\u00e1xima expresi\u00f3n, la anafilaxia, presenta s\u00edntomas cut\u00e1neos, respiratorios, cardiovasculares, digestivos y/o neurol\u00f3gicos, con riesgo de muerte. La prevalencia de anafilaxia en pacientes con mastocitosis sist\u00e9mica es m\u00e1s alta. La familia Hymenoptera, que incluye hormigas coloradas, abejas y avispas, es la causante de las picaduras de mayor riesgo, potencialmente fatales. Los pilares del diagn\u00f3stico son la historia cl\u00ednica, la identificaci\u00f3n del insecto, y las pruebas diagn\u00f3sticas cut\u00e1neas y/o in vitro interpretadas por el especialista en Alergia e Inmunolog\u00eda. La inmunoterapia con veneno es el tratamiento de elecci\u00f3n para prevenir reacciones anafil\u00e1cticas por picaduras de himen\u00f3pteros.\n[Cobertura de los sistemas de pensiones y factores asociados al acceso a una pensi\u00f3n de jubilaci\u00f3n en M\u00e9xico](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4979598)\nMurillo-L\u00f3pez, Sandra; Venegas-Mart\u00ednez, Francisco\n2016-01-01\nResumen Objetivos: obtener estimaciones de indicadores de cobertura de las pensiones por jubilaci\u00f3n o retiro para la poblaci\u00f3n mexicana de 65 y m\u00e1s a\u00f1os, y evaluar el impacto que tienen los sistemas de pensiones en las transiciones al retiro de los adultos en edades medias y avanzadas en M\u00e9xico. Para ello se utilizan datos microecon\u00f3micos provenientes de la Encuesta Nacional de Salud y Envejecimiento. Mediante an\u00e1lisis econom\u00e9trico se identifican los factores sociodemogr\u00e1ficos, econ\u00f3micos, laborales e institucionales que est\u00e1n asociados al acceso a una pensi\u00f3n de jubilaci\u00f3n, o bien, a la dependencia de otras fuentes de ingresos. Se encontr\u00f3 que, en M\u00e9xico, las transiciones al retiro del mercado de trabajo en las etapas avanzadas del ciclo de vida son limitadas debido a las caracter\u00edsticas eminentemente contributivas de los esquemas de pensiones, los cuales favorecen a la poblaci\u00f3n con trayectorias laborales formales y m\u00e1s estables asociadas a: caracter\u00edsticas de g\u00e9nero, oportunidades educativas y posibilidades de inserci\u00f3n en el mercado laboral. PMID:27524936\nValeria Cort\u00e9s, F.; Jaime P\u00e9rez, A.; Lilian Ferrer, L.; Rosina Cianelli, A.; B\u00e1ltica Cabieses, V.\n2009-01-01\nResumen VIH/SIDA es una pandemia que afecta a hombres, mujeres y ni\u00f1os, pero que presenta una tendencia hacia la feminizaci\u00f3n, afectando especialmente a mujeres j\u00f3venes. Su consecuencia es el aumento de la transmisi\u00f3n vertical, durante el embarazo, parto o lactancia materna. Este estudio bibliogr\u00e1fico describe la relaci\u00f3n entre VIH/SIDA y lactancia materna, explicitando factores que influyen en la elecci\u00f3n de la modalidad de alimentaci\u00f3n de madres viviendo con VIH/SIDA. Se describen causas de morbimortalidad infantil asociada y recomendaciones internacionales de lactancia en mujeres con VIH/SIDA. En un mundo globalizado con constantes migraciones poblacionales, estos resultados representan un llamado de atenci\u00f3n para profesionales de salud quienes deben considerar factores sociales que influenciar\u00e1n la toma de decisi\u00f3n de madres viviendo con VIH/SIDA al escoger la modalidad de lactancia. No s\u00f3lo basta conocer el riesgo de transmisi\u00f3n vertical, sino que se debe tomar conciencia de aquellos factores din\u00e1micos y espec\u00edficos de cada comunidad. PMID:20046815\nSantos, Carla Adriana; Fonseca, Jorge; Carolino, Elisabete; Lopes, Teresa; Sousa Guerreiro, Ant\u00f3nio\n2016-03-25\nIntroducci\u00f3n y objetivos: el cobre (Cu) es un oligoelemento muy estudiado, pero poco se sabe de su evoluci\u00f3n en los pacientes alimentados por gastrostom\u00eda endosc\u00f3pica (GEP). Pretendemos evaluar la evoluci\u00f3n del Cu s\u00e9rico desde la gastrostom\u00eda hasta 12 semanas despu\u00e9s de la intervenci\u00f3n en estos pacientes alimentados con preparaciones dom\u00e9sticas. M\u00e9todos: realizamos un estudio observacional prospectivo para evaluar el Cu s\u00e9rico, la alb\u00famina, la transferrina y el \u00edndice de masa corporal (IMC) en el momento de la GEP, tras 4 semanas y 12 semanas despu\u00e9s de la intervenci\u00f3n. Los datos incluyen edad, g\u00e9nero, NRS 2002 y enfermedad subyacente: c\u00e1nceres de cabeza y cuello (CCC) y disfagia neurol\u00f3gica (DN). Despu\u00e9s de la intervenci\u00f3n, estos pacientes fueron alimentados conpreparaciones dom\u00e9sticas. Resultados: 146 enfermos (89 hombres), entre 21-95 a\u00f1os: CCC-56, DN-90. Valores de Cu entre 42-160 \u03bcg/dl (normal: 70-140 \u03bcg/dl); normales 89% (n = 130); bajos 11% (n = 16), alb\u00famina baja: 53% (n = 77), transferrina baja: 65% (n = 94), IMC bajo: 53% (n = 78). Despu\u00e9s de 4 semanas: valores normales de Cu en 93% y bajos en 7%, alb\u00famina baja en 34%, transferrina baja en 52%. Tras 12 semanas: valores normales de Cu en 95% y bajos en 5%, alb\u00famina baja en 25%, transferrina baja en 32%. No encontramos diferencias significativas en el Cus\u00e9rico cuando se compara edad, g\u00e9nero, enfermedad subyacente, IMC, alb\u00famina y transferrina. Conclusiones: la mayor\u00eda de los enfermos presentan Cu s\u00e9rico normal en el momento de la gastrostom\u00eda. Para los enfermos con Cu s\u00e9rico bajo antes del procedimiento, la alimentaci\u00f3n con preparaciones dom\u00e9sticas parece suficiente para su normalizaci\u00f3n progresiva.\n[Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.](https://www.ncbi.nlm.nih.gov/pubmed/26933750)\nGuerra, Iv\u00e1n; P\u00e9rez-Jeldres, Tamara; Iborra, Marisa; Algaba, Alicia; Monfort, David; Calvet, Xavier; Chaparro, Mar\u00eda; Ma\u00f1osa, Miriam; Hinojosa, Esther; Minguez, Miguel; Ortiz de Zarate, Jone; M\u00e1rquez, Luc\u00eda; Prieto, Vanessa; Garc\u00eda-S\u00e1nchez, Valle; Guardiola, Jordi; Rodriguez, G Esther; Mart\u00edn-Arranz, Mar\u00eda Dolores; Garc\u00eda-Tercero, Iv\u00e1n; Sicilia, Beatriz; Masedo, \u00c1ngeles; Lorente, Rufo; Rivero, Montserrat; Fern\u00e1ndez-Salazar, Luis; Guti\u00e9rrez, Ana; Van Domselaar, Manuel; L\u00f3pez-SanRom\u00e1n, Antonio; Ber, Yolanda; Garc\u00eda-Sepulcre, Marif\u00e9; Ramos, Laura; Bermejo, Fernando; Gisbert, Javier P\n2016-04-01\nPsoriasis induced by anti-tumor necrosis factor-\u03b1 (TNF) therapy has been described as a paradoxical side effect. To determine the incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in a large nationwide cohort of inflammatory bowel disease patients. Patients with inflammatory bowel disease were identified from the Spanish prospectively maintained Estudio Nacional en Enfermedad Inflamatoria Intestinal sobre Determinantes gen\u00e9ticos y Ambientales registry of Grupo Espa\u00f1ol de Trabajo en Enfermedad de Croh y Colitis Ulcerosa. Patients who developed psoriasis by anti-TNF drugs were the cases, whereas patients treated with anti-TNFs without psoriasis were controls. Cox regression analysis was performed to identify predictive factors. Anti-TNF-induced psoriasis was reported in 125 of 7415 patients treated with anti-TNFs (1.7%; 95% CI, 1.4-2). The incidence rate of psoriasis is 0.5% (95% CI, 0.4-0.6) per patient-year. In the multivariate analysis, the female sex (HR 1.9; 95% CI, 1.3-2.9) and being a smoker/former smoker (HR 2.1; 95% CI, 1.4-3.3) were associated with an increased risk of psoriasis. The age at start of anti-TNF therapy, type of inflammatory bowel disease, Montreal Classification, and first anti-TNF drug used were not associated with the risk of psoriasis. Topical steroids were the most frequent treatment (70%), achieving clinical response in 78% of patients. Patients switching to another anti-TNF agent resulted in 60% presenting recurrence of psoriasis. In 45 patients (37%), the anti-TNF therapy had to be definitely withdrawn. The incidence rate of psoriasis induced by anti-TNF therapy is higher in women and in smokers/former smokers. In most patients, skin lesions were controlled with topical steroids. More than half of patients switching to another anti-TNF agent had recurrence of psoriasis. In most patients, the anti-TNF therapy could be maintained.\n[Fuentes de variabilidad en el diagn\u00f3stico de gastritis atr\u00f3fica multifocal asociada con la infecci\u00f3n por Helicobacter pylori1](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4176920)\nBravo, Luis Eduardo; Bravo, Juan Carlos; Realpe, Jos\u00e9 Luis; Zarama, Guillermo; Piazuelo, Mar\u00cda Blanca; Correa, Pelayo\n2014-01-01\nRESUMEN Introducci\u00f3n El mapeo de las diferentes regiones del est\u00f3mago y el n\u00famero de fragmentos de mucosa g\u00e1strica disponibles para evaluaci\u00f3n histopatol\u00f3gica son fuentes importantes de variaci\u00f3n en el momento de clasificar y hacer la gradaci\u00f3n de la gastritis cr\u00f3nica. Objetivos Estimar la sensibilidad del n\u00famero de fragmentos de mucosa g\u00e1strica necesarios para establecer los diagn\u00f3sticos de gastritis atr\u00f3fica con metaplasia intestinal (MI), displasia y estado de infecci\u00f3n por Helicobacter pylori. Adem\u00e1s evaluar la variabilidad intra-observador en la clasificaci\u00f3n de estas lesiones precursoras del c\u00e1ncer g\u00e1strico. Materiales y m\u00e9todos En una cohorte de 6 a\u00f1os de seguimiento se evaluaron 1,958 procedimientos de endoscopia realizados por dos gastroenter\u00f3logos. En cada procedimiento y de cada participante se obtuvieron 5 biopsias de mucosa g\u00e1strica que representaban antro, incisura angularis y cuerpo. Un \u00fanico pat\u00f3logo hizo la interpretaci\u00f3n histol\u00f3gica de las 5 biopsias y proporcion\u00f3 un diagn\u00f3stico definitivo global que se utiliz\u00f3 como patr\u00f3n de referencia. Cada fragmento de mucosa g\u00e1strica examinado condujo a un diagn\u00f3stico individual para cada biopsia que se compar\u00f3 con el patr\u00f3n de referencia. La variabilidad intra-observador se evalu\u00f3 en 127 personas que corresponden a una muestra aleatoria de 20% del total de endoscopias hechas a los 72 meses de seguimiento. Resultados La sensibilidad del diagn\u00f3stico de MI y displasia g\u00e1strica aument\u00f3 de manera significativa con el n\u00famero de fragmentos de mucosa g\u00e1strica evaluados El sitio anat\u00f3mico de mayor sensibilidad para el diagn\u00f3stico de MI y displasia fue la incisura angularis. Para descubrir H. pylori se logr\u00f3 alta sensibilidad con el estudio de un solo fragmento de mucosa g\u00e1strica (95.9%) y fue independiente del sitio de obtenci\u00f3n de la biopsia. El acuerdo intra-observador para el diagn\u00f3stico de gastritis cr\u00f3nica fue 86.1% con valor kappa de 0.79 IC 95% (0.76-0.85). Las biopsias fijadas en alcohol fueron inadecuadas para demostrar H. pylori e interpretar los cambios de displasia. Conclusi\u00f3n El n\u00famero de fragmentos de mucosa g\u00e1strica evaluados, el m\u00e9todo de fijaci\u00f3n y la regi\u00f3n del est\u00f3mago donde se obtienen las biopsias son factores muy importantes para lograr una correcta clasificaci\u00f3n de la gastritis cr\u00f3nica atr\u00f3fica multifocal. PMID:25267864\n[[Monitoring respiratory syncytial virus through the Spanish influenza surveillance system, 2006-2014].](https://www.ncbi.nlm.nih.gov/pubmed/25703209)\nJim\u00e9nez-Jorge, Silvia; Delgado-Sanz, Concepci\u00f3n; de Mateo, Salvador; Pozo, Francisco; Casas, Inmaculada; Larrauri, Amparo\n2016-02-01\nThe aim of the study is to analyze the information on respiratory syncytial virus (RSV) obtained through the Spanish Influenza Surveillance System (SISS) and to study its usefulness as supplementary information for the characterization of influenza epidemics. The temporal patterns of both RSV and influenza viruses were analyzed by patterns comparing the weekly viral detection rates from 2006 to 2014. In general, the RSV circulation was characterized by showing a peak between 52-1 weeks, and circulated from 2 to 8 weeks before/prior to influenza viruses. RSV information obtained from the SISS is useful for the characterization of influenza epidemics in Spain. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Analysis of the results of the SEIMC External Quality Control Program. Year 2011].](https://www.ncbi.nlm.nih.gov/pubmed/23453224)\nRuiz de Gopegui Bordes, Enrique; Guna Serrano, M del Remedio; Orta Mira, Nieves; Ovies, Mar\u00eda Rosario; Poveda, Marta; Gimeno Cardona, Concepci\u00f3n\n2013-02-01\nThe External Quality Control Program of the Spanish Society of Infectious Diseases and Clinical Microbiology (Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica [SEIMC]) includes controls for bacteriology, serology, mycology, parasitology, mycobacteria, virology, and molecular microbiology. This article presents the most relevant conclusions and lessons from the 2011 controls. Overall, the results obtained in 2011 confirm the excellent skill and good technical standards found in previous years. Nevertheless, erroneous results can be obtained in any laboratory and in clinically relevant determinations. The results of this program highlight the need to implement both internal and external controls, such as those offered by the SEIMC program, in order to ensure maximal quality of microbiological tests. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. All rights reserved.\n[[Microbiological diagnosis of HIV infection].](https://www.ncbi.nlm.nih.gov/pubmed/18053474)\nL\u00f3pez-Bernaldo de Quir\u00f3s, Juan Carlos; Delgado, Rafael; Garc\u00eda, Federico; Eiros, Jos\u00e9 M; Ortiz de Lejarazu, Ra\u00fal\n2007-12-01\nCurrently, there are around 150,000 HIV-infected patients in Spain. This number, together with the fact that this disease is now a chronic condition since the introduction of antiretroviral therapy, has generated an increasing demand on the clinical microbiology laboratories in our hospitals. This increase has occurred not only in the diagnosis and treatment of opportunistic diseases, but also in tests related to the diagnosis and therapeutic management of HIV infection. To meet this demand, the Sociedad de Enfermedades Infecciosas y Microbiolog\u00eda Clinica (Spanish Society of Infectious Diseases and Clinical Microbiology) has updated its standard Procedure for the microbiological diagnosis of HIV infection. The main advances related to serological diagnosis, plasma viral load, and detection of resistance to antiretroviral drugs are reviewed in this version of the Procedure.\n[[Microbiological diagnosis of bacterial infection associated with delivery and postpartum].](https://www.ncbi.nlm.nih.gov/pubmed/26706393)\nPadilla-Ortega, Bel\u00e9n; Delgado-Palacio, Susana; Garc\u00eda-Garrote, Fernando; Rodr\u00edguez-G\u00f3mez, Juan Miguel; Romero-Hern\u00e1ndez, Beatriz\n2016-05-01\nThe newborn may acquire infections during delivery due to maternal colonization of the birth canal, by microorganisms such as Streptococcus agalactiae that caused early neonatal infection, or acquisition through the placenta, amniotic fluid or birth products. After birth, the newborn that needs hospitalization can develop nosocomial infections during their care and exceptionally through lactation by infectious mastitis or incorrect handling of human milk, which does not require to stop breastfeeding in most cases. It is important and necessary to perform microbiological diagnosis for the correct treatment of perinatal infections, especially relevant in preterm infants with low or very low weight with high mortality rates. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Infection due to Rothia mucilaginosa. A respiratory pathogen?].](https://www.ncbi.nlm.nih.gov/pubmed/24533971)\nRamos, Jos\u00e9 M; Mateo, Ignacio; Vidal, Inmaculada; Rosillo, Eva M; Merino, Esperanza; Portilla, Joaqu\u00edn\n2014-05-01\nTo describe the spectrum of infections caused by Rothia mucilaginosa. Retrospective study of 20 cases diagnosed with R. mucilaginosa from 2009 to 2012. Pulmonary infection was the most frequent clinical presentation (n=14, 70%): bronchiectasis infected (10), followed by pleural empyema (2), pneumonia (1) and acute bronchitis (1). Two episodes were of gastrointestinal origin: cholangitis secondary to biliary drainage and secondary peritonitis. Two episodes included bacteremia in patients with hematological malignancy. One patient had a surgical wound infection with bacteremia, and another had a bacteremic urinary tract infection in a patient with nephrostomy. R. mucilaginosa may be responsible for infections of the lower respiratory tract in predisposed patients. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Urinary tract infection in kidney transplant recipients.](https://www.ncbi.nlm.nih.gov/pubmed/27112976)\nChac\u00f3n-Mora, Natalia; Pach\u00f3n D\u00edaz, Jer\u00f3nimo; Cordero Mat\u00eda, Elisa\n2017-04-01\nInfectious complications remain a major cause of morbidity and mortality among transplant recipients. Urinary tract infection (UTI) is the most common infectious complication in kidney transplant recipients with a reported incidence from 25% to 75%, varies widely likely due to differences in definition, diagnostic criteria, study design, and length of observation. We sought reviews the incidence and importance of urinary tract infection on graft survival, the microbiology with special emphasis on multidrug resistant microorganisms, the therapeutic management of UTI and the prophylaxis of recurrent UTI among solid organ transplant recipients, highlighting the need for prospective clinical trials to unify the clinical management in this population. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[An updated checklist of Phlebotomine sand flies (Diptera: Psychodidae: Phlebotominae) from the Colombian Andean coffee-growing region].](https://www.ncbi.nlm.nih.gov/pubmed/25504134)\nContreras-Guti\u00e9rrez, Mar\u00eda Ang\u00e9lica; V\u00e9lez, Iv\u00e1n Dar\u00edo; Porter, Charles; Uribe, Sandra In\u00e9s\n2014-01-01\nAn updated list of phlebotomine sand flies species in coffee growing areas in the Colombian Andean region is presented. Fifty three species were reported from 12 departments. In addition, species distribution in the region was derived from specimens obtained during intensive field work in five departments, from previously published studies and from the taxonomic revision of specimens in the entomological collection of the Programa de Estudio y Control de Enfermedades Tropicales (PECET). The list includes the genera Brumptomyia (2 species), Lutzomyia (50 species) and Warileya (1 species). The updated list contains eleven new records in the region under study, including Lutzomyia panamensis , a species of medical importance not recorded previously in this zone. Eighteen of the species are considered to be anthropophilic, and many of them have been implicated in the transmission of leishmaniasis.\n[[Measles, mumps, and rubella vaccine. Resurgence of measles in Europe].](https://www.ncbi.nlm.nih.gov/pubmed/26611100)\nGarc\u00e9s-S\u00e1nchez, Mar\u00eda; Renales-Toboso, Mar\u00eda; B\u00f3veda-Garc\u00eda, Mar\u00eda; D\u00edez-Domingo, Javier\n2015-12-01\nMeasles is a rash illness of moderate severity and high risk of serious complications, with recovery in several weeks. It is a viral disease caused by one of the most infectious and contagious pathogens that exists, whose only known reservoir is human. In 1998, the European Region of the WHO set a target of eliminating measles by 2010. This goal has not been achieved. Furthermore, it has been observed the resurgence of the disease in some parts of Europe. We review the disease and its vaccines as well as the epidemiological and social factors that have so far prevented the total control of the disease. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Epidemiological investigation of the first human brucellosis case in Spain due to Brucella suis biovar 1 strain 1330.](https://www.ncbi.nlm.nih.gov/pubmed/27474211)\nComp\u00e9s Dea, Cecilia; Guimbao Besc\u00f3s, Joaqu\u00edn; Alonso P\u00e9rez de \u00c1greda, Juan Pablo; Mu\u00f1oz \u00c1lvaro, Pilar Mar\u00eda; Blasco Mart\u00ednez, Jos\u00e9 Mar\u00eda; Villuendas Us\u00f3n, Mar\u00eda Cruz\n2017-03-01\nNo cases of human brucellosis caused by Brucella suis has been reported in Spain. This study involved interviews with the case and his co-workers, inspection of their workplace, checking infection control measures, and typing the Brucella strain isolated in the blood culture. Brucella suis biovar 1 strain 1330 was isolated from a patient who worked in a waste treatment plant. Food borne transmission, contact with animals, and risk jobs were ruled out. An accidental inoculation with a contaminated needle from a research laboratory waste container was identified as the most probable mode of transmission. There should be controls to ensure that waste containers are sealed. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Rapid diagnosis of sexually transmitted infections.](https://www.ncbi.nlm.nih.gov/pubmed/28238505)\nOtero-Guerra, Luis; Fern\u00e1ndez-Bl\u00e1zquez, Ana; Vazquez, Fernando\nSexually transmitted infections (STIs) are responsible for an enormous burden of morbidity and mortality. Worldwide, millions of cases of STIs, such as syphilis, chlamydia, or gonorrhoea occur every year, and there is now an increase in antimicrobial resistance in pathogens, such as gonococcus. Delay in diagnosis is one of the factors that justifies the difficulty in controlling these infections. Rapid diagnostic tests allow the introduction of aetiological treatment at the first visit, and also leads to treating symptomatic and asymptomatic patients more effectively, as well as to interrupt the epidemiological transmission chain without delay. The World Health Organisation includes these tests in its global strategy against STIs. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Are probiotics effective to prevent travelers diarrhea?](https://www.ncbi.nlm.nih.gov/pubmed/28032856)\nPinos, Yazm\u00edn; Castro-Guti\u00e9rrez, Victoria; Rada, Gabriel\n2016-12-23\nLa diarrea aguda es la enfermedad m\u00e1s com\u00fan que afecta a los viajeros, principalmente aquellos que se dirigen a regiones de alto riesgo. El uso de probi\u00f3ticos podr\u00eda prevenir su aparici\u00f3n, sin embargo, los datos que apoyan su uso no son consistentes y no se recomiendan en las gu\u00edas cl\u00ednicas actuales. Utilizando la base de datos Epistemonikos, la cual es mantenida mediante b\u00fasquedas en m\u00faltiples bases de datos, identificamos cuatro revisiones sistem\u00e1ticas que en conjunto incluyen siete estudios aleatorizados pertinentes a esta pregunta. Realizamos un metan\u00e1lisis y tablas de resumen de los resultados utilizando el m\u00e9todo GRADE. Concluimos que los probi\u00f3ticos podr\u00edan prevenir la diarrea del viajero, pero la certeza de la evidencia es baja.\n[[Expression of gamma interferon during HPV and Chlamydia trachomatis infection in cervical samples].](https://www.ncbi.nlm.nih.gov/pubmed/25541008)\nCol\u00edn-Ferreyra, Mar\u00eda Del Carmen; Mendieta-Zer\u00f3n, Hugo; Romero-Figueroa, Mar\u00eda Del Socorro; Mart\u00ednez-Madrigal, Migdania; Mart\u00ednez-P\u00e9rez, Sergio; Dom\u00ednguez-Garc\u00eda, Mar\u00eda Victoria\n2015-02-01\nThe aim of this study was to mesure the expression of gamma interferon in HPV and Chlamydia trachomatis infection in squamous intraepithelial lesions. Samples from 100 patients diagnosed by colposcopy with or without squamous intraepithelial lesions were used in the present study. Each patient was found to be infected by HPV and C.trachomatis. Relative gamma interferon mRNA expression was assessed using a real-time reverse transcriptase PCR assay (RT-PCR). The relative units of expression of gamma interferon mRNA were 13, 1.8 and 0.3, for HPV and C.trachomatis co-infection, or HPV or C.trachomatis infection, respectively. HPV and C.trachomatis could overstimulate the expression of gamma interferon. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Emerging viral infections and hepatotropic virus].](https://www.ncbi.nlm.nih.gov/pubmed/27156244)\nArsuaga, Marta; de la Calle-Prieto, Fernando; Negredo Ant\u00f3n, Ana; V\u00e1zquez Gonz\u00e1lez, Ana\n2016-10-01\nEnvironmental degradation, population movements and urban agglomerations have broken down the borders for infectious diseases. The expansion of microorganisms has entered an increasing area of transmission vectors. The lack of immunity of the population leads to an increased risk of spreading infectious diseases. Furthermore, the decline in vaccination rates in developed countries and socio-economic difficulties in large regions has meant that diseases in the process of eradication have re-emerged. That is why health care workers must be trained to avoid delaying in diagnosis and to accelerate the implementation of public health measures. A great deal of education and health prevention should fall under the responsibilities of travellers who move around different regions. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Consensus statement on the clinical management of non-AIDS defining malignancies. GeSIDA expert panel].](https://www.ncbi.nlm.nih.gov/pubmed/24953385)\nSantos, Jes\u00fas; Valencia, Eulalia\n2014-10-01\nThis consensus document has been prepared by a panel of experts appointed by GeSIDA. This paper reviews the recommendations on the most important non-AIDS defining malignancies that can affect patients living with AIDS. Lung cancer, hepatocellular carcinoma, anal carcinoma and other less frequent malignancies such as breast, prostate, vagina or colon cancers are reviewed. The aim of the recommendations is to make clinicians who attend to this patients aware of how to prevent, diagnose and treat this diseases. The recommendations for the use of antiretroviral therapy when the patient develops a malignancy are also presented. In support of the recommendations we have used the modified criteria of the Infectious Diseases Society of America. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nPrieto-P\u00e9rez, Laura; P\u00e9rez-Tanoira, Ram\u00f3n; Cabello-\u00dabeda, Alfonso; Petkova-Saiz, Elizabet; G\u00f3rgolas-Hern\u00e1ndez-Mora, Miguel\n2016-01-01\nMillions of people in in rural areas and deprived tropical and subtropical regions are infected by soil-transmitted helminths: Ascaris lumbricoides, Trichuris trichiura, hookworms (Ancylostoma duodenale and Necator americanus), and Strongyloides stercoralis. Large migratory flows have made their worldwide distribution easier. Besides being debilitating and producing a significant mortality, they cause high morbidity, leading to physical and intellectual impairment in millions of children who live in poverty. Along with the use of benzimidazoles (albendazole and mebendazole), large-scale international campaigns for treatment and prevention have decreased the number of affected individuals. However, re-infestations and benzimidazole-resistance are frequent, so there needs to be awareness about the importance and consequences of these neglected parasites. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.](https://www.ncbi.nlm.nih.gov/pubmed/26976381)\nIribarren, Jos\u00e9 Antonio; Rubio, Rafael; Aguirrebengoa, Koldo; Arribas, Jose Ram\u00f3n; Baraia-Etxaburu, Josu; Guti\u00e9rrez, F\u00e9lix; Lopez Bernaldo de Quir\u00f3s, Juan Carlos; Losa, Juan Emilio; Mir\u00f3, Jos\u00e9 Ma; Moreno, Santiago; P\u00e9rez Molina, Jos\u00e9; Podzamczer, Daniel; Pulido, Federico; Riera, Melchor; Rivero, Antonio; Sanz Moreno, Jos\u00e9; Amador, Concha; Antela, Antonio; Arazo, Piedad; Arrizabalaga, Julio; Bachiller, Pablo; Barros, Carlos; Berenguer, Juan; Cayl\u00e1, Joan; Domingo, Pere; Estrada, Vicente; Knobel, Hernando; Locutura, Jaime; L\u00f3pez Aldeguer, Jos\u00e9; Llibre, Josep Ma; Lozano, Fernando; Mallolas, Josep; Malmierca, Eduardo; Miralles, Celia; Miralles, Pilar; Mu\u00f1oz, Agust\u00edn; Ocampo, Agust\u00edn; Olalla, Juli\u00e1n; P\u00e9rez, In\u00e9s; P\u00e9rez El\u00edas, Ma Jes\u00fas; P\u00e9rez Arellano, Jos\u00e9 Luis; Portilla, Joaqu\u00edn; Ribera, Esteban; Rodr\u00edguez, Francisco; Sant\u00edn, Miguel; Sanz Sanz, Jes\u00fas; T\u00e9llez, Ma Jes\u00fas; Torralba, Miguel; Valencia, Eulalia; Von Wichmann, Miguel Angel\n2016-10-01\nDespite the huge advance that antiretroviral therapy represents for the prognosis of infection by the human immunodeficiency virus (HIV), opportunistic infections (OIs) continue to be a cause of morbidity and mortality in HIV-infected patients. OIs often arise because of severe immunosuppression resulting from poor adherence to antiretroviral therapy, failure of antiretroviral therapy, or unawareness of HIV infection by patients whose first clinical manifestation of AIDS is an OI. The present article updates our previous guidelines on the prevention and treatment of various OIs in HIV-infected patients, namely, infections by parasites, fungi, viruses, mycobacteria, and bacteria, as well as imported infections. The article also addresses immune reconstitution inflammatory syndrome. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Protocol for the Production of a Vaccine Against Argentinian Hemorrhagic Fever.](https://www.ncbi.nlm.nih.gov/pubmed/28986845)\nAmbrosio, Ana Mar\u00eda; Mariani, Mauricio Andr\u00e9s; Maiza, Andrea Soledad; Gamboa, Graciela Susana; Fossa, Sebasti\u00e1n Edgardo; Bottale, Alejando Javier\n2018-01-01\nArgentinian hemorrhagic Fever (AHF) is a febrile, acute disease caused by Jun\u00edn virus (JUNV), a member of the Arenaviridae. Different approaches to obtain an effective antigen to prevent AHF using complete live or inactivated virus, as well as molecular constructs, have reached diverse development stages. This chapter refers to JUNV live attenuated vaccine strain Candid #1, currently used in Argentina to prevent AHF. A general standardized protocol used at Instituto Nacional de Enfermedades Virales Humanas (Pergamino, Pcia. Buenos Aires, Argentina) to manufacture the tissue culture derived Candid #1 vaccine is described. Intermediate stages like viral seeds and cell culture bank management, bulk vaccine manufacture, and finished product processing are also separately presented in terms of Production and Quality Control/Quality Assurance requirements, under the Adminitracion Nacional de Medicamentos, Alimentos y Tecnolog\u00eda Medica (ANMAT), the Argentine national regulatory authority.\n[[The polymetabolic syndrome. The experiences of the DRECE study. Dieta y Riesgo de Enfermedades Cardiovasculares en Espa\u00f1a].](https://www.ncbi.nlm.nih.gov/pubmed/7494924)\nGuti\u00e9rrez Fuentes, J A\n1995-01-01\nDifferent risk factors frequent in NIDDM predispose to suffer an early atherosclerosis. Among these and beside lipidic disorders (hypercholesterolemia, hypertriglyceridemia and low HDL-cholesterol levels), hyperinsulinemia and/or insulin resistance, obesity and arterial hypertension are placed. In Spain, 135,000/year deaths from cardiovascular diseases (42% of total deaths) are produced. To plan a preventive strategy requires the knowledge and previous analysis among the population of the situation with regard to risk factors. In order to know in Spain the actual prevalence of cholesterol and other lipidic fractions and their relationship with different dietetic habits and other cardiovascular risk factors, a study on \"Diet and Cardiovascular Risk Diseases in Spain\": DRECE, was performed. Remains to be explained in the mediterranean countries the low incidence of coronary morbid/mortality, in spite of a high fat consume and cholesterol levels. In this direction, the role of a few micronutrients and other common elements in our diet, some of them with antioxidant properties, may have as protector agents in the atherosclerotic ischemic heart disease process, acquires interest.\n[Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas.](https://www.ncbi.nlm.nih.gov/pubmed/10722428)\nCordero, E; Pach\u00f3n, J; Rivero, A; Gir\u00f3n, J A; G\u00f3mez-Mateos, J; Merino, M D; Torres-Tortosa, M; Gonz\u00e1lez-Serrano, M; Aliaga, L; Collado, A; Hern\u00e1ndez-Quero, J; Barrera, A; Nu\u00f1o, E\n2000-03-01\nAlthough Haemophilus influenzae is a common etiologic agent of pneumonia in patients infected with human immunodeficiency virus (HIV), the characteristics of this pneumonia have not been adequately assessed. We have prospectively studied features of H. influenzae pneumonia in 26 consecutive HIV-infected inpatients. Most of these patients were severely immunosuppressed; 73.1% had a CD4+ cell count <100/microL. A subacute clinical presentation was observed in 27% of the patients and was associated with a higher degree of immunosuppression (P=.04). Bilateral lung infiltrates were noted radiographically in 57.7% of the cases. The mortality attributable to H. influenzae pneumonia was 11.5%. Thus, pneumonia caused by H. influenzae affects mainly patients with advanced HIV disease, and since its clinical and radiological features may be diverse, this etiology should be considered when pneumonia occurs in patients with advanced HIV infection. The mortality rate associated with H. influenzae pneumonia is not higher than that occurring in the general population.\n[Velocidades radiales en Collinder 121](http://adsabs.harvard.edu/abs/1996BAAA...40Q..28A) [NASA Astrophysics Data System (ADS)](http://adsabs.harvard.edu/abstract_service.html)\nArnal, M.; Morrell, N.\nSe han llevado a cabo observaciones espectrosc\u00f3picas de unas treinta estrellas que son posibles miembros del c\u00famulo abierto Collinder 121. Las mismas fueron realizadas con el telescopio de 2.15m del Complejo Astron\u00f3mico El Leoncito (CASLEO). El an\u00e1lisis de las velocidades radiales derivadas del material obtenido, confirma la realidad de Collinder 121, al menos desde el punto de vista cinem\u00e1tico. La velocidad radial baricentral (LSR) del c\u00famulo es de +17 \u00b1 3 km.s-1. Esta velocidad coincide, dentro de los errores, con la velocidad radial (LSR) de la nebulosa anillo S308, la cual es de ~20 \u00b1 10 km.s-1. Como S308 se encuentra f\u00edsicamente asociada a la estrella Wolf-Rayet HD~50896, es muy probable que esta \u00faltima sea un miembro de Collinder 121. Desde un punto de vista cinem\u00e1tico, la supergigante roja HD~50877 (K3Iab) tambi\u00e9n pertenecer\u00eda a Collinder 121. Bas\u00e1ndonos en la pertenencia de HD~50896 a Collinder 121, y en la interacci\u00f3n encontrada entre el viento de esta estrella y el medio interestelar circundante a la misma, se estima para este c\u00famulo una distancia del orden de 1 kpc.\n[[Map of Alzheimer's disease and other dementias in Spain. MapEA Project].](https://www.ncbi.nlm.nih.gov/pubmed/29107401)\nMart\u00ednez-Lage, Pablo; Mart\u00edn-Carrasco, Manuel; Arrieta, Enrique; Rodrigo, Jes\u00fas; Formiga, Francesc\nIn the current context of increased life expectancy and progressive aging of the population a very significant increase in the number of people with cognitive impairment and dementia is expected. Consequently, Spain will face an enormous social and health problem in the next decades. The Mapa de la enfermedad de Alzheimer y otras demencias en Espa\u00f1a project aims to analyse plans, prevention and early diagnosis activities, process of care and resources available across the 17 Spanish regions for the management of cognitive impairment and dementia in order to identify improvement areas, as well as to provide a list of recommendations. The working group consisted of an Advisory Committee of 5 national experts and a Committee of Experts from each region made up of professionals in the field of Neurology, Geriatrics, Psychiatry, and Primary Care, as well as representatives of Family Associations of People with Alzheimer's and other dementias. The Expert Committee of each region held meetings in which the current situation of care was reviewed. Plans available in Spain for dementia management are mostly obsolete or have not been implemented. Prevention and early detection activities are generally not carried out. There is great variability of care process that patients must follow for the diagnosis, treatment, and follow-up of the disease, and not all diagnostic test are available in different regions. In general, resources are considered scarce and unknown. The Mapa de la enfermedad de Alzheimer y otras demencias en Espa\u00f1a study has been able to detect the main points that require changing n the management, organisation, and coordination of resources, such as information and training of the personnel involved. Furthermore, the study has revealed that, in Spain, the necessary conditions are in place in Spain, such as the availability and capacity of professionals involved, as well as there being the potential diagnostic and health care resources to address this room\n[Acceptability Study of \"Ascenso\": An Online Program for Monitoring and Supporting Patients with Depression in Chile.](https://www.ncbi.nlm.nih.gov/pubmed/26741190)\nEspinosa, H Daniel; Carrasco, \u00c1lvaro; Moessner, Markus; C\u00e1ceres, Cristian; Gloger, Sergio; Rojas, Graciela; Perez, J Carola; Vanegas, Jorge; Bauer, Stephanie; Krause, Mariane\n2016-07-01\nMajor depression is a highly prevalent and severe mental disease. Despite the effective treatment options available, the risk of relapse is high. Interventions based on information and communication technologies generate innovative opportunities to provide support to patients after they completed treatment for depression. This acceptability study evaluated the Internet-based program Apoyo, Seguimiento y Cuidado de Enfermedades a partir de Sistemas Operativos (ASCENSO) in terms of its feasibility and acceptability in a sample of 35 patients in Chile. The study reveals high rates of acceptance and satisfaction among patients who actively used the program. As obstacles, patients mentioned technical problems, a lack of contact with other participants, and an insufficient connection between the program and the health service professionals. ASCENSO appears to be a promising complement to regular care for depression. Following improvements of the program based on participants' feedback, future research should evaluate its efficacy and cost-effectiveness.\nL\u00f3pez G\u00f3mez, Juan Jos\u00e9; P\u00e9rez Castrill\u00f3n, Jos\u00e9 Luis; Romero Bobillo, Enrique; De Luis Rom\u00e1n, Daniel A\n2016-11-29\nLa obesidad interfiere con el metabolismo \u00f3seo a trav\u00e9s de factores mec\u00e1nicos, hormonales e inflamatorios. El principal tratamiento de dicha enfermedad es la dieta, modificaci\u00f3n de la cantidad y tipo de alimento. Este tratamiento nutricional tiene una influencia sobre el metabolismo \u00f3seo en dos sentidos: modifica el efecto del sobrepeso y la obesidad sobre el hueso e interviene directamente en el turnover\u00f3seo a trav\u00e9s de las caracter\u00edsticas de los nutrientes utilizados. Esta revisi\u00f3n analiza la evidencia del efecto sobre el hueso del descenso de peso y del patr\u00f3n diet\u00e9tico utilizado. Por otra parte, se valorar\u00e1n las modificaciones que se pueden realizar en la dieta indicada en un paciente obeso para prevenir la p\u00e9rdida \u00f3sea, a corto y largo plazo, y disminuir el riesgo de fractura.\n[Microbiota and Human Health: characterization techniques and transference.](https://www.ncbi.nlm.nih.gov/pubmed/28372875)\nDel Campo-Moreno, Rosa; Alarc\u00f3n-Cavero, Teresa; D'Auria, Giuseppe; Delgado-Palacio, Susana; Ferrer-Mart\u00ednez, Manuel\n2018-04-01\nThe human microbiota comprises all the microorganisms of our body, which can also be categorised as commensals, mutualists and pathogens according to their behaviour. Our knowledge of the human microbiota has considerably increased since the introduction of 16S rRNA next generation sequencing (16S rDNA gene). This technological breakthrough has seen a revolution in the knowledge of the microbiota composition and its implications in human health. This article details the different human bacterial ecosystems and the scientific evidence of their involvement in different diseases. The faecal microbiota transplant procedure, particularly used to treat recurrent diarrhoea caused by Clostridium difficile, and the methodological bases of the new molecular techniques used to characterise microbiota are also described. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Who and how many of the potential users would be willing to pay the current or a lower price of the HIV self-test? The opinion of participants in a feasibility study of HIV self-testing in Spain.](https://www.ncbi.nlm.nih.gov/pubmed/24468627)\nRosales-Statkus, M Elena; Belza-Egozcue, Mar\u00eda J; Fern\u00e1ndez-Balbuena, Sonia; Hoyos, Juan; Ruiz-Garc\u00eda, M\u00f3nica; de la Fuente, Luis\n2014-05-01\nWe estimate the proportion of participants willing to pay the US price (\u20ac30) or \u20ac20 for an HIV self-test and analyse their associated factors. In a street-based testing program, 497 participants in a feasibility self-test study answered the question, \"What would be the maximum price you would be willing to pay for a similar test to this one so you can use it at your convenience?\" Only 17.9% would pay \u2265\u20ac30, while 40.0%, \u2265\u20ac20. In the logistic regression, paying more was associated with being tested outside the campuses and having paid or been paid for sex. In Spain, self-testing would not have an impact unless it became more affordable to potential users. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Methods for determining the antimicrobial susceptibility of mycobacteria.](https://www.ncbi.nlm.nih.gov/pubmed/27236235)\nAlcaide, Fernando; Esteban, Jaime; Gonz\u00e1lez-Martin, Juli\u00e0; Palacios, Juan-Jos\u00e9\n2017-10-01\nMycobacteria are a large group of microorganisms, multiple species of which are major causes of morbidity and mortality, such as tuberculosis and leprosy. At present, the emergence and spread of multidrug-resistant strains of Mycobacterium tuberculosis complex are one of the most serious health problems worldwide. Furthermore, in contrast to M. tuberculosis and Mycobacterium leprae, non-tuberculous mycobacteria (NTM) are more frequently isolated and, in many cases, treatment is based on drug susceptibility testing. This article is a review of the different methods to determine the in vitro drug susceptibility of M. tuberculosis complex and the most relevant NTM isolates. The molecular techniques currently used for rapid detection of resistance of clinical specimens are also analysed. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Microbiological diagnosis of human immunodeficiency virus infection].](https://www.ncbi.nlm.nih.gov/pubmed/25444049)\n\u00c1lvarez Est\u00e9vez, Marta; Reina Gonz\u00e1lez, Gabriel; Aguilera Guirao, Antonio; Rodr\u00edguez Mart\u00edn, Carmen; Garc\u00eda Garc\u00eda, Federico\n2015-10-01\nThis document attempts to update the main tasks and roles of the Clinical Microbiology laboratory in HIV diagnosis and monitoring. The document is divided into three parts. The first deals with HIV diagnosis and how serological testing has changed in the last few years, aiming to improve diagnosis and to minimize missed opportunities for diagnosis. Technological improvements for HIV Viral Load are shown in the second part of the document, which also includes a detailed description of the clinical significance of low-level and very low-level viremia. Finally, the third part of the document deals with resistance to antiretroviral drugs, incorporating clinical indications for integrase and tropism testing, as well as the latest knowledge on minority variants. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.](https://www.ncbi.nlm.nih.gov/pubmed/27056581)\nIribarren, Jos\u00e9 Antonio; Rubio, Rafael; Aguirrebengoa, Koldo; Arribas, Jose Ram\u00f3n; Baraia-Etxaburu, Josu; Guti\u00e9rrez, F\u00e9lix; Lopez Bernaldo de Quir\u00f3s, Juan Carlos; Losa, Juan Emilio; Mir\u00f3, Jos\u00e9 Ma; Moreno, Santiago; P\u00e9rez Molina, Jos\u00e9; Podzamczer, Daniel; Pulido, Federico; Riera, Melchor; Rivero, Antonio; Sanz Moreno, Jos\u00e9; Amador, Concha; Antela, Antonio; Arazo, Piedad; Arrizabalaga, Julio; Bachiller, Pablo; Barros, Carlos; Berenguer, Juan; Cayl\u00e1, Joan; Domingo, Pere; Estrada, Vicente; Knobel, Hernando; Locutura, Jaime; L\u00f3pez Aldeguer, Jos\u00e9; Llibre, Josep Ma; Lozano, Fernando; Mallolas, Josep; Malmierca, Eduardo; Miralles, Celia; Miralles, Pilar; Mu\u00f1oz, Agust\u00edn; Ocampo, Agust\u00edn; Olalla, Juli\u00e1n; P\u00e9rez, In\u00e9s; P\u00e9rez El\u00edas, Ma Jes\u00fas; P\u00e9rez Arellano, Jos\u00e9 Luis; Portilla, Joaqu\u00edn; Ribera, Esteban; Rodr\u00edguez, Francisco; Sant\u00edn, Miguel; Sanz Sanz, Jes\u00fas; T\u00e9llez, Ma Jes\u00fas; Torralba, Miguel; Valencia, Eulalia; Von Wichmann, Miguel Angel\n2016-10-01\nOpportunistic infections continue to be a cause of morbidity and mortality in HIV-infected patients. They often arise because of severe immunosuppression resulting from poor adherence to antiretroviral therapy, failure of antiretroviral therapy, or unawareness of HIV infection by patients whose first clinical manifestation of AIDS is an opportunistic infection. The present article is an executive summary of the document that updates the previous recommendations on the prevention and treatment of opportunistic infections in HIV-infected patients, namely, infections by parasites, fungi, viruses, mycobacteria, and bacteria, as well as imported infections. The article also addresses immune reconstitution inflammatory syndrome. This document is intended for all professionals who work in clinical practice in the field of HIV infection. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Mechanical versus manual suture in the jejunal esophageal anastomosis after total gastrectomy in gastric cancer].](https://www.ncbi.nlm.nih.gov/pubmed/11818987)\nCelis, J; Ruiz, E; Berrospi, F; Payet, E\n2001-01-01\nTo compare the leakage rate of esophagojejunal anastomosis performed with stapler or hand sutures. We studied a series of 367 patients who underwent total gastrectomy for gastric cancer at the Instituto de Enfermedades Neopl\u00e1sicas (Lima-Peru) from 1986 to 1999. In 197 patients esophagojejunal anastomosis was performed with stapler and in 170 with manual sutures. There were no differences between both groups with regard to age, TNM stage, operating time and hospital stay. There were 8 anastomotic leakage (4.1%) in the stapler group and 4 (2.4%) in the hand sutures group (p> 0.05). Of these 12 cases, 2 patients (16%) died of causes directly related to the leak of the esophagojejunal anastomosis. There were no statistical differences in the rate of leakage of the esophagojejunal anastomosis performed with stapler or hand sutures, thus both techniques should be accepted as standard procedures.\n[[Role of the hospital environment and equipment in the transmission of nosocomial infections].](https://www.ncbi.nlm.nih.gov/pubmed/24315300)\nL\u00f3pez-Cerero, Lorena\n2014-01-01\nThe hospital environment is both a reservoir and source of infection for the hospital patient. Several areas around the patient should be considered: air, toilet water coming into contact with the patient, staff and medical devices, food, surfaces, and instruments contacting the patient's skin and mucosa, and sterile solutions. There are pathogens classically associated with each mode of transmission and environmental reservoir, but multi-resistant microorganisms have also been recently been associated with environmental acquisition. Protocols are currently available for the prevention of some classic environmental pathogens, as well as recommendations for the prevention of contamination in some procedures. However, these situations do not cover all forms of transmission, and most investigations of reservoirs or environmental sources are restricted to outbreak situations. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Practical considerations for high resolution anoscopy in patients infected with human immunodeficiency virus].](https://www.ncbi.nlm.nih.gov/pubmed/24182418)\nIribarren-D\u00edaz, Mauricio; Ocampo Hermida, Antonio; Gonz\u00e1lez-Carrer\u00f3 Foj\u00f3n, Joaqu\u00edn; Alonso-Parada, Mar\u00eda; Rodr\u00edguez-Girondo, Mar\n2014-12-01\nAnal cancer is uncommon in the general population, however its incidence is increasing significantly in certain risk groups, mainly in men who have sex with men, and particularly those infected with human immunodeficiency virus. High resolution anoscopy technique is currently considered the standard in the diagnosis of anal intraepithelial neoplasia, but at present there is no agreed standard method between health areas. High resolution anoscopy is an affordable technique that can be critical in the screening of anal carcinoma and its precursor lesions, but is not without difficulties. We are currently studying the most effective strategy for managing premalignant anal lesions, and with this article we attempt to encourage other groups interested in reducing the incidence of an increasing neoplasia. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Detection of lipoarabinomannan as a diagnostic test for tuberculosis.](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=265515)\nSada, E; Aguilar, D; Torres, M; Herrera, T\n1992-01-01\nA coagglutination technique was established for the detection of lipoarabinomannan of Mycobacterium tuberculosis in human serum samples and evaluated for its utility in the diagnosis of tuberculosis at the Instituto Nacional de Enfermedades Respiratorias in Mexico City. The test had a sensitivity of 88% in patients with sputum-smear-positive active pulmonary tuberculosis. The sensitivity in patients with active pulmonary tuberculosis negative for acid-fast bacilli in sputum was 67%. Less favorable results were obtained for patients with AIDS and tuberculosis, with a sensitivity of 57%. The specificity in control patients with lung diseases different from tuberculosis and in healthy subjects was 100%. The positive predictive value was 100%, and the negative predictive value for patients with sputum-positive active pulmonary tuberculosis was 97%. The results of this study suggest that the detection of lipoarabinomannan is an accurate test for the diagnosis of pulmonary tuberculosis. PMID:1401008\n[[Meningococcal vaccines. Global epidemiological situation and strategies for prevention by vaccination].](https://www.ncbi.nlm.nih.gov/pubmed/25795150)\nRivero Calle, Irene; Rodriguez-Tenreiro S\u00e1nchez, Carmen; Martin\u00f3n-Torres, Federico\n2015-04-01\nN. meningitidis is a major cause of meningitis and septicemia and a major public health problem in many countries. The disease, that can be fulminant, has a high mortality and may cause serious sequelae, even in cases of apparently optimal medical treatment. Chemoprophylaxis may prevent secondary cases among those in close contact with the ill, but, since secondary cases represent only 1%-2% of all meningococcal disease, chemoprophylaxis has a small impact when fighting most of endemic and epidemic forms. Given that al least 5% -15% of children and young adults are carriers, the fight against meningococcal disease based on chemotherapeutic elimination of nasopharyngeal colonization is virtually impossible. Therefore, immunization is the only rational way to combat this disease. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Galactomannan enzyme immunoassay and quantitative Real Time PCR as tools to evaluate the exposure and response in a rat model of aspergillosis after posaconazole prophylaxis.](https://www.ncbi.nlm.nih.gov/pubmed/26804792)\nCendejas-Bueno, Emilio; Forastiero, Agustina; Ruiz, Isabel; Mellado, Emilia; Buitrago, Mar\u00eda Jos\u00e9; Gavald\u00e0, Joan; Gomez-Lopez, Alicia\n2016-11-01\nA steroid-immunosuppressed rat model of invasive pulmonary aspergillosis was use to examine the usefulness of galactomannan enzyme immunoassay (GM) and quantitative real time PCR (RT-PCR) in evaluating the association between response and exposure after a high dose of prophylactic posaconazole. Two different strains of Aspergillus fumigatus with different in vitro posaconazole susceptibility were used. Serum concentrations demonstrated similar posaconazole exposure for all treated animals. However, response to posaconazole relied on the in vitro susceptibility of the infecting strain. After prophylaxis, galactomannan index and fungal burden only decreased in those animals infected with the most susceptible strain. This study demonstrated that both biomarkers may be useful tools for predicting efficacy of antifungal compounds in prophylaxis. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Prevalencia de s\u00edntomas de enfermedad de la superficie ocular en pacientes que acuden a consulta oftalmol\u00f3gica.](https://www.ncbi.nlm.nih.gov/pubmed/29414972)\nGarza-Le\u00f3n, Manuel; Hern\u00e1ndez-Quintela, Everardo; C\u00e1mara-Castillo, H\u00e9ctor G; Parra-Collin, Paola de la; Covarrubias-Espinosa, Paola; S\u00e1nchez-Huerta, Valeria; Castillo-Ruiz, Alejandro Del; Rodr\u00edguez-Sixtos, Fernando; Pacheco-Patr\u00f3n, Jorge; Ochoa-Tabares, Juan Carlos; Soto-Ortiz, Karina; Hern\u00e1ndez-Olguin, Karen\n2017-01-01\nTo determine the prevalence of symptoms of ocular surface disease (OSDI) surface disease and its relationship with associated risk factors in patients of ophthalmic practices using OSDI questionnaire. A cross-sectional survey was conducted Between September and December 2014 to assess the prevalence and risk factors for OSDI. The OSDI average value was 40.46 \u00b1 23.62 points, with 86.4% of patients (1967) having a OSDI score higher than 12 points. Women had OSDI symptoms more frequently than men (odds ratio: 1.17; 95% confidence interval: 1.08-1.28) and higher OSDI score (42.12 \u00b1 24.03 vs. 38.01 \u00b1 22.81 points). Patients without disease were younger than the patients with severe disease (45.30 \u00b1 18.32 vs. 50.62 \u00b1 18.86). Ophthalmological patients have a prevalence of 80.4% of OSDI. Female and older age was associated with ocular surface disease. Copyright: \u00a9 2017 Secretar\u00cda de Salud\n[[Osteoarticular pneumococcal infections observed in a tertiary hospital over a period of 11 years].](https://www.ncbi.nlm.nih.gov/pubmed/25444359)\nFern\u00e1ndez-Garc\u00eda, Magdalena; Casado-D\u00edez, Amaia; Salas-Venero, Carlos Antonio; Hern\u00e1ndez-Hern\u00e1ndez, Jos\u00e9 Luis\n2015-04-01\nOsteoarticular pneumococcal infection is an infrequent complication of pneumococcal bacteremia, due to the advances in antibiotic therapy and in the pattern of immunization. A retrospective study was conducted on patients diagnosed with osteoarticular pneumococcal infection between January 2003 and December 2013 in the University Hospital Marqu\u00e9s de Valdecilla in Santander. Five out of 321 patients diagnosed with pneumococcal bacteremia had osteoarticular infection. All of them had at least one chronic underlying disease and had been immunized according to the standard vaccination schedule. Hip and vertebra were the most common joints involved. Outcome was favorable in all cases. The clinical findings of pneumococcal osteoarticular infection should be borne in mind. Its optimal prevention in high-risk patients should include the 13V conjugate vaccine. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).](https://www.ncbi.nlm.nih.gov/pubmed/28215487)\nAriza, Javier; Cobo, Javier; Baraia-Etxaburu, Josu; Benito, Natividad; Bori, Guillermo; Cabo, Javier; Corona, Pablo; Esteban, Jaime; Horcajada, Juan Pablo; Lora-Tamayo, Jaime; Murillo, Oscar; Palomino, Juli\u00e1n; Parra, Jorge; Pigrau, Carlos; Del Pozo, Jos\u00e9 Luis; Riera, Melchor; Rodr\u00edguez, Dolores; S\u00e1nchez-Somolinos, Mar; Soriano, Alex; Del Toro, M Dolores; de la Torre, Basilio\n2017-03-01\nThe incidence of prosthetic joint infection (PJI) is expected to increase in the coming years. PJI has serious consequences for patients, and high costs for the health system. The complexity of these infections makes it necessary to organize the vast quantity of information published in the last several years. The indications for the choice of a given surgical strategy and the corresponding antimicrobial therapy are specifically reviewed. The authors selected clinically relevant questions and then reviewed the available literature in order to give recommendations according to a pre-determined level of scientific evidence. The more controversial aspects were debated, and the final composition was agreed at an ad hoc meeting. Before its final publication, the manuscript was made available online in order that all SEIMC members were able to read it and make comments and suggestions. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Diagnosis and therapeutic approach of latent tuberculosis infection.](https://www.ncbi.nlm.nih.gov/pubmed/29295754)\nDom\u00ednguez, Jos\u00e9; Latorre, Irene; Santin, Miguel\n2018-05-01\nDetection and treatment of latent tuberculosis infection (LTBI) is an essential measure for tuberculosis (TB) control in low-incidence countries. However, such strategy is limited by the low predictive ability of the diagnostic tests for the development of active TB among infected people and the long-term and toxic treatment regimens. The in vitro interferon-gamma release assays are more specific and sensitive than the tuberculin skin test (TST), and enable a better selection of cases requiring treatment. Nonetheless, their capacity to predict development of TB is still poor. In addition, treatment regimens for LTBI are long, and compliance rates are low. This review discusses the use of the available diagnostic tests and the new approaches to the diagnosis of LTBI, as well as its management in different clinical scenarios. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[HIV infection and immigration].](https://www.ncbi.nlm.nih.gov/pubmed/27016136)\nMonge, Susana; P\u00e9rez-Molina, Jos\u00e9 A\n2016-01-01\nMigrants represent around one third of patients newly diagnosed with HIV in Spain and they constitute a population with higher vulnerability to its negative consequences due to the socio-cultural, economical, working, administrative and legal contexts. Migrants are diagnosed later, which worsens their individual prognosis and facilitates the maintenance of the HIV epidemic. In spite of the different barriers they experience to access healthcare in general, and HIV-related services in particular, access to antiretroviral treatment has been similar to that of the autochthonous population. However, benefits of treatment have been not, with women in general and men from Sub-Saharan Africa exhibiting the worse response to treatment. We need to proactively promote earlier diagnosis of HIV infection, the adoption of preventive measures to avoid new infections, and to deliver accessible, adapted and high-quality health-care. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Level of impact on the public health of universal human immunodeficiency virus screening in an Emergency Department.](https://www.ncbi.nlm.nih.gov/pubmed/26341042)\nReyes-Urue\u00f1a, Juliana; Fern\u00e0ndez-L\u00f3pez, Laura; Force, Luis; Daza, Manel; Agust\u00ed, Cristina; Casabona, Jordi\nThe aim of this study was to determine the prevalence of HIV and the acceptability of rapid testing in an emergency department (ED), Barcelona (6/07/2011 to 8/03/2013). A convenience sample was used, depending on nurse availability in the ED. Participants signed an informed consent. Results were confirmed by conventional methods. A total of 2,140 individuals were offered testing, and 5% rejected taking part (107/2,140). Three subjects (3/2,033 [0.15%]) had confirmed reactive test. Individuals with a higher education were more likely to perform a rapid HIV test in ED (P<.005). A low prevalence of new HIV diagnoses was found among participants, although there was a high acceptability rate to perform rapid testing in the ED. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Design of PREVENCION: a population-based study of cardiovascular disease in Peru.](https://www.ncbi.nlm.nih.gov/pubmed/16243113)\nMedina-Lezama, Josefina; Chirinos, Julio A; Zea D\u00edaz, Humberto; Morey, Oscar; Bolanos, Juan F; Munoz-Atahualpa, Edgar; Chirinos-Pacheco, Julio\n2005-11-02\nLatin America is undergoing the epidemiologic transition that occurred earlier in developed countries, and is likely to face a gigantic epidemic of heart disease in the next few years unless urgent action is taken. The first essential component of any effective cardiovascular disease (CVD) control program is to establish reliable estimates of cardiovascular disease-related morbidity and mortality. However, such data from population-based studies in Latin America are still lacking. In this paper, we present the design and operation of PREVENCION (Estudio Peruano de Prevalencia de Enfermedades Cardiovasculares, for Peruvian Study of the Prevalence of Cardiovascular diseases). PREVENCION is an ongoing population-based study on a representative sample of the civilian non-institutionalized population of the second largest city in Peru. Its population is comparable to the rest of the Peruvian urban population and closely resembles other Latin American populations in countries such as Bolivia and Ecuador. Our study will contribute to the enormous task of understanding and preventing CVD in Latin America.\n[[Safety in the Microbiology laboratory].](https://www.ncbi.nlm.nih.gov/pubmed/25444041)\nRojo-Molinero, Estrella; Alados, Juan Carlos; de la Pedrosa, Elia G\u00f3mez G; Leiva, Jos\u00e9; P\u00e9rez, Jos\u00e9 L\n2015-01-01\nThe normal activity in the laboratory of microbiology poses different risks - mainly biological - that can affect the health of their workers, visitors and the community. Routine health examinations (surveillance and prevention), individual awareness of self-protection, hazard identification and risk assessment of laboratory procedures, the adoption of appropriate containment measures, and the use of conscientious microbiological techniques allow laboratory to be a safe place, as records of laboratory-acquired infections and accidents show. Training and information are the cornerstones for designing a comprehensive safety plan for the laboratory. In this article, the basic concepts and the theoretical background on laboratory safety are reviewed, including the main legal regulations. Moreover, practical guidelines are presented for each laboratory to design its own safety plan according its own particular characteristics. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Microbiological methods for surveillance of carrier status of multiresistant bacteria.](https://www.ncbi.nlm.nih.gov/pubmed/26869070)\nOteo, Jes\u00fas; Bou, Germ\u00e1n; Chaves, Fernando; Oliver, Antonio\n2017-12-01\nThe presence of colonised patients is one of the main routes for the spread of multiresistant bacteria, and its containment is a clinical and public health priority. Surveillance studies are essential for early detection of colonisation by these bacteria. This article discusses the different microbiological methods, both based on culturing and molecular methods, for detection of carriers of multiresistant bacteria. Those species with a high clinical/epidemiological impact or generating therapeutic difficulties are included: Methicillin-resistant Staphylococcus aureus, Enterococcus spp. resistant to glycopeptides, enterobacteriaceae producing extended spectrum \u03b2-lactamases and plasmid-mediated AmpC, carbapenemases producing enterobacteriaceae, Acinetobacter baumannii and multiresistant Pseudomonas aeruginosa. The information in this document should be considered as a structure matrix to be tailored to the specific needs of each centre. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Molecular methods for septicemia diagnosis.](https://www.ncbi.nlm.nih.gov/pubmed/28427796)\nMarco, Francesc\n2017-11-01\nSepticemia remains a major cause of hospital mortality. Blood culture remains the best approach to identify the etiological microorganisms when a bloodstream infection is suspected but it takes long time because it relies on bacterial or fungal growth. The introduction in clinical microbiology laboratories of the matrix-assisted laser desorption ionization time-of-flight mass spectrometry technology, DNA hybridization, microarrays or rapid PCR-based test significantly reduce the time to results. Tests for direct detection in whole blood samples are highly desirable because of their potential to identify bloodstream pathogens without waiting for blood cultures to become positive. Nonetheless, limitations of current molecular diagnostic methods are substantial. This article reviews these new molecular approaches (LightCycler SeptiFast, Magicplex sepsis real time, Septitest, VYOO, PCR/ESI-MS analysis, T2Candida). Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[First case of imported Zika virus infection in Spain.](https://www.ncbi.nlm.nih.gov/pubmed/26994814)\nBachiller-Luque, Pablo; Dom\u00ednguez-Gil Gonz\u00e1lez, Marta; \u00c1lvarez-Manzanares, Jes\u00fas; V\u00e1zquez, Ana; De Ory, Fernando; S\u00e1nchez-Seco Fari\u00f1as, M Paz\n2016-04-01\nWe report a case of Zika virus (ZIKV) infection in a patient with diarrhea, fever, synovitis, non-purulent conjunctivitis, and with discreet retro-orbital pain, after returning from Colombia in January 2016. The patient referred several mosquito bites. Presence of ZIKV was detected by PCR (polymerase chain reaction) in plasma. Rapid microbiological diagnosis of ZIKV infection is needed in European countries with circulation of its vector, in order to avoid autochthonous circulation. The recent association of ZIKV infection with abortion and microcephaly, and a Guillain-Barr\u00e9 syndrome highlights the need for laboratory differentiation of ZIKV from other virus infection. Women with potential risk for Zika virus infection who are pregnant or planning to become pregnant must mention that fact during prenatal visits in order to be evaluated and properly monitored. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?].](https://www.ncbi.nlm.nih.gov/pubmed/24913991)\nBastida, Carla; Also, Maria Antonia; Pericas, Juan Manuel; Letang, Emili; Tuset, Montse; Mir\u00f3, Josep Maria\n2014-11-01\nDrugs like statins may induce rhabdomyolysis. Simvastatin and lovastatin have a high hepatic metabolism and their potential toxicity could be increased by interactions with other drugs that reduce their metabolism. A case-report is presented of an HIV-infected patient treated with antiretroviral drugs who developed a rhabdomyolysis-induced renal failure and liver toxicity when simvastatin was substituted for atorvastatin. A literature review is also presented. The patient required hospital admission and showed a favorable response after hydration and urine alkalinization. There were 4 additional cases published of which there was one death. Drug-drug interactions can increase the risk of statin induced rhabdomyolysis. In order to evaluate them properly, physicians at all levels of clinical care should be aware of all drugs prescribed to their patients and the contraindicated combinations. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Management of Infection and Febrile Neutropenia in Patients with Solid Cancer.](https://www.ncbi.nlm.nih.gov/pubmed/26279208)\nAguado, Jos\u00e9 Mar\u00eda; Cruz, Juan Jes\u00fas; Virizuela, Juan Antonio; Aguilar, Manuela; Carmona, Alberto; Cassinello, Javier; Gudiol, Carlota; Jim\u00e9nez Fonseca, Paula; Lizasoain, Manuel; Marco, Francesc; Ruiz, Isabel; Ruiz, Maribel; Salavert, Miguel; Vicente, David; Carratal\u00e0, Jordi\nA group of experts from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Society of Medical Oncology (SEOM) have reviewed in this paper the main aspects to be considered in the evaluation of patients with solid cancer and infectious diseases. They have established a series of recommendations on the prevention of the most prevalent infections in these patients, the use of vaccines, the control measures of vascular catheter infection and prevention of infections before certain surgical procedures. Also the criteria for management of febrile neutropenia and the use of colony-stimulating factors were revised. Finally they provide a series of recommendations for the treatment of cancer patients with severe infection. The document is completed with a series of measures for the control of hospital infection. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Infectious diseases in the adult population admitted to a general hospital].](https://www.ncbi.nlm.nih.gov/pubmed/25541012)\nRamos, Jos\u00e9 M; Pinargote, H\u00e9ctor; Torr\u00fas, Diego; S\u00e1nchez-Mart\u00ednez, Rosario; Merino, Esperanza; Portilla, Joaqu\u00edn\n2015-10-01\nTo determine the infectious diseases (ID) that led to hospital admission of the foreign population>14 years. A retrospective study of foreign patients admitted to hospital (2000-2012). A total of 3,087 foreigners were admitted with infectious diseases. Of these, 73.6% were from low income countries, and 26.4% from high income countries. Most of them (86.9%) were admitted with common ID, 11.8% with transmissible ID, and 1.6% with tropical ID. Tropical ID and transmissible ID were higher in patients from low income countries (14.7%) than from high income countries (9.7%, p<0.001). The main tropical ID was malaria (74%). The main transmissible ID were tuberculosis (40.3%), hepatitis (27.8%), and HIV/AIDS (27.5%). Common ID were the main reason for admission in foreign population. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Serratia marcescens outbreak due to contaminated 2% aqueous chlorhexidine.](https://www.ncbi.nlm.nih.gov/pubmed/27495382)\nde Frutos, M\u00f3nica; L\u00f3pez-Urrutia, Luis; Dom\u00ednguez-Gil, Marta; Arias, Marta; Mu\u00f1oz-Bellido, Juan Luis; Eiros, Jos\u00e9 Mar\u00eda; Ramos, Carmen\n2017-12-01\nAn outbreak of Serratia marcescens infections outbreak is described, as well as the epidemiological study that linked the outbreak to the use of 2% aqueous chlorhexidine antiseptic. In late November 2014 an increasing incidence of S. marcescens isolates was detected in patients treated in the emergency department. It was considered a possible outbreak, and an epidemiological investigation was started. S. marcescens was isolated in 23 samples from 16 patients and in all new bottles of two lots of 2% aqueous chlorhexidine. The contaminated disinfectant was withdrawn, and the Spanish Drugs Agency was alerted (COS 2/2014). The epidemiological study showed that strains isolated from clinical samples and from chlorhexidine belonged to the same clone. No further isolates were obtained once the disinfectant was withdrawn. The suspicion of an outbreak and the epidemiological study were essential to control the incidence. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Malaria and intestinal protozoa].](https://www.ncbi.nlm.nih.gov/pubmed/26832999)\nRojo-Marcos, Gerardo; Cuadros-Gonz\u00e1lez, Juan\n2016-03-01\nMalaria is life threatening and requires urgent diagnosis and treatment. Incidence and mortality are being reduced in endemic areas. Clinical features are unspecific so in imported cases it is vital the history of staying in a malarious area. The first line treatments for Plasmodium falciparum are artemisinin combination therapies, chloroquine in most non-falciparum and intravenous artesunate if any severity criteria. Human infections with intestinal protozoa are distributed worldwide with a high global morbid-mortality. They cause diarrhea and sometimes invasive disease, although most are asymptomatic. In our environment populations at higher risk are children, including adopted abroad, immune-suppressed, travelers, immigrants, people in contact with animals or who engage in oral-anal sex. Diagnostic microscopic examination has low sensitivity improving with antigen detection or molecular methods. Antiparasitic resistances are emerging lately. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Collection, transport and general processing of clinical specimens in Microbiology laboratory.](https://www.ncbi.nlm.nih.gov/pubmed/29426791)\nS\u00e1nchez-Romero, M Isabel; Garc\u00eda-Lechuz Moya, Juan Manuel; Gonz\u00e1lez L\u00f3pez, Juan Jos\u00e9; Orta Mira, Nieves\n2018-02-06\nThe interpretation and the accuracy of the microbiological results still depend to a great extent on the quality of the samples and their processing within the Microbiology laboratory. The type of specimen, the appropriate time to obtain the sample, the way of sampling, the storage and transport are critical points in the diagnostic process. The availability of new laboratory techniques for unusual pathogens, makes necessary the review and update of all the steps involved in the processing of the samples. Nowadays, the laboratory automation and the availability of rapid techniques allow the precision and turn-around time necessary to help the clinicians in the decision making. In order to be efficient, it is very important to obtain clinical information to use the best diagnostic tools. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[A two-hour antibiotic susceptibility test by ATP-bioluminescence.](https://www.ncbi.nlm.nih.gov/pubmed/25979598)\nMarch Rossell\u00f3, Gabriel Alberto; Garc\u00eda-Loygorri Jord\u00e1n de Urries, Mar\u00eda Cristina; Guti\u00e9rrez Rodr\u00edguez, Mar\u00eda Purificaci\u00f3n; Simarro Grande, Mar\u00eda; Ordu\u00f1a Domingo, Antonio; Bratos P\u00e9rez, Miguel \u00c1ngel\n2016-01-01\nThe antibiotic susceptibility test (AST) in Clinical Microbiology laboratories is still time-consuming, and most procedures take 24h to yield results. In this study, a rapid antimicrobial susceptibility test using ATP-bioluminescence has been developed. The design of method was performed using five ATCC collection strains of known susceptibility. This procedure was then validated against standard commercial methods on 10 strains of enterococci, 10 staphylococci, 10 non-fermenting gram negative bacilli, and 13 Enterobacteriaceae from patients. The agreement obtained in the sensitivity between the ATP-bioluminescence method and commercial methods (E-test, MicroScan and VITEK2) was 100%. In summary, the preliminary results obtained in this work show that the ATP-bioluminescence method could provide a fast and reliable AST in two hours. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Diagnosis and treatment of imported malaria in Spain: Recommendations from the Malaria Working Group of the Spanish Society of Tropical Medicine and International Health (SEMTSI)].](https://www.ncbi.nlm.nih.gov/pubmed/24656967)\nMu\u00f1oz, Jose; Rojo-Marcos, Gerardo; Ram\u00edrez-Olivencia, Germ\u00e1n; Salas-Coronas, Joaqu\u00edn; Trevi\u00f1o, Bego\u00f1a; Perez Arellano, Jos\u00e9 Luis; Torr\u00fas, Diego; Mu\u00f1oz Vilches, Maria Jose; Ramos, Jose Manuel; Alegr\u00eda, I\u00f1aki; L\u00f3pez-V\u00e9lez, Rogelio; Aldasoro, Edelweiss; Perez-Molina, Jose Antonio; Rubio, Jose Miguel; Bassat, Quique\n2015-01-01\nMalaria is a common parasitic disease diagnosed in the returned traveler. Mortality in travelers with imported malaria is around 2-3%, and one of the main factors associated with poor prognosis is the delay in the diagnosis and treatment. Imported malaria cases usually present with fever, headache and myalgia, but other symptoms may appear. The diagnosis should be performed as soon as possible, using thick smear or rapid diagnostic tests, and a blood smear. Treatment should be initiated urgently. In cases of severe malaria, the use of intravenous artemisinins has proved to be superior to intravenous quinine. This document reviews the recommendations of the expert group of the Spanish Society of Tropical Medicine and International Health (SEMTSI) for the diagnosis and treatment of imported malaria in Spain. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Proposal of a five MIRU-VNTR panel to screen clinical isolates of Mycobacterium tuberculosis in Mexico].](https://www.ncbi.nlm.nih.gov/pubmed/25500299)\nBolado-Mart\u00ednez, Enrique; Candia-Plata, Maria Del Carmen; Zenteno-Cuevas, Roberto; Mendoza Dami\u00e1n, Fabiola; Avil\u00e9s-Acosta, Magali; \u00c1lvarez-Hern\u00e1ndez, Gerardo\n2015-11-01\nTuberculosis is a public health problem across Mexico. This paper aims to select a panel, with a minimum number of repetitive elements (MIRU-VNTR) for genotypic characterization of Mycobacterium tuberculosis (M. tuberculosis) clinical isolates. In this study, a full panel of 24 MIRU-VNTR loci was used to discriminate 65 clinical isolates of M. tuberculosis from three different geographical regions of Mexico. Those loci with the highest discriminatory power were subsequently selected. The panel, including five loci, was obtained by selecting the highest values of allelic diversity among the genotypes obtained. The dendrogram, generated by the panel MIRU-VNTR 5, showed a high discriminatory power with 65 unique genotype profiles and formed clusters according to the geographical region of origin. The panel MIRU-VNTR 5 can be useful for characterizing clinical isolates of M. tuberculosis in Mexico. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Tuberculosis and immigration].](https://www.ncbi.nlm.nih.gov/pubmed/26851978)\nSalas-Coronas, Joaqu\u00edn; Rogado-Gonz\u00e1lez, M Cruz; Lozano-Serrano, Ana Bel\u00e9n; Cabezas-Fern\u00e1ndez, M Teresa\n2016-04-01\nThe incidence of tuberculosis worldwide is declining. However, in Western countries this decline is slower due to the impact of immigration. Tuberculosis in the immigrant population is related to health status in the country of origin and with overcrowding and poverty conditions in the host country. Immigrants with tuberculosis are younger, have a higher prevalence of extrapulmonary forms, greater proportion of drug resistance and higher treatment default rates than those of natives. New molecular techniques not only reduce diagnostic delay time but also allow the rapid identification of resistances and improve knowledge of transmission patterns. It is necessary to implement measures to improve treatment compliance in this population group like facilitating access to health card, the use of fixed-dose combination drugs, the participation of cultural mediators and community health workers and gratuity of drugs. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Association between ovine protein polymorphisms and geographical variables in Europe and south-west Asia.](https://www.ncbi.nlm.nih.gov/pubmed/21395817)\nOrdas, J G; Carriedo, J A\n1997-01-12\nThe spatial distribution of six blood-protein polymorphisms in European and south-west Asian ovine breeds was analysed. Latitudinal clines were found for haemoglobin and transferrin loci. The respective F(ST) values are not significantly greater than those for protein-X, esterase, carbonic anhydrase, and albumin, where gene frequencies are not associated with latitude. The results suggest that historical processes of gene flow, rather than adaptation to different environments, have played a major role in determining the observed lives of gene frequencies. RESUMEN: Asociaci\u00f3n entre polimorfismos proteicos ovinos y variables geogr\u00e1ficas en Europa y sudoeste de Asia Se ha analizado la distribuci\u00f3n espacial de seis polimorfismos proteicos sangu\u00edneos en razas ovinas de Europa y del sudoeste de Asia. La hemoglobina y la transferrina muestran clinas latitudinales. Los valores de F(ST) para estos dos loci no son significativamente m\u00e1s grandes que los de la prote\u00edna-X, esterasa, anhidrasa carb\u00f3nica y alb\u00famina, cuyas frecuencias g\u00e9nicas no est\u00e1n asociadas con la latitud. Los resultados sugieren que la distribuci\u00f3n de las frecuencias g\u00e9nicas de la hemoglobina y la transferrina se debe a procesos hist\u00f3ricos de flujo g\u00e9nico y deriva gen\u00e9tica. 1997 Blackwell Verlag GmbH.\n[Desgarros del epitelio pigmentario de la retina: factores de riesgo, mecanismo y control terap\u00e9utico.](https://www.ncbi.nlm.nih.gov/pubmed/28693028)\nClemens, Christoph R; Eter, Nicole\n2017-07-11\nLos desgarros del epitelio pigmentario de la retina (EPR) se asocian en la mayor\u00eda de los casos con los desprendimientos vascularizados del EPR debido a una degeneraci\u00f3n macular asociada a la edad (DMAE), y normalmente implican una p\u00e9rdida adversa de la agudeza visual. Estudios recientes indican que ha habido un aumento en la incidencia de desgarros del EPR desde la introducci\u00f3n de f\u00e1rmacos anti-factor de crecimiento del endotelio vascular (anti-VEGF) as\u00ed como una asociaci\u00f3n temporal entre el desgarro y la inyecci\u00f3n intrav\u00edtrea. Dado que el n\u00famero de pacientes con DMAE y el n\u00famero de inyecciones anti-VEGF va en aumento, tanto la dificultad de prevenir desgarros del EPR como el tratamiento tras la formaci\u00f3n de los desgarros han adquirido una mayor relevancia. De forma paralela, la evoluci\u00f3n de la imagenolog\u00eda de la retina ha contribuido de manera significativa a comprender mejor el desarrollo de los desgarros del EPR en los \u00faltimos a\u00f1os. Esta revisi\u00f3n resume los conocimientos que se poseen actualmente sobre el desarrollo, los factores pron\u00f3sticos y las estrategias terap\u00e9uticas de los desgarros del EPR antes y despu\u00e9s de que estos se formen. \u00a9 2017 S. Karger AG, Basel.\n[[Cytochrome P-450 and the response to antimalarial drugs].](https://www.ncbi.nlm.nih.gov/pubmed/16536934)\nGuzm\u00e1n, Valentina; Carmona-Fonseca, Jaime\n2006-01-01\nTo assess the relationship between the genetic and phenotypic factors linked to the cytochrome P-450 enzyme system and the response to the antimalarial drugs chloroquine, amodiaquine, mefloquine, and proguanil, as well as to determine how certain biological and social factors of the host influence the behavior of this enzymatic complex. We performed a systematic review of the medical bibliographic databases PubMed, Excerpta Medica, LILACS, and SciELO by using the following Spanish and English descriptors: \"CYP-450\" and \"citocromo P-450\" in combination with \"proguanil\" (and with \"mefloquina,\" \"cloroquina,\" and \"amodiaquina\"), \"farmacocin\u00e9tica de proguanil\" (and the same using \"mefloquina,\" \"cloroquina,\" and \"amodiaquina\"), \"resistencia a proguanil\" (and the same using \"mefloquina,\" \"cloroquina,\" and \"amodiaquina\"), \"metabolismo,\" \"farmacogen\u00e9tica,\" \"enfermedad,\" \"inflamaci\u00f3n,\" \"infecci\u00f3n,\" \"enfermedad hep\u00e1tica,\" \"malaria,\" \"nutrici\u00f3n,\" and \"desnutrici\u00f3n.\" The same terms were used in English. The search included only articles published in Spanish, English, and Portuguese on or before 30 June 2005 that dealt with only four antimalarial drugs: amodiaquine, chloroquine, mefloquine, and proguanil. Some genetic factors linked to human cytochrome P-450 (mainly its polymorphism), as well as other biological and social factors (the presence of disease itself, or of inflammation and infection, the use of antimalarials in their various combinations, and the patient's nutritional status) influence the behavior of this complex enzymatic system. It has only been in the last decade that the genetics of the cytochromes has been explored and that the mechanisms underlying some therapeutic interactions and aspects of drug metabolism have been uncovered, making it possible to characterize the biotransformation pathway of amodiaquine and chloroquine. Hopefully new research will help answer the questions that still remain, some of which pertain to the metabolism of other\n[Las dificultades de sentir: el rol de las emociones en la estigmatizaci\u00f3n del VIH/SIDA](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2832313)\nMARZ\u00c1N-RODR\u00cdGUEZ, Melissa; VARAS-D\u00cdAZ, Nelson\n2009-01-01\nResumen El Virus de Inmunodeficiencia Humana (VIH) y el S\u00edndrome de Inmunodeficiencia Adquirida (SIDA) han sido motivo de estigmatizaci\u00f3n para las personas que viven con ellos. Esta estigmatizaci\u00f3n se ha estudiado consecuentemente desde la perspectiva de opiniones de agentes estigmatizantes. Estas opiniones han obviado sistem\u00e1ticamente el rol de las emociones en el proceso de estigmatizaci\u00f3n. Llevamos a cabo este estudio con el prop\u00f3sito de identificar el rol de las emociones en el proceso de estigmatizaci\u00f3n de las personas que viven con el virus (PVVS) por parte de profesionales de la salud. Para lograr este objetivo utilizamos un dise\u00f1o exploratorio y cualitativo en el cual utilizamos la t\u00e9cnica de entrevistas semiestructuradas a profundidad. La muestra estuvo compuesta por 80 profesionales de la salud y estudiantes de las siguientes especialidades: psicolog\u00eda, trabajo social, medicina y enfermer\u00eda. Los resultados reflejaron la existencia de emociones asociadas al VIH/SIDA tales como pena, l\u00e1stima, compasi\u00f3n, asco, fobia y miedo entre los/as profesionales y estudiantes que participaron. Las personas participantes evidenciaron la necesidad de controlar sus emociones al interactuar con PVVS. Los resultados apuntan a la necesidad de explorar aquellos factores que mediatizan las emociones, tales como el contexto social en que se manifiestan y ante qui\u00e9nes se revelan, para lograr entender a cabalidad el estigma que rodea al VIH/SIDA. PMID:20212916\nMarz\u00e1n-Rodr\u00edguez, Melissa; Varas-D\u00edaz, Nelson\n2006-01-01\nEl Virus de Inmunodeficiencia Humana (VIH) y el S\u00edndrome de Inmunodeficiencia Adquirida (SIDA) han sido motivo de estigmatizaci\u00f3n para las personas que viven con ellos. Esta estigmatizaci\u00f3n se ha estudiado consecuentemente desde la perspectiva de opiniones de agentes estigmatizantes. Estas opiniones han obviado sistem\u00e1ticamente el rol de las emociones en el proceso de estigmatizaci\u00f3n. Llevamos a cabo este estudio con el prop\u00f3sito de identificar el rol de las emociones en el proceso de estigmatizaci\u00f3n de las personas que viven con el virus (PVVS) por parte de profesionales de la salud. Para lograr este objetivo utilizamos un dise\u00f1o exploratorio y cualitativo en el cual utilizamos la t\u00e9cnica de entrevistas semiestructuradas a profundidad. La muestra estuvo compuesta por 80 profesionales de la salud y estudiantes de las siguientes especialidades: psicolog\u00eda, trabajo social, medicina y enfermer\u00eda. Los resultados reflejaron la existencia de emociones asociadas al VIH/SIDA tales como pena, l\u00e1stima, compasi\u00f3n, asco, fobia y miedo entre los/as profesionales y estudiantes que participaron. Las personas participantes evidenciaron la necesidad de controlar sus emociones al interactuar con PVVS. Los resultados apuntan a la necesidad de explorar aquellos factores que mediatizan las emociones, tales como el contexto social en que se manifiestan y ante qui\u00e9nes se revelan, para lograr entender a cabalidad el estigma que rodea al VIH/SIDA.\n[Selling antimicrobials without prescription - Far beyond an administrative problem.](https://www.ncbi.nlm.nih.gov/pubmed/27866752)\nGuinovart, Maria C; Figueras, Albert; Llor, Carles\n2018-05-01\nSelling antibiotics without prescription is common in many countries; beyond the administrative restrictions, this practice is a risk for patients and society. The aim of the study was to evaluate the information provided by the staff of the pharmacy to a simulated patient requesting an antibiotic. A prospective study was carried out in January 2013 - February 2014 in the Health Region of Tarragona, in which a mystery shopper visited 220 pharmacies requesting an antibiotic to be sold. The actress was not asked about allergies in 73.9% of cases and never was asked about possible pregnancy. Recommendation to see a doctor was observed in 36.1% of cases. When antibiotics were not sold, the explanation provided by the staff was reasoned only in 9.9% of the cases. It is necessary and urgent to improve the training of pharmacists in dispensing antibiotics but also strengthen basic health knowledge among the population. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Typhoid fever causing haemophagocytic lymphohistiocytosis in a non-endemic country - first case report and review of the current literature.](https://www.ncbi.nlm.nih.gov/pubmed/29887216)\nS\u00e1nchez-Moreno, Paula; Olbrich, Peter; Falc\u00f3n-Neyra, Lola; Lucena, Jose Manuel; Aznar, Javier; Neth, Olaf\n2018-06-07\nDevelopment of secondary haemophagocytic lymphohistiocytosis (sHLH) in the context of typhoid fever (TF) is a very rare but serious complication. Description of the first pediatric case of typhoid fever acquired in a non-endemic area complicated by sHLH. A systematic literature review of sHLH in the context of TF was performed with extraction of epidemiological, clinical and laboratory data. The literature search revealed 17 articles (22 patients). Fifteen patients were eligible for data analysis (53.4% children). All patients had fever and pancytopenia. Transaminases and LDH were frequently elevated (46.6%). Salmonella typhi was detected mainly by blood culture (64.3%). All the patients received antibiotics whereas immunomodulation (dexamethasone) was used in two cases. A high suspicion index for this condition is needed even in non-endemic areas. The addition of immunmodulation to standard antimicrobial therapy should be considered in selected cases. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Pylephlebitis: incidence and prognosis in a tertiary hospital.](https://www.ncbi.nlm.nih.gov/pubmed/24844192)\nBelhassen-Garc\u00eda, Moncef; Gomez-Munuera, Mercedes; Pardo-Lledias, Javier; Velasco-Tirado, Virginia; Perez-Persona, Ernesto; Galindo-Perez, Inmaculada; Alvela-Su\u00e1rez, Lucia; Romero-Alegr\u00eda, Angela; Mu\u00f1oz-Bellvis, Luis; Cordero-S\u00e1nchez, Miguel\n2014-01-01\nSeptic thrombophlebitis of the portal vein or its branches, most often secondary to intra-abdominal infection is known as pylephlebitis. The frequency and the prognosis of this complication are unknown. The aim of this study was to determine the global and relative incidence of the most frequent intra-abdominal infections and the real prognosis of this disease. An observational retrospective study was conducted in a tertiary care hospital (University Hospital of Salamanca, Spain) from January 1999 to December 2008. A total of 7796 patients with intra-abdominal infection were evaluated, of whom 13 (0.6%) had been diagnosed with pylephlebitis. Diverticulitis was the most frequent underlying process, followed by biliary infection. Early mortality was 23%. Survivors had no recurrences, but one of them developed portal cavernomatosis. Pylephlebitis is a rare complication of intra-abdominal infection, with a high early mortality, but with a good prognosis for survivors. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Self-assessment of patterns of antibiotic use in a university hospital].](https://www.ncbi.nlm.nih.gov/pubmed/24889543)\nG\u00f3mez, J; Garc\u00eda-V\u00e1zquez, E; Bonillo, C; Hern\u00e1ndez, A; Bermejo, M; Canteras, M\n2014-10-01\nA questionnaire was used to determine the knowledge, attitudes and practices of antibiotic prescribing among doctors at a university hospital. An anonymous questionnaire was directly distributed by a staff member of the Infectious Diseases Department. A total of 316 questionnaires were distributed with 100% response rate; antibiotic dose, route of administration, and treatment duration were always adjusted according to site of infection and underlying conditions in 65, 68 and 45%, respectively. Antibiotic de-escalation was recognized as usual practice in 20%; 31 and 10% considered potential microbiological resistances and economical-cost when taking prescription decisions, respectively; 16% admitted often prescribing antibiotics with no clinical indication. There were no major significant differences between staff and training physicians, or between surgical or medical specialists. The self-perception of physicians and residents in our hospital is that they make improper use of antimicrobials. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Strategies for the cure of HIV infection.](https://www.ncbi.nlm.nih.gov/pubmed/29510860)\nRodr\u00edguez-Mu\u00f1oz, Jes\u00fas; Moreno, Santiago\n2018-03-03\nThe disadvantages of the long-term administration of antiretroviral therapy as well as the huge number of affected persons have placed the cure of HIV as a primary goal of Public Health. HIV may persist in the organism by at least four mechanisms: a latently infected cellular reservoir, the persistent replication of HIV in spite of ART, anatomic sanctuaries, and the immune dysfunction. Several strategies directed against these mechanisms have been developed. With all this, a complete eradication of HIV has been achieved in a patient using the transplantation of haemopoietic stem cells that were resistant to HIV-infection, and there are examples of functional cure either spontaneously (elite controllers) or after antiretroviral therapy (post-treatment controllers). However, no strategies have been successful in reducing the reservoir size, nor in achieving constant, uniform remissions. The failure of isolated strategies makes it likely that the combination of several of them may be the future solution. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Microbiological diagnosis of human papilloma virus infection.](https://www.ncbi.nlm.nih.gov/pubmed/27353835)\nMateos-Lindemann, Maria Luisa; P\u00e9rez-Castro, Sonia; Rodr\u00edguez-Iglesias, Manuel; P\u00e9rez-Gracia, Maria Teresa\n2017-11-01\nInfection with human papillomavirus (HPV) is the leading cause of sexually transmitted infection worldwide. This virus generally causes benign lesions, such as genital warts, but persistent infection may lead to cervical cancer, anal cancer, vaginal cancer, and oropharyngeal cancer, although less frequently. Cervical cancer is a severe disease with a high mortality in some countries. Screening with cytology has been very successful in the last few years, but nowadays there are numerous studies that confirm that cytology should be replaced with the detection of HPV as a first line test in population based screening. There are several commercially available FDA approved tests for screening of cervical cancer. A new strategy, based on individual detection of the high risk genotypes HPV16 and HPV18, present in 70% of cervical cancer biopsies, has been proposed by some experts, and is going to be implemented in most countries in the future. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Recommendations from MENSURA for selection of antimicrobial agents for susceptibility testing and criteria for the interpretation of antibiograms].](https://www.ncbi.nlm.nih.gov/pubmed/10856132)\n2000-03-01\nThis document includes the recommendations from the Spanish antibiogram committee (The MENSURA group, Mesa Espa\u00f1ola de Normalizaci\u00f3n de la Sensibilidad y Resistencia a los Antimicrobianos, under the auspices of the Sociedad Espa\u00f1ola de Quimioterapia and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica) for the selection of antimicrobials for susceptibility testing. Separate tables for each group of organism with proposed susceptibility and resistance breakpoints are updated and comparatively presented with those of other groups, such us NCCLS, CA-SFM and BSAC. The susceptibility breakpoint tends to identify the fully susceptible population, which probably lacks any specific resistance mechanism. The analysis of MIC distributions for different homogeneous populations (same species) is used to define breakpoints for susceptibility. The resistance breakpoint is based on pharmacological and clinical data obtained when the corresponding antibiotic is administered with a conventional schedule. The primary objective of the Spanish MENSURA group is to contribute to the international consensus on the establishment of breakpoints.\n[Implementing and expanding HIV testing in immigrant populations in Europe: Comparing guideline's recommendations and expert's opinions.](https://www.ncbi.nlm.nih.gov/pubmed/26481661)\n\u00c1lvarez-Del Arco, D\u00e9bora; Monge, Susana; Rivero-Montesdeoca, Yaiza; Burns, Fiona; Noori, Teymur; Del Amo, Julia\n2017-01-01\nImmigrant populations, especially those from endemic countries, living in the European Union (EU) suffer a disproportionate burden of HIV, delayed diagnosis and poorer access to antiretroviral treatment. While International Organisations are developing recommendations aimed at increasing the uptake of HIV testing, the feasibility and real outcomes of these measures remain unexplored. The aim of this review was, firstly to identify the recommendations of the main International Organisations (IO) on HIV testing in immigrants. Secondly, to describe the challenges for implementing and expanding HIV testing and counselling interventions targeting immigrants by interviewing key informants. The importance of HIV testing in immigrants is discussed, along with the appropriateness of universal HIV testing approaches vs most at risk targeted approaches. Also addressed is, pre- and post-HIV test counselling characteristics and community initiatives suitable to reach this population and, finally the legal issues regarding access to treatment for illegal immigrants. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018).](https://www.ncbi.nlm.nih.gov/pubmed/29759422)\n2018-05-11\nThis update to the document on antiretroviral therapy (ART) in adults, which has been prepared jointly by GeSIDA and the Spanish National AIDS Plan for the last two decades, supersedes the document published in 2017. 1 The update provides physicians treating HIV-1-infected adults with evidence-based recommendations to guide their therapeutic decisions. The main difference with respect to the previous document concerns recommended initial ART regimens, only three of which are maintained as preferential. All three include dolutegravir or raltegravir, together with emtricitabine/tenofovir alafenamide or abacavir/lamivudine. Other differences concern the section on switching ART in patients with suppressed viral replication, which now includes new two- and three-drug regimens, and the antiretroviral drugs recommended for pregnant women and patients with tuberculosis. A recommendation has also been added for patients who present with acute HIV infection after pre-exposure prophylaxis. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).](https://www.ncbi.nlm.nih.gov/pubmed/24986715)\nBerenguer, Juan; Polo, Rosa; Lozano, Fernando; L\u00f3pez Aldeguer, Jos\u00e9; Antela, Antonio; Arribas, Jos\u00e9 Ram\u00f3n; Asensi, V\u00edctor; Blanco, Jos\u00e9 Ram\u00f3n; Clotet, Bonaventura; Domingo, Pere; Galindo, Mar\u00eda Jos\u00e9; Gatell, Jos\u00e9 Mar\u00eda; Gonz\u00e1lez-Garc\u00eda, Juan; Iribarren, Jos\u00e9 Antonio; Locutura, Jaime; L\u00f3pez, Juan Carlos; Mallolas, Josep; Mart\u00ednez, Esteban; Miralles, Celia; Mir\u00f3, Jos\u00e9 M; Moreno, Santiago; Palacios, Rosario; P\u00e9rez El\u00edas, Mar\u00eda Jes\u00fas; Pineda, Juan Antonio; Podzamczer, Daniel; Portilla, Joaqu\u00edn; Pulido, Federico; Ribera, Esteban; Riera, Melchor; Rubio, Rafael; Santos, Jes\u00fas; Sanz, Jes\u00fas; Tuset, Montserrat; Vidal, Francesc; Rivero, Antonio\n2014-01-01\nIn this update, antiretroviral therapy (ART) is recommended for all patients infected by type 1 human immunodeficiency virus (HIV-1). The strength and grade of the recommendation varies with clinical circumstances, number of CD4 cells, comorbid conditions and prevention of transmission of HIV. The objective of ART is to achieve an undetectable plasma viral load. Initial ART should always comprise a combination of 3 drugs, including 2 nucleoside reverse transcriptase inhibitors and a third drug from a different family (non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or integrase inhibitor). This update presents the causes and criteria for switching ART in patients with undetectable plasma viral load and in cases of virological failure. An update is also provided for the specific criteria for ART in special situations (acute infection, HIV-2 infection, and pregnancy) and with comorbid conditions (tuberculosis or other opportunistic infections, kidney disease, liver disease, and cancer). Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Variability of nutrients intake, lipid profile and cardiovascular mortality among geographical areas in Spain: The DRECE study.](https://www.ncbi.nlm.nih.gov/pubmed/29239557)\nG\u00f3mez de la C\u00e1mara, Agust\u00edn; De Andr\u00e9s Esteban, Eva; Urr\u00fatia Cuch\u00ed, Gerard; Calder\u00f3n Sandubete, Enrique; Rubio Herrera, Miguel \u00c1ngel; Men\u00e9ndez Orenga, Miguel; Lora Pablos, David\n2017-11-07\nIt has often been suggested that cardiovascular mortality and their geographical heterogeneity are associated with nutrients intake patterns and also lipid profile. The large Spanish study Dieta y Riesgo de Enfermedades Cardiovasculares en Espa\u00f1a (DRECE) investigated this theory from 1991 to 2010. Out of the 4,783 Spanish individuals making up the DRECE cohort, 220 subjects (148 men and 72 women) died (4.62%) during the course of the study. The mean age of patients who died from cardiovascular causes (32 in all) was 61.08 years 95% CI (57.47-64.69) and 70.91% of them were males. The consumption of nutrients and the lipid profile by geographical area, studied by geospatial models, showed that the east and southern area of the country had the highest fat intake coupled to a high rate of unhealthy lipid profile. It was concluded that the spatial geographical analysis showed a relationship between high fat intake, unhealthy lipid profile and cardiovascular mortality in the different geographical areas, with a high variability within the country.\n[[GEIPC-SEIMC (Study Group for Infections in the Critically Ill Patient of the Spanish Society for Infectious Diseases and Clinical Microbiology) and GTEI-SEMICYUC ( Working Group on Infectious Diseases of the Spanish Society of Intensive Medicine, Critical Care, and Coronary Units) recommendations for antibiotic treatment of gram-positive cocci infections in the critical patient].](https://www.ncbi.nlm.nih.gov/pubmed/17692213)\nAstigarraga, P M Olaechea; Montero, J Garnacho; Cerrato, S Grau; Colomo, O Rodr\u00edguez; Mart\u00ednez, M Palomar; Crespo, R Zaragoza; Garc\u00eda-Paredes, P Mu\u00f1oz; Cerd\u00e1, E Cerd\u00e1; Lerma, F Alvarez\n2007-01-01\nIn recent years, an increment of infections caused by gram-positive cocci has been documented in nosocomial and hospital-acquired-infections. In diverse countries, a rapid development of resistance to common antibiotics against gram-positive cocci has been observed. This situation is exceptional in Spain but our country might be affected in the near future. New antimicrobials active against these multi-drug resistant pathogens are nowadays available. It is essential to improve our current knowledge about pharmacokinetic properties of traditional and new antimicrobials to maximize its effectiveness and to minimize toxicity. These issues are even more important in critically ill patients because inadequate empirical therapy is associated with therapeutic failure and a poor outcome. Experts representing two scientific societies (Grupo de estudio de Infecciones en el Paciente Cr\u00edtico de la SEIMC and Grupo de trabajo de Enfermedades Infecciosas de la SEMICYUC) have elaborated a consensus document based on the current scientific evidence to summarize recommendations for the treatment of serious infections caused by gram-positive cocci in critically ill patients.\n[Fast methods of fungal and bacterial identification. MALDI-TOF mass spectrometry, chromogenic media.](https://www.ncbi.nlm.nih.gov/pubmed/28108122)\nSiller-Ruiz, Mar\u00eda; Hern\u00e1ndez-Egido, Sara; S\u00e1nchez-Juanes, Fernando; Gonz\u00e1lez-Buitrago, Jos\u00e9 Manuel; Mu\u00f1oz-Bellido, Juan Luis\n2017-05-01\nMALDI-TOF mass spectrometry is now a routine resource in Clinical Microbiology, because of its speed and reliability in the identification of microorganisms. Its performance in the identification of bacteria and yeasts is perfectly contrasted. The identification of mycobacteria and moulds is more complex, due to the heterogeneity of spectra within each species. The methodology is somewhat more complex, and expanding the size of species libraries, and the number of spectra of each species, will be crucial to achieve greater efficiency. Direct identification from blood cultures has been implemented, since its contribution to the management of severe patients is evident, but its application to other samples is more complex. Chromogenic media have also contributed to the rapid diagnosis in both bacteria and yeast, since they accelerate the diagnosis, facilitate the detection of mixed cultures and allow rapid diagnosis of resistant species. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Vaccination for international travelers].](https://www.ncbi.nlm.nih.gov/pubmed/26920587)\nArrazola, M Pilar; Serrano, Almudena; L\u00f3pez-V\u00e9lez, Rogelio\n2016-05-01\nTraveler's vaccination is one of the key strategies for the prevention of infectious diseases during international travel. The risk of acquiring an infectious disease is determined in each case by the characteristics of the traveler and the travel, so the pre-departure medical advice of the traveler must be individualized. The World Health Organization classifies traveler\u015b vaccines into three groups. - Vaccines for routine use in national immunization programs: Haemophilus influenzae type b, hepatitis B, polio, measles-mumps-rubella, tetanus-diphtheria-whooping a cough, and chickenpox. - Vaccinations required by law in certain countries before to enter them: yellow fever, meningococcal disease and poliomyelitis. - Vaccines recommended depending on the circumstances: cholera, japanese encephalitis, tick-borne encephalitis, meningococcal disease, typhoid fever, influenza, hepatitis A, hepatitis B, rabies and BCG. This review is intended to introduce the reader to the field of international vaccination. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Pneumococcal vaccines. New conjugate vaccines for adults].](https://www.ncbi.nlm.nih.gov/pubmed/26474708)\nCampins Mart\u00ed, Magda\n2015-11-01\nPneumococcal infections are a significant cause of morbidity and mortality, and are one of the 10 leading causes of death worldwide. Children under 2 years have a higher incidence rate, followed by adults over 64 years. The main risk group are individuals with immunodeficiency, and those with anatomical or functional asplenia, but can also affect immunocompetent persons with certain chronic diseases. Significant progress has been made in the last 10 years in the prevention of these infections. Until a few years ago, only the 23-valent non-conjugate pneumococcal vaccine was available. Its results were controversial in terms of efficacy and effectiveness, and with serious limitations on the type of immune response induced. The current possibility of using the 13-valent conjugate vaccine in adults has led to greater expectations in improving the prevention of pneumococcal disease in these age groups. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Molecular aspects of the antiviral response against hepatitis C virus implicated in vaccines development].](https://www.ncbi.nlm.nih.gov/pubmed/24529681)\nLlanes, Mar\u00eda Soledad; Palacios, Natalia Soledad; Piccione, Magal\u00ed; Ruiz, Mar\u00eda Guillermina; Layana, Carla\n2015-04-01\nHepatitis C is a contagious liver disease caused by hepacivirus of the Flaviviridae family. It has a RNA genome, a unique highly variable molecule. It encodes ten proteins which are necessary to infect cells and multiply. Replication occurs only in hepatocytes. Because of its wide genomic variability and the absence of symptoms, it is difficult to make an early diagnosis and successful treatment. In this review we analyze the molecular mechanism by which the virus infects the hepatocytes and causes the disease. We focused the analysis on different therapies, with the possibility of improving treatment with the use of new specific vaccines. We highlight the use of new therapies based on nucleic acids, mainly DNA vectors. In the near future, once this treatment is adequately evaluated in clinical trials, and the costs are calculated, it could be a very beneficial alternative to conventional methods. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Comparison of the CT OligoGen kit with cobas 4800 assay for detection of Chlamydia trachomatis.](https://www.ncbi.nlm.nih.gov/pubmed/25858681)\nParra-S\u00e1nchez, Manuel; Marcuello-L\u00f3pez, Ana; Garc\u00eda-Rey, Silvia; Zakariya-Yousef, Ismail; Sivianes-Valdecantos, Nieves; Sierra-Atienza, Celestina; Bernal-Mart\u00ednez, Samuel; Pueyo-Rodr\u00edgez, Isabel; Mart\u00edn-Mazuelos, Estrella; Palomares-Fol\u00eda, Jos\u00e9 Carlos\n2015-12-01\nA prospective study was designed to assess the performance of the new CT OligoGen kit and the cobas 4800 assay for detection of Chlamydia trachomatis. A set of samples that included urine samples (n=212), endocervical (n=167), rectal (n=53), pharyngeal (n=7) and urethral swabs (n=3). The samples were sent from a regional sexually transmitted diseases (STD) clinic in Seville, Spain, and were collected from 261 men and 181 women. Discordant results were re-analyzed and clinical data and other tests were reviewed in order to resolve them. Sensitivity, specificity, positive predicative value (PPV), negative predictive value (NPV) and kappa value for C. trachomatis detection using the CT OligoGen kit were 98.5%, 100%, 100%, 95.4% and 0.97, respectively. This new kit had a high sensitivity, specificity, PPV and NPV for C. trachomatis, therefore the performance profile confirms the usefulness and reliable results of this new assay. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Executive summary of the consensus document on post-exposure prophylaxis against HIV, HBV and HCV in adults and children.](https://www.ncbi.nlm.nih.gov/pubmed/26474709)\nPolo Rodriguez, Rosa; Lozano, Fernando; Gonz\u00e1lez de Castro, Pedro; Jim\u00e9nez, Ma Alonso; Mir\u00f3, Oscar; Ram\u00f3n Blanco, Jose; Moreno, David; Due\u00f1as, Carlos; Mu\u00f1oz Plat\u00f3n, Enriqueta; Fern\u00e1ndez Escribano, Marina; Sanz Sanz, Jes\u00fas; Fumaz, Carmina; Santos, Ignacio; Garc\u00eda, Federico; T\u00e9llez, Ma Jes\u00fas; Gonz\u00e1lez Montero, Ra\u00fal; Vals Jimenez, Ma Victoria; Losa, Juan Emilio; Valle Robles, Ma Luisa; Iribarren, Jose Antonio; Ortega, Enrique\n2016-02-01\nPost-exposure prophylaxis (PEP) can be a secondary measure to prevent infection by human immunodeficiency virus (HIV) when primary prevention has failed. PEP is advised for people with sporadic and exceptional risk exposure to HIV. This consensus document about occupational and non-occupational PEP recommendations aims to be a technical document for healthcare professionals. Its main objective is to facilitate the appropriate use of PEP. To this end, some recommendations have been established to assess the risk of transmission in different types of exposure, situations where PEP should be recommended, special circumstances to take into account, antiretroviral (ARV) guidelines including start and end of the treatment, early monitoring of tolerance and adherence to the treatment, subsequent monitoring of people exposed, independently of having received PEP or not, and need of psychological support. This document is intended for all professionals who work in clinical practice in the field of HIV infection. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI).](https://www.ncbi.nlm.nih.gov/pubmed/25976754)\nVidal, Elisa; Cervera, Carlos; Cordero, Elisa; Armi\u00f1anzas, Carlos; Carratal\u00e1, Jordi; Cisneros, Jos\u00e9 Miguel; Fari\u00f1as, M Carmen; L\u00f3pez-Medrano, Francisco; Moreno, Asunci\u00f3n; Mu\u00f1oz, Patricia; Orig\u00fcen, Julia; Sab\u00e9, N\u00faria; Valerio, Maricela; Torre-Cisneros, Juli\u00e1n\n2015-12-01\nUrinary tract infections (UTIs) are one of the most common infections in solid organ transplant (SOT) recipients. Experienced SOT researchers and clinicians have developed and implemented this consensus document in support of the optimal management of these patients. A systematic review was conducted, and evidence levels based on the available literature are given for each recommendation. This article was written in accordance with international recommendations on consensus statements and the recommendations of the Appraisal of Guidelines for Research and Evaluation II (AGREE II). Recommendations are provided on the management of asymptomatic bacteriuria, and prophylaxis and treatment of UTI in SOT recipients. The diagnostic-therapeutic management of recurrent UTI and the role of infection in kidney graft rejection or dysfunction are reviewed. Finally, recommendations on antimicrobials and immunosuppressant interactions are also included. The latest scientific information on UTI in SOT is incorporated in this consensus document. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Pathogenesis of tuberculosis and other mycobacteriosis.](https://www.ncbi.nlm.nih.gov/pubmed/29198784)\nCardona, Pere-Joan\n2018-01-01\nThe evolution between Mycobacterium tuberculosis infection and active tuberculosis is multifactorial and involves different biological scales. The synthesis of ESAT-6 or the induction of alveolar macrophage necrosis are key, but to understand it, it is necessary to consider the dynamics of endogenous and exogenous reinfection, drainage of lung parenchyma and respiratory mechanics, local fibrosis processes and blood supply. Paradoxically, the immune response generated by the infection is highly protective (90%) against active tuberculosis, although as it is essentially based on the proliferation of Th1 lymphocytes, it cannot prevent reinfection. Severe immunosuppression can only explain 10% of active tuberculosis cases, while the remainder are attributable to comorbidities, a proinflammatory environment and an unknown genetic propensity. The pathogenic capacity of environmental mycobacteria is discrete, linked to deficits in the innate and acquired immune response. The ability to generate biofilms and the ability of M. ulcerans to generate the exotoxin mycolactone is remarkable. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Identification of Streptococcus pneumoniae lytA, plyA and psaA genes in pleural fluid by multiplex real-time PCR.](https://www.ncbi.nlm.nih.gov/pubmed/28818481)\nSanz, Juan Carlos; R\u00edos, Esther; Rodr\u00edguez-Avial, Iciar; Ramos, Bel\u00e9n; Mar\u00edn, Mercedes; Cercenado, Emilia\n2017-08-14\nThe aim was to evaluate the utility of a multiplex real-time PCR to detect Streptococcus pneumoniae lytA, plyA and psaA genes in pleural fluid (PF). A collection of 81 PF samples was used. Sixty were considered positive for S. pneumoniae according to previous results (54 by an in-house lytA gene PCR and eight by universal rRNA PCR). The sensitivity for detection of the lytA, plyA and psaA genes by multiplex PCR was 100% (60/60), 98.3% (59/60) and 91.7% (55/60), respectively. The detection of all three genes was negative in 21 samples formerly confirmed as negative for S. pneumoniae (100% specificity) by the other procedures (9 by in-house lytA PCR and 12 by rRNA PCR). The use of this multiplex PCR may be a useful option to identify S. pneumoniae directly in PF samples. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Recognition of excretory/secretory antigens of Anisakis type I and evolution of IgE in experimentally infected rats].](https://www.ncbi.nlm.nih.gov/pubmed/24211134)\nG\u00f3mez-Mateos, Magdalena; Valero-L\u00f3pez, Adela; de la Rubia-Nieto, Teresa; Romero-L\u00f3pez, Mar\u00eda Del Carmen; D\u00edaz-S\u00e1ez, Victoriano\n2014-10-01\nAnisakis spp., during parasitism, release excretory-secretory antigens that, in contact with the human immune system, can trigger a hypersensitivity response mediated by IgE, causing various allergic symptoms. To evaluate the IgE response in Wistar rats after infection with L3 larvae of the parasite Anisakis spp. Some determining factors involved in the technique have been improved in this work, such as: the concentration of polyacrylamide used in the preparation of the gels, the antigen concentration used, and the temperature required for denaturation of proteins. Immune responses (Ag-Ab) observed by the immunoblotting technique showed a greater intensity with serum obtained after reinfection, which have recognized proteins that may correspond to the major antigen Ani s 1 and other polypeptides of interest in the diagnosis of human anisakiasis. This paper concludes that immunoblotting is a useful technique to detect IgE antibodies against Anisakis proteins. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Syphilis and human immunodeficiency virus infection: an endemic infection in men who have sex with men].](https://www.ncbi.nlm.nih.gov/pubmed/25444048)\nGonz\u00e1lez-Domenech, Carmen M; Antequera Mart\u00edn-Portugu\u00e9s, Isabel; Clavijo-Frutos, Encarnaci\u00f3n; M\u00e1rquez-Solero, Manuel; Santos-Gonz\u00e1lez, Jes\u00fas; Palacios-Mu\u00f1oz, Rosario\n2015-01-01\nto analyse epidemiological, clinical, and analytical features of HIV-infected men who have sex with men (MSM) diagnosed with syphilis in the Infectious Diseases Unit (Hospital Virgen de la Victoria, M\u00e1laga, Spain) during 2004-2013. An observational study was conducted on 196 syphilis episodes in 167 MSM infected with HIV (2004-2013). Epidemiological, clinical, and analytical data were collected. Annual syphilis incidence among HIV-MSM is calculated as the number of syphilis episodes among MSM in one year divided by the number of MSM followed up in that year. Incidence ranged from 1.2% (2007) to 7.8% (2012). There were asymptomatic episodes in 42.8% cases, and an HIV-syphilis coincident diagnosis in 28.5%. The annual incidence of syphilis has increased within HIV infected MSM. One third of the syphilis episodes were simultaneous to HIV diagnosis and near half of them were asymptomatic. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Lekking behavior of Anastrepha Fraterculus (Diptera: Tephritidae)](https://www.osti.gov/biblio/20942922-lekking-behavior-anastrepha-fraterculus-diptera-tephritidae) [DOE Office of Scientific and Technical Information (OSTI.GOV)](http://www.osti.gov/search)\nSegura, D.; Petit-Marty, N.; Cladera, J.\nquimicas) para atraer a las hembras con el proposito de aparearse. Las hembras visitan el lek y eligen entre los machos para copular. La informacion acerca de los principales factores involucrados en la eleccion de la hembra y de la influencia del comportamiento de los machos en los leks en esta eleccion es escasa para A. fraterculus . Esta informacion es importante en el contexto de programas de control que incluyen la Tecnica del Insecto Esteril. En el presente estudio se evaluo el comportamiento sexual de machos de A. fraterculus dentro de los leks, y la asociacion de su comportamiento y de rasgos morfometricos con el exito copulatorio. El lugar preferido de agrupamiento de los machos fue evaluado en jaulas de campo con arboles en su interior y dividiendo el arbol en sectores de acuerdo a un sistema de tres dimensiones. Los machos fueron individualmente pesados, marcados y observados cada quince minutos. Luego de finalizado el ensayo se midieron los rasgos morfometricos. El mayor exito correspondio a machos agrupados en una region del arbol caracterizada por tener la mayor intensidad de luz en las dos primeras horas de la manana. Los resultados mostraron que la actividad de llamado con feromonas esta asociada con el exito copulatorio. Las copulas fueron mas frecuentes para machos que llamaron dentro del lek, indicando que la actividad de llamado con feromonas y la presencia dentro del lek son factores importantes en la obtencion de la copula. Los analisis morfometricos revelaron una asociacion positiva entre el exito copulatorio y el largo del ojo, y que algunas caracteristicas de la cara estan asociadas ademas con la duracion de la copula y la latencia. (author)\u00ab less\n[[Consensus document on spasticity in patients with multiple sclerosis. Grupo de Enfermedades Desmielinizantes de la Sociedad Espa\u00f1ola de Neurolog\u00eda].](https://www.ncbi.nlm.nih.gov/pubmed/24081891)\nOreja-Guevara, Celia; Montalban, Xavier; de Andr\u00e9s, Clara; Casanova-Estruch, Bonaventura; Mu\u00f1oz-Garc\u00eda, Delicias; Garc\u00eda, Inmaculada; Fern\u00e1ndez, \u00d3scar\n2013-10-16\nMultiple sclerosis is a chronic neurological inflammatory demyelinating disease. Specialists involved in the symptomatic treatment of this disease tend to apply heterogeneous diagnostic and treatment criteria. To establish homogeneous criteria for treating spasticity based on available scientific knowledge, facilitating decision-making in regular clinical practice. A group of multiple sclerosis specialists from the Spanish Neurological Society demyelinating diseases working group met to review aspects related to spasticity in this disease and draw up the consensus. After an exhaustive bibliographic search and following a metaplan technique, a number of preliminary recommendations were established to incorporate into the document. Finally, each argument was classified depending on the degree of recommendation according to the SIGN (Scottish Intercollegiate Guidelines Network) system. The resulting text was submitted for review by the demyelinating disease group. An experts' consensus was reached regarding spasticity triggering factors, related symptoms, diagnostic criteria, assessment methods, quality of life and therapeutic management (drug and non-drug) criteria. The recommendations included in this consensus can be a useful tool for improving the quality of life of multiple sclerosis patients, as they enable improved diagnosis and treatment of spasticity.\n[Diversity of amphibians and reptiles associated with grasslands of Janos-Casas Grandes, Chihuahua, Mexico (La diversidad de anfibios y reptiles asociada a los pastizales de Janos-Casas Grandes, Chihuahua, Mexico)](https://www.fs.usda.gov/treesearch/pubs/22732)\nGeorgina Santos-Barrera; Jesus Pacheco-Rodriguez\n2006-01-01\nPrairie-dog (Cynomys ludovicianus) colonies in northwest Chihuahua, Mexico, have been of great significance not only in initiating protection programs for the species but also in learning about the biological diversity (flora and fauna) of the natural grasslands of Janos-Casas Grandes, Chihuahua. Therefore a study of the herpetological fauna within the prairie-dog...\n[Nursing interventions for rehabilitation in Parkinson's disease: cross mapping of terms.](https://www.ncbi.nlm.nih.gov/pubmed/27508903)\nTosin, Michelle Hyczy de Siqueira; Campos, D\u00e9bora Moraes; Andrade, Leonardo Tadeu de; Oliveira, Beatriz Guitton Renaud Baptista de; Santana, Rosimere Ferreira\n2016-08-08\ncom a taxonomia e o refinamento feito pelos especialistas, resultaram em 32 interven\u00e7\u00f5es equivalentes ao sistema de Classifica\u00e7\u00e3o das Interven\u00e7\u00f5es de Enfermagem. \"Ensino: Processo da doen\u00e7a\", \"Contrato com o Paciente\" e \"Facilita\u00e7\u00e3o da Aprendizagem\" estiveram presentes em 100% dos prontu\u00e1rios. Para essas, foram descritas 40 atividades, representando 13 atividades por interven\u00e7\u00e3o prescrita. o mapeamento cruzado permitiu levantar os termos correspondentes \u00e0s Interven\u00e7\u00f5es de Enfermagem utilizados no cotidiano dos enfermeiros de reabilita\u00e7\u00e3o e compar\u00e1-los ao sistema de Classifica\u00e7\u00e3o das Interven\u00e7\u00f5es de Enfermagem. realizar el mapeo cruzado de t\u00e9rminos del lenguaje de Enfermer\u00eda con el Sistema de Clasificaci\u00f3n de las Intervenciones de Enfermer\u00eda en historias cl\u00ednicas de pacientes con enfermedad de Parkinson en rehabilitaci\u00f3n. estudio de investigaci\u00f3n documental para realizaci\u00f3n de mapeo cruzado. Muestra probabil\u00edstica de tipo aleatoria simple, compuesta por 67 historias cl\u00ednicas de pacientes con enfermedad de Parkinson que participaron del programa de rehabilitaci\u00f3n entre marzo de 2009 y abril de 2013. Investigaci\u00f3n realizada en tres etapas donde fueron mapeados los t\u00e9rminos de Enfermer\u00eda en lenguaje libre y cruzados con el sistemas de Clasificaci\u00f3n de Intervenciones de Enfermer\u00eda. se identificaron 1077 intervenciones normalizadas que, despu\u00e9s del cruzamiento con la taxonom\u00eda y el refinamiento hecho por los especialistas, resultaron en 32 intervenciones equivalentes al sistema de Clasificaci\u00f3n de Intervenciones de Enfermer\u00eda. \"Ense\u00f1anza: Proceso de la enfermedad\", \"Contrato con el paciente\" y \"Facilitaci\u00f3n del aprendizaje\" estuvieron presentes en 100% de las historias cl\u00ednicas. Para \u00e9stas, se describieron 40 actividades, representando 13 actividades por cada intervenci\u00f3n prescripta. el mapeo cruzado permiti\u00f3 encontrar los t\u00e9rminos correspondientes a las Intervenciones en Enfermer\u00eda utilizados en el d\u00eda a d\u00eda de los\n[Use of the polymerase chain reaction to directly detect malaria parasites in blood samples from the Venezuelan Amazon.](https://www.ncbi.nlm.nih.gov/pubmed/8116809)\nLaserson, K F; Petralanda, I; Hamlin, D M; Almera, R; Fuentes, M; Carrasquel, A; Barker, R H\n1994-02-01\nWe have examined the reproducibility, sensitivity, and specificity of detecting Plasmodium falciparum using the polymerase chain reaction (PCR) and the species-specific probe pPF14 under field conditions in the Venezuelan Amazon. Up to eight samples were field collected from each of 48 consenting Amerindians presenting with symptoms of malaria. Sample processing and analysis was performed at the Centro Amazonico para la Investigacion y Control de Enfermedades Tropicales Simon Bolivar. A total of 229 samples from 48 patients were analyzed by PCR methods using four different P. falciparum-specific probes. One P. vivax-specific probe and by conventional microscopy. Samples in which results from PCR and microscopy differed were reanalyzed at a higher sensitivity by microscopy. Results suggest that microscopy-negative, PCR-positive samples are true positives, and that microscopy-positive and PCR-negative samples are true negatives. The sensitivity of the DNA probe/PCR method was 78% and its specificity was 97%. The positive predictive value of the PCR method was 88%, and the negative predictive value was 95%. Through the analysis of multiple blood samples from each individual, the DNA probe/PCR methodology was found to have an inherent reproducibility that was highly statistically significant.\n[Economic impact of rapid diagnostic methods in Clinical Microbiology: Price of the test or overall clinical impact.](https://www.ncbi.nlm.nih.gov/pubmed/29033026)\nCant\u00f3n, Rafael; G\u00f3mez G de la Pedrosa, Elia\n2017-12-01\nThe need to reduce the time it takes to establish a microbiological diagnosis and the emergence of new molecular microbiology and proteomic technologies has fuelled the development of rapid and point-of-care techniques, as well as the so-called point-of-care laboratories. These laboratories are responsible for conducting both techniques partially to response to the outsourcing of the conventional hospital laboratories. Their introduction has not always been accompanied with economic studies that address their cost-effectiveness, cost-benefit and cost-utility, but rather tend to be limited to the unit price of the test. The latter, influenced by the purchase procedure, does not usually have a regulated reference value in the same way that medicines do. The cost-effectiveness studies that have recently been conducted on mass spectrometry in the diagnosis of bacteraemia and the use of antimicrobials have had the greatest clinical impact and may act as a model for future economic studies on rapid and point-of-care tests. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Antibiotic resistance: A global crisis].](https://www.ncbi.nlm.nih.gov/pubmed/25475657)\nAl\u00f3s, Juan-Ignacio\n2015-12-01\nThe introduction of antibiotics into clinical practice represented one of the most important interventions for the control of infectious diseases. Antibiotics have saved millions of lives and have also brought a revolution in medicine. However, an increasing threat has deteriorated the effectiveness of these drugs, that of bacterial resistance to antibiotics, which is defined here as the ability of bacteria to survive in antibiotic concentrations that inhibit/kill others of the same species. In this review some recent and important examples of resistance in pathogens of concern for mankind are mentioned. It is explained, according to present knowledge, the process that led to the current situation in a short time, evolutionarily speaking. It begins with the resistance genes, continues with clones and genetic elements involved in the maintenance and dissemination, and ends with other factors that contribute to its spread. Possible responses to the problem are also reviewed, with special reference to the development of new antibiotics. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Evaluation of the status of patients with severe infection, criteria for intensive care unit admittance. Spanish Society for Infectious Diseases and Clinical Microbiology. Spanish Society of Intensive and Critical Medicine and Coronary Units].](https://www.ncbi.nlm.nih.gov/pubmed/19409668)\nOlaechea, Pedro M; Alvarez-Lerma, Francisco; S\u00e1nchez, Miguel; Torres, Antonio; Palomar, Mercedes; Fern\u00e1ndez, Pedro; Mir\u00f3, Jos\u00e9 M; Cisneros, Jos\u00e9 Miguel; Torres, Manuel\n2009-06-01\nRecent studies have shown that early attention in patients with serious infections is associated with a better outcome. Assistance in intensive care units (ICU) can effectively provide this attention; hence patients should be admitted to the ICU as soon as possible, before clinical deterioration becomes irreversible. The objective of this article is to compile the recommendations for evaluating disease severity in patients with infections and describe the criteria for ICU admission, updating the criteria published 10 years ago. A literature review was carried out, compiling the opinions of experts from the Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica (SEIMC, Spanish Society for Infectious Diseases and Clinical Microbiology) and the Sociedad Espa\u00f1ola de Medicina Intensiva, Cr\u00edtica y Unidades Coronarias (SEMICYUC, Spanish Society for Intensive Medicine, Critical Care and Coronary Units) as well as the working groups for infections in critically ill patients (GEIPC-SEIMC and GTEI-SEMICYUC). We describe the specific recommendations for ICU admission related to the most common infections affecting patients, who will potentially benefit from critical care. Assessment of the severity of the patient's condition to enable early intensive care is stressed.\n[Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid.](https://www.ncbi.nlm.nih.gov/pubmed/26139304)\nLlorca Otero, Laura; Gir\u00f3n Moreno, Rosa; Buend\u00eda Moreno, Buenaventura; Valenzuela, Claudia; Guiu Mart\u00ednez, Alba; Alarc\u00f3n Cavero, Teresa\n2016-03-01\nAchromobacter xylosoxidans is an emerging pathogen in cystic fibrosis (CF). Although the rate of colonization by this microorganism is variable, prevalence is increasing in CF units. A microbiological/clinical study was conducted on of adult CF patients harboring A. xylosoxidans. Identification and susceptibility testing were performed using MicroScan (Siemens). Decline in lung function was assessed using the variable, annual percentage loss of FEV1 (forced expiratory volume in 1s). A. xylosoxidans was isolated in 18 (19.8%) of 91 patients over a 14-year period. Mean age was 26.6 years (18-39 years). Nine patients (9.8%) were chronically colonized. Piperacillin/tazobactam and imipenem were the most active antibiotics. Mean annual decline in lung function in chronically colonized patients was 2.49%. A. xylosoxidans is a major pathogen in CF. A decreased lung function was observed among patients who were chronically colonized by A. xylosoxidans. Antibiotic therapy should be started early in order to prevent chronic colonization by this microorganism. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Detection of carbapenemases and other mechanisms of enzymatic resistance to \u03b2-lactams in Enterobacteriaceae with diminished susceptibility to carbapenems in a tertiary care hospital.](https://www.ncbi.nlm.nih.gov/pubmed/28888401)\nG\u00f3mara, Marta; L\u00f3pez-Calleja, Ana Isabel; Iglesia, Berta Mar\u00eda Pilar Vela; Cer\u00f3n, Isabel Ferrer; L\u00f3pez, Antonio Rezusta; Pinilla, Mar\u00eda Jos\u00e9 Revillo\n2018-05-01\nOur objective was to characterize the enzymatic \u03b2-lactam resistance in clinical Enterobacteriaceae isolates with diminished susceptibility to carbapenems from 2013 to 2014 at Hospital Universitario Miguel Servet. A total of 63 clinical isolates were analyzed for the presence of carbapenemases (KPC, OXA-48 and MBL), ESBLs and AmpC enzymes by combined disk methods and PCR detection of carbapenemase-encoding and beta-lactamase-encoding genes. Fifteen isolates had a phenotypic test compatible with carbapenemase production; two of these were confirmed by PCR as OXA-48 producers. ESBL detection was positive in 27 isolates (43%); plasmid-mediated AmpC was detected in nine isolates (14.2%) and derepressed AmpC \u03b2-lactamase was present in 18 isolates (28%). During the study period, the decreased susceptibility to carbapenems in Enterobacteriaceae in our area was not due to true carbapenemases but rather to \u03b2-lactamase activity (82.5% were ESBL or AmpC producers), probably in combination with decreased permeability of the outer membrane. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nFern\u00e1ndez Castillo, Rafael; Ca\u00f1adas de la Fuente, Gustavo R; Ca\u00f1adas de la Fuente, Guillermo A; De la Fuente Solana, Emilia Inmaculada; Esteban de la Rosa, Rafael Jos\u00e9; Bravo Soto, Juan\n2016-07-19\nIntroducci\u00f3n: la obesidad y el sobrepeso presentan efectos adversos sobre la salud, lo que contribuye a la aparici\u00f3n de enfermedades metab\u00f3licas y cardiovasculares que ponen en peligro la integridad del injerto.Objetivo: investigar la influencia del IMC pretrasplante renal sobre el funcionamiento del injerto renal al a\u00f1o de trasplante mediante el estudio de cuatro m\u00e9todos distintos de medir la filtraci\u00f3n glomerular.Material y m\u00e9todos: en este trabajo se ha seguido a 1.336 pacientes de ambos sexos trasplantados renales; se les realizaron mediciones pretrasplante y postrasplante de par\u00e1metros bioqu\u00edmicos, mediciones antropom\u00e9tricas y funci\u00f3n renal mediante medidas de filtrado glomerular.Resultados: a mayor \u00edndice de masa corporal pretrasplante se produce una disminuci\u00f3n del filtrado glomerular medido por cuatro m\u00e9todos distintos, as\u00ed como mayor porcentaje de rechazos.Conclusiones: un IMC elevado pretrasplante contribuye a la disfunci\u00f3n del injerto, a una disminuci\u00f3n del filtrado glomerular y a complicaciones del injerto en el primer a\u00f1o postrasplante.\n[[Pharmacokinetic/pharmacodynamic analysis in microbiology: a tool for the evaluation of the antimicrobial treatment].](https://www.ncbi.nlm.nih.gov/pubmed/23850188)\nCanut Blasco, Andr\u00e9s; Aguilar Alfaro, Lorenzo; Cobo Reinoso, Javier; Gim\u00e9nez Mestre, M Jos\u00e9; Rodr\u00edguez-Gasc\u00f3n, Alicia\n2015-01-01\nThe selection of multiresistant microorganisms, as a side-effect of the use of antimicrobials, together with the lack of new therapeutic drugs expected in the near future, forces to a rational use of antibiotics. The optimisation of antibacterial treatments based on pharmacokinetic/pharmacodynamic analysis (PK/PD) may contribute to prolong the life of antibiotics and to contain the bacterial resistance to them. A review is made of the importance of the appropriateness of the dose regimen selected, the application of PK/PD analysis of antimicrobials, the Monte Carlo simulation, PK/PD indices for efficacy, and PK/PD cut-off points. PK/PD analysis is also applicable to the prevention of bacterial resistance. Different methods have been used to study the factors that lead to its emergence and spread, such as in vitro and animal models, and resistance prevention studies (mutant selection window). Although the PK/PD analysis is a very useful tool for the selection of the most appropriate dose regimen of antibiotics, several problems limit its use in clinical practice. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Trend and seasonality of community-acquired Escherichia coli antimicrobial resistance and its dynamic relationship with antimicrobial use assessed by ARIMA models.](https://www.ncbi.nlm.nih.gov/pubmed/29217096)\nAsencio Egea, Mar\u00eda \u00c1ngeles; Huertas Vaquero, Mar\u00eda; Carranza Gonz\u00e1lez, Rafael; Herr\u00e1ez Carrera, \u00d3scar; Redondo Gonz\u00e1lez, Olga; Arias Arias, \u00c1ngel\n2017-12-04\nWe studied the trend and seasonality of community-acquired Escherichia coli resistance and quantified its correlation with the previous use of certain antibiotics. A time series study of resistant community-acquired E. coli isolates and their association with antibiotic use was conducted in a Primary Health Care Area from 2008 to 2012. A Poisson regression model was constructed to estimate the trend and seasonality of E. coli resistance. A significant increasing trend in mean E. coli resistance to cephalosporins, aminoglycosides and nitrofurantoin was observed. Seasonal resistance to ciprofloxacin and amoxicillin-clavulanic acid was significantly higher in autumn-winter. There was a delay of 7, 10 and 12 months between the use of cotrimoxazole (P<0.038), fosfomycin (P<0.024) and amoxicillin-clavulanic acid (P<0.015), respectively, and the occurrence of E. coli resistance. An average delay of 10 months between the previous use of amoxicillin-clavulanic acid, cotrimoxazole and fosfomycin and the appearance of resistant community-acquired E. coli strains was detected. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Procedure for the marketing authorization of an antibacterial agent].](https://www.ncbi.nlm.nih.gov/pubmed/25124488)\nL\u00f3pez Navas, Antonio; Garc\u00eda-Escribano R\u00e1ez, Nuria; Flores Juber\u00edas, \u00c1ngela; Su\u00e1rez Gea, Mar\u00eda Luisa\n2014-10-01\nThe marketing authorization of a new medicinal product is the first step before being placed on the market, and includes the full investigation programme. In order to ensure their quality, safety and efficacy, medicinal products are closely regulated from their initial phases of investigation to their use in clinical practice. For registration purposes, the results of all the clinical and preclinical studies, along with quality data and the description of the manufacturing process should be submitted. All information collected is presented for review by the competent authority. The European Medicines Agency regulates the registration of medicines in Europe, and national agencies in each EU member state are responsible for the assessment of the marketing authorisation application. To facilitate the development of clinical programmes, there is a common framework for the evaluation of an antibacterial, which includes guidelines and an addendum, detailing the specific requirements that must be carried out in clinical trials to assess the efficacy and safety for most of the infections. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Serological diagnosis of mumps: Value of the titration of specific IgG.](https://www.ncbi.nlm.nih.gov/pubmed/28126326)\nSanz, Juan Carlos; Ramos, Bel\u00e9n; Fern\u00e1ndez, Aurora; Garc\u00eda-Comas, Luis; Echevarr\u00eda, Juan Emilio; de Ory, Fernando\n2018-03-01\nThe aim of this study was to evaluate a cut-off point of the titration of IgG by ELISA in the diagnosis of mumps. A study was made of serum samples from 85 mumps cases (confirmed by PCR in saliva) and 2,351 controls of the general population of the Region of Madrid. The IgM detection was positive in 21 cases (sensitivity of 24.7%). The best cut-off point corresponded to IgG titres \u22654,900 (sensitivity of 64.7% and specificity of 86.1%). Among 42 patients immunised with at least one dose of measles mumps, rubella vaccine IgM was detected in 4 cases. However, the detection of IgG \u22654,900 was positive in 29 (sensitivity of 69.0%). An IgG result of \u22654.900 was almost 5 times more probable in a patient with mumps than in a non-infected patient. The detection of high titres of IgG against mumps could improve the IgM results in vaccinated people. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[A safe an easy method for building consensus HIV sequences from 454 massively parallel sequencing data.](https://www.ncbi.nlm.nih.gov/pubmed/27712849)\nFern\u00e1ndez-Caballero Rico, Jose \u00c1ngel; Chueca Porcuna, Natalia; \u00c1lvarez Est\u00e9vez, Marta; Mosquera Guti\u00e9rrez, Mar\u00eda Del Mar; Marcos Maeso, Mar\u00eda \u00c1ngeles; Garc\u00eda, Federico\n2018-02-01\nTo show how to generate a consensus sequence from the information of massive parallel sequences data obtained from routine HIV anti-retroviral resistance studies, and that may be suitable for molecular epidemiology studies. Paired Sanger (Trugene-Siemens) and next-generation sequencing (NGS) (454 GSJunior-Roche) HIV RT and protease sequences from 62 patients were studied. NGS consensus sequences were generated using Mesquite, using 10%, 15%, and 20% thresholds. Molecular evolutionary genetics analysis (MEGA) was used for phylogenetic studies. At a 10% threshold, NGS-Sanger sequences from 17/62 patients were phylogenetically related, with a median bootstrap-value of 88% (IQR83.5-95.5). Association increased to 36/62 sequences, median bootstrap 94% (IQR85.5-98)], using a 15% threshold. Maximum association was at the 20% threshold, with 61/62 sequences associated, and a median bootstrap value of 99% (IQR98-100). A safe method is presented to generate consensus sequences from HIV-NGS data at 20% threshold, which will prove useful for molecular epidemiological studies. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Widespread increase of empirical carbapenem use in acute care hospitals in Catalonia, Spain.](https://www.ncbi.nlm.nih.gov/pubmed/29703463)\nGrau, Santiago; Fondevilla, Esther; Echeverr\u00eda-Esnal, Daniel; Alcorta, Amaia; Limon, Enric; Gudiol, Francesc\n2018-04-24\nThe overall increase in the use of carbapenems could lead to the selection of carbapenem-resistant bacteria. The objectives of this study were to analyze carbapenem use from 2008 to 2015 and their prescription profile in 58 hospitals affiliated to the VINCat Programme (nosocomial infection vigilance system). Retrospective, longitudinal and descriptive study of carbapenem use. Consecutive case-series study, looking for carbapenem prescription characteristics, conducted in January 2016. Use was calculated in defined daily doses (DDD)/100 patient-days (PD); prescription profiles were assessed using a standardized survey. Carbapenem use increased 88.43%, from 3.37 DDD/100-PD to 6.35 DDD/100-PD (p<0.001). A total of 631 patients were included in the prescription analysis. Carbapenems were prescribed empirically in 76.2% of patients, mainly for urinary tract and intra-abdominal infections due to suspicion of polymicrobial mixed infection (27.4%) and severity (25.4%). A worrying increase in carbapenem use was found in Catalonia. Stewardship interventions are required to prevent carbapenem overuse. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults.](https://www.ncbi.nlm.nih.gov/pubmed/25749416)\nGatell Artigas, Josep Mar\u00eda; Arribas L\u00f3pez, Jos\u00e9 Ram\u00f3n; L\u00e1zaro Y de Mercado, Pablo; Blasco Bravo, Antonio Javier\n2016-01-01\nThe National AIDS Plan and the Spanish AIDS study group (GESIDA) proposes \"preferred regimens\" (PR) of antiretroviral treatment (ART) as initial therapy in HIV-infected patients. In 2013, the recommended regimens were all triple therapy regimens. The Gardel Study assessed the efficacy of a dual therapy (DT) combination of lopinavir/ritonavir (LPV/r) plus lamivudine (3TC). Our objective is to evaluate the GESIDA PR and the DT regimen LPV/r+3TC cost/efficacy ratios. Decision tree models were built. probability of having viral load <50 copies/mL at week 48. ART regime cost: costs of ART, adverse effects, and drug resistance tests during the first 48 weeks. Cost/efficacy ratios varied between 5,817 and 13,930 euros per responder at 48 weeks, for the DT of LPV/r+3TC and tenofovir DF/emtricitabine+raltegravir, respectively. Taking into account the official Spanish prices of ART, the most efficient regimen was DT of LPV/r+3TC, followed by the triple therapy with non-nucleoside containing regimens. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC).](https://www.ncbi.nlm.nih.gov/pubmed/28017477)\nde Cueto, Marina; Aliaga, Luis; Al\u00f3s, Juan-Ignacio; Canut, Andres; Los-Arcos, Ibai; Mart\u00ednez, Jose Antonio; Mensa, Jose; Pintado, Vicente; Rodriguez-Pardo, Dolors; Yuste, Jose Ramon; Pigrau, Carles\n2017-05-01\nMost urinary tract infections (UTI) are uncomplicated infections occurring in young women. An extensive evaluation is not required in the majority of cases, and they can be safely managed as outpatients with oral antibiotics. Escherichia coli is by far the most common uropathogen, accounting for >80% of all cases. Other major clinical problems associated with UTI include asymptomatic bacteriuria, and patients with complicated UTI. Complicated UTIs are a heterogeneous group associated with conditions that increase the risk of acquiring infection or treatment failure. Distinguishing between complicated and uncomplicated UTI is important, as it influences the initial evaluation, choice, and duration of antimicrobial therapy. Diagnosis is especially challenging in the elderly and in patients with in-dwelling catheters. The increasing prevalence of resistant uropathogens, including extended-spectrum \u03b2-lactamases and carbapenemase-producing Enterobacteriaceae, and other multidrug-resistant Gram-negative organisms further compromises treatment of both complicated and uncomplicated UTIs. The aim of these Clinical Guidelines is to provide a set of recommendations for improving the diagnosis and treatment of UTI. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[An\u00e1lisis de los determinantes socioecon\u00f3micos del gasto de bolsillo en medicamentos en seis zonas geogr\u00e1ficas de Panam\u00e1.](https://www.ncbi.nlm.nih.gov/pubmed/29709795)\nHerrera-Ballesteros, Victor H; Castro, Franz; G\u00f3mez, Beatriz\n2018-04-27\nCaracterizar el gasto de bolsillo privado en medicamentos en funci\u00f3n de los determinantes sociodemogr\u00e1ficos y socioecon\u00f3micos. MATERIALES Y M\u00e9TODOS: La fuente de datos es la Encuesta de Gasto de Bolsillo en Medicamentos de 2014. Se caracteriz\u00f3 el gasto de bolsillo privado mediante variables explicativas sociodemogr\u00e1ficas (SOD) y socioecon\u00f3micas (SES). Se hizo an\u00e1lisis factorial por componentes principales, regresi\u00f3n log\u00edstica y lineal simple. Los Odds Ratio demuestran que la educaci\u00f3n y la zona geogr\u00e1fica son determinantes fundamentales que inciden en el gasto de bolsillo. Los medicamentos son productos necesarios, en adici\u00f3n a que el gasto de bolsillo aumenta a un promedio del 2% por cada a\u00f1o de vida cronol\u00f3gica adicional. Existe mayor vulnerabilidad en las zonas m\u00e1s pauperizadas respecto del acceso a medicamentos, en especial en las ind\u00edgenas e implica un mayor riesgo de gasto catastr\u00f3fico a menor ingreso ante la mayor prevalencia de enfermedades cr\u00f3nicas. Copyright \u00a9 2018. Published by Elsevier Inc.\n[[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].](https://www.ncbi.nlm.nih.gov/pubmed/25303781)\nGorriz, Jos\u00e9 L; Guti\u00e9rrez, F\u00e9lix; Trull\u00e0s, Joan C; Arazo, Piedad; Arribas, Jose R; Barril, Guillermina; Cervero, Miguel; Cof\u00e1n, Frederic; Domingo, Pere; Estrada, Vicente; Fulladosa, Xavier; Galindo, Mar\u00eda J; Gr\u00e0cia, S\u00edlvia; Iribarren, Jos\u00e9 A; Knobel, Hernando; L\u00f3pez-Aldeguer, Jos\u00e9; Lozano, Fernando; Mart\u00ednez-Castelao, Alberto; Mart\u00ednez, Esteban; Mazuecos, Maria A; Miralles, Celia; Monta\u00f1\u00e9s, Rosario; Negredo, Eugenia; Palacios, Rosario; P\u00e9rez-El\u00edas, Mar\u00eda J; Portilla, Joaqu\u00edn; Praga, Manuel; Quereda, Carlos; Rivero, Antonio; Santamar\u00eda, Juan M; Sanz, Jos\u00e9; Sanz, Jes\u00fas; Mir\u00f3, Jos\u00e9 M\n2014-11-01\nThe aim of this article is to update the 2010 recommendations on the evaluation and management of renal disease in human immunodeficiency virus (HIV)-infected patients. Renal function should be monitored in all HIV-infected patients. The basic renal work-up should include measurements of serum creatinine, estimated glomerular filtration rate by CKD-EPI, urine protein-to-creatinine ratio, and urinary sediment. Tubular function tests should include determination of serum phosphate levels and urine dipstick for glycosuria. In the absence of abnormal values, renal screening should be performed annually. In patients treated with tenofovir, or with risk factors for chronic kidney disease (CKD), more frequent renal screening is recommended. In order to prevent disease progression, potentially nephrotoxic antiretroviral drugs are not recommended in patients with CKD or risk factors for CKD. The document provides indications for renal biopsy and advises on the optimal time for referral of a patient to the nephrologist. The indications for and evaluation and management of dialysis and renal transplantation are also addressed. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Helminthosis and eosinophilia in Spain (1990-2015).](https://www.ncbi.nlm.nih.gov/pubmed/26827134)\nCarranza-Rodr\u00edguez, Cristina; Escamilla-Gonz\u00e1lez, Miriam; Fuentes-Corripio, Isabel; Perteguer-Prieto, Mar\u00eda-Jes\u00fas; G\u00e1rate-Ormaechea, Teresa; P\u00e9rez-Arellano, Jos\u00e9-Luis\n2018-02-01\nThe finding of blood eosinophilia in a patient is a relatively frequent reason to refer him/her to a Clinical Department of Infectious Diseases. The doctor usually intends to rule out a parasitic disease in the autochthonous population, travelers or immigrants. It is uncommon for an eosinophilia to be produced by protozoa infection, whereas helminth parasites are more frequently associated with an increase of eosinophil counts in the infected patient. Eosinophilia can be the only abnormal finding, or it could be part of more complex clinical manifestations suffered by the patient. Furthermore, many, but not all, helminth infections are associated with eosinophilia, and the eosinophil level (low, high) differs according to parasite stages, helminth species, and worm co-infections. The purpose of the present article is to carry out a systematic review of cases and case series on helminth infections and eosinophilia reported in Spain from 1990 to 2015, making a distinction between autochthonous and imported (immigrants and travelers) cases, and studying their relationship with immunodepression situations. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Teaching infectious diseases in the Medical Degree within the European higher education area].](https://www.ncbi.nlm.nih.gov/pubmed/25746206)\nGuti\u00e9rrez, F\u00e9lix; Masi\u00e1, Mar\n2016-01-01\nDuring their medical studies, students must acquire basic competencies in different areas of knowledge, one of which is infectious diseases. Training in infectious diseases is essential for general medical practice and for academic or professional expertise in many areas of medicine, both medical and surgical. The vast amount of knowledge that is continuously generated about infectious diseases requires a well-structured undergraduate medical education program and framed in a setting dominated by globalization. The incorporation of Spain to the European higher education area has forced medical schools to adapt their curriculum and to establish the content and learning objectives of all courses of study. In this paper, we discuss the implications of the integration of the Spanish university system in the European higher education area (\u00abBologna Process\u00bb) in the teaching of infectious diseases in the Degree of Medicine, and describe the learning program in infectious diseases of the University Miguel Hern\u00e1ndez of Elche (Alicante, Spain) based on learning outcomes and competencies. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[MGMT promoter methylation in Peruvian patients with glioblastoma](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5834313)\nBelmar-Lopez, Carolina; Castaneda, Carlos A; Castillo, Miluska; Garc\u00eda-Corrochano, Pamela; Orrego, Enrique; Mel\u00e9ndez, Barbara; Casavilca, Sandro; Flores, Claudio; Orrego, Enrique\n2018-01-01\nPurpose O6-methylguanine\u2013DNA methyltransferase (MGMT) promoter methylation predicts the outcome and response to alkylating chemotherapy in glioblastoma. The aim of this study is to evaluate the prevalence of MGMT methylation in Peruvian glioblastoma cases. Patients and methods We evaluated retrospectively 50 cases of resected glioblastoma during the period 2008\u20132013 at Instituto Nacional de Enfermedades Neoplasicas in Peru. Samples consisted of paraffin embedded and frozen tumour tissue. MGMT-promoter methylation status and the expression level of MGMT gene were evaluated by methylation-specific PCR and real-time PCR, respectively. Results Unmethylated, methylated and partially methylated statuses were found in 54%, 20% and 26% of paraffin-embedded samples, respectively. Methylation status was confirmed in the Virgen de la Salud Hospital and frozen samples. There was an association between the status of MGMT-promoter methylation and the level of gene expression (p = 0.001). Methylation was associated with increased progression-free survival (p = 0.002) and overall survival (OS) (p < 0.001). Conclusion MGMT-promoter methylation frequency in Peruvian glioblastoma is similar to that reported in other populations and the detection test has been standardised. PMID:29515653\n[[Susceptibility to azithromycin and other antibiotics in recent isolates of Salmonella, Shigella and Yersinia].](https://www.ncbi.nlm.nih.gov/pubmed/24698008)\nMart\u00edn-Pozo, Angeles; Arana, David M; Fuentes, Miriam; Al\u00f3s, Juan-Ignacio\n2014-01-01\nAzithromycin represents an alternative option to treat bacterial diarrhea when the antibiotic therapy is indicated. Little is known regarding the susceptibility to azithromycin in enteropathogens in Spain. The MICs of azithromycin were determined by E-test against Salmonella non-typhi (SNT), Shigella and Yersinia isolates collected over the last three years (2010-2012). In addition, the susceptibility to other antibiotics usually used to treat gastrointestinal diseases was determined in these isolates by using a microdilution method. A total of 139 strains of SNT, Shigella and Yersinia were studied. All of them, except one strain, had a MIC\u226416mg/L of azithromycin. In the adult population, 14.7% and 40.6% of SNT and Shigella isolates, respectively, were resistant to at least 2 of following antibiotics: amoxicillin, trimethoprim-sulfamethoxazole and ciprofloxacin. In the pediatric population, 10% of SNT clinical isolates and 28.6% (2/7) of Shigella isolates were resistant to amoxicillin and trimethoprim-sulfamethoxazole. In our experience, azithromycin would be a useful antibiotic alternative to treat bacterial diarrhea. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[To whom is HIV pre-exposure prophylaxis proposed?](https://www.ncbi.nlm.nih.gov/pubmed/27445176)\nAyerdi-Aguirrebengoa, Oskar; Vera-Garc\u00eda, Mar; Puerta-L\u00f3pez, Teresa; Raposo-Utrilla, Montserrat; Rodr\u00edguez-Mart\u00edn, Carmen; Del Romero-Guerrero, Jorge\n2017-05-01\nHIV Pre-Exposure Prophylaxis (PrEP) consists of administering antiretroviral drugs to seronegative individuals with high risk practices. The aim of the study was to describe the characteristics of recent seroconverted HIV patients in order to determine the profile of the appropriate candidates for PrEP. A descriptive study of all patients diagnosed with HIV infection in 2014, and who had achieved a documented negative serology over the previous 12 months. A specific form was completed to determine the sociodemographic, behavioural, and clinical features, with complementary tests being performed for other sexually transmitted infections. Almost all (98.4%) of the 61 recent seroconverted were men who have sex with men, and aged between 20 to 39 years (88.5%). They also had a background of sexually transmitted infections (80.3%), performed multiple and unprotected sexual practices (82.7%), and under the effect of recreational drugs (87%). The evaluation of the risk factors for HIV infection in seronegative patients should enable the appropriate candidates for PrEP to be identified. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas.](https://www.ncbi.nlm.nih.gov/pubmed/11112115)\nCordero, E; Pach\u00f3n, J; Rivero, A; Gir\u00f3n, J A; G\u00f3mez-Mateos, J; Merino, M D; Torres-Tortosa, M; Gonz\u00e1lez-Serrano, M; Aliaga, L; Collado, A; Hern\u00e1ndez-Quero, J; Barrera, A; Nu\u00f1o, E\n2000-12-01\nSeverity criteria for community-acquired pneumonia (CAP) have always excluded patients with human immunodeficiency virus (HIV) infection. A 1-yr, multicenter, prospective observational study of HIV-infected patients with bacterial CAP was done to validate the criteria used in the American Thoracic Society (ATS) guidelines for CAP, and to determine the prognosis-associated factors in the HIV-infected population with bacterial CAP. Overall, 355 cases were included, with an attributable mortality of 9.3%. Patients who met the ATS criteria had a longer hospital stay (p = 0.01), longer duration of fever (p < 0.001), and higher attributable mortality (13.1% versus 3.5%, p = 0.02) than those who did not. Three factors were independently related to mortality: CD4(+) cell count < 100/microl, radiologic progression of disease, and shock. Pleural effusion, cavities, and/or multilobar infiltrates at admission were independently associated with radiologic progression. A prognostic rule based on the five criteria of shock, CD4(+) cell count < 100/microl, pleural effusion, cavities, and multilobar infiltrates had a high negative predictive value for mortality (97.1%). The attributable mortality for severe pneumonia was 11.3%, as compared with 1.3% for nonsevere disease (p = 0.008). The ATS severity criteria are valid in HIV-infected patients with bacterial CAP. Our study provides the basis for identification of patients who may require hospitalization determined by clinical judgment and the five clinical criteria of shock, a CD4(+) cell count < 100/microl, pleural effusion, cavities, and multilobar involvement. These prognostic factors should be validated in independent cohort studies.\n[Prospective evaluation of fever of unknown origin in patients infected with the human immunodeficiency virus. Grupo Andaluz para el Estudio de las Enfermedades Infecciosas.](https://www.ncbi.nlm.nih.gov/pubmed/8922569)\nLozano, F; Torre-Cisneros, J; Bascu\u00f1ana, A; Polo, J; Viciana, P; Garc\u00eda-Ord\u00f3\u00f1ez, M A; Hern\u00e1ndez-Quero, J; M\u00e1rquez, M; Vergara, A; D\u00edez, F; Pujol, E; Torres-Tortosa, M; Pasquau, J; Hern\u00e1ndez-Burruezo, J J; Su\u00e1rez, I\n1996-09-01\nThe aim of this study was to determine the frequency and aetiology of fever of unknown origin (FUO) in patients infected with the human immunodeficiency virus (HIV), to assess the value of the tests used in its diagnosis, and to evaluate possible models of diagnosis for the causes found most frequently. One hundred twenty-eight (3.5%) of 3603 hospitalised HIV-positive patients evaluated from October 1992 to December 1993 had FUO, defined by established criteria. Eighty-six percent of patients with FUO had previously progressed to AIDS. The median CD4+ cell count was 46/mm3. A definite diagnosis was made in 96 (75%) of the 128 patients and a possible diagnosis in 24 (18.7%). whilst no diagnosis was made in eight cases (6.2%). Tuberculosis (48.3%), visceral leishmaniasis (16%), and infection by Mycobacterium avium complex (6.9%) were the diseases found most frequently. The most useful diagnostic tests were liver biopsy (68.9%) and bone marrow aspirate/biopsy (39.7%). It is not possible to predict clinically the cases of FUO due to tuberculosis, whilst thrombocytopaenia < 100,000 cells/mm3 alone is useful for differentiating the cases of visceral leishmaniasis, with a negative predictive value of 95.2%.\nCuerda, Cristina; \u00c1lvarez, Julia; Ramos, Primitivo; Ab\u00e1nades, Juan Carlos; Garc\u00eda-de-Lorenzo, Abelardo; Gil, Pedro; De-la-Cruz, Juan Jos\u00e9\n2016-03-25\nIntroducci\u00f3n: la desnutrici\u00f3n relacionada con la enfermedad (DRE) es un problema sociosanitario frecuente que afecta preferentemente a los mayores de 65 a\u00f1os, que aumenta la morbimortalidad y disminuye la calidad de vida. Objetivo: estudiar la prevalencia de DRE en mayores de 65 a\u00f1os en diferentes centros sociosanitarios del Servicio Regional de Bienestar Social de la Comunidad de Madrid. M\u00e9todos: estudio transversal en 33 centros sociosanitarios de Madrid (6 centros de atenci\u00f3n primaria [AP], 9 centros de mayores [CM], 9 hospitales [H] y 9 residencias [R]) seleccionados mediante muestreo poliet\u00e1pico. Las variables estudiadas fueron edad, sexo, nivel de dependencia seg\u00fan la escala de incapacidad de la Cruz Roja, motivo de ingreso y enfermedad de base, h\u00e1bitat (urbano-periurbano-rural) y distribuci\u00f3n geogr\u00e1fica (norte centro-sur). Como herramienta de cribado nutricional se utiliz\u00f3 el Mini Nutritional Assessment (MNA-cribaje) en todos los centros. En los pacientes con cribado positivo (en riesgo-desnutrici\u00f3n) se realiz\u00f3 el MNA-evaluaci\u00f3n. El estudio estad\u00edstico se realiz\u00f3 con el paquete SSS 21.0 e incluy\u00f3 estad\u00edstica descriptiva, test de Chi-cuadrado y prueba exacta de Fisher, ANOVA de un factor, Kruskal-Wallis y an\u00e1lisis de regresi\u00f3n log\u00edstica (RL) binaria univariante y multivariante. Se consider\u00f3 significaci\u00f3n estad\u00edstica p < 0,05. Resultados: se reclutaron 1.103 sujetos (275 AP, 278 CM, 281 H, 269 R), edad media de 79,5 \u00b1 8,4 a\u00f1os (41,2% varones, 58,8% mujeres). Los sujetos procedentes de H y R tuvieron un mayor grado de incapacidad (p < 0,001). La prevalencia global de DRE fue del 10%, encontr\u00e1ndose un 23,3% en riesgo de desnutrici\u00f3n, con diferencias entre los cuatro tipos de centros sociosanitarios (p < 0,001). El an\u00e1lisis univariante de RL mostr\u00f3 diferencia significativas en la prevalencia de desnutrici\u00f3n seg\u00fan la edad, sexo, grado de dependencia, tipo de centro sociosanitario, h\u00e1bitat y zona geogr\u00e1fica. Sin embargo, en el\n[Teor\u00ed\u00c2as de primer y segundo orden sobre el potencial de ciertas figuras de equilibrio de cuerpos celestes](http://adsabs.harvard.edu/abs/2010PhDT.......232G) [NASA Astrophysics Data System (ADS)](http://adsabs.harvard.edu/abstract_service.html)\nGumbau, Manuel Forner\n2010-11-01\nUno de los problemas que aborda la Mec\u00e1nica Celeste es la determinaci\u00f3n de las figuras de equilibrio de los cuerpos celestes. Para investigar su soluci\u00f3n mediante m\u00e9todos directos, se precisa evaluar el potencial generado por su autogravitaci\u00f3n, el generado por su fuerza centr\u00ed\u00c2fuga y el generado por la fuerza de atracci\u00f3n entre los cuerpos. Los m\u00e9todos cl\u00e1sicos de Finlay y Kopal que afrontan estos problemas, para determinar el potencial autogravitatorio en las configuraciones de equilibrio, emplean desarrollos en serie de los potenciales interior y exterior del potencial autogravitatorio. Estos m\u00e9todos incurren en el error de suponer la convergencia en capas donde resulta cuestionable dicha convergencia para estos desarrollos en serie. En este trabajo se han elaborado unos algoritmos que contemplan toda la casu\u00ed&stica y que permiten una manipulaci\u00f3n efic iente del producto de polinomios de Legendre, del producto de funciones asociada s de Legendre y del producto de arm\u00f3nicos esf\u00e9ricos como combinaci\u00f3on lineal de ellos mismos, respectivamente. Se han obtenido, para primer y segundo orden en las amplitudes, los desarrollos correctos para los potencial es interior y exterior del potencial autogravitatorio para configuraciones de equilibrio aisladas, y , en primer orden de amplitudes, los mismos potenciales para los sistemas binarios pr\u00f3ximos. Se ha elaborado un m\u00e9todo anal\u00edtico, en primer orden respecto de las amplitudes, para la determinaci\u00f3n del potencial de marea en sistemas binarios pr\u00f3ximos en el cual se manifiesta la forma de la componente secundaria del sistema\n[Dietary habits and cardiovascular risk in the Spanish population: the DRECE study (II) micronutrient intake. Dieta y Riesgo de Enfermedades Cardiovasculares en Espa\u00f1a.](https://www.ncbi.nlm.nih.gov/pubmed/11111133)\nBallesteros-Pomar, M D; Rubio-Herrera, M A; Guti\u00e9rrez-Fuentes, J A; G\u00f3mez-Gerique, J A; G\u00f3mez-de-la-C\u00e1mara, A; Pascual, O; G\u00e1rate, I; Montero, R; Campi\u00f1a, S\n2000-01-01\nTo evaluate the dietary micronutrient intake in the adult Spanish population participating in the DRECE study. The cross-sectional study was performed in two stages in 1991 and 1996 in 43 primary care clinics. One thousand two hundred people 'with cardiovascular risk' and 600 'without risk' answered a food frequency questionnaire. Significant increases in vitamin C, retinol, lycopenes, beta-cryptoxanthin and vitamin E intakes were found. Vitamin A, alpha-carotenoid and lutein intakes decreased. Vitamin B(12), B(6) and folic acid intakes increased in people with cardiovascular risk, whereas only the last two increased in the control group. Nearly 100% of the people consumed the recommended dietary allowances for vitamins B(12) and B(6) and >70% for folic acid. Calcium, iron, and zinc intake increased in both groups, but magnesium and selenium intake increased only in people at risk. Vitamin A, B(1) and zinc intakes have decreased, and >50% of the people do not consume the recommended dietary allowance. Antioxidant vitamins and vitamin B(12), B(6) and folic acid intakes seem to be adequate in the adult Spanish population, no significant differences appear regarding their cardiovascular risk status. Vitamin A, B(1) and zinc intakes are not appropriate. Copyright 2000 S. Karger AG, Basel.\n[[Is it ethically acceptable to invite a pregnant woman to enroll in a clinical trial with Tdap if it could entail not being vaccinated with Tdap before delivery?](https://www.ncbi.nlm.nih.gov/pubmed/26169070)\nDal-R\u00e9, Rafael\n2017-02-01\nPertussis incidence has increased in recent years, especially among infants aged <2months. A number of Spanish regions have started a vaccination program with Tdap vaccine to all pregnant women in the third trimester of pregnancy. An observational study has shown that this strategy reduces the number of cases of pertussis by 90% in infants aged <2months. Mathematical models showed that a cocooning strategy (i.e. vaccination of the mother at immediate postpartum, and other adults and adolescents who have close contact with the newborn and caregivers) will reduce the incidence of pertussis by 70% in infants aged <2months. It is intended to conduct a clinical trial in which 340 pregnant women will receive Tdap vaccine, whereas another 340 pregnant woman will be vaccinated soon after delivery. Vaccination with Tdap will be offered to all partners and caregivers of the newborn. After assessing both the ethical and scientific reasons supporting the trial, it is concluded that it is ethically and legally acceptable to invite pregnant women living in communities where Tdap vaccination has been implemented to participate in the trial. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nFort Casamartina, Eduard; Arribas Hortiguela, Lorena; Bleda P\u00e9rez, Carmen; Mu\u00f1oz S\u00e1nchez, Carme; Peiro Mart\u00ednez, Imma; Perayre Bad\u00eda, Mar\u00eda; Clop\u00e9s Estela, Ana\n2016-06-03\nDurante la \u00faltima d\u00e9cada, el conocimiento de nuevos mecanismos implicados en el desarrollo del c\u00e1ncer ha permitido el dise\u00f1o de nuevos f\u00e1rmacos para su tratamiento y la mayor parte de ellos son f\u00e1rmacos que se administran por v\u00eda oral. Uno de los principales problemas de los pacientes oncohematol\u00f3gicos es la desnutrici\u00f3n, que suele tener causas multifactoriales (de la propia enfermedad, de los pacientes y de los diferentes tratamientos administrados). Para minimizar el impacto de la desnutrici\u00f3n es necesaria una intervenci\u00f3n nutricional, ya sea adaptando la dieta o mediante la instauraci\u00f3n de soporte nutricional artificial, en funci\u00f3n de la gravedad de cada caso. En cualquier paciente que est\u00e9 recibiendo un tratamiento oncol\u00f3gico hay que evaluar las posibles interacciones que pueden existir con el soporte nutricional instaurado, ya sea dieta oral, suplementaci\u00f3n oral o nutrici\u00f3n enteral. Estas interacciones pueden disminuir la eficacia, aumentar la toxicidad de los tratamientos o producir d\u00e9ficits nutricionales. Se detallan las principales interacciones que se pueden producir, las interacciones entre los tratamientos oncol\u00f3gicos y el soporte nutricional.\n[HCV core-antigen assay as an alternative to HCV RNA quantification: A correlation study for the assessment of HCV viremia.](https://www.ncbi.nlm.nih.gov/pubmed/28245938)\nAlonso, Roberto; P\u00e9rez-Garc\u00eda, Felipe; L\u00f3pez-Roa, Paula; Alcal\u00e1, Luis; Rode\u00f1o, Pilar; Bouza, Emilio\n2018-03-01\nDetection of hepatitis C virus (HCV) RNA and the HCV core antigen assay (HCV-Ag) are reliable techniques for the diagnosis of active and chronic HCV infection. Our aim was to evaluate the HCV-Ag assay as an alternative to quantification of HVC RNA. A comparison was made of the sensitivity and specificity of an HCV-Ag assay (204 serum samples) with those of a PCR assay, and the correlation between the two techniques was determined. The sensitivity and specificity of HCV-Ag was 76.6% and 100%, respectively. Both assays were extremely well correlated (Pearson coefficient=0.951). The formula (LogCV=1.15*LogAg+2.26) was obtained to calculate the viral load by PCR from HCV-Ag values. HCV-Ag was unable to detect viral loads below 5000IU/mL. Although the HCV-Ag assay was less sensitive than the PCR assay, the correlation between both assays was excellent. HCV-Ag can be useful as a first step in the diagnosis of acute or chronic HCV infection and in emergency situations. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Principles of antisepsis, disinfection and sterilization].](https://www.ncbi.nlm.nih.gov/pubmed/25023372)\nHern\u00e1ndez-Navarrete, Mar\u00eda-Jes\u00fas; Celorrio-Pascual, Jos\u00e9-Miguel; Lapresta Moros, Carlos; Solano Bernad, Victor-Manuel\n2014-12-01\nThis article aims to provide a brief review of the main concepts on which the prevention and control of infection are based. Antisepsis comprises a set of techniques aimed at the total sterilization, or at most, disinfection, removing germs that contaminate an environment. Both procedures must be preceded by an environmental cleanup in the location in which they intend to be applied. The disinfection is carried out using biocides or germicides. Antimicrobial chemicals, that have mechanisms of action and resistances very similar to antibiotics, are generating concern due to the possibility of crossing genetic information that aggravates the problem of bacterial resistance. Most biocides can act as antiseptics, and applied to skin tissue, or disinfectants on inanimate materials. The spectrum of action of germicides depends on the product itself and external controllable factors: temperature, concentration, exposure time, etc. Sterilization techniques are primarily physical, by exposing the material to steam, or sterilizing gas, using autoclaves. Major advances are the use of low temperatures with shorter exposure times, in parallel with technological advances in instrumentation in order to avoid high temperatures and high use rotations due to workload. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Preventive measures for avoiding transmission of microorganisms between hospitalised patients. Hand hygiene].](https://www.ncbi.nlm.nih.gov/pubmed/24661995)\nLupi\u00f3n, Carmen; L\u00f3pez-Cort\u00e9s, Luis Eduardo; Rodr\u00edguez-Ba\u00f1o, Jes\u00fas\n2014-11-01\nHealth-care associated infections are an important public health problem worldwide. The rates of health-care associated infections are indicators of the quality of health care. The infection control activities related to prevention of transmission of hospital microorganisms can be grouped in 4 mayor areas: standard precautions, specific precautions (including isolation if appropriate), environmental cleaning and disinfection, and surveillance activities (including providing infection rates and monitoring procedures). Hand hygiene and the correct use of gloves are the most important measures to prevent health-care associated infections and to avoid the dissemination of multidrug-resistant microorganisms. Continuous educational activities aimed at improving adherence to hand hygiene are needed. Periodical assessment of adherence to hand hygiene recommendations with feed-back have been shown to provide sustained improvement. Several complementary activities are being evaluated, including skin decolonization prior to certain surgeries, a package of measures in patients with central venous catheters or mechanical ventilation, and universal body hygiene with chlorhexidine. The present area of discussion concerns in which situations and in which groups would such measures be effective and efficient. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nSan Mauro Mart\u00edn, Ismael; Garicano Vilar, Elena; Le\u00f3n Fern\u00e1ndez, Joana; Ciudad Caba\u00f1as, Mar\u00eda Jos\u00e9; Collado Yurrita, Luis\n2016-07-19\nIntroducci\u00f3n: recientemente ha surgido el inter\u00e9s por el posible papel de la microbiota intestinal como agente potenciador del r\u00e1pido aumento que se est\u00e1 observando en el aumento de la prevalencia de obesidad en todo el mundo.Objetivos: relacionar las modificaciones que puede ocasionar el consumo de antibi\u00f3ticos en la microflora intestinal con la obesidad.M\u00e9todos: se extrajeron, de las Encuestas Nacionales de Salud de Espa\u00f1a, entre los a\u00f1os 2001 y 2011, las cifras de ingesta de antibi\u00f3ticos y la prevalencia (%) de obesidad en el mismo rango de edad, g\u00e9nero y a\u00f1o. La media total de encuestados fue de 29.904 participantes.Resultados: se encontraron correlaciones significativas (p=0,09) en la asociaci\u00f3n de la prevalencia de obesidad y la ingesta de antibi\u00f3ticos. Adem\u00e1s, se objetiv\u00f3 que en el sexo masculino esta influencia es el doble que en el femenino.Conclusiones: los descubrimientos recientes en el campo de la microbiota intestinal y su relaci\u00f3n con el hu\u00e9sped abren nuevos caminos en la comprensi\u00f3n de ciertas enfermedades inflamatorias y metab\u00f3licas, como la obesidad.\n[High prevalence of antibodies against hepatitis E virus in HIV-infected patients with unexplained liver disease.](https://www.ncbi.nlm.nih.gov/pubmed/25533742)\nMerchante, Nicol\u00e1s; Parra-S\u00e1nchez, Manuel; Rivero-Ju\u00e1rez, Antonio; Cifuentes, Celia; Camacho, \u00c1ngela; Mac\u00edas, Juan; Mart\u00ednez-Due\u00f1as, Loreto; P\u00e9rez-Navarro, Elisabet; Rivero, Antonio; Pineda, Juan A\n2015-10-01\nTo look for evidence of hepatitis E virus (HEV) exposure in HIV-infected patients with unexplained elevations of liver stiffness (LS). Case-control study conducted in 31 HIV-infected patients with unexplained elevations of LS and in 31 HIV-controls with normal LS, matched by age, sex and CD4 cell-counts. Serum HEV antibodies were tested by two ELISA procedures and by Immunoblot. We defined exposure to HEV as the detection of serum HEV antibodies by at least one of the two ELISA assays, provided that it was confirmed by Immunoblot. A real-time PCR RNA assay was conducted in all plasma samples to identify subjects with active HEV infection. Exposure to HEV was demonstrated, according to the criteria used in this study, in 9 (29%) of the cases, whereas it was shown in 5 (16%) of the controls (p=.3). Serum HEV RNA was detected in none of the controls and in only in one case. This patient had a documented chronic hepatitis E with progression to cirrhosis. HEV antibodies are frequently found in HIV-infected patients with unexplained liver disease. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Prevalence study of the genetic markers associated with slow progression of human inmunodefiency virus type 1 in the Galician population (Northwest of Spain)].](https://www.ncbi.nlm.nih.gov/pubmed/26100217)\nRodr\u00edguez-Da Silva, Alfredo; Miralles, Celia; Ocampo, Antonio; Valverde, Diana\n2017-02-01\nThe deletion in the CCR5 gene (CCR5\u039432), the HLA-B*27:05, and polymorphisms rs2395029 and rs9264942 have been associated with slower progression of HIV-1. An analysis was performed on 408 patients on follow-up. The analysis of viral load, CD4+ Tlymphocytes and other clinical variables since the diagnosis of the infection were collected. The prevalence of the genetic markers rs9264942, CCR5wt/\u039432, rs2395029, HLA-B*27:05 was 17.9%, 11.5%, 7.6%, and 6.4%, respectively. Of all the patients, 354 were classified as progressors and 46 as long-term non-progressors (LTNPs). Except for the HLA-B*27:05 allele, other genetic markers were associated with slower progression: CCR5wt/\u039432 (P=.011) and SNPs rs2395029 and rs9264942 (P<.0001), as well as their association (P<.0001). The prevalence of the HLA-B*57:01 allele was higher than described nationally. No association could be found between the HLA-B*27:05 allele and the presence of slower disease progression. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Linkage to care among new human immunodeficiency virus diagnoses in Spain].](https://www.ncbi.nlm.nih.gov/pubmed/24200033)\nOliva, Jes\u00fas; Malo, Carmen; Fern\u00e1ndez, Ana; Izquierdo, Ana; Marcos, Henar; Cevallos, Carlos; Castilla, Jes\u00fas; Garc\u00eda, Rocio; D\u00edez, Mercedes\n2014-03-01\nTo describe linkage to care among new HIV diagnoses in Spain; and to estimate factors associated to linkage to care within three months after diagnosis. The distribution of the time elapsing between the date of HIV diagnosis and the date of first determination of CD4 (considered to be the date of linkage to care) was calculated among new HIV diagnoses in 2010 in the seven Autonomous Regions participating, where data on date of CD4 count was available. Linkage to care was considered \u00abcorrect\u00bb if done within three months after diagnosis. Factors associated to correct linkage to care were estimated using logistic regression. A total of 1769 new HIV diagnoses were included. Of them, 83.1% had evidence of linkage to care within a year, and 75.7% were linked within three months after diagnosis. Being an injectable drug user (IDU) was the only factor inversely associated with linkage to care within 3 months (OR = 0.3; 95% CI: 0.2-0.6). In Spain linkage to care after HIV diagnosis is good, but there is still room for improvement, especially among IDUs. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2016).](https://www.ncbi.nlm.nih.gov/pubmed/27068257)\n2016-01-01\nIn this update, antiretroviral therapy (ART) is recommended for all patients infected by type 1 human immunodeficiency virus (HIV-1). The objective of ART is to achieve an undetectable plasma viral load (PVL). Initial ART should comprise 3 drugs, namely, 2 nucleoside reverse transcriptase inhibitors (NRTI), and 1 drug from another family. Four of the recommended regimens, all of which have an integrase strand transfer inhibitor (INSTI) as the third drug, are considered a preferred regimen; a further 6 regimens, which are based on an INSTI, a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor boosted with cobicistat or ritonavir (PI/COBI, PI/r), are considered alternatives. The reasons and criteria for switching ART are presented both for patients with an undetectable PVL and for patients who experience virological failure, in which case the rescue regimen should include 3 (or at least 2) drugs that are fully active against HIV. The specific criteria for ART in special situations (acute infection, HIV-2 infection, pregnancy) and comorbid conditions (tuberculosis and other opportunistic infections, kidney disease, liver disease, and cancer) are updated. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Consensus Document on post-exposure prophylaxis against HIV, HBV and HCV in adults and children].](https://www.ncbi.nlm.nih.gov/pubmed/26409726)\n2016-02-01\nThis consensus document is an update of occupational and non-occupational prophylaxis guidelines in HIV-patients, promoting appropriate use of them, from the standpoint of care. This document has been approved by expert panel of SPNS, GESIDA, SEMST and different scientific societies related, after reviewing the results of efficacy and safety clinical trials, cohort and pharmacokinetic studies published in biomedical journals (PubMed and Embase) or presented at conferences and different guidelines. The strength of the recommendation and gradation of their evidence are based on the GRADE system. We have developed recommendations for assessing the risk of transmission in different types of exposure situations in which post-exposure prophylaxis should be recommended, special circumstances to consider, patterns of antiretroviral with the start and duration of early monitoring of tolerance and adherence to treatment, the subsequent monitoring of exposed persons regardless of whether they received post-exposure prophylaxis or not, and the need of psychological support. These new guidelines updated previous recommendations regarding occupational post-exposure prophylaxis and non-occupational, in adults and children. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Drawbacks of the use of cotrimoxazole in foreign-body infections.](https://www.ncbi.nlm.nih.gov/pubmed/28818482)\nEl Haj, Cristina; Ribera, Alba; Lloberas, Nuria; Tubau, Fe; Ariza, Javier; Murillo, Oscar\nThe anti-staphylococcal efficacy of cotrimoxazole in the setting of difficult-to-treat infections seems to be compromised by large amounts of pus and devitalized tissue, and, therefore, high levels of thymidine. Our objective was to evaluate the activity of cotrimoxazole against a staphylococcal foreign-body infection experimental model, which also yields significant quantities of thymidine. We used a rat tissue-cage model of infection (with high inherent thymidine levels) caused by a strain of methicillin-susceptible Staphylococcus aureus (MSSA; ATCC 29213). MIC values were determined (microdilution method) and compared in the presence or absence of tissue-cage fluid samples. The inefficacy of cotrimoxazole was found to be similar to that of the control group. The MIC of cotrimoxazole was 4-8 fold higher in the presence of rat tissue-cage fluid. The inefficacy of cotrimoxazole in our foreign-body infection model by MSSA, and the probable negative impact of the presence of thymidine on its efficacy, challenge the use of this drug in acute phases of foreign-body infections. It should be reserved as an alternative treatment when the infection is more controlled. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Unusual presence of the immune evasion gene cluster in livestock-associated MRSA of lineage CC398 causing peridural and psoas abscesses in a poultry farmer.](https://www.ncbi.nlm.nih.gov/pubmed/27592463)\nP\u00e9rez-Moreno, Mar Olga; Centelles-Serrano, Mar\u00eda Jos\u00e9; Nogales-L\u00f3pez, Julio; Domenech-Spanedda, Marie France; Lozano, Carmen; Torres, Carmen\n2017-12-01\nTo characterize a methicillin-resistant Staphylococcus aureus (MRSA) isolate responsible for an aggressive infection (peridural and psoas abscess secondary to haematogenous septic arthritis) in a poultry farmer. Molecular characterization was performed, including spa- and multilocus sequence typing of the isolate, assessment of its resistance phenotype and detection of tetracycline resistance and of virulence and immune evasion cluster (IEC) genes were performed. The MRSA isolate was tetracycline- and fluorquinolone-resistant, and was ascribed to CC398, spa-t1451. The isolate harboured tet(M) (distinctive of livestock-associated (LA) MRSA-CC398 clade) and IEC-type B system (characteristic of the methicillin-susceptible human lineage, but typically absent in LA-MRSA-CC398 strains), and lacked toxin-coding genes lukF/lukS-PV, tsst-1, eta and etb. IEC re-acquisition by LA-MRSA-CC398-LA strains is an unusual finding, but could constitute an emerging public health problem. It would represent an evolutionary step towards LA-MRSA-CC398's adaptation to human hosts, and might enhance its invasiveness and ability to be transmitted to humans. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Epidemiology of the sarcomas of the jaws in a Peruvian population](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3448309)\nSacsaquispe-Contreras, Sonia J.; Morales-Vadillo, Rafael; S\u00e1nchez Lih\u00f3n, Juvenal\n2012-01-01\nObjective: Analysis of the clinical characteristics of patients with Sarcomas of the Jaws treated in the \u201cInstituto Nacional de Enfermedades Neoplasicas. Dr. Eduardo Caceres Graziani\u201d from 1952-2007. Study Design: Review of 155 clinical records of patients with Sarcomas of the Jaws and record of age, gender, size, location, clinical symptoms and signs, histopathological diagnoses and type of treatment. The data obtained were analyzed by means of Student\u2019s statistical t-test, Fisher and Friedman\u2019s test. Results: Analysis of 155 Sarcomas of the Jaws. The average age of patients was 36.8 years old (range: 1-80 years); the female gender was the most frequent (52.9%); the average tumor size was 5.5 cm; in upper jaw 54.84% occurred and 45.16% in the lower jaw; the predominant sign was facial asymmetry (87.74%) and the predominant symptom: pain (63.23%). The most frequent diagnosis was Osteosarcoma 50.3% followed by Chondrosarcoma 18%. Surgery plus radiation therapy was the treatment type of choice with 21.94% of cases. Conclusion: The results of this study demonstrate the delayed diagnosis and facial asymmetry and pain appear as the most important events for the diagnosis of Sarcomas of the Jaws. Key words: Sarcoma, jaw, jaw neoplasms, mouth neoplasms. PMID:22143684\n[[Consensus statement: recommendations for the management of metabolic bone disease in human immunodeficiency virus patients].](https://www.ncbi.nlm.nih.gov/pubmed/24332711)\nMart\u00ednez, Esteban; J\u00f3dar Gimeno, Esteban; Reyes Garc\u00eda, Rebeca; Carpintero, Pedro; Casado, Jos\u00e9 Luis; Del Pino Montes, Javier; Domingo Pedrol, Pere; Estrada, Vicente; Maalouf, Jorge; Negredo, Eugenia; Ocampo, Antonio; Mu\u00f1oz-Torres, Manuel\n2014-04-01\nTo provide practical recommendations for the evaluation and treatment of metabolic bone disease in human immunodeficiency virus (HIV) patients. Members of scientific societies related to bone metabolism and HIV: Grupo de Estudio de Sida (GeSIDA), Sociedad Espa\u00f1ola de Endocrinolog\u00eda y Nutrici\u00f3n (SEEN), Sociedad Espa\u00f1ola de Investigaci\u00f3n \u00d3sea y del Metabolismo Mineral (SEIOMM), and Sociedad Espa\u00f1ola de Fractura Osteopor\u00f3tica (SEFRAOS). A systematic search was carried out in PubMed, and papers in English and Spanish with a publication date before 28 May 2013 were included. Recommendations were formulated according to GRADE system (Grading of Recommendations, Assessment, Development, and Evaluation) setting both their strength and the quality of supporting evidence. Working groups were established for each major part, and the final resulting document was later discussed in a face-to-face meeting. All the authors reviewed the final written document and agreed with its content. The document provides evidence-based practical recommendations on the detection and treatment of bone disease in HIV-infected patients. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Diagn\u00f3stico diferencial en la encefalitis por anticuerpos contra el receptor NMDA](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3101880)\nGonz\u00e1lez-Valc\u00e1rcel, J.; Rosenfeld, M.R.; Dalmau, J.\n2011-01-01\nResumen Introducci\u00f3n La encefalitis por anticuerpos contra el receptor de NMDA (NMDAR) suele desarrollarse como un s\u00edndrome caracter\u00edstico de evoluci\u00f3n multif\u00e1sica y diagn\u00f3stico diferencial amplio. Pacientes Presentamos a 2 pacientes diagnosticadas de encefalitis por anticuerpos NMDAR con un cuadro cl\u00ednico t\u00edpico, pero que inicialmente se\u00f1al\u00f3 otras etiolog\u00edas. Discusi\u00f3n La afectaci\u00f3n frecuente de pacientes j\u00f3venes con manifestaciones psiqui\u00e1tricas prominentes indica frecuentemente otras consideraciones diagn\u00f3sticas; las m\u00e1s frecuentes son las encefalitis virales, los procesos psiqui\u00e1tricos y el s\u00edndrome neurol\u00e9ptico maligno. Varios s\u00edndromes previamente definidos de manera parcial o descriptiva en adultos y pacientes pedi\u00e1tricos probablemente eran casos de encefalitis anti-NMDAR. Conclusiones La encefalitis anti-NMDAR debe considerarse en pacientes j\u00f3venes con manifestaciones psiqui\u00e1tricas subagudas, movimientos anormales y alteraciones auton\u00f3micas. La caracterizaci\u00f3n cl\u00ednica e inmunol\u00f3gica de esta enfermedad ha llevado a la identificaci\u00f3n de nuevos anticuerpos que afectan a procesos de memoria, aprendizaje, conducta y psicosis. PMID:20964986\n[Prevalence and re-infection rate of C. trachomatis genital infections in young people under 25 years in Catalonia.](https://www.ncbi.nlm.nih.gov/pubmed/26304641)\nL\u00f3pez-Corbeto, Evelin; Gonz\u00e1lez, Victoria; Casabona, Jordi\nChlamydia trachomatis infection is the most common bacterial sexually transmitted disease. Re-infections are a major problem in its control as they increase the probability of developing sequellae. To estimate the prevalence of C.trachomatis and re-infection rate after 6 months of treatment by determining the possible causes. Cross-sectional study in which a urine sample was analysed by PCR in a convenience sample of 506 sexually active youths aged 16-25years. An epidemiological survey and re-test was performed at 3months. The prevalence of C.trachomatis was 8.5%. The age (OR=2.34; 95%CI: 1.21-4.55) and concurrency (OR=3.64; 95% CI: 3.58-26.39) were determining factors for acquiring C.trachomatis. The re-infection rate was 10.34%. The high prevalence of C.trachomatis, as well as the rate of reinfection, suggest the need to assess the effectiveness of the opportunistic screening program and ensure high levels of reporting of sexual partners. Ensuring these approaches facilitate the control of C.trachomatis among young people. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Factors associated with mortality in patients undergoing coronary artery bypass grafting.](https://www.ncbi.nlm.nih.gov/pubmed/27508918)\nKoerich, Cintia; Lanzoni, Gabriela Marcellino de Melo; Erdmann, Alacoque Lorenzini\n2016-08-08\nidade de 65 anos. O infarto agudo do mioc\u00e1rdio foi o diagn\u00f3stico de interna\u00e7\u00e3o que apresentou maior representatividade. A maioria das intercorr\u00eancias registradas durante a interna\u00e7\u00e3o caracterizou-se por altera\u00e7\u00f5es do sistema cardiovascular e o maior tempo de interna\u00e7\u00e3o teve rela\u00e7\u00e3o direta com \u00f3bito por choque s\u00e9ptico. os dados fornecem subs\u00eddios para a enfermagem atuar com medidas preventivas e identifica\u00e7\u00e3o precoce de intercorr\u00eancias associadas \u00e0 cirurgia de revasculariza\u00e7\u00e3o do mioc\u00e1rdio. Refor\u00e7a-se a import\u00e2ncia da utiliza\u00e7\u00e3o dos dados como indicadores de qualidade objetivando garantir um cuidado pautado em informa\u00e7\u00f5es confi\u00e1veis que orientem gestores no planejamento da assist\u00eancia ao paciente e dos servi\u00e7os de sa\u00fade de alta complexidade. conocer los factores asociados a la mortalidad de pacientes sometidos a cirug\u00eda de revascularizaci\u00f3n del miocardio en un hospital de referencia cardiovascular en el estado de Santa Catarina. estudio cuantitativo, exploratorio, descriptivo y retrospectivo. Fueron analizados las fichas m\u00e9dicas de 1.447 pacientes, entre 2005 y 2013; las variables relacionadas estad\u00edsticamente fueron: perfil, diagn\u00f3stico de la internaci\u00f3n, factores de riesgo para enfermedad arterial coronariana, complicaciones registradas en la internaci\u00f3n, tiempo de internaci\u00f3n y causa de la muerte. la tasa de mortalidad fue de 5,3%, en el per\u00edodo del estudio. Las muertes fueron m\u00e1s frecuentes en negros, sexo femenino y promedio de edad de 65 a\u00f1os. El infarto agudo del miocardio fue el diagn\u00f3stico de internaci\u00f3n que present\u00f3 mayor representatividad. La mayor\u00eda de las complicaciones registradas durante la internaci\u00f3n se caracteriz\u00f3 por alteraciones del sistema cardiovascular; el mayor tiempo de internaci\u00f3n tuvo relaci\u00f3n directa con muerte por choque s\u00e9ptico. los datos suministran informaciones para que la enfermer\u00eda pueda actuar con medidas preventivas e identificar precozmente complicaciones asociadas a la cirug\n[Educational intervention in Primary Care for the prevention of congenital syphilis.](https://www.ncbi.nlm.nih.gov/pubmed/28146181)\nLazarini, Flaviane Mello; Barbosa, Dulce Aparecida\n2017-01-30\n\u00e7\u00e3o em Excel e a an\u00e1lise estat\u00edstica no Statistical Package for Social Sciences, vers\u00e3o 2.1. Realizou-se an\u00e1lise descritiva e inferencial. a m\u00e9dia de respostas corretas passou de 53% para 74,3% ap\u00f3s a interven\u00e7\u00e3o (p < 0,01). A ades\u00e3o ao treinamento dos profissionais foi de 92,6%. Existiu redu\u00e7\u00e3o importante na taxa de transmiss\u00e3o vertical da s\u00edfilis de 75% em 2013 para 40,2% em 2015. Em 2014 e 2015 n\u00e3o ocorreram registros de mortalidade infantil por esse agravo. a interven\u00e7\u00e3o educacional aumentou significativamente o conhecimento dos profissionais de sa\u00fade sobre a s\u00edfilis e colaborou para a redu\u00e7\u00e3o da taxa de transmiss\u00e3o vertical do agravo. evaluar la eficiencia de la intervenci\u00f3n educacional en el conocimiento de los profesionales de la salud de la Atenci\u00f3n Primaria y verificar el impacto en las tasas de transmisi\u00f3n vertical de la s\u00edfilis cong\u00e9nita. estudio casi experimental, realizado en la ciudad de Londrina, Paran\u00e1, en el per\u00edodo entre 2013 y 2015. Fue realizada una intervenci\u00f3n educacional sobre diagn\u00f3stico, tratamiento y notificaci\u00f3n, con 102 profesionales, midiendo el conocimiento antes y despu\u00e9s de la intervenci\u00f3n. Los datos de incidencia y mortalidad por la s\u00edfilis cong\u00e9nita fueron obtenidos del Sistema de Informaci\u00f3n de Enfermedades de Notificaci\u00f3n (SINAN) y del Sistema de Informaci\u00f3n sobre Mortalidad (SIM). La tabulaci\u00f3n fue realizada en el Excel y el an\u00e1lisis estad\u00edstico en el Statistical Package for Social Sciences, versi\u00f3n 2.1. Se realiz\u00f3 un an\u00e1lisis descriptivo e inferencial. la media de respuestas correctas pas\u00f3 de 53% para 74,3%, despu\u00e9s de la intervenci\u00f3n (p < 0,01). La adhesi\u00f3n al entrenamiento de los profesionales fue de 92,6%. Existi\u00f3 reducci\u00f3n importante en la tasa de transmisi\u00f3n vertical de la s\u00edfilis de 75% en 2013 para 40,2% en 2015. En 2014 y 2015 no ocurrieron registros de mortalidad infantil por esa enfermedad. la intervenci\u00f3n educacional aument\u00f3 significativamente el conocimiento de los\n[Neuropsychiatric symptoms of the elderly with Alzheimer's disease and the family caregivers' distress.](https://www.ncbi.nlm.nih.gov/pubmed/27533264)\nStorti, Luana Baldin; Quintino, D\u00e9bora Teles; Silva, Nat\u00e1lia Michelato; Kusumota, Luciana; Marques, Sueli\n2016-08-15\nidade 80,8 anos, 56,2% possu\u00edam doen\u00e7a de Alzheimer e 43,7%, dem\u00eancia mista. Dos cuidadores, 90,6% eram mulheres, m\u00e9dia de idade 56 anos, 70,8% cuidavam do pai/m\u00e3e e 64,6% moravam com o idoso. Houve correla\u00e7\u00e3o forte (r=0,82) e significativa (p<0,01) entre o escore total do Invent\u00e1rio Neuropsiqui\u00e1trico e o escore total do Invent\u00e1rio Neuropsiqui\u00e1trico Desgaste e correla\u00e7\u00e3o forte (r=0,80) e significativa (p<0,01) entre o escore total do Invent\u00e1rio Neuropsiqui\u00e1trico Desgaste e o n\u00famero de sintomas neuropsiqui\u00e1tricos, ou seja, quanto maiores o n\u00famero, a frequ\u00eancia e a gravidade destes sintomas nos idosos maior \u00e9 o desgaste do cuidador. a presen\u00e7a dos sintomas neuropsiqui\u00e1tricos nos idosos apresentou rela\u00e7\u00e3o com maior desgaste nos cuidadores. analizar la relaci\u00f3n entre el desgaste del cuidador familiar y la presencia de s\u00edntomas neuropsiqui\u00e1tricos en pacientes ancianos con enfermedad de Alzheimer o demencia mixta. estudio descriptivo, transversal, realizado en la cl\u00ednica de Geriatr\u00eda y Demencias de un hospital general terciario, con 96 ancianos con enfermedad de Alzheimer o demencia mixta y sus cuidadores familiares. Se utilizaron cuestionarios para caracterizar los ancianos y cuidadores y el Inventario Neuropsiqui\u00e1trico. Se realizaron estad\u00edsticas descriptivas y prueba de correlaci\u00f3n de Pearson. el 68,7% de los ancianos eran mujeres, con una edad promedio de 80,8 a\u00f1os, el 56,2% ten\u00edan enfermedad de Alzheimer y el 43,7%, demencia mixta. Entre los cuidadores, el 90,6% eran mujeres, con una media de 56 a\u00f1os, el 70,8% se hac\u00eda cargo del padre / madre y el 64,6% viv\u00eda con los ancianos. Hubo una fuerte (r = 0,82) y significativa (p <0,01) correlaci\u00f3n entre la puntuaci\u00f3n total en el Inventario Neuropsiqui\u00e1trico y la puntuaci\u00f3n total en el Inventario Neuropsiqui\u00e1trico-Desgaste y fuerte correlaci\u00f3n (r = 0,80) y significativa (p <0 01) entre la puntuaci\u00f3n total en el Inventario Neuropsiqui\u00e1trico-Desgaste y el n\u00famero de s\n[Comparative study of bacteremias caused by Enterococcus spp. with and without high-level resistance to gentamicin. The Grupo Andaluz para el estudio de las Enfermedades Infecciosas.](https://www.ncbi.nlm.nih.gov/pubmed/9466769)\nCaballero-Granado, F J; Cisneros, J M; Luque, R; Torres-Tortosa, M; Gamboa, F; D\u00edez, F; Villanueva, J L; P\u00e9rez-Cano, R; Pasquau, J; Merino, D; Menchero, A; Mora, D; L\u00f3pez-Ruz, M A; Vergara, A\n1998-02-01\nA prospective, multicenter study was carried out over a period of 10 months. All patients with clinically significant bacteremia caused by Enterococcus spp. were included. The epidemiological, microbiological, clinical, and prognostic features and the relationship of these features to the presence of high-level resistance to gentamicin (HLRG) were studied. Ninety-three patients with enterococcal bacteremia were included, and 31 of these cases were caused by HLRG (33%). The multivariate analysis selected chronic renal failure, intensive care unit stay, previous use of antimicrobial agents, and Enterococcus faecalis species as the independent risk factors that influenced the development of HLRG. The strains with HLRG showed lower levels of susceptibility to penicillin and ciprofloxacin. Clinical features (except for chronic renal failure) were similar in both groups of patients. HLRG did not influence the prognosis for patients with enterococcal bacteremia in terms of either the crude mortality rate (29% for patients with bacteremia caused by enterococci with HLRG and 28% for patients not infected with strains with HLRG) or the hospital stay after the acquisition of enterococcal bacteremia. Hemodynamic compromise, inappropriate antimicrobial therapy, and mechanical ventilation were revealed in the multivariate analysis to be the independent risk factors for mortality. Prolonged hospitalization was associated with the nosocomial acquisition of bacteremia and polymicrobial infections.\n[[Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Grupo de Estudio de Nuevas Terapias de Enfermedades reum\u00e1ticas (GENTE)].](https://www.ncbi.nlm.nih.gov/pubmed/19736814)\nD\u00edaz-Jouanen, Efra\u00edn; Abud-Mendoza, Carlos; Garza-Elizondo, Mario Alberto; Medrano-Ram\u00edrez, Gabriel; Burgos-Vargas, Rub\u00e9n; Orozco-Alcal\u00e1, Jos\u00e9 Javier; Pacheco-Tena, C\u00e9sar Francisco; Pineda, Carlos; Pozos-Esp\u00edndola, Juan Carlos; Ramos-Niembro, Francisco; Robles-San-Rom\u00e1n, Manuel; Santana-Sahag\u00fan, Jes\u00fas Ernesto\n2009-01-01\nRecommendations for the use of Disease-Modifying Antirheumatic Drugs (DMARD) with both conventional and biological agents in Rheumatoid Arthritis (RA) must be based on their safety profile, adverse effects, risks, and advantages. With the purpose of presenting the most updated information about the safety of tumor necrosis factor alpha (TNFalpha) antagonists, in this article we summarize the literature published during the last three years about this sort of biological agents in specific clinical situations, such as risk of developing infections, cancer, cardiovascular diseases, and autoimmunity; as well as their administration to patients who will undergo surgical procedures, pregnant and/or breast-feeding women, and patients who need immunizations. Likewise, in this analysis we offer specific recommendations, based on evidence, for the best anti-TNF-alfa management.\n[Malformaciones arteriovenosas revisi\u00f3n y an\u00e1lisis descriptivo de 52 mavs tratadas durante el periodo de 2000-2010](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4623613)\nRinaldi, Mariano; Mezzano, Emilio; Berra, Matias S.; Par\u00e9s, Herald R.; Olocco, Ricardo V.; Papalini, Francisco R.\n2015-01-01\nObjetivo: Describir nuestra experiencia en el manejo de las Mavs analizando las caracter\u00edsticas cl\u00ednicas de los pacientes y los resultados postoperatorios. M\u00e9todo de an\u00e1lisis: Realizamos un an\u00e1lisis retrospectivo de 52 pacientes admitidos en el Servicio de neurocirug\u00eda para manejo quir\u00fargico: La informaci\u00f3n de referencia incluyo s\u00edntomas al inicio, diagnostico de admisi\u00f3n, hallazgos neurol\u00f3gicos y hallazgos en estudio por im\u00e1genes tales como tomograf\u00eda cerebral, IRM cerebral y angiograf\u00eda por sustracci\u00f3n digital. Los hallazgos postoperatorios de inter\u00e9s fueron: Mortalidad, examen neurol\u00f3gico postoperatorio y complicaciones asociadas. Presentamos nuestro an\u00e1lisis estad\u00edstico. Resultados: Edad promedio: 37,7 a\u00f1os. Distribuci\u00f3n: Hombres: 61,5%. Motivos de consulta m\u00e1s frecuentes: Cefalea 63,5%, evento hemorr\u00e1gico 59,6%, convulsiones 26,9%. Localizaci\u00f3n: Supratentorial: 92,9%, Infratentorial: 7,2%. 30,8%, de las Mavs fueron grado 2 y grado 3 Cincuenta por ciento del total presentaron aneurismas, del total de la MAVs, 59,6% debut\u00f3 con sangrado, 26,9% con Crisis Convulsivas y 13,5% con d\u00e9ficit neurol\u00f3gico. Recibieron tratamiento endovascular previo a cirug\u00eda 30,7%. Durante el postoperatorio 23,1% presentaron mejor\u00eda cl\u00ednica, 57,7% no presento modificaci\u00f3n, 19,2% empeoraron en el postoperatorio. La mortalidad fue 13,5%. Conclusi\u00f3n: Creemos que el subgrupo de Mavs grados III a V representan una entidad que requiere una compleja toma de decisiones dada la alta incidencia de aneurismas asociados que presentan y su asociaci\u00f3n con eventos de sangrado. Nuestra mortalidad postoperatoria coincide con la bibliograf\u00eda. Palabras clave, Mavs- aneurismas asociados- Acv hemorr\u00e1gico- convulsiones. PMID:26600984\n[Relaciones entre el sue\u00f1o y la adicci\u00f3n](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5047372)\nCa\u00f1ellas, Francesca; de Lecea, Luis\n2016-01-01\nResumen La interacci\u00f3n entre los trastornos del sue\u00f1o y el abuso de sustancias es ya conocida, pero seguramente m\u00e1s compleja de lo que se pensaba. Existe tanto una relaci\u00f3n positiva entre tener un trastorno por uso de substancias y sufrir un trastorno de sue\u00f1o, como viceversa. Los efectos sobre el sue\u00f1o dependen de la substancia utilizada, pero se ha demostrado que tanto durante su uso como en per\u00edodo de abstinencia los consumidores tienen diferentes problemas de sue\u00f1o y fundamentalmente un sue\u00f1o m\u00e1s fragmentado. Sabemos que hay que tener en cuenta los problemas de sue\u00f1o para evitar reca\u00eddas en la adicci\u00f3n. Investigaciones recientes indican que el sistema hipocretin\u00e9rgico definido por el neurop\u00e9ptido hipocretina/orexina (Hcrt/ox), localizado en el hipot\u00e1lamo lateral e implicado entre otros en la regulaci\u00f3n del ciclo sue\u00f1o-vigilia, jugar\u00eda un papel importante en las conductas adictivas. Diferentes estudios han demostrado interacciones entre el sistema hipocretin\u00e9rgico, los circuitos de respuesta aguda al estr\u00e9s y los sistemas de recompensa. Tambi\u00e9n sabemos que la activaci\u00f3n optogen\u00e9tica selectiva del sistema hipocretin\u00e9rgico incrementa la probabilidad de la transici\u00f3n del sue\u00f1o a la vigilia, y tambi\u00e9n es suficiente para iniciar un comportamiento compulsivo de reca\u00edda adictiva. La activaci\u00f3n del sistema hipocretin\u00e9rgico podr\u00eda explicar la hipervigilia asociada al estr\u00e9s y a la adicci\u00f3n. El mayor conocimiento de esta interacci\u00f3n permitir\u00eda entender mejor los mecanismos de la adicci\u00f3n y encontrar nuevas estrategias para el tratamiento de las adicciones. PMID:23241715\nL\u00f3pez-Fuenzalida, Antonio; Rodr\u00edguez Canales, Carolina; Reyes Ponce, \u00c1lvaro; Contreras Molina, \u00c1ngela; Fern\u00e1ndez Quezada, Javiera; Aguirre Polanco, Carolina\n2016-03-25\nIntroducci\u00f3n: dado el incremento del sobrepeso y obesidad infantil, es relevante estudiar no solo las consecuencias metab\u00f3licas, sino tambi\u00e9n aquellas de \u00edndole musculoesquel\u00e9ticas que pueden afectar la funcionalidad motriz, como es el pie plano, en esta poblaci\u00f3n. Objetivo: identificar la asociaci\u00f3n entre el estado nutricional y la prevalencia de pie plano en ni\u00f1os y ni\u00f1as chilenos de 6 a 10 a\u00f1os. M\u00e9todos: el z-score del \u00edndice de masa corporal (IMC) y el registro y an\u00e1lisis de las huellas plantares seg\u00fan la metodolog\u00eda de Hern\u00e1ndez-Corvo fue llevado a cabo en 388 escolares (52,3% ni\u00f1as). Un test de diferencia para dos proporciones fue utilizado para evaluar las diferencias entre los grupos. Se considera una significancia estad\u00edstica con p \u2264 0,05. Resultados: la prevalencia del exceso de peso fue de m\u00e1s del 40%. Esta prevalencia fue m\u00e1s alta en las ni\u00f1as (47,8%) que en los ni\u00f1os (42,7%). La prevalencia de pie plano en todos los ni\u00f1os fue del 17%, presentando valores m\u00e1s elevados el pie derecho (18,3%) que el izquierdo (15,7%). Hay un incremento significativo de la prevalencia de pie plano en los ni\u00f1os obesos en relaci\u00f3n con los ni\u00f1os con sobrepeso y normopeso. Conclusi\u00f3n: el estado nutricional est\u00e1 asociado con incrementos en la prevalencia de pie plano en ni\u00f1os. En la poblaci\u00f3n infantil de 6 a 10 a\u00f1os de edad, la obesidad est\u00e1 asociada con la alteraci\u00f3n morfol\u00f3gica del pie.\nPrieto Boh\u00f3rquez, Signed Esperanza; Rodr\u00edguez Vel\u00e1squez, Javier Oswaldo; Correa Herrera, Catalina; Pardo Oviedo, Juan Mauricio; Ardila, Javier\n2018-03-23\nIntroducci\u00f3n: una ley exponencial se ha hallado para los sistemas din\u00e1micos ca\u00f3ticos cardiacos, logrando cuantificar las diferencias entre din\u00e1micas cardiacas normales y patol\u00f3gicas.Metodolog\u00eda: Se analizaron 120 registros electrocardiogr\u00e1ficos, 40 correspond\u00edan a sujetos dentro de los l\u00edmites de normalidad y 80 con diferentes patolog\u00edas. Para cada holter se analizaron los atractores generados con los datos durante 18 horas y durante toda la din\u00e1mica. Se calcul\u00f3 la dimensi\u00f3n fractal del atractor y su ocupaci\u00f3n espacial. A estas medidas se aplic\u00f3 la evaluaci\u00f3n matem\u00e1tica diagnostica desarrollada previamente, comparando la evaluaci\u00f3n para 18 horas y para todo el registro; finalmente se calcul\u00f3 la sensibilidad, especificidad y coeficiente Kappa.Resultados: Para las din\u00e1micas normales los espacios de ocupaci\u00f3n en la rejilla Kp estuvieron entre 200 y 381 en la evaluaci\u00f3n de la totalidad del holter, y entre 201 y 384 en la evaluaci\u00f3n durante 18 horas, mostrando la cercan\u00eda en las medidas, lo que permite que la disminuci\u00f3n en el tiempo de la evaluaci\u00f3n sea consistente, esta misma cercan\u00eda se observ\u00f3 para las din\u00e1micas enfermas y agudas.Conclusi\u00f3n: Se evidenci\u00f3 la aplicabilidad cl\u00ednica en 18 horas de la ley exponencial en la din\u00e1mica cardiaca ca\u00f3tica asociada a arritmias mostrando ser de utilidad para la predicci\u00f3n de la evoluci\u00f3n hacia estados agudos de la din\u00e1mica.\n[Estrategia innovadora enfocada en parejas del mismo sexo para disminuir la infecci\u00f3n del VIH en hombres Latinos](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4286892)\nMartinez, Omar; Wu, Elwin; Sandfort, Theo; Shultz, Andrew Z.; Capote, Jonathan; Ch\u00e1vez, Silvia; Moya, Eva; Dodge, Brian; Morales, Gabriel; Porras, Antonio; Ovejero, Hugo\n2014-01-01\nResumen El VIH es un problema de salud importante dentro de la comunidad latina de los Estados Unidos. Gracias a los esfuerzos de prevenci\u00f3n, los niveles de contagio entre los latinos se han mantenido estables por m\u00e1s de una d\u00e9cada. Sin embargo, esta poblaci\u00f3n sigue siendo afectada a niveles muy altos, en particular entre hombres que tienen sexo con hombres (HSH), de origen latino y que hablan principalmente el idioma espa\u00f1ol. Existen varios factores que contribuyen a la transmisi\u00f3n del VIH entre esta poblaci\u00f3n, como son: el uso de drogas; la violencia dentro de la pareja; la presencia de infecciones de transmisi\u00f3n sexual; relaciones sexuales sin protecci\u00f3n, dentro y fuera de la pareja; el evadir la b\u00fasqueda de recursos (prueba y tratamiento adecuado) por temor a ser discriminado o por su estatus migratorio; la escasez de recursos econ\u00f3micos o estado de pobreza y los patrones relacionados a la migraci\u00f3n. En particular, Investigaciones Epidemiol\u00f3gicas de Comportamientos han determinado: c\u00f3mo algunas din\u00e1micas en parejas est\u00e1n directamente asociadas a los comportamientos sexuales de riesgos. En consecuencia, es necesaria mayor investigaci\u00f3n para identificar esas din\u00e1micas, y a su vez, realizar intervenciones dirigidas a la reducci\u00f3n de conductas de riesgo enfocadas en parejas de hombres del mismo sexo. En este escrito, se describe la importancia del uso de las relaciones de pareja como estrategia en la reducci\u00f3n de la trasmisi\u00f3n del VIH/SIDA en HSH de origen latino y que hablan principalmente el idioma espa\u00f1ol en los Estados Unidos. PMID:25580466\n[First Enterovirus D68 (EV-D68) cases detected in hospitalised patients in a tertiary care university hospital in Spain, October 2014.](https://www.ncbi.nlm.nih.gov/pubmed/25735714)\nGimferrer, Laura; Campins, Magda; Codina, Maria Gema; Esperalba, Juliana; Martin, Maria Del Carmen; Fuentes, Francisco; Pumarola, Tomas; Anton, Andres\n2015-11-01\nSeveral outbreaks of Enterovirus 68 (EV-D68) have recently been reported in the USA and Canada, causing substantial hospitalisation of children with severe respiratory disease. The acute flaccid paralysis detected in the USA and Canada among children with EV-D68 infection has raised concerns about the aetiological role of this EV serotype in severe neurological disease. The circulation of EV-D68 in the general European population seems to be low, but European Centre for Disease Prevention and Control (ECDC) recommends being vigilant to new cases, particularly in severely ill hospitalised patients. In October 2014, enteroviruses were detected in respiratory samples collected from five hospitalised patients, children and adults. Phylogenetic analysis of partial VP1 sequences confirmed that the detected enteroviruses belonged to the D68 serotype, which were also similar to strains reported in USA (2014). However, all five patients developed respiratory symptoms, but only one required ICU admission. None of the patients described had symptoms of neurological disease. Other considerations related to the detection methods used for the diagnosis of respiratory enteroviruses are also discussed. In conclusion, additional evidence has been provided that supports the role of EV-D68 in respiratory infections in hospitalised patients. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Pleural mesothelioma in a Mexican population: clinical and radiological similarities among histopathologic patterns].](https://www.ncbi.nlm.nih.gov/pubmed/19241668)\nP\u00e9rez-Guzm\u00e1n, Carlos; Vargas, Mario H; Torre-Bouscoulet, Luis\n2008-01-01\nTo describe clinical and radiological features of patients with pleural mesothelioma, according to main histological types. Clinical records of inpatients admitted with diagnosis of pleural mesothelioma to the Instituto Nacional de Enfermedades Respiratorias in the last 11 years, were reviewed. We analyzed 85 cases confirmed by immunohistochemistry. The most frequent histological type was epithelial (84.7 %), followed by sarcomatous (12.9 %) and mixed (2.4 %) types. Comparison between epithelial and sarcomatous types showed no differences in age (53.7 +/- 13.1 vs. 55.9 +/- 11.0 years, respectively), male : female ratio (2.3 : 1 vs. 1.8 : 1), history of asbestos exposure (34.7 vs. 27.2 %), tobacco habit (54.2 vs 45.4 %), occupation, evolution time (4.8 +/- 3.3 vs. 4.4 +/- 3.7 months), pain, dyspnea and cough, right-side predominance (55.6 vs. 81.8 %), radiological image with pleural effusion (59.7 vs. 36.4 %) or pleural thickening (38.9 vs. 63.6 %), and diagnostic efficiency of closed pleural biopsy (58.3 vs. 27.2 %). Our results suggest that clinical and radiological features of epithelial and sarcomatous histological types are very similar. Additionally, we found a high frequency of epithelial mesothelioma, which contrasts with findings from other countries, suggesting that the type of asbestos or other factors involved in the development of pleural mesothelioma differ from those existing in other regions of the world.\n[[Study of human immunodeficiency virus transmission chains in Andalusia: analysis from baseline antiretroviral resistance sequences].](https://www.ncbi.nlm.nih.gov/pubmed/25648468)\nP\u00e9rez-Parra, Santiago; Chueca-Porcuna, Natalia; \u00c1lvarez-Estevez, Marta; Pasquau, Juan; Omar, Mohamed; Collado, Antonio; Vinuesa, David; Lozano, Ana Belen; Garc\u00eda-Garc\u00eda, Federico\n2015-11-01\nProtease and reverse transcriptase HIV-1 sequences provide useful information for patient clinical management, as well as information on resistance to antiretrovirals. The aim of this study is to evaluate transmission events, transmitted drug resistance, and to georeference subtypes among newly diagnosed patients referred to our center. A study was conducted on 693 patients diagnosed between 2005 and 2012 in Southern Spain. Protease and reverse transcriptase sequences were obtained for resistance to cART analysis with Trugene(\u00ae) HIV Genotyping Kit (Siemens, NAD). MEGA 5.2, Neighbor-Joining, ArcGIS and REGA were used for subsequent analysis. The results showed 298 patients clustered into 77 different transmission events. Most of the clusters were formed by pairs (n=49), of men having sex with men (n=26), Spanish (n=37), and below 45 years of age (73.5%). Urban areas from Granada, and the coastal areas of Almeria and Granada showed the greatest subtype heterogeneity. Five clusters were formed by more than 10 patients, and 15 clusters had transmitted drug resistance. The study data demonstrate how the phylogenetic characterization of transmission clusters is a powerful tool to monitor the spread of HIV, and may contribute to design correct preventive measures to minimize it. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[TECNOLOG\u00cdAS DE INFORMACI\u00d3N Y COMUNICACI\u00d3N PARA LA PREVENCI\u00d3N Y CONTROL DE LA INFECCI\u00d3N POR EL VIH Y OTRAS ITS*](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4556424)\nCurioso, Walter H.; Blas, Magaly M.; Kurth, Ann E.; Klausner, Jeffrey D.\n2010-01-01\nAvances tecnol\u00f3gicos innovadores como Internet, computadoras personales de bolsillo, tel\u00e9fonos celulares y otros equipos son un arsenal en crecimiento en el esfuerzo de impedir y controlar el VIH y otras infecciones de transmisi\u00f3n sexual (ITS). A pesar que existe una diversidad de tecnolog\u00edas de informaci\u00f3n y comunicaci\u00f3n en diferentes etapas de desarrollo para la prevenci\u00f3n del VIH e ITS, la investigaci\u00f3n en esta \u00e1rea se encuentra a\u00fan en crecimiento, y el impacto en la incidencia de enfermedad, las evaluaciones con dise\u00f1os rigurosos y los estudios econ\u00f3micos todav\u00eda son muy limitados. Sin embargo, algunas de estas evidencias son prometedoras y poseen un gran potencial para su uso en nuestro medio. En este art\u00edculo hemos realizado una revisi\u00f3n sistem\u00e1tica de la literatura relacionada con el uso de la tecnolog\u00eda aplicada a la prevenci\u00f3n y control del VIH e ITS. De ser usada apropiadamente, esta tecnolog\u00eda podr\u00eda mejorar la vigilancia del VIH y otras ITS, diagn\u00f3stico, notificaci\u00f3n de parejas, prevenci\u00f3n, manejo cl\u00ednico, y capacitaci\u00f3n de profesionales de la salud. PMID:26339254\n[[Analysis of the epidemiological pattern of Shigellosis in Barcelona between 1988 and 2012: Is it an emerging sexually transmitted infection?].](https://www.ncbi.nlm.nih.gov/pubmed/25487603)\nCulqui, Dante R; Garc\u00eda-de-Olalla-Rizo, Patricia; Alva-Chavez, Kenedy Pedro; Lafuente, Sarah; Rius, Cristina; de Sim\u00f3n, Merc\u00e8; Sabater, Sarah; Cayl\u00e1, Joan A\n2015-01-01\nThe aim of this study was to describe the evolution and epidemiologic characteristics of shigellosis patients over a 25 year period in a large city. Shigellosis is a notifiable disease in Spain since 1988. Cases are analyzed in Barcelona residents included in the registry between 1988-2012. A descriptive analysis by sex, age, mode of transmission and Shigella species is presented. Trend analysis and time series were performed. Of the 559 cases analyzed, 60.15% were males. A sustained increase was observed in the trend since 2008 in males (p<0,05), especially at the expense of males who had no history of food poisoning or travel to endemic areas. The increasing tendency was greater in males from 21 to 60 years, both for S. flexneri (since 2009), and for S. sonnei (since 2004). In 2012 it was noted that in the men with S. flexneri, the 63% were men who have sex with men. An increased trend was detected in men who had no history of food poisoning or travel to endemic areas. This increase points to a change in the pattern of shigellosis, becoming predominantly male and its main mechanism probably by sexual transmission. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Consensus document on psychiatric and psychological aspect in adults and children with HIV infection].](https://www.ncbi.nlm.nih.gov/pubmed/26409725)\n2016-01-01\nThis consensus document is an update of psychiatric and psychological disorders guidelines in HIV-patientes, from the standpoint of care. This document has been approved by expert panel of SPNS, SEP, GESIDA and SEIP, after reviewing the results of efficacy and safety of clinical trials, cohort and pharmacokinetic studies published in biomedical journals (PubMed and Embase) or presented at conferences. The strength of recommendation and gradation of their evidence are based onthe GRADE system. HIV Patient care should include psychological and psychiatric care which is necessary for early detection thereof. Should suicidal ideation, refer the patient to a psychiatric unit. Pharmacological treatment is recommended when there is comorbidity with moderate or severe depression. You should look for the etiology of neuropsychiatric disorder before using psychoactive drugs in HIV patients. The overall management of the health of HIV adolescents should include an assessment of mental health, environmental stressors and support systems. Training in the management of the patient both own emotions is critical to getting provide optimal care. These new guidelines updated previous recommendations regarding psychiatric and psychological disorders, including the most common pathologies in adults and children. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Influenza vaccination. Effectiveness of current vaccines and future challenges].](https://www.ncbi.nlm.nih.gov/pubmed/26232121)\nOrtiz de Lejarazu, Ra\u00fal; Tamames, Sonia\n2015-01-01\nSeasonal influenza is an annual challenge for health-care systems, due to factors such as co-circulation of 2 influenza A subtypes jointly with 2 influenza B lineages; the antigenic drift of these virus, which eludes natural immunity, as well as immunity conferred by vaccination; together with influenza impact in terms of morbidity and mortality. Influenza vaccines have been available for more than 70 years and they have progressed in formulation, production and delivery route. Recommendations on vaccination are focused on those with a higher probability of severe disease, and have a progressively wider coverage, and classically based on inactivated vaccines, but with an increasing importance of attenuated live vaccines. More inactivated vaccines are becoming available, from adyuvanted and virosomal vaccines to intradermal delivery, cell-culture or quadrivalent. Overall vaccine effectiveness is about 65%, but varies depending on characteristics of vaccines, virus, population and the outcomes to be prevented, and ranges from less than 10% to almost 90%. Future challenges are formulations that confer more extensive and lasting protection, as well as increased vaccination coverage, especially in groups such as pregnant women and health-care professionals, as well as being extended to paediatrics. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Fondaparinux in the initial and long-term treatment of venous thromboembolism.](https://www.ncbi.nlm.nih.gov/pubmed/25543161)\nPesavento, Raffaele; Amitrano, Maria; Trujillo-Santos, Javier; Di Micco, Pierpaolo; Mangiacapra, Sara; L\u00f3pez-Jim\u00e9nez, Luciano; Falg\u00e1, Conxita; Garc\u00eda-Bragado, Fernando; Piovella, Chiara; Prandoni, Paolo; Monreal, Manuel\n2015-02-01\nEven in the absence of evidence on its long-term efficacy and safety, a number of patients with venous thromboembolism (VTE) receive long-term therapy with fondaparinux alone in everyday practice. We used the Registro Informatizado de Enfermedad Tromboemb\u00f3lica (RIETE) registry to compare the rate of VTE recurrences and major bleeding at 10 and 90 days in patients with and without cancer. For long-term therapy, fondaparinux was compared with vitamin K antagonists (VKA) in patients without cancer and with low-molecular-weight heparin (LMWH) in those with cancer. Of 47,378 patients recruited, 46,513 were initially treated with heparin, 865 with fondaparinux. Then, 263 patients (78 with cancer) were treated for at least 3 months with fondaparinux. After propensity-score matching, there were no differences between patients receiving initial therapy with heparin or fondaparinux. Among patients with cancer, there were no differences between fondaparinux and LMWH. Among patients without cancer, the long-term use of fondaparinux was associated with an increased risk of major bleeding (3.24 % vs. 0.95 %, p<0.05). An unexpected high rate of major bleeding was observed in non-cancer patients treated with long-term fondaparinux. Our small sample does not allow to derive relevant conclusions on the use of fondaparinux in cancer patients. Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.\n[[Implementation of a post-discharge surgical site infection system in herniorrhaphy and mastectomy procedures].](https://www.ncbi.nlm.nih.gov/pubmed/24054042)\nSan Juan Sanz, Isabel; D\u00edaz-Agero-P\u00e9rez, Cristina; Robustillo-Rodela, Ana; Pita L\u00f3pez, Mar\u00eda Jos\u00e9; Oliva I\u00f1iguez, Lourdes; Monge-Jodr\u00e1, Vicente\n2014-10-01\nMonitoring surgical site infection (SSI) performed during hospitalization can underestimate its rates due to the shortening in hospital stay. The aim of this study was to determine the actual rates of SSI using a post-discharge monitoring system. All patients who underwent herniorraphy or mastectomy in the Hospital Universitario Ram\u00f3n y Cajal from 1 January 2011 to 31 December 2011 were included. SSI data were collected prospectively according to the continuous quality improvement indicators (Indicadores Clinicos de Mejora Continua de la Calidad [INCLIMECC]) monitoring system. Post-discharge follow-up was conducted by telephone survey. A total of 409patients were included in the study, of whom 299 underwent a herniorraphy procedure, and 110 underwent a mastectomy procedure. For herniorrhaphy, the SSI rate increased from 6.02% to 7.6% (the post-discharge survey detected 21.7% of SSI). For mastectomy, the SSI rate increased from 1.8% to 3.6% (the post-discharge survey detected 50% of SSI). Post-discharge monitoring showed an increased detection of SSI incidence. Post-discharge monitoring is useful to analyze the real trend of SSI, and evaluate improvement actions. Post-discharge follow-up methods need to standardised. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[First multicenter epidemiological research using the Latin American Guide for Psychiatric Diagnosis (GLADP) in Argentina].](https://www.ncbi.nlm.nih.gov/pubmed/22432093)\nKlubok, El\u00edas; Huanambal, David; Rubinetti, H\u00e9ctor; Stagnaro, Juan Carlos\n2011-01-01\nClassification systems usually employed in clinical investigation as well as for epidemiological purposes present different characteristics. In latinamerican region it has been developed a Guide called Gu\u00eda Latinoamericana para el Diagn\u00f3stico de las Enfermedades Mentales (GLADP), originally based on the one proposed by the World Health Organization with several modifications. It has been employed in investigations performed in Mexico and Peru. In this work we inform the epidemiological results obtained by the employment of the GLADP in a sample of 374 patients consulting in public hospitals or mental health services in different regions of Argentina. Most prevalent disorders were anxiety and mood disorders (depressive disorders), psychosis and addictive disorders. Among context factors reported as having impact in mental health status, the more frequently mentioned was the family. 25% of the sample was unemployed. An original characterist of GLADP is the inclusion of qualitative data. By the qualitative interview it became clear a relationship between occupation and education status and quality of life, being more favorable for proffesionals and business men in comparison with people employed by a third party. People with tertiary or secundary studies reported also a better quality of life than people with primary studies. These preliminary data, obtained for the first time by the employment of the GLADP in Argentina should be further confirmed.\n[[Eradication of Staphylococcus aureus in carrier patients undergoing joint arthroplasty].](https://www.ncbi.nlm.nih.gov/pubmed/24880651)\nBarbero Allende, Jos\u00e9 M; Romanyk Cabrera, Juan; Montero Ruiz, Eduardo; Vall\u00e9s Purroy, Alfonso; Melgar Molero, Virginia; Agudo L\u00f3pez, Rosa; Gete Garc\u00eda, Luis; L\u00f3pez \u00c1lvarez, Joaqu\u00edn\n2015-02-01\nProsthetic joint infection (PJI) is a complication with serious repercussions and its main cause is Staphylococcus aureus. The purpose of this study is to determine whether decolonization of S.aureus carriers helps to reduce the incidence of PJI by S.aureus. An S.aureus screening test was performed on nasal carriers in patients undergoing knee or hip arthroplasty between January and December 2011. Patients with a positive test were treated with intranasal mupirocin and chlorhexidine soap 5 days. The incidence of PJI was compared with patients undergoing the same surgery between January and December 2010. A total of 393 joint replacements were performed in 391 patients from the control group, with 416 joint replacements being performed in the intervention group. Colonization study was performed in 382 patients (91.8%), of which 102 were positive (26.7%) and treated. There was 2 PJI due S.aureus compared with 9 in the control group (0.5% vs 2.3%, odds ratio [OR]: 0.2, 95% confidence interval [CI]: 0.4 to 2.3, P=.04). In our study, the detection of colonization and eradication of S.aureus carriers achieved a significant decrease in PJI due to S.aureus compared to a historical group. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Characterization of phenotypic and genotypic drug resistance patterns of Mycobacterium tuberculosis isolates from a city in Mexico.](https://www.ncbi.nlm.nih.gov/pubmed/24953252)\nFlores-Trevi\u00f1o, Samantha; Morf\u00edn-Otero, Rayo; Rodr\u00edguez-Noriega, Eduardo; Gonz\u00e1lez-D\u00edaz, Esteban; P\u00e9rez-G\u00f3mez, H\u00e9ctor Ra\u00fal; Mendoza-Olazar\u00e1n, Soraya; Balderas-Renter\u00eda, Isa\u00edas; Gonz\u00e1lez, Gloria Mar\u00eda; Garza-Gonz\u00e1lez, Elvira\n2015-03-01\nThe emergence of multidrug-resistant (MDR) Mycobacterium tuberculosis strains has become a worldwide health care problem, making treatment of tuberculosis difficult. The aim of this study was to determine phenotypic resistance and gene mutations associated with MDR of clinical isolates of Mycobacterium tuberculosis from Guadalajara, Mexico. One hundred and five isolates were subjected to drug susceptibility testing to first line drugs using the proportion and Mycobacteria Growth Indicator Tube (MGIT) methods. Genes associated with isoniazid (inhA, katG, ahpC) and rifampicin (rpoB) resistance were analyzed by either pyrosequencing or PCR-RFLP. Resistance to any drug was detected in 48.6% of isolates, of which 40% were isoniazid-resistant, 20% were rifampicin-resistant and 19% were MDR. Drug-resistant isolates had the following frequency of mutations in rpoB (48%), katG (14%), inhA (26%), ahpC (26%). Susceptible isolates also had a mutation in ahpC (29%). This is the first analysis of mutations associated with MDR of M. tuberculosis in Guadalajara. Commonly reported mutations worldwide were found in rpoB, katG and inhA genes. Substitution C to T in position -15 of the ahpC gene may possibly be a polymorphism. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[A six-month Serratia marcescens outbreak in a Neonatal Intensive Care Unit.](https://www.ncbi.nlm.nih.gov/pubmed/26900002)\nMorillo, \u00c1urea; Gonz\u00e1lez, Ver\u00f3nica; Aguayo, Josefa; Carre\u00f1o, Concepci\u00f3n; Torres, Mar\u00eda Jos\u00e9; Jarana, Daniel; Artacho, Mar\u00eda Jos\u00e9; Jim\u00e9nez, Francisco; Conde, Manuel; Aznar, Javier\n2016-12-01\nTo investigate a Serratia marcescens (S. marcescens) outbreak in a Neonatal Unit in a tertiary university hospital. Descriptive study of children admitted to the Unit with S. marcescens infection from November 2012 to March 2013. Conventional microbiological methods for clinical and environmental samples were used. The clonal relationship between all available isolates was established by molecular methods. A multidisciplinary team was formed, and preventive measures were taken. S. marcescens was isolated from 18 children. The overall attack rate was 12%, and the case fatality rate in the Intensive Care Unit was 23.5%. The most prevalent types of infections were pneumonia (6), conjunctivitis (6), and bloodstream infection (5). Clinical isolates and environmental isolates obtained from an incubator belonged to a unique clone. The clonal relationship between all S. marcescens strains helped us to identify the possible source of the outbreak. Isolation of S. marcescens from stored water in a container, and from the surface of an incubator after cleaning, suggests a possible environmental source as the outbreak origin, which has been perpetuated due to a failure of cleaning methods in the Unit. The strict hygiene and cleaning measures were the main factors that contributed to the end of the outbreak. Copyright \u00c2\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Molecular (ticks) and serological (humans) study of Crimean-Congo hemorrhagic fever virus in the Iberian Peninsula, 2013-2015.](https://www.ncbi.nlm.nih.gov/pubmed/28291670)\nPalomar, Ana M; Portillo, Ar\u00e1nzazu; Santib\u00e1\u00f1ez, Sonia; Garc\u00eda-\u00c1lvarez, Lara; Mu\u00f1oz-Sanz, Agust\u00edn; M\u00e1rquez, Francisco J; Romero, Lourdes; Eiros, Jos\u00e9 M; Oteo, Jos\u00e9 A\nCrimean-Congo hemorrhagic fever (CCHF) is a viral disease, mainly transmitted through tick bite, of great importance in Public Health. In Spain, Crimean-Congo hemorrhagic fever virus (CCHFV) was detected for the first time in 2010 in Hyalomma lusitanicum ticks collected from deer in C\u00e1ceres. The aim of this study was to investigate the presence of CCHFV in ticks from C\u00e1ceres, and from other Spanish areas, and to evaluate the presence of antibodies against the virus in individuals exposed to tick bites. A total of 2053 ticks (1333 Hyalomma marginatum, 680 H. lusitanicum and 40 Rhipicephalus bursa) were analyzed using molecular biology techniques (PCR) for CCHFV detection. The determination of specific IgG antibodies against CCHFV in 228 serum samples from humans with regular contact with ticks (at risk of acquiring the infection) was performed by indirect immunofluorescence assay. The CCHFV was not amplified in ticks, nor were antibodies against the virus found in the serum samples analyzed. The absence of the CCHFV in the ticks studied and the lack of antibodies against the virus in individuals exposed to tick bites would seem to suggest a low risk of acquisition of human infection by CCHFV in Spain. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Feasibility and cosmetic outcome of oncoplastic surgery in breast cancer treatment].](https://www.ncbi.nlm.nih.gov/pubmed/26055287)\nSherwell-Cabello, Santiago; Maffuz-Aziz, Antonio; Villegas-Carlos, Felipe; Dom\u00ednguez-Reyes, Carlos; Labastida-Almendaro, Sonia; Rodr\u00edguez-Cuevas, Sergio\n2015-01-01\nBreast cancer is the leading oncological cause of death in Mexican women over 25 years old. Given the need to improve postoperative cosmetic results in patients with breast cancer, oncoplastic surgery has been developed, which allows larger tumour resections and minor cosmetic alterations. To determine the oncological feasibility and cosmetic outcome of oncoplastic surgery at the Instituto de Enfermedades de la Mama, FUCAM, AC. A review was conducted from January 2010 to July 2013, which included patients with breast cancer diagnosis treated with conventional breast-conserving surgery or with oncoplastic surgery in the Institute of Diseases of the Breast, FUCAM AC. Clinical and histopathological parameters were compared between the two groups, and a questionnaire of cosmetic satisfaction and quality of life was applied. Of the 171 patients included, 95 of them were treated with conventional breast-conserving surgery and 76 with oncoplastic surgery. Pathological tumour size was significantly larger in patients treated with oncoplastic surgery (p = 0.002). There were no differences found between the groups as regards the number of patients with positive surgical margin, the rate of complications, and cosmetic satisfaction. This study demonstrates the oncological feasibility and high cosmetic satisfaction of oncoplastic surgery with minimal psycho-social impact on patients. Copyright \u00a9 2015 Academia Mexicana de Cirug\u00eda A.C. Published by Masson Doyma M\u00e9xico S.A. All rights reserved.\n[[Acute outbreak of hepatitis C in human immunodeficiency virus-infected patients].](https://www.ncbi.nlm.nih.gov/pubmed/25124489)\nMart\u00ednez-Rebollar, Maria; Mallolas, Josep; P\u00e9rez, I\u00f1aki; Gonz\u00e1lez-Cord\u00f3n, Ana; Lonc\u00e0, Montserrat; Torres, Berta; Rojas, Jhon-Fredy; Monteiro, Polyana; Blanco, Jos\u00e9-Luis; Mart\u00ednez, Esteban; Gatell, Jos\u00e9-Mar\u00eda; Laguno, Montserrat\n2015-01-01\nRecent studies suggest an increased incidence of acute infection with hepatitisC virus (AHC) in men who have sex with men (MSM) co-infected with HIV. Early treatment with interferon-alpha, alone or in combination with ribavirin, significantly reduces the risk of chronic evolution. This retrospective study includes all HIV patients with AHC in our centre from 2003 to March 2013. AHC was defined by seroconversion of HCV antibodies and detection of serum HCV RNA. 93 episodes of AHC were diagnosed in 89 patients. All but three were MSM with a history of unprotected sex. Thirty-seven (40%) patients had other associated sexually transmitted disease. The 29% (27) had any symptoms suggestive of AHC. HCV genotype 4 was the most common (41%), followed by genotype1. Seventy patients started treatment with interferon-alfa and weight-adjusted ribavirin. Currently 46 have completed treatment and follow-up, reaching 26 of them (56.5%) sustained viral response. The incidence of AHC in HIV MSM patients from our centre has increased exponentially in recent years; sexual transmission remains the main route of infection. Early treatment with interferon-alpha and ribavirin achieved a moderate response in these patients. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Guidelines for the diagnosis and treatment of patients with bacteriemia. Guidelines of the Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica].](https://www.ncbi.nlm.nih.gov/pubmed/17288909)\nCisneros-Herreros, Jos\u00e9 Miguel; Cobo-Reinoso, Javier; Pujol-Rojo, Miquel; Rodr\u00edguez-Ba\u00f1o, Jes\u00fas; Salavert-Llet\u00ed, Miguel\n2007-02-01\nBacteremia is a complex clinical syndrome in constant transformation that is an important, growing cause of morbidity and mortality. Even though there is a great deal of specific information about bacteremia, few comprehensive reviews integrate this information with a practical AIM. The main objective of these Guidelines, which target hospital physicians, is to improve the clinical care provided to patients with bacteremia by integrating blood culture results with clinical data, and optimizing the use of diagnostic procedures and antimicrobial testing. The document is structured into sections that cover the epidemiology and etiology of bacteremia, stratified according to the various patient populations, and the diagnostic work-up, therapy, and follow-up of patients with bacteremia. Diagnostic and therapeutic decisions are presented as recommendations based on the grade of available scientific evidence.\n[Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas.](https://www.ncbi.nlm.nih.gov/pubmed/8540716)\nSolera, J; Rodr\u00edguez-Zapata, M; Geijo, P; Largo, J; Paulino, J; S\u00e1ez, L; Mart\u00ednez-Alfaro, E; S\u00e1nchez, L; Sepulveda, M A; Ruiz-Rib\u00f3, M D\n1995-09-01\nBrucellosis is a common zoonosis in many parts of the world; the best regimen for the treatment of brucellosis has not been clearly determined. We have carried out a multicenter, open, controlled trial in five general hospitals in Spain to compare the efficacy and safety of doxycycline and rifampin (DR) versus doxycycline and streptomycin (DS) for the treatment of human brucellosis. The study included 194 ambulatory or hospitalized patients with acute brucellosis, without endocarditis or neurobrucellosis. The diagnostic criterion was isolation of Brucella species from blood or other tissues (n = 120) or a standard tube agglutination titer of 1/160 or more for anti-Brucella antibodies with compatible clinical findings (n = 74). Patients were randomly assigned to receive either 100 mg of doxycycline twice daily plus rifampin, 900 mg/day, in a single morning dose for 45 days (DR group) or the same dose of doxycycline for 45 days plus streptomycin, 1 g/day, intramuscularly for 14 days (DS group). A lack of therapeutic efficacy developed in 8 of the 100 patients in the DR group (8%) and in 2 of the 94 patients in the DS group (2%)(P = 0.10). Relapses occurred in 16 of the 100 patients in the DR group (16%) but in only 5 of the 94 patients in the DS group (5.3%) (P = 0.02). When relapse was considered in combination with initial lack of efficacy, 26 patients in the DR group (24%) and 7 patients in the DS group (7.45%) failed to respond to therapy (P = 0.0016). In general, therapy was well tolerated and only four patients (4%) in the DR group and two (2%) in the DS group had episodes of adverse effects necessitating discontinuation of treatment (P> 0.2). We conclude that a doxycycline-and-rifampin regimen is less effective than the doxycycline-and-streptomycin regimen in patients with acute brucellosis.\n[Regulando la Enfermedad a trav\u00e9s de la Definici\u00f3n y la Restricci\u00f3n: Profesionales de la Salud Hablan sobre el VIH/SIDA1](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3198801)\nRivera, Souhail Malav\u00e9; D\u00edaz, Nelson Varas\n2009-01-01\nResumen Las profesiones de la salud tienen un papel social dual. Por un lado, velan por el mantenimiento de la salud de la poblaci\u00f3n protegiendo el bien com\u00fan. Por el otro, dictaminan las formas saludables, y por lo tanto socialmente apropiadas, de ser, actuar y pensar. Este \u00faltimo papel, est\u00e1 m\u00e1s ligado al control social de la poblaci\u00f3n que a una preocupaci\u00f3n altruista hacia la misma. A trav\u00e9s de esta supervisi\u00f3n y control, se construyen los sujetos a los cuales todos/as debemos aspirar a ser para gozar de aceptaci\u00f3n social. Los/as profesionales de la salud han jugado un rol protag\u00f3nico en dicho proceso, siendo los agentes que delimitan y definen lo que es enfermo vs. saludable, \u00fatil vs. in\u00fatil, apropiado vs. inapropiado. En el caso de la epidemia del VIH, este esfuerzo se ha hecho cada vez m\u00e1s vigente ya que estos/as profesionales juegan un papel importante en el tratamiento de las personas que viven con VIH/SIDA (PVVS). Sin embargo, su funci\u00f3n est\u00e1 plasmada de definiciones que sirven para criminalizar a las PVVS. El objetivo de este estudio fue explorar la manera en que una muestra de profesionales de la salud en Puerto Rico construyen a las PVVS. Con este prop\u00f3sito, entrevistamos 80 profesionales de la salud y estudiantes de estas profesiones. Estas entrevistas fueron grabadas, transcritas y sometidas a un an\u00e1lisis de discurso. Los resultados reflejaron que seg\u00fan las personas participantes: 1) la PVVS no es una persona \u201cnormal\u201d o funcional bajo los est\u00e1ndares sociales debido a que su salud no se los permite, 2) representa una carga para la sociedad incluyendo familiares, amigos/as, el mundo del trabajo, e incluso para el gobierno, 3) debe ser vigilada porque representa un riesgo para la persona seronegativa que es descrita como saludable y productiva, y 4) necesita que su salud y conducta sexual sean controladas por v\u00eda legal y/o por las personas que representan las instituciones sociales, como lo son los/as profesionales de la salud. En este art\u00edculo abordamos el potencial rol de la psicolog\u00eda para servir como veh\u00edculo de reconstrucci\u00f3n de dichas nociones, tomando en consideraci\u00f3n su propio rol en la formaci\u00f3n y mantenimiento de dicho sujeto socialmente deseable. PMID:22025907\n[Health-care management of an unexpected case of Ebola virus disease at the Alcorc\u00f3n Foundation University Teaching Hospital.](https://www.ncbi.nlm.nih.gov/pubmed/25600217)\nRodr\u00edguez-Caravaca, Gil; Timermans, Rafael; Parra-Ram\u00edrez, Juan Manuel; Dom\u00ednguez-Hern\u00e1ndez, Francisco Javier; Algora-Weber, Alejandro; Delgado-Iribarren, Alberto; Hermida-Guti\u00e9rrez, Guillermo\n2015-04-01\nThe first Ebola virus infected patient outside Africa was diagnosed and treated at Alcorc\u00f3n Foundation University Teaching Hospital (AFUTH). We describe the integrated management strategy (medical, occupational health, preventive and public health) applied to the case. Descriptive study of health-care management of an unexpected case of Ebola virus disease (EVD) at AFUTH treated on 6 October 2014. We describe the clinical evolution of the patient while he was attended at the Emergency Department, the drawing-up process of the action protocol, the process of training of hospital staff, the administrative management for transferring the patient to the referral centre, and the measures implemented for cleaning, disinfection and management of waste. Qualitative variables are expressed as percentages. Our centre designed and updated, from May to October, five versions of the acting and care protocol for patients with EVD. The protocol was in force at the AFUTH when a nursing assistant was attended on 6 October 2014. All preventive, diagnostic and therapeutic measures outlined in the protocol were applied and 206 professionals had received training and information about care procedures with a suspect case. Health-care management of an unexpected case of EVD was adequate and there was no secondary cases in our staff as a result. All resources available should be used to fight EVD. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nBallesteros-Pomar, Mar\u00eda; Villar-Taibo, Roc\u00edo; Calleja-Fern\u00e1ndez, Alicia; Pintor-de-la-Maza, Bego\u00f1a; \u00c1lvarez-Del-Campo, Cecilia; Vidal-Casariego, Alfonso; Cano-Rodr\u00edguez, Isidoro\n2016-06-03\nLos datos del estudio PREDYCES\u00ae nos revelaron que en Espa\u00f1a la desnutrici\u00f3n relacionada con la enfermedad (DRE) afecta a uno de cada cuatro pacientes hospitalizados. Esta cifra aumenta hasta el 36,8% en los pacientes hematol\u00f3gicos. Se calcula que un 20% de los pacientes oncol\u00f3gicos muere por complicaciones relacionadas con la DRE. Nuestro grupo se plante\u00f3 en 2011 comenzar la implantaci\u00f3n de un cribado nutricional en los servicios con mayor riesgo de DRE. La presente revisi\u00f3n trata de describir todo el proceso que hemos seguido para mejorar la situaci\u00f3n nutricional en los pacientes ingresados en el Servicio de Hematolog\u00eda del Complejo Asistencial Universitario de Le\u00f3n (CAULE), mayoritariamente con diagn\u00f3stico de neoplasias hematol\u00f3gicas. En un primer estudio piloto, detectamos una alta prevalencia de desnutrici\u00f3n, que tendi\u00f3 a aumentar durante la hospitalizaci\u00f3n. Adem\u00e1s, solo el 8,3% los enfermos valorados recibieron alg\u00fan tipo de soporte nutricional y no se estaban cubriendo sus necesidades ni cal\u00f3ricas ni proteicas, lo que se asociaba a un peor pron\u00f3stico. Por este motivo, nos decidimos a implantar de manera sistem\u00e1tica un cribado y una intervenci\u00f3n nutricional adecuada, que comenz\u00f3 en 2011 y que ha recibido el reconocimiento como Buena Pr\u00e1ctica del Sistema Nacional de Salud.\n[Evaluation of a new rapid diagnostic test for the detection of influenza and RSV.](https://www.ncbi.nlm.nih.gov/pubmed/26139303)\nG\u00f3mez, Sara; Prieto, Columbiana; Vera, Carmen; R Otero, Joaqu\u00edn; Folgueira, Lola\n2016-05-01\nInfluenza viruses and respiratory syncytial virus (RSV) can cause an acute respiratory disease that occurs seasonally in epidemic waves. This retrospective study was conducted to evaluate the Sofia(\u00ae) Influenza A+B and the Sofia(\u00ae) RSV fluorescence immunoassays (FIAs), two novel rapid detection tests (RDTs) for influenza A and B and RSV. Two hundred and nine breath samples were selected from patients with respiratory symptoms determined to be positive/negative for influenza A, influenza B or RSV using one of the reference diagnostic techniques, cell culture and/or RT-PCR (Simplexa\u2122Flu A/B & RSV). The Sofia Influenza A+B FIA was tested on 123 samples (63 from children and 60 from adults) and the Sofia RSV FIA was tested on 86 pediatric samples. Sensitivity and specificity values of both assays were calculated assuming the reference techniques as the gold standard. Sensitivity and specificity values for the Sofia Influenza A+B FIA were 73.1% and 97.8%, respectively. Sensitivity and specificity values for the Sofia RSV FIA were 87.5% and 86.7%, respectively. The sensitivity results obtained for the two assays were considerably higher than those reported for other RDTs. In conclusion, the Sofia Influenza A+B and the Sofia RSV FIAs are appropriate tools for the rapid diagnosis of these viruses. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Population study of seroprevalence of antibodies against hepatitis A virus in the Community of Madrid, 2008-2009].](https://www.ncbi.nlm.nih.gov/pubmed/25728853)\nGarc\u00eda-Comas, Luis; Ordob\u00e1s, Mar\u00eda; Sanz, Juan Carlos; Ramos, Bel\u00e9n; Arce, Araceli; Barranco, Dolores\n2016-01-01\nSeroprevalence surveys enable the level of endemicity of hepatitis A (HAV) to be assessed. The aim of this study was to estimate the seroprevalence (SP) antibody against HAV by age group, and compare it with those obtained in previous surveys. Observational cross-sectional study. The target population consists of residents from 2 to 60 years old in the Community of Madrid. Two-stage cluster sampling was performed with stratification of first stage units. After signing the informed consent, a serum sample was extracted from each participant and sociodemographic data were collected by a questionnaire. SP antibodies to hepatitis A is 46.8% (95% CI 44.6 to 49.0). The SP increases with age. It is higher in the population from more endemic countries and people with less education and lower social class. In relation to the previous survey, SP increased in the population under 30 years old, and a decline after that age is observed. If only the autochthonous population and from countries with very low endemicity is observed, the increase is statistically significant in the 2-5 years age group. Our region has a very low level of endemicity thus, following the recommendations of WHO, vaccination should be targeted at specific risk groups. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nRodr\u00edguez, Yarimar Rosa; D\u00edaz, Nelson Varas\n2008-01-01\nEl proceso de estigmatizaci\u00f3n asume una devaluaci\u00f3n de la persona debido a una caracter\u00edstica o marca que haya sido identificada socialmente y que permita que se le describa como diferente. Desde que se desat\u00f3 la epidemia del VIH/SIDA, vivir con la enfermedad ha sido se\u00f1alado de manera social como una marca estigmatizante. Las manifestaciones de dicha estigmatizaci\u00f3n se han documentado entre profesionales de la salud. Este estigma puede afectar los servicios de salud que las personas que viven con VIH/SIDA reciben de estos profesionales. Los objetivos de esta investigaci\u00f3n fueron explorar: 1) la percepci\u00f3n que tienen estudiantes y profesionales de la salud sobre su nivel de competencia para ofrecer servicios a personas que viven con VIH/SIDA, 2) las opiniones de \u00e9stos sobre el tipo de adiestramiento profesional recibido y la necesidad del mismo, y 3) la manifestaci\u00f3n de actitudes estigmatizantes como indicadores de necesidad de adiestramiento profesional. La muestra total del estudio estuvo compuesta por 80 de diversas profesiones de la salud. Los resultados reflejan que algunos/as de los/as participantes han recibido formaci\u00f3n en VIH pero \u00e9sta no ha sido suficiente para contrarrestar las nociones estigmatizantes. Discutimos las implicaciones de los resultados para investigaciones futuras y el desarrollo de intervenciones con v\u00edas de minimizar las nociones estigmatizantes en los escenarios de salud.\n[[Epidemiology of hepatitis E virus infection in Spain].](https://www.ncbi.nlm.nih.gov/pubmed/24447919)\nEchevarr\u00eda, Jos\u00e9 Manuel; Fogeda, Marta; Avell\u00f3n, Ana\n2015-04-01\nThe general features of the epidemiology and ecology of hepatitis E virus in Spain are already known after 20 years of investigations. Genotype 3 strains, mainly from sub-genotype 3f, circulated among swine livestock and certain wild mammals, and would be sporadically transmitted to humans through direct contact with the reservoirs or by consumption of foods derived from them. Bivalve shellfish contaminated by hepatitis E virus from sewage could also play a role in transmission. Although the interpretation of results from seroprevalence studies in low endemic settings is still controversial, antibody to hepatitis E virus displays an overall prevalence less than 10% among the population of Spain, increasing significantly with age. From the, approximately, 150 cases of acute hepatitis E recorded in the international literature, males older than 40 years, suffering a mild, locally acquired disease predominate. In addition, hepatitis E might be more frequent in the North of the country than in other regions. Although the disease does not usually have a great clinical relevance, the occasional finding of cases of fulminant hepatitis, and of ribavirin-resistant, chronic hepatitis E virus infections among the immunocompromised would recommend the surveillance of the infection by the public health authority and a better implementation of specific diagnostic procedures in clinical laboratories. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Immune reconstitution inflammatory syndrome in HIV-infected patients with Pneumocystis jirovecii pneumonia.](https://www.ncbi.nlm.nih.gov/pubmed/29187293)\nRoade Tato, Luisa; Burgos Cibrian, Joaqu\u00edn; Curran F\u00e1bregas, Adri\u00e0; Navarro Mercad\u00e9, Jordi; Willekens, Rein; Mart\u00edn G\u00f3mez, Mar\u00eda Teresa; Ribera Pascuet, Esteban; Falc\u00f3 Ferrer, Vicen\u00e7\n2017-11-26\nThe incidence of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients after an episode of Pneumocystis jirovecii pneumonia (PJP) seems to be lower than with other opportunistic infections. We conducted an observational study in order to determine the incidence, clinical characteristics and outcome of patients diagnosed with PJP-related IRIS. We conducted an observational study of HIV patients diagnosed with PJP-related IRIS from January 2000 to November 2015. We analyzed epidemiological and clinical characteristics as well as laboratory findings. We also carried out a systematic review of published cases. Six cases of IRIS out of 123 (4.9%) HIV-infected patients with PJP who started ART were diagnosed. All six cases were men with a median age of 34 (IQR: 8) years. The six patients developed paradoxical IRIS. Subjects younger than 40 years old (p=0.084) and with an HIV-RNA viral load >100000 copies/ml (p=0.081) at diagnosis showed a tendency to develop IRIS. Thirty-seven published cases of PJP-related IRIS were identified. Although 51% of cases involved respiratory failure, no deaths were reported. PJP-related IRIS is rare condition compared to other opportunistic infections. It can lead to a severe respiratory failure in a significant proportion of cases, although no deaths have been reported. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015).](https://www.ncbi.nlm.nih.gov/pubmed/26021186)\nBerenguer, Juan; Polo, Rosa; Aldeguer, Jos\u00e9 L\u00f3pez; Lozano, Fernando; Aguirrebengoa, Koldo; Arribas, Jos\u00e9 Ram\u00f3n; Blanco, Jos\u00e9 Ram\u00f3n; Boix, Vicente; Casado, Jos\u00e9 Luis; Clotet, Bonaventura; Crespo, Manuel; Domingo, Pere; Estrada, Vicente; Garc\u00eda, Federico; Gatell, Jos\u00e9 Mar\u00eda; Gonz\u00e1lez-Garc\u00eda, Juan; Guti\u00e9rrez, F\u00e9lix; Iribarren, Jos\u00e9 Antonio; Knobel, Hernando; Llibre, Josep Mar\u00eda; Locutura, Jaime; L\u00f3pez, Juan Carlos; Mir\u00f3, Jos\u00e9 M; Moreno, Santiago; Podzamczer, Daniel; Portilla, Joaqu\u00edn; Pulido, Federico; Ribera, Esteban; Riera, Melchor; Rubio, Rafael; Santos, Jes\u00fas; Sanz-Moreno, Jos\u00e9; Sanz, Jes\u00fas; T\u00e9llez, Mar\u00eda Jes\u00fas; Tuset, Montserrat; Rivero, Antonio\n2015-10-01\nIn this update, antiretroviral therapy (ART) is recommended for all patients infected by type 1 human immunodeficiency virus (HIV-1). The strength and grade of the recommendation vary depending on the CD4+ T-lymphocyte count, the presence of opportunistic infections or comorbid conditions, age, and the efforts to prevent the transmission of HIV. The objective of ART is to achieve an undetectable plasma viral load (PVL). Initial ART should comprise three drugs, namely, two nucleoside reverse transcriptase inhibitors (NRTI) and one drug from another family. Three of the recommended regimens, all of which have an integrase strand transfer inhibitor (INSTI) as the third drug, are considered a preferred regimen; a further seven regimens, which are based on an INSTI, an non-nucleoside reverse transcriptase inhibitor (NNRTI), or a protease inhibitor boosted with ritonavir (PI/r), are considered alternatives. The reasons and criteria for switching ART are presented both for patients with an undetectable PVL and for patients who experience virological failure, in which case the rescue regimen should include three (or at least two) drugs that are fully active against HIV. The specific criteria for ART in special situations (acute infection, HIV-2 infection, pregnancy) and comorbid conditions (tuberculosis and other opportunistic infections, kidney disease, liver disease, and cancer) are updated. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Consensus statement on metabolic disorders and cardiovascular risks in patients with human immunodeficiency virus].](https://www.ncbi.nlm.nih.gov/pubmed/25176009)\nPolo Rodr\u00edguez, Rosa; Galindo Puerto, Mar\u00eda Jos\u00e9; Due\u00f1as, Carlos; G\u00f3mez Candela, Carmen; Estrada, Vicente; Villar, Noem\u00ed G P; Locutura, Jaime; Mari\u00f1o, Ana; Pascua, Javier; Palacios, Rosario; von Wichmman, Miguel \u00c1ngel; \u00c1lvarez, Julia; Asensi, Victor; Lopez Aldeguer, Jos\u00e9; Lozano, Fernando; Negredo, Eugenia; Ortega, Enrique; Pedrol, Enric; Guti\u00e9rrez, F\u00e9lix; Sanz Sanz, Jes\u00fas; Mart\u00ednez Chamorro, Esteban\n2015-01-01\nThis consensus document is an update of metabolic disorders and cardiovascular risk (CVR) guidelines for HIV-infected patients. This document has been approved by an expert panel of GEAM, SPNS and GESIDA after reviewing the results of efficacy and safety of clinical trials, cohort and pharmacokinetic studies published in biomedical journals (PubMed and Embase) or presented in medical scientific meetings. Recommendation strength and the evidence in which they are supported are based on the GRADE system. A healthy lifestyle is recommended, no smoking and at least 30min of aerobic exercise daily. In diabetic patients the same treatment as non-HIV infected patients is recommended. HIV patients with dyslipidemia should be considered as high CVR, thus its therapeutic objective is an LDL less than 100mg/dL. The antihypertensive of ACE inhibitors and ARAII families are better tolerated and have a lower risk of interactions. In HIV-patients with diabetes or metabolic syndrome and elevated transaminases with no defined etiology, the recommended is to rule out a hepatic steatosis Recommendations for action in hormone alterations are also updated. These new guidelines update previous recommendations regarding all those metabolic disorders involved in CVR. Hormone changes and their management and the impact of metabolic disorders on the liver are also included. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Imported malaria in children in Madrid, Spain, 2007-2013.](https://www.ncbi.nlm.nih.gov/pubmed/28237435)\nS\u00e1nchez, Beatriz Soto; Tato, L M Prieto; Mart\u00edn, S Guill\u00e9n; P\u00e9rez, E; Grasa, C; Valderrama, S; Augusto, I de; Sierra, M; Ros, M Garc\u00eda; Aguado, I; Hortelano, M Garc\u00eda L\u00f3pez\nThe majority of malaria cases diagnosed in Europe in the last few years have occurred in people living in non-endemic areas travelling back to their home country to visit friends and relatives (VFRs). Children account for 15-20% of imported malaria, with known higher risk of severe disease. A retrospective multicentre study was conducted in 24 hospitals in Madrid (Spain) including patients under 16 years diagnosed with malaria (2007-2013). A total of 149 episodes in 147 children were reported. Plasmodium falciparum was the species most commonly isolated. Twenty-five patients developed severe malaria and there was one death related to malaria. VFR accounted for 45.8% of our children. Only 17 VFRs had received prophylaxis, and 4 of them taken appropriately. They presented more frequently with fever (98% vs. 69%), a longer time with fever (55 vs. 26%), delay in diagnosis of more than three days (62 vs. 37%), and more thrombocytopenia (65 vs. 33%) than non-VFRs, and with significant differences (p<0.05). VFRs represent a large proportion of imported malaria cases in our study. They seldom took adequate prophylaxis, and delayed the visit to the physician, increasing the length of fever and subsequent delaying in diagnosis. Appropriate preventive measures, such as education and pre-travel advices should be taken in this population. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Genetic profiling of Giardia intestinalis by polimerase chain in human and dogs samples of Colombian Caribean Coast].](https://www.ncbi.nlm.nih.gov/pubmed/24144785)\nArroyo-Salgado, B\u00e1rbara; Buelvas-Montes, Yaleyvis; Villalba-Vizca\u00edno, Vivian; Salom\u00f3n-Arzuza, Octavio\n2014-01-01\nGiardia intestinalis (G. Intestinalis) is a protozoan that causes diarrheal disease and malabsorption syndrome in humans and other mammals. It presents a high genetic diversity evidenced in the recognition of 7 genotypes (A-G). Genotypes A and B are commonly associated to humans and domestic animals such as dogs. The aim of this study was to conduct a preliminary genetic characterization of G. intestinalis in humans and dogs from two cities on the Caribbean coast of Colombia. Sampling areas were selected according to the highest numbers of acute diarrheal disease. Stool samples were collected from children under 7 years old, with positive medical tests for G. intestinalis. Cysts were purified by sucrose gradient and DNA samples were isolated by extraction with organic solvents. Molecular characterization was performed by amplifying the gene triose phosphate isomerase (tpi) by using a semi-nested PCR. A total of 202 samples of DNA were obtained; of these, 111 were positive in coproparasitological analysis (13 dogs and 98 children). Genotype distribution in positive samples was: 5.1% belonged to genotype A and 92.3% to genotype B. Genotype B was present in humans and animals. The most common genotype in both human and animal samples was genotype B, suggesting a zoonotic transmission cycle. Copyright \u00a9 2012 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Spread of genetically related methicillin-susceptible Staphylococcus aureus belonging to CC45, in healthy nasal carriers in Child Day Care Centers of Medellin, Colombia].](https://www.ncbi.nlm.nih.gov/pubmed/26048720)\nRodr\u00edguez-Tamayo, Erika Andrea; Ruiz-Cadavid, Alejandra; S\u00e1nchez-Gonz\u00e1lez, Leidy Maritza; Garc\u00eda-Valencia, Natalia; Jim\u00e9nez-Quiceno, Judy Natalia\n2016-03-01\nColonization plays a major role in the epidemiology and pathogenesis of Staphylococcus aureus infections. The child population is one of the most susceptible to colonization; however, community and children studies are limited in Colombia. To assess the clonal relationship of S.aureus strains isolated from colonized children in eight day care centers (DCCs) from Medellin and to determine the presence of epidemiological characteristics in these populations. An observational cross-sectional study was conducted on a sample of 200 children aged from 6 months to 5 years attending eight DCCs in Medellin, Colombia, during 2011. Nasal samples were collected from each nostril. The isolates species and methicillin resistance were molecularly confirmed using nuc and mec genes. Genotypic analysis included SCCmec typing, spa typing, PFGE and MLST. Epidemiological information was obtained from the parents and analyzed using the statistics program SPSS 21.0 RESULTS: The colonization frequency in DCCs ranged from 16.7% (n=3) to 53.6% (n=15). Genetically related isolates were identified inside four DCCs. Half (50%) of the isolates were grouped in 3 clusters, which belonged to the clonal complexes CC45, CC30, and CC121. Molecular typing of isolates from colonized children and comparison among DCCs showed the spread of colonizing strains inside DCCs in Medellin; predominantly the CC45 clone, a successful child colonizer. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[An outbreak of mumps in a high school: Estimation of vaccine effectiveness. Zaragoza 2011].](https://www.ncbi.nlm.nih.gov/pubmed/25475656)\nComp\u00e9s-Dea, Cecilia; Guimbao-Besc\u00f3s, Joaqu\u00edn; Gaspar-Escayola, Jos\u00e9 Ignacio; L\u00e1zaro-Belanche, Mar\u00eda \u00c1ngeles; Aznar-Brieba, Amaya\n2015-01-01\nMumps outbreaks continue to occur, even after the consolidation of vaccination programs. An outbreak of mumps occurred in a high school in Zaragoza during December 2011. To describe the outbreak and estimate vaccine effectiveness. unilateral or bilateral swelling of the parotid or other salivary glands for three or more days without any other apparent cause. People attending the 'Parque Goya' High School or with transmission chain origin in the High School. From two days before the onset of symptoms of the first case to five days after the last case. Samples were collected for virus confirmation (IgM, urine culture and oropharyngeal exudate), and isolates were processed for genotyping. A retrospective cohort study was performed in two high school classrooms to estimate vaccine efficacy. Public health authorities conducted active surveillance, isolation of cases, and vaccination of susceptible contacts. There were 27 cases. Twenty-one (77.8%) were vaccinated with two doses of Measles-Mumps-Rubella vaccine. Twelve (44%) were confirmed microbiologically. G1 genotype was determined in six cases. According to the cohort study, vaccine efficacy for one dose was 34% (95%CI: -44 to 70), and was 67% (95%CI: 28 to 83) for two doses. Vaccine effectiveness was lower than expected. Early detection and isolation of cases have been instrumental in preventing new cases in schools. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Usefulness of human papillomavirus testing in anal intraepithelial neoplasia screening in a risk behaviour population].](https://www.ncbi.nlm.nih.gov/pubmed/24908497)\nPadilla-Espa\u00f1a, Laura; Repiso-Jim\u00e9nez, Bosco; Fern\u00e1ndez-S\u00e1nchez, Fernando; Frieyro-Elicegui, Marta; Fern\u00e1ndez-Morano, Teresa; Pereda, Teresa; Rivas-Ruiz, Francisco; Redondo, Maximino; de-Troya Mart\u00edn, Magdalena\n2014-11-01\nThe incidence of intraepithelial anal neoplasia is increasing in certain risk behaviour groups, and human papillomavirus (HPV) infection is involved in its pathogenesis. The systematic use of anal cytology, and more recently HPV detection by hybrid capture and genotyping, have been introduced into screening programs in recent decades. A retrospective cohort study was carried out on individuals with risk behaviours of developing intraepithelial anal neoplasia and who attended Sexually Transmitted Infections clinics in the Dermatology area of the Hospital Costa del Sol from January 2010 to December 2012. The intraepithelial anal neoplasia screening was performed using anal cytology and HPV genotyping. Half (50%) of the study population were HIV positive. A high frequency of anal dysplasia and presence of HPV in cytology (82.1%) and genotype (79%) was found. A statistically significant association (P<.005) was obtained between the presence of high-risk HPV genotypes and the presence of high-grade dysplasia in the second directed cytology. HPV genotyping enabled 17 cases (22%) of severe dysplasia to be identified that were under-diagnosed in the first cytology. Cases of high-grade dysplasia can be under-diagnosed by a first anal cytology. Detection of HPV can supplement this procedure, leading to the identification of those patients most at risk of developing high-grade anal dysplasia. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[The antibiotic policy. The Infection Committee and antimicrobial use].](https://www.ncbi.nlm.nih.gov/pubmed/24656969)\nCisneros, Jos\u00e9 Miguel; P\u00e9rez-Moreno, M Antonia; Gil-Navarro, M Victoria\n2014-10-01\nThe antibiotic policy is the set of strategies and activities undertaken to organize the antimicrobial treatment in the hospital, and achieve health outcomes for patients. The basic principles are to be direct evidence-based medicine, local epidemiology and freedom for prescribing physicians. An antibiotic policy is now more necessary than ever for clinical, epidemiological and economic reasons. The Infection Committee is responsible for the antibiotics policy in hospitals. Its functions as an advisory body to the medical directorate are the analysis of the epidemiology of the infections in the center, measures for its prevention and control, improving the appropriate use of antimicrobials, training, and knowledge production. To achieve clinical, environmental and economic policy objectives of antibiotics is not easy. The agreement of hundreds of professionals for recommendations on indications, dosage and duration of antibiotic treatment, based on the best scientific evidence and local guides is complex, but it can be done. The key to this is that the Infection Committee develops antimicrobial stewardship through a multidisciplinary team and professional leadership, and has the institutional support to ensure that the proper use of antimicrobials is a priority for the center, and therefore of each of the services involved, and that the team has the resources for antimicrobial stewardship. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[ENVEJECIMIENTO, SALUD Y ECONOM\u00cdA: La Encuesta Nacional sobre Salud y Envejecimiento en M\u00e9xico*](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5783560)\n2017-01-01\nRESUMEN M\u00e9xico vive una transici\u00f3n demogr\u00e1fica en la cual el porcentaje de la poblaci\u00f3n mayor de 50 a\u00f1os de edad crece aceleradamente como resultado de un aumento considerable en la esperanza de vida. Dicha poblaci\u00f3n tiene necesidades particulares que deben ser tomadas en cuenta en la formulaci\u00f3n de pol\u00edticas, sobre todo en materia de acceso a servicios de salud y seguridad social. En este art\u00edculo presentamos una descripci\u00f3n general de la Encuesta Nacional de Salud y Envejecimiento (Enasem), un estudio de panel que comenz\u00f3 en 2001 y que ofrece una oportunidad \u00fanica para abordar temas demogr\u00e1ficos y econ\u00f3micos complejos por medio de la exploraci\u00f3n de las caracter\u00edsticas personales, transferencias socioecon\u00f3micas e indicadores de salud para una muestra de 15 186 adultos de edad media y avanzada. Tambi\u00e9n presentamos los resultados m\u00e1s relevantes de diferentes estudios que han utilizado la Enasem hasta la fecha. Nuestra revisi\u00f3n indica que M\u00e9xico enfrenta desaf\u00edos considerables para satisfacer la demanda de servicios m\u00e9dicos para una poblaci\u00f3n que es amenazada por una creciente presencia de enfermedades cr\u00f3nicas, sobre todo para la poblaci\u00f3n de edad avanzada que no cuenta con cobertura de seguro m\u00e9dico. PMID:29375164\n[[An outbreak of Burkholderia cepacia bacteremia in a hemodialysis unit, Cadiz, 2014].](https://www.ncbi.nlm.nih.gov/pubmed/25824991)\nMonta\u00f1o-Remacha, Carmen; M\u00e1rquez-Cruz, Mar\u00eda Dolores; Hidalgo-Guzm\u00e1n, Pilar; S\u00e1nchez-Porto, Antonio; T\u00e9llez-P\u00e9rez, Francisco de Paula\n2015-12-01\nIn January 2014 a possible outbreak of Burkholderia cepacia bacteremia occurred in a hemodialysis center situated in La Linea de la Concepci\u00f3n (Cadiz). An investigation was begun to confirm the outbreak, identify the source, and implement control measures. A descriptive analysis was performed to describe the characteristics of the patients affected with Burkholderia cepacia bacteremia from November 2013 to February 2014. Environmental samples were taken. A molecular typing study was performed using pulsed field gel electrophoresis (SpeI PFGE) and MLST analysis in order to determine the genetic similarity between the isolates. The bacterium was isolated from blood cultures of 7 patients during the study period. Three of the samples (2 of which were also cases) were endoluminal fluid from catheter locks, and 4 chlorhexidine bottle samples. The patients were coincident in 2 of the 6 work shifts. The mean age of the cases was 67 years of whom 57% were women. Human samples and an environmental sample was analyzed and found to be genetically identical (ST653 clone). The analysis confirmed the outbreak of Burkholderia cepacia, with 7 cases among the patients of the hemodialysis center. The outbreak was due to the same strain, probably a common source and secondary transmission from person to person. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Human papillomavirus vaccine. Efficacy and safety].](https://www.ncbi.nlm.nih.gov/pubmed/25937455)\nBruni, Laia; Serrano, Beatriz; Bosch, Xavier; Castellsagu\u00e9, Xavier\n2015-05-01\nHuman papillomavirus (HPV) related disease remains a major cause of morbidity and mortality worldwide. Prophylactic vaccines have been recognized as the most effective intervention to control for HPV-related diseases. This article reviews the major phaseii/iii trials of the bivalent (HPVs16/18), quadrivalent (HPVs6/11/16/18), and the recently approved 9-valent vaccine (HPVs6/11/16/18/31/33/45/52/58). Large trials have been conducted showing the safety, immunogenicity and high efficacy of the bivalent and quadrivalent vaccines in the prevention of pre-invasive lesions and infection, especially when administered at young ages before exposure to HPV. Trials of the 9-valent vaccine have also demonstrated the safety, immunogenicity and efficacy of the vaccine in the prevention of infection and disease associated with the vaccine types, and its potential to substantially increase the overall prevention of HPV-related diseases. Post-licensure country reports have shown the recent and early impact of these vaccines at population level after the implementation of established HPV vaccination programs, including decreases in the prevalence of vaccine HPV types, the incidence of genital warts, and the incidence of high-grade cervical abnormalities. If widely implemented, current HPV vaccines may drastically reduce the incidence of cervical cancer and other HPV-related cancers and diseases. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Acellular vaccines (DTPa/dTpa) against whooping cough, protection duration].](https://www.ncbi.nlm.nih.gov/pubmed/25735715)\nRigo-Medrano, M Vicenta; Mendoza-Garc\u00eda, Jos\u00e9 L; Gimeno-Gasc\u00f3n, Adelina; Roda-Ram\u00f3n, Jorge; Cremades-Bernabe\u00fa, Israel; Antequera-Rodr\u00edguez, Pedro; Alcal\u00e1-Minagorre, Pedro J; Ortiz-de la Tabla, Victoria; Rodr\u00edguez-D\u00edaz, Juan Carlos\n2016-01-01\nAn increase in whooping cough in most of the developed countries has been detected in the last decade. To determine whether the administration of dTpa vaccine instead of DTPa fifth dose is contributing to the appearance of these cases. A descriptive study based on cases of whooping cough reported during an epidemic period in the city of Alicante in the first 5 months of 2014. Only pertussis cases confirmed by PCR were included in the study, and only those vaccinated with 5 doses were included in the analysis of the period of protection. A total of 104 cases of pertussis confirmed by PCR were reported, with 85 cases (82%) having had 5 doses of vaccine. The mean time and standard deviation (SD) of protection was 2.1\u00b11.1 years with dTpa, and 5.1\u00b11.5 years with DTPa (p<.001). In the protection, adjusted for age, it was observed that, after 3 years, only 47.6% of people vaccinated with dTpa were still protected, while people vaccinated with DTPa were 100% protected (P<.001). This study found that people who were properly vaccinated against pertussis and received their last re-vaccination dose with dTpa had a shorter period of protection than those who were vaccinated with DTPa. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Clinical and epidemiological differences between Bordetella pertussis and respiratory syncytial virus infections in infants: a matched case control study].](https://www.ncbi.nlm.nih.gov/pubmed/24054972)\nGim\u00e9nez-S\u00e1nchez, Francisco; Cobos-Carrascosa, Elena; S\u00e1nchez-Forte, Miguel; L\u00f3pez-S\u00e1nchez, Mar\u00eda \u00c1ngeles; Gonz\u00e1lez-Jim\u00e9nez, Yolanda; Azor-Mart\u00ednez, Ernestina\n2014-01-01\nAn increase in cases of pertussis, mainly in young infants, has been reported in the last few years. The clinical presentation of this disease is very similar to that produced by respiratory syncytial virus (RSV), which makes the diagnosis difficult. To compare the clinical and epidemiological characteristics between Bordetella pertussis and RSV infections in infants admitted to hospital. An analytical matched case-control study was conducted during the period 2008-2011. Cases were defined as infants admitted with pertussis confirmed by PCR in nasopharyngeal aspirate. Each case was matched by age, sex and date of admission to two controls defined as patients with RSV infection detected by immunochromatography in nasal aspirate. Demographic, clinical, laboratory data were compared. Seventy eight patients (26 cases of pertussis and 52 controls RSV+) were included. Sociodemographic characteristics were similar in both groups. Cases had more days of symptoms prior to admission, longer hospital stays, and increased frequency of epidemic family environment. Apnoea and cyanosis were more frequent. Cases of pertussis were more likely to have apnoea, cyanosis, and lymphocytosis while RSV infections had more frequent fever, vomiting and respiratory distress. The clinical presentations of pertussis and RSV infection are similar, but there are some characteristics that can help to distinguish between them. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Percepci\u00f3n de competencia y adiestramiento profesional especializado relativos al VIH/SIDA en estudiantes y profesionales de la salud: el estigma como un indicador de necesidad](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2792930)\nRODR\u00cdGUEZ, Yarimar ROSA; D\u00cdAZ, Nelson VARAS\n2009-01-01\nEl proceso de estigmatizaci\u00f3n asume una devaluaci\u00f3n de la persona debido a una caracter\u00edstica o marca que haya sido identificada socialmente y que permita que se le describa como diferente. Desde que se desat\u00f3 la epidemia del VIH/SIDA, vivir con la enfermedad ha sido se\u00f1alado de manera social como una marca estigmatizante. Las manifestaciones de dicha estigmatizaci\u00f3n se han documentado entre profesionales de la salud. Este estigma puede afectar los servicios de salud que las personas que viven con VIH/SIDA reciben de estos profesionales. Los objetivos de esta investigaci\u00f3n fueron explorar: 1) la percepci\u00f3n que tienen estudiantes y profesionales de la salud sobre su nivel de competencia para ofrecer servicios a personas que viven con VIH/SIDA, 2) las opiniones de \u00e9stos sobre el tipo de adiestramiento profesional recibido y la necesidad del mismo, y 3) la manifestaci\u00f3n de actitudes estigmatizantes como indicadores de necesidad de adiestramiento profesional. La muestra total del estudio estuvo compuesta por 80 de diversas profesiones de la salud. Los resultados reflejan que algunos/as de los/as participantes han recibido formaci\u00f3n en VIH pero \u00e9sta no ha sido suficiente para contrarrestar las nociones estigmatizantes. Discutimos las implicaciones de los resultados para investigaciones futuras y el desarrollo de intervenciones con v\u00edas de minimizar las nociones estigmatizantes en los escenarios de salud. PMID:20011236\n[La mortalidad en adolescentes con c\u00e1ncer: caracter\u00edsticas clinicoepidemiol\u00f3gicas de muerte y aspectos \u00e9ticos emergentes.](https://www.ncbi.nlm.nih.gov/pubmed/29420514)\nCicero-Oneto, Carlo Egysto; Mata-Valderrama, Guadalupe; Valdez-Mart\u00ednez, Edith\nDescribir los aspectos epidemiol\u00f3gicos, cl\u00ednicos y \u00e9ticos de la mortalidad de los adolescentes con c\u00e1ncer en -M\u00e9xico. Se revisaron 63 expedientes cl\u00ednicos de adolescentes (de 14 a 18 a\u00f1os de edad) con c\u00e1ncer, fallecidos entre 2011 y 2014, para obtener informaci\u00f3n cl\u00ednica y epidemiol\u00f3gica de su muerte. Los sitios de estudio fueron tres hospitales de concentraci\u00f3n en la Ciudad de M\u00e9xico. De los 40 adolescentes con criterios de fase terminal, 16 (40%) continuaron recibiendo tratamiento con fines curativos. De los 51 cuyo lugar de muerte era conocido, 45 (88%) murieron en hospital. De los 41 que murieron dentro de los 30 d\u00edas de su \u00faltima hospitalizaci\u00f3n, las muertes fueron principalmente debidas a complicaciones (51%), a progresi\u00f3n de la enfermedad (41%) o bien fueron muertes en tratamiento paliativo (7%, 3/41). La pr\u00e1ctica oncol\u00f3gica descansa en lo que es conocido como modelo biom\u00e9dico. Los resultados del estudio sugieren y apoyan la urgente necesidad de implementar verdaderos servicios de cuidados paliativos, pero m\u00e1s importante que eso, est\u00e1 el \u00edmpetu de poner la \u00e9tica de la pr\u00e1ctica cl\u00ednica en acci\u00f3n, y de ese modo reforzar la buena pr\u00e1ctica de la medicina. Copyright: \u00a9 2018 Secretar\u00cda de Salud\n[Usefulness of a novel multiplex real-time PCR assay for the diagnosis of sexually-transmitted infections.](https://www.ncbi.nlm.nih.gov/pubmed/26706392)\nFern\u00e1ndez, Gema; Martr\u00f3, Elisa; Gonz\u00e1lez, Victoria; Saludes, Ver\u00f3nica; Bascu\u00f1ana, Elisabet; Marc\u00f3, Clara; Rivaya, Bel\u00e9n; L\u00f3pez, Evelin; Coll, Pep; Matas, Lurdes; Ausina, Vicente\n2016-10-01\nSexually transmitted infections (STI) are currently on the increase worldwide. New molecular tools have been developed in the past few years in order to improve their diagnosis. An evaluation was carried out using a new commercially available real-time PCR assay, Anyplex\u2122 II STI-7 (Seegene, Seoul, Korea), which detects seven major pathogens in a single reaction - Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma hominis, Mycoplasma genitalium, Ureaplasma urealyticum, and Ureaplasma parvum - and compared with conventional methods performed in our laboratory. Two different populations were included, and 267 specimens from different sites of infection (urines, endocervical swabs, rectal swabs, vaginal swabs, urethral swabs and one inguinal adenopathy) were processed for both methods. The parameters of clinical performance were calculated for C. trachomatis, N. gonorrhoeae, and T. vaginalis, and the assay achieved sensitivities (SE) from 93.94% to 100%, and specificities (SP) from 96.55% to 100%, with negative predictive values (NPV) from 93.33% to 98.85%, and positive predictive values (PPV) from 96.88% to 100%, with a very good agreement (kappa index from 0.88 to 1). Anyplex\u2122 II STI-7 is a good tool for the reliable diagnosis of STI. Its ease of use and processing allows it to be incorporated into the day to day laboratory work. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica].](https://www.ncbi.nlm.nih.gov/pubmed/19254641)\nGudiol, Francisco; Aguado, Jos\u00e9 Mar\u00eda; Pascual, Alvaro; Pujol, Miquel; Almirante, Benito; Mir\u00f3, Jos\u00e9 Mar\u00eda; Cercenado, Emilia; Dom\u00ednguez, Mar\u00eda de Los Angeles; Soriano, Alex; Rodr\u00edguez-Ba\u00f1o, Jes\u00fas; Vall\u00e9s, Jordi; Palomar, Mercedes; Tornos, Pilar; Bouza, Emilio\n2009-02-01\nBacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA) are prevalent and clinically important. The rise in MRSA bacteremia and endocarditis is related with the increasing use of venous catheters and other vascular procedures. Glycopeptides have been the reference drugs for treating these infections. Unfortunately their activity is not completely satisfactory, particularly against MRSA strains with MICs > 1 microg/mL. The development of new antibiotics, such as linezolid and daptomycin, and the promise of future compounds (dalvabancin, ceftobiprole and telavancin) may change the expectatives in this field.The principal aim of this consensus document was to formulate several recommendations to improve the outcome of MRSA bacteremia and endocarditis, based on the latest reported scientific evidence. This document specifically analyzes the approach for three clinical situations: venous catheter-related bacteremia, persistent bacteremia, and infective endocarditis due to MRSA.\nAlmeida Dos Santos, Alyne Dayana; Sabino Pinho, Cl\u00e1udia Porto; Santos do Nascimento, Alexsandra Camila; Oliveira Costa, Ana Carolina\n2016-03-25\nIntroducci\u00f3n: la sarcopenia se define como un s\u00edndrome geri\u00e1trico, multifactorial, caracterizado por la p\u00e9rdida progresiva de masa muscular esquel\u00e9tica, asociada a consecuencias graves, tales como comorbideces, mala calidad de vida y mortandad. Objetivo: identificar la prevalencia y los factores asociados a la sarcopenia en ancianos atendidos ambulatoriamente. M\u00e9todos: estudio transversal y observacional realizado con pacientes ancianos de ambos sexos atendidos en ambulatorio geri\u00e1trico, entre junio y diciembre de 2014, en un hospital universitario ubicado en el nordeste brasile\u00f1o. Se determin\u00f3 la sarcopenia a trav\u00e9s de la masa muscular (circunferencia de la pantorrilla < 31 cm), fuerza muscular (evaluada por la fuerza de prensi\u00f3n palmar < 30 kg para hombres y < 20 kg para mujeres) y velocidad de marcha (< 0,8 metros/segundo). Entre las variables de asociaci\u00f3n, se consideraron aspectos socioecon\u00f3micos y demogr\u00e1ficos, variables cl\u00ednicas, estilo de vida y antropometr\u00eda. La tabulaci\u00f3n y an\u00e1lisis de los datos se realizaron por medio del paquete estad\u00edstico SPSS versi\u00f3n 13.0. Resultados: la muestra se compuso de 50 pacientes, con promedio de edad de 73,9 (\u00b1 7,4) a\u00f1os, en la que se verific\u00f3 una prevalencia de sarcopenia del 18%. La sarcopenia fue m\u00e1s prevalente en individuos con edad \u2265 80 a\u00f1os (p = 0,012), en los ancianos con bajo peso seg\u00fan el IMC (p < 0,001), con desnutrici\u00f3n de acuerdo con la CB (p = 0,004) y en los pacientes sin hipertensi\u00f3n arterial (p = 0,027), no encontr\u00e1ndose asociaci\u00f3n con variables socioecon\u00f3micas, cl\u00ednicas y del estilo de vida. Conclusiones: la prevalencia de la sarcopenia fue significativa y semejante a la descrita por otros autores, encontr\u00e1ndose asociaci\u00f3n con la edad avanzada, desnutrici\u00f3n y ausencia de hipertensi\u00f3n.\nOyarce Merino, Karina; Valladares Vega, Macarena; Elizondo-Vega, Roberto; Obreg\u00f3n, Ana Mar\u00eda\n2016-11-29\nIntroducci\u00f3n: cambios socioculturales como el incremento en el sedentarismo y el consumo de alimentos ricos en grasas y az\u00facares, sumado a caracter\u00edsticas gen\u00e9ticas, han producido un aumento en las cifras de obesidad a nivel mundial. La evaluaci\u00f3n temprana en ni\u00f1os, mediante el establecimiento de perfi les gen\u00e9ticos asociados a obesidad y a la regulaci\u00f3n metab\u00f3lica y hed\u00f3nica de la alimentaci\u00f3n, complementado con estudios de la conducta alimentaria, nos permitir\u00eda predecir la predisposici\u00f3n a la obesidad en etapas adultas.Objetivo: revisar los conceptos asociados a la conducta alimenticia, enfoc\u00e1ndose en la regulaci\u00f3n hed\u00f3nica, que puede convertirse en un par\u00e1metro predictivo de obesidad en ni\u00f1os.Material y m\u00e9todos: se revis\u00f3 la bibliograf\u00eda asociada a obesidad infantil y a la regulaci\u00f3n homeost\u00e1tica y hed\u00f3nica de la obesidad, como tambi\u00e9n par\u00e1metros g\u00e9nicos asociados a la obesidad. En la b\u00fasqueda de art\u00edculos se incluy\u00f3 el trabajo en animales y humanos (adultos y ni\u00f1os, pero con \u00e9nfasis en ni\u00f1os).Resultados: se analizaron los mecanismos celulares de la regulaci\u00f3n de la ingesta, as\u00ed como los estudios de conducta alimentaria en ni\u00f1os, entregando antecedentes y carencias en el desarrollo investigativo para la predicci\u00f3n de la obesidad infantil.Conclusi\u00f3n: la regulaci\u00f3n hed\u00f3nica de la ingesta alimenticia en ni\u00f1os, como perfi les gen\u00e9ticos asociados a receptores de dopamina, puede convertirse en un importante predictor de la obesidad. Es necesario incrementar el n\u00famero de estudios que permitan defi nir de mejor forma, cu\u00e1les son los mejores par\u00e1metros para predecir el desarrollo de la obesidad adulta.\n[C\u00f3mo aumentar la actividad f\u00edsica de los ni\u00f1os durante el per\u00edodo del recreo en las escuelas](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4576453)\nLudwig, David\n2014-01-01\nObjetivos. Analizamos si la participaci\u00f3n de las escuelas en el Programa de Mejoramiento del Recreo (PMR) en la primavera del a\u00f1o 2011 estuvo asociada a tasas m\u00e1s altas de actividad f\u00edsica intensa en los ni\u00f1os. M\u00e9todos. En el PMR, un coordinador dirige a los ni\u00f1os para que practiquen juegos adecuados para la edad a fin de aumentar su nivel de actividad f\u00edsica. Durante el recreo en 25 escuelas primarias p\u00fablicas de la ciudad de Nueva York (15 participantes en el PMR, 10 no participantes en el PMR) los investigadores observaron algunas \u00e1reas predeterminadas (n = 1 339 observaciones) y registraron el n\u00famero de ni\u00f1os que estaban sedentarios, caminando o muy activos. Resultados. Tras el an\u00e1lisis estad\u00edstico con m\u00faltiples variables se encontr\u00f3 que la participaci\u00f3n en el PMR era una variable predictiva significativa (P = 0,027) de la tasa de actividad f\u00edsica intensa (porcentaje de ni\u00f1os muy activos en las \u00e1reas de observaci\u00f3n) cuyas medias de los m\u00ednimos cuadrados fueron de 41% en las escuelas participantes en el PMR y de 27% en escuelas no participantes en el PMR. En las escuelas participantes en el PMR se sigui\u00f3 registrando una tasa significativamente superior incluso cuando el coordinador de juegos no estaba en el \u00e1rea de observaci\u00f3n, lo que sugiere un cambio en la cultura del recreo en las escuelas que participan en este programa. Conclusiones. La tasa de actividad f\u00edsica intensa en las escuelas participantes en el PMR fue 14 puntos porcentuales (o 52%) superior a la tasa registrada en las escuelas no participantes en el PMR. Esta intervenci\u00f3n de bajo costo podr\u00eda ser un agregado valioso a las herramientas para combatir la obesidad infantil y podr\u00eda valer la pena reproducirla en otros sitios. PMID:24899455\n[Prevalence of Escherichia coli O157:H7 From House Flies (Diptera: Muscidae) and Dairy Samples in North Central Florida1.](https://www.ncbi.nlm.nih.gov/pubmed/28025247)\nBurrus, Roxanne G; Hogsette, Jerome A; Kaufman, Phillip E; Maruniak, James E; Simonne, Amy H; Mai, Volker\n2017-05-01\nLa detecci\u00f3n de Escherichia coli O157:H7 en las lecher\u00edas es importante para mejorar la seguridad de los productos l\u00e1cteos, y se ha llevado a cabo principalmente mediante el aislamiento de las bacterias a partir de las muestras de esti\u00e9rcol. Sin embargo, los componentes biliares presentes en el esti\u00e9rcol complica la identificaci\u00f3n gen\u00e9tica utilizando la t\u00e9cnica del PCR, y el aislamiento microbiol\u00f3gico se dificulta por la presencia de bacterias competidoras que comparten caracter\u00edsticas microbiol\u00f3gicas similares. El aislamiento de E. coli O157:H7 a partir de la mosca dom\u00e9stica evita las dificultades asociadas con el esti\u00e9rcol del ganado. El aislamiento de pat\u00f3genos a partir de las moscas dom\u00e9sticas proporciona informaci\u00f3n adicional sobre el potencial impacto epidemiol\u00f3gico de la dispersi\u00f3n de la mosca dom\u00e9stica en la distribuci\u00f3n de pat\u00f3genos, ya que las moscas dom\u00e9sticas se dispersan desde las lecher\u00edas donde la E. coli O157:H7 existe en forma end\u00e9mica en el ganado. En este estudio, se encontr\u00f3 que las moscas dom\u00e9sticas son 2,6 veces m\u00e1s sensibles para la detecci\u00f3n de E. coli O157:H7 en las lecher\u00edas. Las moscas son m\u00e1s f\u00e1ciles de capturar y manejar que el esti\u00e9rcol, y deber\u00edan ser utilizadas en cualquier ensayo para detectar E. coli O157:H7 en las lecher\u00edas y otros establecimientos. Published by Oxford University Press on behalf of Entomological Society of America 2016. This work is written by US Government employees and is in the public domain in the US.\n[A diet enriched with mackerel (Scomber scombrus)-derived products improves the endothelial function in a senior population (Prevenci\u00f3n de las Enfermedades Cardiovasculares: Estudio Santo\u00f1a--PECES project).](https://www.ncbi.nlm.nih.gov/pubmed/19260945)\nde Berrazueta, J R; G\u00f3mez de Berrazueta, J M; Amado Se\u00f1ar\u00eds, J A; Pe\u00f1a Sarabia, N; Fern\u00e1ndez Viadero, C; Garc\u00eda-Unzueta, M T; S\u00e1ez de Adana, M; Sanchez Ovejero, C J; Llorca, J\n2009-03-01\nRegular consumption of fish reduces cardiovascular risks. Here, we investigate if the consumption of products with mackerel (Scomber scombrus) with 8.82 g of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) content per 100 g of product improves parameters of endothelial function in a controlled population. Subjects maintained a 12-week diet with products with mackerel. The population consisted of 58 senior subjects (12 withdrawals, 25 women), aged 82.08 +/- 8.13 years (Group A). Twenty-three senior subjects (13 women) on a regular diet were used as the control group (Group B). Subjects of Group A received 57 portions throughout 12 weeks (four to five portions a week of products with a mean EPA + DHA content of 2.5 g a day). A continuous follow-up and a final evaluation were performed to determine the level of consumption. Plasma samples were stored at -70 degrees C for a biochemical study. Endothelial function was analysed by reactive hyperemia with a mercury strain gauge plethysmography with measurement of blood flow in the forearm, both baseline and at the end of the 12-week diet. Endothelium-dependent vasodilatation significantly increased in Group A subjects (P < 0.001). No changes were found in Group B. The subgroup analyses showed that improvements were produced in Group A subjects without cardiovascular disease (P < 0.001). Nitrites/nitrates and von Willebrand factor plasma concentrations were higher in participants after the 12-week diet. The consumption of mackerel meat products improves endothelium-dependent, flow-mediated vasodilatation in a senior population. This finding might explain some of the cardioprotective effects of fish consumption.\n[Emergent and Reemergent Arboviruses in South America and the Caribbean: Why So Many and Why Now?](https://www.ncbi.nlm.nih.gov/pubmed/28399216)\nMarcondes, Carlos Brisola; Contigiani, Marta; Gleiser, Raquel Miranda\n2017-05-01\nVarios arbovirus han emergido y/o reemergido en el Nuevo Mundo en las \u00faltimas d\u00e9cadas. Los virus Zika y chikungunya, anteriormente restringidos a \u00c1frica y quiz\u00e1s Asia, invadieron el continente, causando gran preocupaci\u00f3n; adem\u00e1s siguen ocurriendo brotes causados por el virus dengue en casi todos los pa\u00edses, con millones de casos por a\u00f1o. El virus West Nile invadi\u00f3 r\u00e1pidamente Am\u00e9rica del Norte, y ya se han encontrado casos en Am\u00e9rica Central y del Sur. Otros arbovirus, como Mayaro y el virus de la encefalitis equina del este han aumentado su actividad y se han encontrado en nuevas regiones. Se han documentado cambios en la patogenicidad de algunos virus que conducen a enfermedades inesperadas. Una fauna diversa de mosquitos, cambios clim\u00e1ticos y en la vegetaci\u00f3n, aumento de los viajes, y urbanizaciones no planificadas que generan condiciones adecuadas para la proliferaci\u00f3n de Aedes aegypti (L.), Culex quinquefasciatus Say y otros mosquitos vectores, se han combinado para influir fuertemente en los cambios en la distribuci\u00f3n y la incidencia de varios arbovirus. Se enfatiza la necesidad de realizar estudios exhaustivos de la fauna de mosquitos y modificaciones de las condiciones ambientales, sobre todo en las zonas urbanas fuertemente influenciadas por factores sociales, pol\u00edticos y econ\u00f3micos. \u00a9 The Authors 2017. Published by Oxford University Press on behalf of Entomological Society of America. All rights reserved. For Permissions, please email: journals.permissions@oup.com.\n[[Diabetic foot osteomyelitis: is conservative treatment possible?].](https://www.ncbi.nlm.nih.gov/pubmed/24913994)\nJordano-Monta\u00f1ez, Queralt; Mu\u00f1iz-Tatay, Montse; Viad\u00e9-Juli\u00e0, Jordi; Jaen-Manzanera, Angeles; Royo-Serrando, Josep; Cuch\u00ed-Burgos, Eva; Anglada-Barcel\u00f3, Jordi; de la Sierra-Iserte, Alejandro\n2014-11-01\nThe aim of the present study is to determine the proportion of foot ulcers, complicated by osteomyelitis in diabetic patients, that heal without amputation. Furthermore, an attempt is made to analyze the main clinical and microbiological characteristics of episodes, and to identify potential predictive factors leading to the failure of conservative treatment. A prospective observational study was carried out between 2007 and 2009 on diabetic patients with a foot lesion and attending a diabetic foot clinic. A percutaneous bone biopsy was required to be included in the study. A total of 81 episodes of diabetic foot osteomyelitis in 64 patients were evaluated. Staphylococcus aureus (28/81) and coagulase negative Staphylococcus (22/81) were the most frequent organisms isolated. Among the gramnegative group (34/81), non-fermenting gram negative bacteria were the most prevalent organisms isolated (14/81). Conservative treatment was successful in 73% of episodes. After a logistic regression analysis using the most significant prognostic variables, only lesion size greater than 2cm independently predicted failure of conservative treatment. Culture guided antibiotic treatment was associated with a better prognosis. Conservative treatment, including culture-guided antibiotics, is successful without amputation in a large proportion of diabetic patients with diabetic foot osteomyelitis. Considering empiric therapy directed at non-fermenting gramnegative bacteria could be advisable in some cases, because they are frequently isolated in our setting. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Psychosocial aspects in a cohort of vertically transmitted human immunodeficiency virus-infected adolescents].](https://www.ncbi.nlm.nih.gov/pubmed/24461249)\nGarc\u00eda-Navarro, Cristina; Garc\u00eda, Isabel; Med\u00edn, Gabriela; Ramos-Amador, Jos\u00e9 Tom\u00e1s; Navarro-G\u00f3mez, Marisa; Mellado-Pe\u00f1a, M Jos\u00e9; G\u00f3mez, M I de Jos\u00e9; Cort\u00e9s, Marisol; Zamora Crespo, Berta; Mu\u00f1oz-Fernandez, M Angeles; Gamero, Daniel Bl\u00e1zquez; Gonz\u00e1lez-Tom\u00e9, M Isabel\n2014-12-01\nThanks to advances in antiretroviral treatment, children with HIV infections through vertical transmission have improved their life expectancy. However, new challenges have emerged. We propose this study in order to determine the psychosocial aspects and knowledge of infections in a cohort of adolescents with vertically transmitted HIV infections. Patients with vertically-acquired HIV infection between 12 and 19 years old were included. Data were obtained through semi-structured interviews and a Strengths and Difficulties Questionnaire for emotional and behavioral disorders screening. We evaluated 96 patients (58% females) with a median age of 15 years (11-19.1) and a median age at diagnosis of 1.70 years (0-12.2). The median CD4 count was 626cells/mm(3) (132-998), and the viral load was<50cp/ml in 72% of patients. Among them, 90% attended school and 60% repeated at least one course. Although 81% of them knew of their diagnosis, only 30% understood their disease, with 18.2% having discussed it with friends. Six unwanted pregnancies occurred during the study period. Strengths and Difficulties Questionnaire showed hyperactivity risk in 33%. A high percentage of adolescents show difficulties in several areas (disease knowledge, peer relationship, school failure...) that can have an impact on their adult lives. Further studies are needed to evaluate their origin and development in depth, as well as interventions to modify this situation. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Chlamydia trachomaatis DNA in leukocytes of peripheral blood from neonates].](https://www.ncbi.nlm.nih.gov/pubmed/25533744)\nL\u00f3pez-Hurtado, Marcela; Cuevas-Recillas, Karla N; Flores-Salazar, Ver\u00f3nica R; Guerra-Infante, Fernando M\n2015-01-01\nDiagnosis of Chlamydia trachomatis infection in newborns is difficult; however, this diagnosis is performed by cell culture or by detection of IgM antibodies against C. trachomatis. Detection of C. trachomatis DNA in peripheral blood leukocytes using polymer chain reaction (PCR) may be a better tool for the diagnosis of infection by this pathogen. A total of 44 premature newborns, all weighing less than 2500g, were included in the study. A blood sample and nasopharyngeal lavages were obtained from each newborn. Leukocyte DNA was obtained by phenol-chloroform extraction technique. Detection of C. trachomatis was performed by amplifying the ompA gene using the PCR endpoint. Cell culture tests and the detection of IgM antibodies against C. trachomatis by microimmunofluorescence assay were also performed. Twenty newborns were PCR-positive (45.5%), with this test being significantly associated with the presence of pneumonia (RR=2.28; 95%CI: 1.01 to 5.17; P=.035). The cell culture of nasopharyngeal lavage was positive in only 7 samples and no significant association was observed with any clinical or laboratory data. The titer of IgM antibodies against C. trachomatis associated with PCR-positive was 1:32 (RR=2.74; 95%CI: 1.21 to 6.23; P=.008), however this titer was not associated with the presence of pneumonia. DNA detection in peripheral blood leukocytes could be useful for diagnosis of C. trachomatis infection. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Quality of care indicators for the care of human immunodeficiency virus-infected individuals, adapted to the pediatric age].](https://www.ncbi.nlm.nih.gov/pubmed/23582193)\nSoler-Palac\u00edn, Pere; Provens, Ana Clara; Mart\u00edn-Nalda, Andrea; Espiau, Mar\u00eda; Fern\u00e1ndez-Polo, Aurora; Figueras, Concepci\u00f3\n2014-03-01\nSince infection with human immunodeficiency virus (HIV) was first described, there have been many advances in its diagnosis, monitoring and treatment. However, few contributions are related to the area of health care quality. In this sense, the Spanish Study Group on AIDS (GESIDA) has developed a set of quality care indicators for adult patients living with HIV infection that includes a total of 66 indicators, 22 of which are considered to be relevant. Standards were calculated for each of them in order to reflect the level of the quality of care offered to these patients. Similar documents for pediatric patients are currently lacking. Preparation of a set of quality care indicators applicable to pediatric patients based on the GESIDA document and the Spanish Guidelines for monitoring of pediatric patients infected with HIV. Each indicator was analysed with respect to the required standards in all patients under 18 years of age followed-up in our Unit, with the aim of evaluating the quality of care provided. A total of 61 indicators were collected (51 from the GESIDA document and 10 from currently available pediatric guidelines), 30 of which were considered to be relevant. An overall compliance of 81%-83% was obtained when assessing the relevant indicators. The availability of health care quality standards is essential for the care of pediatric HIV-infected patients. The assessment of these indicators in our Unit yielded satisfactory results. Copyright \u00a9 2012 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nDom\u00ednguez, Ra\u00fal; Garnacho-Casta\u00f1o, Manuel Vicente; Mat\u00e9-Mu\u00f1oz, Jos\u00e9 Luis\n2016-06-30\nLa fuerza influye directamente en el estado de salud y en la capacidad de fitness, motivo por el que el entrenamiento contra resistencias o resistance training (RT) se incluye dentro de aquellos programas de ejercicio encaminados a mejorar la salud y calidad de vida. Debido a que muchasenfermedades cursan con alteraci\u00f3n de la masa y funcionalidad muscular y a que el RT es la principal modalidad de ejercicio encaminada a mejorar la funci\u00f3n muscular, el objetivo de la presente revisi\u00f3n bibliogr\u00e1fica ha sido exponer las evidencias actuales sobre las adaptaciones delRT, as\u00ed como su posible aplicaci\u00f3n en patolog\u00edas como la obesidad, diabetes, dislipemia, hipertensi\u00f3n, c\u00e1ncer, Parkinson, esclerosis m\u00faltiple o fibromialgia. El RT en estas enfermedades puede aumentar los niveles de masa muscular, disminuyendo los niveles de masa grasa, los nivelesde \u00e1cidos grasos en sangre y la glucemia, incrementando la sensibilidad a la insulina, y disminuyendo los niveles de citokinas inflamatorias. El RT, adem\u00e1s, mejora el gasto cardiaco y la funcionalidad endotelial, regulando la tensi\u00f3n arterial e incrementando el consumo de ox\u00edgeno. Las ganancias de fuerza muscular mejoran la funcionalidad y la calidad de vida, especialmente en poblaci\u00f3n con una afectaci\u00f3n neuromuscular grave, como pudieran ser los enfermos de esclerosis m\u00faltiple, fibromialgia o Parkinson. Por ello, el RT debe ser incorporado como parte del tratamiento en las personas que presentan determinado tipo de patolog\u00edas.\n[[Hospitalization due to whooping cough in Spain (1997-2011)].](https://www.ncbi.nlm.nih.gov/pubmed/24447922)\nFern\u00e1ndez-Cano, Mar\u00eda Isabel; Armadans-Gil, Llu\u00eds; Alvarez-Bartolom\u00e9, Mercedes; Rodrigo-Pend\u00e1s, Jos\u00e9 \u00c1ngel; Campins-Mart\u00ed, Magda\n2014-12-01\nPertussis incidence has increased in recent years in countries with high vaccination coverage. The aim of this study was to determine the health impact of pertussis in Spain in the period 1997-2011 in relation to hospitalizations, mortality, and associated costs. We retrospectively analyzed hospital discharges included in the Minimum Data Set (MDS) in Spain for the period 1997-2011, with a primary or secondary diagnosis related to pertussis. We calculated incidence rates of hospitalization for pertussis (per 100,000) per year, by age group and by Autonomous Region, along with the mortality and lethality rates. A total of 8,331 hospital discharges with a diagnosis of pertussis were recorded in Spain between 1997 and 2011. The overall incidence of pertussis hospitalizations was 1.3 cases per 100,000 inhabitants. The large majority (92%) of hospitalizations occurred in children under one year of age, with an incidence of 115.2 hospitalizations per 100,000. There were 47 deaths, 37 (79%) in the group of children under 1 year and 6 (13%) in the group older than 65 years. The estimated cost of hospitalization for pertussis was 1,841 euros. The epidemiology of severe cases of pertussis, and its clinical and economic impact, confirms the need to modify the vaccination strategies for Spain to achieve more effective control in the most vulnerable groups. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Direct bacterial identification from positive blood cultures using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry: A systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/29110928)\nRuiz-Arag\u00f3n, Jes\u00fas; Ballestero-T\u00e9llez, M\u00f3nica; Guti\u00e9rrez-Guti\u00e9rrez, Bel\u00e9n; de Cueto, Marina; Rodr\u00edguez-Ba\u00f1o, Jes\u00fas; Pascual, \u00c1lvaro\n2017-10-27\nThe rapid identification of bacteraemia-causing pathogens could assist clinicians in the timely prescription of targeted therapy, thereby reducing the morbidity and mortality of this infection. In recent years, numerous techniques that rapidly and directly identify positive blood cultures have been marketed, with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) being one of the most commonly used. The aim of this systematic review and meta-analysis was to evaluate the accuracy of MALDI-TOF (Bruker \u00ae ) for the direct identification of positive blood culture bottles. A meta-analysis was performed to summarize the results of the 32 studies evaluated. The overall quality of the studies was moderate. For Gram-positive bacteria, overall rates of correct identification of the species ranged from 0.17 to 0.98, with a cumulative rate (random-effects model) of 0.72 (95% CI: 0.64-0.80). For Gram-negative bacteria, correct identification rates ranged from 0.66 to 1.00, with a cumulative effect of 0.92 (95% CI: 0.88-0.95). For Enterobacteriaceae, the rate was 0.96 (95% CI: 0.94-0.97). MALDI-TOF mass spectrometry shows high accuracy for the correct identification of Gram-negative bacteria, particularly Enterobacteriaceae, directly from positive blood culture bottles, and moderate accuracy for the identification of Gram-positive bacteria (low for some species). Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Evaluation of mass spectrometry for the identification of clinically interesting yeasts].](https://www.ncbi.nlm.nih.gov/pubmed/25444360)\nGal\u00e1n, F\u00e1tima; Garc\u00eda-Agudo, Lidia; Guerrero, Inmaculada; Mar\u00edn, Pilar; Garc\u00eda-Tapia, Ana; Garc\u00eda-Martos, Pedro; Rodr\u00edguez-Iglesias, Manuel\n2015-01-01\nIdentification of yeasts is based on morphological, biochemical and nutritional characteristics, and using molecular methods. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, a new method for the identification of microorganisms, has demonstrated to be very useful. The aim of this study is to evaluate this new method in the identification of yeasts. A total of 600 strains of yeasts isolated from clinical specimens belonging to 9 genera and 43 species were tested. Identification was made by sequencing of the ITS regions of ribosomal DNA, assimilation of carbon compounds (ID 32C), and mass spectrometry on a Microflex spectrometer (Bruker Daltonics GmbH, Germany). A total of 569 strains (94.8%) were identified to species level by ID 32C, and 580 (96.7%) by MALDI-TOF. Concordance between both methods was observed for 553 strains (92.2%), with 100% in clinically relevant species: C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and almost 100% in C. krusei. MALDI-TOF identified species requiring molecular methods: Candida dubliniensis, C. nivariensis, C. metapsilosis and C. orthopsilosis. Some irregularities were observed in the identification of arthroconidia yeast and basidiomycetes. MALDI-TOF is a rapid, effective and economic method, which enables the identification of most clinically important yeasts and the differentiation of closely related species. It would be desirable to include more species in its database to expand its performance. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy].](https://www.ncbi.nlm.nih.gov/pubmed/25487604)\nIveli, Pablo; Noguera-Julian, Antoni; Soler-Palac\u00edn, Pere; Mart\u00edn-Nalda, Andrea; Rovira-Girabal, N\u00faria; Fortuny-Guasch, Cl\u00e0udia; Figueras-Nadal, Concepci\u00f3\n2016-01-01\nThe use of nevirapine in HIV-infected pregnant women is discouraged due to its potential to cause hepatotoxicity. There is limited information available on the toxicity in non-HIV infected newborn exposed to this drug during pregnancy. The aim of the study is to determine the extent of hepatotoxicity in the newborn exposed to nevirapine and HIV during pregnancy. A cross-sectional, observational, multicenter study was conducted on a cohort of healthy infants born to HIV-infected mothers, in whom the first determination of alanine aminotransferase (ALT), before 6weeks of age, was collected. Patients were allocated to 2groups according to exposure to nevirapine during pregnancy. Hepatotoxicity was rated according to the AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS). This study included 160newborns from 159pregnancies (88exposed to nevirapine-based regimens and 71 exposed to protease inhibitors-based therapies). No cases of hepatotoxicity were observed according to the DAIDS Table for Grading. Two cases of ALT above normal values (2.8%; 95%CI: 0.3-9.8%) were observed in patients not exposed to nevirapine, and one case (1.1%; 95%CI: 0.0-6.1%) in the group exposed to nevirapine (P=.585). The lack of differences between groups suggests that highly active antiretroviral treatment regimens including nevirapine administered during pregnancy do not involve a higher risk of liver disease compared to other treatment combinations. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Does the prescribing of antibiotics in paediatrics improve after a multidisciplinary intervention?].](https://www.ncbi.nlm.nih.gov/pubmed/25124487)\nLalana-Josa, Pilar; Laclaustra-Mendiz\u00e1bal, Blanca; Aza-Pascual-Salcedo, M Mercedes; Carcas-de-Benavides, Cristina; Lallana-\u00c1lvarez, M Jes\u00fas; Pina-Gadea, M Bel\u00e9n\n2015-02-01\nAntibiotics overuse is linked to elevated antimicrobial resistance. In Aragon, Spain, the highest antibiotic prescription rates occur among children from 1 to 4 years old. The rate of use in this age group is over 60%. To evaluate the effect of multi-faceted intervention on Primary Care paediatricians to reduce antibiotic use and to improve antibiotic prescribing for paediatric outpatients. Outpatient antimicrobial prescribing was analysed before and after an intervention in paediatricians. The intervention included a clinical education session about diagnosis and treatment in the most prevalent paediatric infectious diseases, a clinical interview and communication skills, a workshop on rapid Streptococcus antigen detection test and patient information leaflets and useful internet websites for parents. The control group included paediatricians without this educational intervention on antibiotics. Antibiotic prescribing decreased from 19.17 defined daily doses per 1000 inhabitants/day (DID) to 14.36 DID among intervention paediatricians vs 19.84 DID to 16.02 DID in controls. The decreasing was higher in the intervention group, but the effect was not statistically significant. Macrolides and broad-spectrum penicillins prescribing decreased in both groups. Antibiotic prescribing decreased, but there were no statistically significant differences between the two groups. The high satisfaction of paediatricians in the intervention group makes it necessary to continue with these kinds of strategies to improve antibiotic use in outpatients. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Evaluation of the usefulness of a quantitative blood culture in the diagnosis of catheter-related bloodstream infection: Comparative analysis of two periods (2002 and 2012).](https://www.ncbi.nlm.nih.gov/pubmed/26778796)\nPlanes, Anna Maria; Calleja, Raquel; Bernet, Albert; Campins-Mart\u00ed, Magda; Almirante, Benito; Pumarola, Tom\u00e0s; Fern\u00e1ndez-Hidalgo, N\u00faria\n2016-10-01\nA retrospective study was conducted to investigate the usefulness of systematic quantitative blood culture (QBC) in the diagnosis of catheter-related bloodstream infection (CRBSI) during two 1-year periods (2002 and 2012). The study included all QBC requests sent to the microbiology laboratory for suspected CRBSI in adults (\u226518 years) with any type of intravascular catheter (IVC). Based on a ratio of \u22654:1CFU/mL of the same microorganism between IVC blood culture from any lumen and peripheral blood culture, 5 diagnostic groups were defined: confirmed or probable CRBSI, primary BSI, other focus of infection, and colonization. In total, 4521 QBCs were evaluated; 24% positive in 2002 and 16% in 2012 (P<0.0001). There were 243 episodes of suspected CRBSI (101 in 2002 and 142 in 2012). Confirmed CRBSI episodes were higher in 2002 than 2012 (56% vs 34%) (P<0.0001), whereas colonization episodes were lower (18% vs 38%) (P=0.0006). Gram-positive cocci decrease in 2012 relative to 2002 (56% vs 79.7%) (P=0.022). Almost one-third (32%) of confirmed CRBSI would have been missed if blood from all catheter lumens had not been cultured. QBC is a useful method for diagnosing CRBSI. Blood samples from all catheter lumens must be cultured to avoid missing around one-third of CRBSI diagnoses. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Sexually transmitted infections clinics as strategic venues for targeting high risk populations for HIV research and sexual health interventions.](https://www.ncbi.nlm.nih.gov/pubmed/21932709)\nClatts, Michael C; Rodr\u00edguez-D\u00edaz, Carlos E; Garc\u00eda, Hermes; Vargas-Molina, Ricardo L; Col\u00f3n-L\u00f3pez, Vivian; P\u00e9rez-Rios, Naydi; Goldsamt, Lloyd; Jovet-Toledo, Gerardo G\n2011-09-01\nPuerto Rico has one of the highest incidence rates of HIV in the U.S. Concurrent with increases in sexually transmitted infections (STI), an increasing share of the new infections in PR are associated with sexual transmission. Much of the available research on sexual risk in PR derives from STI/HIV surveillance data. There is limited social and epidemiological research on sexual risk in PR, particularly in hidden and often hard-to-reach populations at high risk. Despite the absence of substantial resources that most epidemiological studies require, a research collaboration was initiated in 2007 between researchers in the School of Public Health at the University of Puerto Rico and the Centro Latinoamericano de Enfermedades de Transmisi\u00f3n Sexual (CLETS), one of the largest publicly funded centers for STI/HIV screening and treatment in the San Juan metropolitan area. Structured as a case study in the development of community-based research collaborations, this paper describes the early history and development of the project, including formative research, recruitment and training of students, and evolution in the study design that contributed to the current configuration of the ongoing \"Core\" study. Preliminary data are presented, highlighting data from a number of subpopulations that may contribute to our understanding of the role of behavioral risk in the STI/HIV epidemics in PR. More generally, the paper may guide the development of similar collaboration elsewhere in the Caribbean where HIV risk is increasing but where resources for research in high risk settings and groups are scarce.\n[[Validation and adhesion to GESIDA quality indicators in patients with HIV infection].](https://www.ncbi.nlm.nih.gov/pubmed/26530224)\nRiera, Melchor; Esteban, Herminia; Suarez, Ignacio; Palacios, Rosario; Lozano, Fernando; Blanco, Jose R; Valencia, Eulalia; Ocampo, Antonio; Amador, Concha; Frontera, Guillem; vonWichmann-de Miguel, Miguel Angel\n2016-01-01\nThe objective of the study is to validate the relevant GESIDA quality indicators for HIV infection, assessing the reliability, feasibility and adherence to them. The reliability was evaluated using the reproducibility of 6 indicators in peer review, with the second observer being an outsider. The feasibility and measurement of the level of adherence to the 22 indicators was conducted with annual fragmented retrospective collection of information from specific databases or the clinical charts of the nine participating hospitals. Reliability was very high, with interobserver agreement levels higher than 95% in 5 of the 6 indicators. The median time to achieve the indicators ranged between 5 and 600minutes, but could be achieved progressively from specific databases, enabling obtaining them automatically. As regards adherence to the indicators related with the initial evaluation of the patients, instructions and suitability of the guidelines for ART, adherence to ART, follow-up in clinics, and achieve an undetectable HIV by PCR at week 48 of the ART. Indicators of quality related to the prevention of opportunistic infections and control of comorbidities, the standards set were not achieved, and significant heterogeneity was observed between hospitals. The GESIDA quality indicators of HIV infection enabled the relevant indicators to be feasibly and reliably measured, and should be collected in all the units that care for patients with HIV infection. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Adaptation into Spanish of the Internalised Stigma of Mental Illness scale to assess personal stigma.](https://www.ncbi.nlm.nih.gov/pubmed/26971249)\nBengochea-Seco, Rosario; Arrieta-Rodr\u00edguez, Marta; Fern\u00e1ndez-Modamio, Mar; Santacoloma-Cabero, Iciar; G\u00f3mez de Tojeiro-Roce, Juan; Garc\u00eda-Polavieja, B\u00e1rbara; Santos-Zorroz\u00faa, Borja; Gil-Sanz, David\n2016-03-09\nPatients with schizophrenia sometimes internalise social stigma associated to mental illness, and they develop personal stigma. Personal stigma includes self-stigma (internalisation of negative stereotypes), perceived stigma (perception of rejection), and experienced stigma (experiences of discrimination). Personal stigma is linked with a poorer treatment adherence, and worst social functioning. For this reason, it is important to have good measurements of personal stigma. One of the most frequently used measurements is the Internalised Stigma of Mental Illness (ISMI) scale. There is a Spanish version of the scale available, although its psychometric properties have not been studied. The main aim of this study is to analyse the psychometric properties of a new Spanish version of the ISMI scale. The new version was translated as Estigma Interiorizado de Enfermedad Mental (EIEM). Internal consistency and test-retest reliability were calculated in a sample of 69 patients with a diagnosis of schizophrenia or schizoaffective disorder. The rate of patients showing personal stigma was also studied, as well as the relationship between personal stigma and sociodemographic and clinical variables. The adapted version obtained good values of internal consistency and test-retest reliability, for the total score of the scale (0.91 and 0.95 respectively), as well as for the five subscales of the EIEM, except for the Stigma Resistance subscale (Cronbach's alpha 0.42). EIEM is an appropriate measurement tool to assess personal stigma in a Spanish population with severe mental disorder, at least in those with a diagnosis of schizophrenia or schizoaffective disorder. Copyright \u00a9 2016. Published by Elsevier Espa\u00f1a.\nNorte Navarro, Aurora Isabel; Sansano Perea, Miriam; Mart\u00ednez Sanz, Jos\u00e9 Miguel; Sospedra L\u00f3pez, Isabel; Hurtado S\u00e1nchez, Jos\u00e9 Antonio; Ortiz Moncada, Roc\u00edo\n2016-06-30\nIntroducci\u00f3n y objetivos: las enfermedades cardiovasculares (ECV) son la principal causa de muerte mundial, por ello el objetivo de este estudio es analizar los factores de riesgo de ECV en los trabajadores de la Universidad de Alicante.Material y m\u00e9todos: estudio transversal descriptivo. Muestra aleatoria (n = 124), 46,6% mujeres y 53,4% hombres, de edades entre 25-68 a\u00f1os. Recogida de datos mediante cuestionario online autocumplimentado. sociodemogr\u00e1ficas, peso y talla autorreferidos, consumo de tabaco, actividad f\u00edsica, consumo diario de aceite de oliva, hortalizas-verduras, mantequilla-margarina-nata y consumo semanal de reposter\u00eda comercial y frutos secos. Se realiz\u00f3 un an\u00e1lisis descriptivo con el paquete estad\u00edstico SPSS 19.0.Resultados: el 12% de mujeres y el 10,5% de los hombres mayores de 44 a\u00f1os presentan obesidad; adem\u00e1s, el 32% de mujeres y el 23,7% de los hombres no realizan actividad f\u00edsica. Consume aceite de oliva a diario el total de la muestra a estudio.Conclusi\u00f3n: los h\u00e1bitos alimentarios de los estudiados se asemejan a los patrones diet\u00e9ticos mediterr\u00e1neos considerados saludables. Destacar el cumplimiento de las recomendaciones de consumo de aceite de oliva y la realizaci\u00f3n de actividad f\u00edsica habitual como protectores de las ECV. El entorno laboral de la poblaci\u00f3n estudiada favorece unos h\u00e1bitos saludables.\n[Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patients.](https://www.ncbi.nlm.nih.gov/pubmed/24616542)\nFont, Carme; Carmona-Bayonas, Alberto; Fern\u00e1ndez-Martinez, Aranzazu; Beato, Carmen; Vargas, Andr\u00e9s; Gascon, Pere; Otero, Remedios\n2014-03-01\nThe purpose of this prospective cohort study was to assess the feasibility of outpatient treatment in patients with cancer and objectively confirmed pulmonary embolism (PE), and to compare the performance of the different prognostic scales available in this setting. Patients were selected for outpatient management according to a set of exclusion criteria. Outcomes at 30 and 90 days of follow-up included thromboembolic recurrences, major bleeding, and all-cause death. The performance of 4 prognostic scales (Pulmonary Embolism Severity Index, Geneva Prognostic Score, POMPE-C, and Registro Informatizado de Enfermedad Tromboemb\u00f3lica [RIETE registry]) was evaluated. Of 138 patients, 62 (45%) were managed as outpatients. Incidental PE constituted 47% of the sample. Most patients treated at home had an incidentally detected PE (89%). The rate of recurrence and major bleeding events was similar in both groups. Mortality rates were higher for patients admitted to the hospital compared with outpatients at 30 days (18% vs 3%; P=.06) and 90 days (34% vs 10%; P=.001) of follow-up. None of the patients selected for home treatment required further admission because of PE complications. None of the prognostic models developed for symptomatic PE was significantly associated with 30-day mortality. Improved survival outcomes were observed in incidentally detected PEs compared with acute symptomatic events (overall mortality rates, 3.2% vs 18.4%; P=.006). A large proportion of patients with cancer and PE may be safely treated as outpatients, especially those with incidental PE. Cancer-specific prognostic scales including incidental PE should be developed for the optimal management of PE in this setting.\n[[Perceived satisfaction and usefulness of suicide prevention information for patients and relatives].](https://www.ncbi.nlm.nih.gov/pubmed/24210519)\nTri\u00f1anes, Y; Senra-Rivera, C; Seoane-Pesqueira, G; Gonz\u00e1lez-Garc\u00eda, A; \u00c1lvarez-Ariza, M; de-Las-Heras-Li\u00f1ero, E; Atienza, G\n2014-01-01\nTo assess the satisfaction of persons with suicidal behaviour and their relatives using patient information material included in the Clinical Practice Guidelines on Prevention and Treatment of Suicidal Behaviour. The sample was made up of 57 patients with suicidal ideation or behaviour, and 52 relatives. The participants were recruited through a suicide prevention programme (Programa de intervenci\u00f3n intensiva en conducta suicida [PII] - Suicidal Behaviour Intensive Intervention Programme) and a family association (Federaci\u00f3n de Asociaciones de Familiares y Personas con enfermedad mental de Galicia [FEAFES] - Galician Federation of Associations of Relatives and Persons with mental diseases). An ad-hoc questionnaire was designed to ascertain the degree of perceived satisfaction and usefulness of using the information included in the guidelines. The descriptive data of the sample is presented, along with an exploratory factorial analysis of the questionnaire that yielded two dimensions, i.e., format and usefulness. Patients scored significantly lower than the relatives in two dimensions; nevertheless, no significant differences were found between the two groups in the level of general satisfaction. The socio-demographic variables did not influence the results. Similarly, no differences were observed between patients with and without history of suicidal behaviour. Participants stressed that Primary Care was the setting best suited for dissemination of this type of information. In general, both patients and relatives displayed a high level of satisfaction with the patient information material assessed. Furnishing information of this type to patients with suicidal ideation and/or behaviour could act as a preventive-educational tool. Copyright \u00a9 2013 SECA. Published by Elsevier Espana. All rights reserved.\n[Preclinical atherosclerosis at the time of pre-eclamptic pregnancy and up to 10 years postpartum: systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/27859887)\nMilic, N M; Milin-Lazovic, J; Weissgerber, T L; Trajkovic, G; White, W M; Garovic, V D\n2017-01-01\nLtd. La preeclampsia (PE) es un trastorno hipertensivo espec\u00edfico del embarazo que ha sido asociada con factores de riesgo cardiovascular y cambios vasculares, tales como aterosis aguda en los vasos sangu\u00edneos de la placenta, similares a las primeras etapas de la aterosclerosis. El objetivo de este estudio fue determinar si las mujeres con PE han aumentado la carga ateroscler\u00f3tica, seg\u00fan lo determinado por el espesor del complejo \u00edntima-media de la arteria car\u00f3tida (CIMT, por sus siglas en ingl\u00e9s), en comparaci\u00f3n con las mujeres sin PE. M\u00c9TODOS: Se realiz\u00f3 una revisi\u00f3n sistem\u00e1tica y un metaan\u00e1lisis de estudios que reportaron el CIMT, una medida no invasiva de la aterosclerosis subcl\u00ednica obtenida mediante ecograf\u00eda, comparando mujeres con PE y mujeres sin ella. Solo se incluyeron estudios llevados a cabo durante el embarazo o durante la primera d\u00e9cada despu\u00e9s del parto, y en los que se midi\u00f3 el CIMT en la arteria car\u00f3tida com\u00fan. Se usaron las bases de datos de PubMed, EMBASE y Web of Science para identificar estudios publicados antes del 7 marzo de 2016. Dos revisores utilizaron formularios y protocolos preestablecidos para evaluar de forma independiente la elegibilidad de los estudios, a partir de los t\u00edtulos y los res\u00famenes, y para realizar un cribado del texto completo, un resumen de los datos y una evaluaci\u00f3n de calidad. La heterogeneidad se evalu\u00f3 mediante el test estad\u00edstico I 2 . Se us\u00f3 la diferencia de medias estandarizada (SMD, por sus siglas en ingl\u00e9s) como una medida de la magnitud del efecto. En el metaan\u00e1lisis se incluyeron catorce estudios. Siete de los estudios se llevaron a cabo durante embarazos complicados por PE, 10 se realizaron hasta 10 a\u00f1os despu\u00e9s del parto y tres incluyeron mediciones tomadas en ambos per\u00edodos. Las mujeres con PE tuvieron un CIMT significativamente mayor que aquellas que no la ten\u00edan, tanto en el momento del diagn\u00f3stico (SMD 1,10 (I 95%, 0,73-1,48), P <0,001) como en la primera d\u00e9cada despu\n[[Prevalence and genotype distribution changes in hepatitis C virus co-infection among human immunodeficiency virus-infected patients].](https://www.ncbi.nlm.nih.gov/pubmed/25510595)\nCifuentes, Celia; Mancebo-Hern\u00e1ndez, Mar\u00eda; P\u00e9rez-Navarro, Elisabet; Recio, Eva; Monje-Agudo, Patricia; Valiente, Adoraci\u00f3n; Pineda, Juan A\n2015-02-01\nThe prevalence of hepatitisC is decreasing among new diagnoses of HIV/HCV coinfection in Spain. The increasing use of the HCV treatment could have changed the HCV genotype distribution. The aim of this study is to analyze changes in the prevalence of HCV coinfection and in HCV genotype distribution among HIV-infected patients. A serial cross-sectional study was conducted that included all HIV-infected patients who attended the Outpatient Clinic of a hospital in Andalusia, between September 2008 and February 2009 (first period), and between January 2013 and June 2013 (second period). A total of 520 and 651 patients were included in the first and second period, respectively. The risk factors of HCV infection in the first vs. second period were: IDU, 319 (61%) vs. 348 (53%); heterosexual contact, 111 (21%) vs. 135 (21%); homosexual men, 76 (15%) vs. 114 (22%) (P=.006). The prevalence of HCV antibody per period was: 358 (69%) vs. 380 (58%) (P=<.001), and for the HCV-RNA was 255 (49%) vs. 240 (37%) (P=<.001). In both periods, the HCV genotype distribution was: 1, 137 (60%) vs. 138 (59%); 3, 45 (20%) vs. 42 (18%); 4, 42 (18%) vs. 47 (20%) (P=.881). The prevalence of HCV infection in HIV-infected patients has decreased in our area, including overall exposure to HCV virus and active infection during the last 5 years. However, the HCV genotype distribution has not changed. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Desarrollo de la Escala sobre el Estigma Relacionado con el VIH/SIDA para Profesionales de la Salud mediante el uso de m\u00e9todos mixtos123](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2843427)\nVaras-D\u00edaz, Nelson; Neilands, Torsten B.; Guilamo-Ramos, Vincent; Cintr\u00f3n Bou, Francheska N.\n2009-01-01\nEl estigma relacionado con el VIH/SIDA contin\u00faa siendo un obst\u00e1culo para la prevenci\u00f3n primaria y secundaria del VIH. Las consecuencias para las personas que viven con la enfermedad han sido muy documentadas y contin\u00faan siendo una gran preocupaci\u00f3n para las personas que proveen servicios de salud y para aquellas que investigan el tema. Estas consecuencias son preocupantes cuando el estigma emana de profesionales de la salud porque se puede limitar el acceso a los servicios. Uno de los principales obst\u00e1culos para la investigaci\u00f3n del estigma relacionado con el VIH en Puerto Rico es la falta de instrumentos cuantitativos para evaluar las manifestaciones del estigma entre profesionales de la salud. El objetivo principal de este estudio fue desarrollar y probar las propiedades psicom\u00e9tricas de una escala sobre el estigma relacionado con el VIH/SIDA culturalmente apropiada para personas que proveen servicios de salud puertorrique\u00f1as y desarrollar una versi\u00f3n corta de la escala que pudiera usarse en escenarios cl\u00ednicos con tiempo limitado. El instrumento desarrollado estuvo basado en evidencia cualitativa recopilada entre profesionales y estudiantes de profesiones de la salud puertorrique\u00f1os/as (n=80) y administrado a una muestra de 421 profesionales de la salud en adiestramiento. La escala conten\u00eda 12 dimensiones del estigma relacionado con el VIH/SIDA. El an\u00e1lisis cuantitativo corrobor\u00f3 11 de ellas, teniendo como resultado un instrumento con validez y confiabilidad satisfactoria. Estas dimensiones, a su vez, fueron subcomponentes de un factor de estigma general superior. PMID:20333258\n[Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5860754)\nOtero, Remedios; Jimenez, David; Praena-Fernandez, Juan Manuel; Font, Carme; Falga, Conxita; Soler, Silvia; Riesco, David; Verhamme, Peter; Monreal, Manuel\n2018-01-01\nThe usefulness of a diagnostic workup for occult cancer in patients with venous thromboembolism (VTE) is controversial. We used the RIETE (Registro Informatizado Enfermedad Trombo Emb\u00f3lica) database to perform a nested case-control study to validate a prognostic score that identifies patients with unprovoked VTE at increased risk for cancer. We dichotomized patients as having low- (\u22642 points) or high (\u22653 points) risk for cancer, and tried to validate the score at 12 and 24 months. From January 2014 to October 2016, 11,695 VTE patients were recruited. Of these, 1,360 with unprovoked VTE (11.6%) were eligible for the study. At 12 months, 52 patients (3.8%; 95%CI: 2.9\u20135%) were diagnosed with cancer. Among 905 patients (67%) scoring \u22642 points, 22 (2.4%) had cancer. Among 455 scoring \u22653 points, 30 (6.6%) had cancer (hazard ratio 2.8; 95%CI 1.6\u20135; p<0.01). C-statistic was 0.63 (95%CI 0.55\u20130.71). At 24 months, 58 patients (4.3%; 95%CI: 3.3\u20135.5%) were diagnosed with cancer. Among 905 patients scoring \u22642 points, 26 (2.9%) had cancer. Among 455 patients scoring \u22653 points, 32 (7%) had cancer (hazard ratio 2.6; 95%CI 1.5\u20134.3; p<0.01). C-statistic was 0.61 (95%CI, 0.54\u20130.69). We validated our prognostic score at 12 and 24 months, although prospective cohort validation is needed. This may help to identify patients for whom more extensive screening workup may be required. PMID:29558509\n[[How is the implementation of the new legal framework for health care affecting HIV-infected immigrants in an irregular situation in Spain?].](https://www.ncbi.nlm.nih.gov/pubmed/25553717)\nP\u00e9rez-Molina, Jos\u00e9 A; Pulido, Federico\n2015-01-01\nThe entry into force of Royal Decree (RD) 16/2012 in Spain in September 2012 led to the exclusion of the group of irregular immigrants from the National Healthcare System. With this work, GESIDA attempts to measure the impact of the entry into force of the RD in relation to its application by the Autonomous Communities (CCAA), and how it has affected the health care of irregular immigrants infected with HIV. Information was requested from the 17 CCAA of the existence of measures to ensure the care and treatment of people with HIV infection that were left unprotected because of the implementation of the RD. Likewise, a survey was conducted on health professionals and NGOs involved in the care of these people, to find out how it has affected the implementation of the RD to their daily healthcare work and the availability of information on regulations to implement it. The response of the CCAA was variable, hardly contributing, in some cases, to mitigate the negative effect of the RD. To this is added a complex bureaucracy to access the benefits offered by some regions, often inaccessible to the most vulnerable subjects. Lack of information for health-care professionals and NGOs involved in the care of immigrants, hinders access of this population to health care and the establishment of control measures for diseases with an impact on the public health. The RD 16/2012 has had a negative impact on daily healthcare working, generating the appearance of deep inequities throughout the country. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Correlation of inflammatory and cardiovascular biomarkers with pneumonia severity scores.](https://www.ncbi.nlm.nih.gov/pubmed/24054971)\nLacoma, Alicia; Bas, Albert; Tudela, Pere; Gim\u00e9nez, Montse; M\u00f2dol, Josep Maria; P\u00e9rez, Miguel; Ausina, Vicente; Dominguez, Jose; Prat-Aymerich, Cristina\n2014-03-01\nTo assess the correlation of procalcitonin (PCT), C-reactive protein (CRP), neopterin, mid-regional pro-atrial natriuretic peptide (MR-proANP), and mid-regional pro-adrenomedullin (MR-proADM) with severity risk scores: severe CAP (SCAP) and SMART-COP in patients with community-acquired pneumonia (CAP), as well as short term prognosis and to determine the correlation with mortality risk scores. Eighty-five patients with a final diagnosis of pneumonia were consecutively included during a two month period. Epidemiological, clinical, microbiological, and radiological data were recorded. Patients were stratified according to the PSI, CURB-65, SCAP and SMART-COP. Complications were defined as respiratory failure/shock, need of ICU, and death. Plasma samples were collected at admission. MR-proANP and MR-proADM showed significantly higher levels in high risk SCAP group in comparison to low risk. When considering SMART-COP none of the biomarkers showed statistical differences. MR-proADM levels were high in patients with high risk of needing intensive respiratory or vasopressor support according to SMRT-CO. Neopterin and MR-proADM were significantly higher in patients that developed complications. PCT and MR-proADM showed significantly higher levels in cases of a definite bacterial diagnosis in comparison to probable bacterial, and unknown origin. MR-proANP and MR-proADM levels increased statistically according to PSI and CURB-65. Biomarker levels are higher in pneumonia patients with a poorer prognosis according to SCAP and SMART-COP indexes, and to the development of complications. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[The neurological work of Artur Galcer\u00e1n i Gran\u00e9s (1850-1919).](https://www.ncbi.nlm.nih.gov/pubmed/21163243)\nArboix, A; Fabregas, M G\n2011-05-01\nTo analyze the neurological work of Artur Galcer\u00e1n i Gran\u00e9s (Girona 1850-Barcelona 1919) founder of the Society of Psychiatry and Neurology of Barcelona in 1911. We performed a literature search using MEDLINE from the keywords\"Galceran Gran\u00e9s\" and \"Society of Psychiatry and Neurology of Barcelona\", using the doctoral thesis of M. G. Fabregas Camps: \"History of Neurology in Catalonia. From 1882 to 1949 \", and original historical bibliographical sources of the Library of the Academy of Sciences M\u00e8diques de Catalunya i Balears. Artur Galcer\u00e1n i Gran\u00e9s was a disciple of the school of psychiatry of Dr. Joan Gin\u00e9 i Partag\u00e0s. His highlighting neurological work was: 1) \"Some static and dynamic inferences about the brain, which may serve to clarify the concept of localization\", 2) \"Treatment of epilepsy\" and 3) \"Neuropathology and General Psychiatry\". He was editor of \"Archivos de Terape\u00fatica de las enfermedades nerviosas y mentales\" and \"Anales de la Sociedad de Psiquiatr\u00eda y Neurolog\u00eda\". He was director of the mental asylum in Sant Boi of Llobregat and Pere Mata of Reus. In 1911 he founded the first Catalan and Spanish neurological society in Barcelona. The neurological work of Artur Galcer\u00e1n i Granes is remarkable and significant. He was the founder of the first Catalan and Spanish neurological society: The Society of Psychiatry and Neurology of Barcelona in 1911, the forerunner of the Catalan Society of Neurology. Copyright \u00a9 2010 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espana. All rights reserved.\n[[Polio, the long walk to the endgame].](https://www.ncbi.nlm.nih.gov/pubmed/25595690)\nGarc\u00eda-S\u00e1nchez, Jos\u00e9 El\u00edas; Garc\u00eda-S\u00e1nchez, Enrique; Garc\u00eda-Merino, Enrique; Fresnadillo-Mart\u00ednez, Mar\u00eda Jos\u00e9\n2015-12-01\nAlthough the WHO original target date for the global eradication of poliomyelitis was the year 2000 -thanks to vaccination and institutional, public and private, resources for that purpose-, in 2013 the disease remained endemic in three countries, Afghanistan, Pakistan and Nigeria, and some cases were described in five others. The circulation of wild type 1 poliovirus in Israel, Gaza and the West Bank and the cases in Syria were a wakeup call, as at that time there were polioviruses derived from the oral vaccine that are still circulating among the human population and can cause the development of the disease. Travelling \"from\" and \"to\" endemic areas are factors to consider in poliovirus exportation and in its spread when it reaches areas with poor immunogenicity. Wars, terrorism, intolerance, lack of culture and proliferation of anti-vaccine groups and the rise of the anti-vaccination movement are important factors in the maintenance and expansion of the virus and in the \"non-vaccination\" against it. Based on the international situation to date, the Emergency Committee of WHO met in May 2014 to address the problem. It is still necessary to enhance the knowledge of the disease and its agent. In the first case to perform a differential diagnosis of flaccid paralysis and to continue vaccination programs, and in the second case to keep studying and looking for the poliovirus in environmental samples, which is a model for the study of many other viruses. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Changes in clinic-epidemiological characteristics of new cases of HIV-1 infection in Castell\u00f3n (Spain), and its impact on delayed presentation (1987-2011)].](https://www.ncbi.nlm.nih.gov/pubmed/25027695)\nM\u00ednguez-Gallego, Carlos; Vera-Remartinez, Enrique J; Albert-Coll, Monica; Rold\u00e1n-Puchalt, M Concepci\u00f3n; Aguilar-Climent, Manuel; Rovira-Ferrando, Rosa E; Andr\u00e9s-Soler, Jorge; Roig-Espert, Bel\u00e9n; Penad\u00e9s-Vidal, Mar\u00eda; Us\u00f3-Blasco, Jorge\n2015-03-01\nTo describe the trend of the clinical and epidemiological characteristics of a cohort of HIV-1 infected patients in Castell\u00f3n (Spain), and its impact on the delayed presentation. Data from HIV-1 infected outpatients presenting for care for the first time between 1987 and 2011 were retrospectively analyzed. There have been significant changes in the characteristics of the 1001 newly presented patients during the period studied. An increase in the mean age was observed (increasing from about 30 years before 1996, to approximately 35 after the 2000-2002 period), as well as an increase in the percentage of immigrants (<2% before 1997, to 50% in the 2009-2011 period), and a decline in the proportion of intravenous drug use as the main transmission route (changing from being 92.3% before 1988 to below 20% after the 2003-2005 period), together with a decrease in the proportion of hepatitis-C coinfection. The rate of late presentation has not significantly changed, being 47.1% in the period studied. Factors associated with this late presentation were: older age, hospital diagnosis, an increased delay between estimated infection time and diagnosis, and between diagnosis and initial presentation. The epidemiology of HIV-1 infection in our area has dramatically changed since the beginning of the disease. The increasing delay between estimated infection time and diagnosis is an important cause of the lack of variation in the late presentation rate, and highlights the low impact of early diagnosis strategies. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Early diagnosis of human immunodeficiency virus-1 in infants: The prevention of mother-to-child transmission program in Equatorial Guinea].](https://www.ncbi.nlm.nih.gov/pubmed/26778797)\nPrieto-Tato, Luis Manuel; Vargas, Antonio; \u00c1lvarez, Patr\u00edcia; Avedillo, Pedro; Nzi, Eugenia; Abad, Carlota; Guill\u00e9n, Sara; Fern\u00e1ndez-McPhee, Carolina; Ramos, Jos\u00e9 Tom\u00e1s; Holgu\u00edn, \u00c1frica; Rojo, Pablo; Obiang, Jacinta\n2016-11-01\nGreat efforts have been made in the last few years in order to implement the prevention of mother-to-child transmission (PMTCT) program in Equatorial Guinea (GQ). The aim of this study was to evaluate the rates of mother-to-child HIV transmission based on an HIV early infant diagnosis (EID) program. A prospective observational study was performed in the Regional Hospital of Bata and Primary Health Care Centre Maria Rafols, Bata, GQ. Epidemiological, clinical, and microbiological characteristics of HIV-1-infected mothers and their exposed infants were recorded. Dried blood spots (DBS) for HIV-1 EID were collected from November 2012 to December 2013. HIV-1 genome was detected using Siemens VERSANT HIV-1 RNA 1.0 kPCR assay. Sixty nine pairs of women and infants were included. Sixty women (88.2%) had WHO clinical stage 1. Forty seven women (69.2%) were on antiretroviral treatment during pregnancy. Forty five infants (66.1%) received postnatal antiretroviral prophylaxis. Age at first DBS analysis was 2.4 months (IQR 1.2-4.9). One infant died before a HIV-1 diagnosis could be ruled out. Two infants were HIV-1 infected and started HAART before any symptoms were observed. The rate of HIV-1 transmission observed was 2.9% (95%CI 0.2-10.5). The PMTCT rate was evaluated for the first time in GQ based on EID. EID is the key for early initiation of antiretroviral therapy and to reduce the mortality associated with HIV infection. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Time to positivity of blood cultures in patients with bloodstream infections: A useful prognostic tool.](https://www.ncbi.nlm.nih.gov/pubmed/27916290)\nMart\u00edn-Guti\u00e9rrez, Guillermo; Mart\u00edn-P\u00e9rez, Carlos; Guti\u00e9rrez-Pizarraya, Antonio; Lepe, Jos\u00e9 A; Cisneros, Jos\u00e9 M; Aznar, Javier\n2017-12-01\nThe time to positivity (TTP) of blood cultures in patients with bloodstream infections (BSIs) has been considered to be a possible prognostic tool for some bacterial species. However, notable differences have been found between sampling designs and statistical methods in published studies to date, which makes it difficult to compare results or to derive reliable conclusions. Our objective was to evaluate the clinical and microbiological implications of TTP among patients with BSI caused by the most common pathogens. A total of 361 episodes of BSI were reported for 332 patients. The survival of the entire cohort was measured from the time of blood culture sampling. In order to compare our results with those of previous studies, TTP was divided in three different groups based on log rank (short TTP <12h; medium TTP \u226512h to \u226427h, and long TTP >27h). Cox proportional hazard models were used to calculate crude and adjusted hazard ratios (HR). The Cox proportional hazard model revealed that TTP is an independent predictor of mortality (HR=1.00, p=0.031) in patients with BSIs. A higher mortality was found in the group of patients with the shortest TTP (<12h) (HR=2.100, p=0.047), as well as those with longest TTP (>27h) (HR=3.277, p=0.031). It seems that TTP may provide a useful prognostic tool associated with a higher risk of mortality, not only in patients with shorter TTP, but also in those with longer TTP. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Seroprevalence of varicella-zoster virus antibodies after the recent introduction of the universal childhood immunisation schedule in the Community of Madrid].](https://www.ncbi.nlm.nih.gov/pubmed/26860417)\nGarc\u00eda-Comas, Luis; Ordob\u00e1s Gav\u00edn, Mar\u00eda; Sanz Moreno, Juan Carlos; Ramos Bl\u00e1zquez, Bel\u00e9n; Guti\u00e9rrez Rodr\u00edguez, M Angeles; Barranco Ord\u00f3\u00f1ez, Dolores\n2016-12-01\nIn November 2006, the Community of Madrid included the chickenpox vaccine into the immunisation schedule for children from 15 months of age. This was withdrawn in January 2014. Seroprevalence of antibodies to the virus is estimated after the first 2-3 years from the inclusion of the vaccine, and as well as its evolution since 1999. A cross-sectional study was conducted on the target population consisting of residents in the Community of Madrid between 2 and 60 years of age. Measurement of IgG antibodies was performed using an ELISA technique. Seroprevalence was estimated according to sociodemographic characteristics using multiple logistic regressions. The results are compared with previous surveys. Also, the seroprevalence and geometric mean of the antibody according immunisation status and history of the disease are presented. The confidence level used is 95%. A total of 4,378 subjects were included, with a response rate of 69%. The estimated seroprevalence was 95.3% (95% CI: 94.6% - 95.9%). Over 90% of children from the age of 10 have antibodies. The seroprevalence was higher in people with less education. The seroprevalence of immunity vaccine exceeds 90% in the first year after vaccination, but in the second year decreased to 82.6% (95% CI 56.0 - 94.7). Significant differences, attributable to universal vaccination, were found compared to previous surveys. Continued surveillance is needed in order to assess the impact of the withdrawal of the recommendation to vaccinate at 15 months. Copyright \u00c2\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Bibliometric analysis of the Spanish scientific production in Infectious Diseases and Microbiology].](https://www.ncbi.nlm.nih.gov/pubmed/26049175)\nRamos, Jos\u00e9 Manuel; Gonz\u00e1lez-Alcaide, Gregorio; Guti\u00e9rrez, F\u00e9lix\n2016-03-01\nThe bibliometric analysis of production and impact of documents by knowledge area is a quantitative and qualitative indicator of research activity in this field. The aim of this article is to determine the contribution of Spanish research institutions in Infectious Diseases and Microbiology in recent years. Documents published in the journals included in the categories \"Infectious Diseases\" and \"Microbiology\" of the Web of Science (Science Citation Index Expanded) of the ISI Web of Knowledge from the year 2000-2013 were analysed. In Infectious Diseases, Spain ranked fourth worldwide, and contributed 5.7% of the 233,771 documents published in this specialty. In Microbiology, Spain was in sixth place with a production rate of 5.8% of the 149,269 documents of this category. The Spanish production increased over the study period, both in Infectious Diseases and Microbiology, from 325 and 619 documents in 2000 to 756 and 1245 documents in 2013, with a growth rate of 131% and 45.8%, respectively. The journal with the largest number of documents published was Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica, with 8.6% and 8.2% of papers published in the categories of Infectious Diseases and Microbiology, respectively, and was the result of international collaborations, especially with institutions in the United States. The \"index h\" was 116 and 139 in Infectious Diseases and Microbiology, placing Spain in fifth place in both categories within countries of the European Union. In recent years, Spanish research in Infectious Diseases and Microbiology has reached a good level of production and international visibility, reaching a global leadership position. Copyright \u00a9 2015. Published by Elsevier Espa\u00f1a, S.L.U.\n[Vaccination coverage against pertussis in pregnant women of Catalonia in the first year of implementation of the immunisation program.](https://www.ncbi.nlm.nih.gov/pubmed/27769682)\nFern\u00e1ndez-Cano, Mar\u00eda Isabel; Espada-Trespalacios, Xavier; Reyes-Lacalle, Azahara; Manresa Dom\u00ednguez, Josep Maria; Armadans-Gil, Llu\u00eds; Campins-Mart\u00ed, Magda; Falguera-Puig, Gemma; Toran Monserrat, Pere\n2017-11-01\nThe re-emergence of pertussis and the severity of its complications in infants younger than 3 months, were determining factors for starting a vaccination program for pregnant women in the third trimester of gestation in Catalonia in February 2014. This was the first autonomous community to introduce it in Spain. The aim of the study was to estimate the coverage of the program in its first year of implementation. A retrospective analysis was performed on the data from the Primary Care Centre computerised medical records of pregnant women attending Sexual and Reproductive Health Care centres of the Metropolitan Nord area of the province of Barcelona, part of the Catalan Institute of Health. The overall coverage was estimated, as well as the sociodemographic variables of Tdap vaccination of women who had registered a delivery of a live birth between August 2014 and August 2015. A total of 6,697 deliveries of live births were recorded, and 1,713 pregnant women were vaccinated, which represented an overall coverage of 25.6% (95% CI; 24.1-26.1). Vaccination coverage was higher in pregnant women under 18 years and Spanish women (P=.018 and P=.036, respectively). The estimation of vaccine coverage against pertussis in pregnant women in the third trimester of pregnancy, after the first year of implementation of the program in a health area of Catalonia was lower than the objective set. Strategies need to be designed in order to improve program coverage. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Computerised sepsis protocol management. Description of an early warning system.](https://www.ncbi.nlm.nih.gov/pubmed/28087145)\nde Dios, Bego\u00f1a; Borges, Marcio; Smith, Timothy D; Del Castillo, Alberto; Socias, Antonia; Guti\u00e9rrez, Leticia; Nicol\u00e1s, Jordi; Llad\u00f3, Bartolom\u00e9; Roche, Jose A; D\u00edaz, Maria P; Llad\u00f3, Yolanda\n2018-02-01\nNew strategies need to be developed for the early recognition and rapid response for the management of sepsis. To achieve this purpose, the Multidisciplinary Sepsis Team (MST) developed the Computerised Sepsis Protocol Management (PIMIS). The aim of this study was to evaluate the convenience of using PIMIS, as well as the activity of the MST. An analysis was performed on the data collected from solicited MST consultations (direct activation of PIMIS by attending physician or telephone request) and unsolicited ones (by referral from the microbiology laboratory or an automatic referral via the hospital vital signs recording software [SIDCV]), as well as the hospital department, source of infection, treatment recommendation, and acceptance of this. Of the 1,581 first consultations, 65.1% were solicited consultations (84.1% activation of PIMIS and 15.9% by telephone). The majority of unsolicited consultations were generated by the microbiology laboratory (95.2%), and 4.8% from the SIDCV. Referral from solicited consultations were generated sooner (5.63days vs 8.47days; P<.001) and came from clinical specialties rather than from the surgical ward (73.0% vs 39.1%; P<.001). A recommendation was made for antimicrobial prescription change in 32% of first consultations. The treating physician accepted 78.1% of recommendations. The high rate of solicited consultations and acceptance of recommended prescription changes suggest that a MST is seen as a helpful resource, and that PIMIS software is perceived to be useful and convenient to use, as it is the main source of referral. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Dermatological manifestations in onchocerciasis: A retrospective study of 400 imported cases.](https://www.ncbi.nlm.nih.gov/pubmed/29275076)\nPuente, Sabino; Ramirez-Olivencia, German; Lago, Mar; Subirats, Mercedes; Perez-Blazquez, Eugenio; Bru, Fernando; Garate, Teresa; Vicente, Bel\u00e9n; Belhassen-Garcia, Moncef; Muro, Antonio\n2017-12-20\nOnchocerciasis is caused by Onchocerca volvulus and mainly leads to pruritus and skin and visual disorders, including blindness. Seventeen million people are infected in 38 countries; 31 of these are in sub-Saharan Africa, six in Latin America and one on the Arabian Peninsula. More than 99% of cases occur in sub-Saharan Africa where 120 million people are at risk of infection. Eye disorders have been well-documented; however, skin disorders have not been described accurately. The objective of our study was to describe the epidemiology, main skin manifestations and treatment of imported onchocerciasis. A retrospective study was thus conducted by analysing the main demographic, clinical and treatment data regarding a cohort of 400 patients attending a reference clinical unit over a 17-year period. Most patients were female (55%) with mean age 37.5\u00b116.7 years. All the migrants came from sub-Saharan countries. The most frequently occurring dermatological symptom was pruritus. Ivermectin had been used as first-line therapy and adverse reactions had been described in 11 patients (3.2%). The results indicate the fact that there should be a clinical suspicion of onchocerciasis regarding immigrants from endemic areas having skin lesions compatible with the disease's profile or asymptomatic patients having eosinophilia or unexplained high IgE. Moreover, skin snips from the buttocks region were very fruitful and treatment with ivermectin was seen to be safe. This is the largest case series regarding imported onchocerciasis described up to the present time. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Neural Tube Defects in Costa Rica, 1987\u20132012: Origins and Development of Birth Defect Surveillance and Folic Acid Fortification](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4539153)\nde la Paz Barboza-Arg\u00fcello, Mar\u00eda; Uma\u00f1a-Sol\u00eds, Lila M.; Azofeifa, Alejandro; Valencia, Diana; Flores, Alina L.; Rodr\u00edguez-Aguilar, Sara; Alfaro-Calvo, Thelma; Mulinare, Joseph\n2015-01-01\nOur aim was to provide a descriptive overview of how the birth defects surveillance and folic acid fortification programs were implemented in Costa Rica\u2014through the establishment of the Registry Center for Congenital Anomalies (Centro de Registro de Enfermedades Cong\u00e9nitas\u2014CREC), and fortification legislation mandates. We estimated the overall prevalence of neural tube defects (i.e., spina bifida, anencephaly and encephalocele) before and after fortification captured by CREC. Prevalence was calculated by dividing the total number of infants born with neural tube defects by the total number of live births in the country (1987\u20132012).A total of 1,170 newborns with neural tube defects were identified from 1987 to 2012 (1992\u20131995 data excluded); 628 were identified during the baseline pre-fortification period (1987\u20131991; 1996\u20131998); 191 during the fortification period (1999\u20132002); and 351 during the post-fortification time period (2003\u20132012). The overall prevalence of neural tube defects decreased from 9.8 per 10,000 live-births (95 % CI 9.1\u201310.5) for the pre-fortification period to 4.8 per 10,000 live births (95 % CI 4.3\u20135.3) for the post\u2013fortification period. Results indicate a statistically significant (P < 0.05) decrease of 51 % in the prevalence of neural tube defects from the pre-fortification period to the post-fortification period. Folic acid fortification via several basic food sources has shown to be a successful public health intervention for Costa Rica. Costa Rica\u2019s experience can serve as an example for other countries seeking to develop and strengthen both their birth defects surveillance and fortification programs. PMID:24952876\n[Executive summary of imported infectious diseases after returning from foreign travel: Consensus document of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC).](https://www.ncbi.nlm.nih.gov/pubmed/28396090)\nP\u00e9rez-Arellano, Jos\u00e9 Luis; G\u00f3rgolas-Hern\u00e1ndez-Mora, Miguel; Salvador, Fernando; Carranza-Rodr\u00edguez, Cristina; Ram\u00edrez-Olivencia, Germ\u00e1n; Mart\u00edn-Echeverr\u00eda, Esteban; Rodr\u00edguez-Guardado, Azucena; Norman, Francesca; Velasco-Tirado, Virginia; Zubero-Sulibarr\u00eda, Zuri\u00f1e; Rojo-Marcos, Gerardo; Mu\u00f1oz-Gutierrez, Jos\u00e9; Ramos-Rinc\u00f3n, Jos\u00e9 Manuel; S\u00e1nchez-Seco-Fari\u00f1as, M Paz; Velasco-Arribas, Mar\u00eda; Belhassen-Garc\u00eda, Moncef; Lago-Nu\u00f1ez, Mar; Ca\u00f1as Garc\u00eda-Otero, El\u00edas; L\u00f3pez-V\u00e9lez, Rogelio\n2018-03-01\nIn a global world, knowledge of imported infectious diseases is essential in daily practice, both for the microbiologist-parasitologist and the clinician who diagnoses and treats infectious diseases in returned travelers. Tropical and subtropical countries where there is a greater risk of contracting an infectious disease are among the most frequently visited tourist destinations. The SEIMC considers it appropriate to produce a consensus document that will be useful to primary care physicians as well as specialists in internal medicine, infectious diseases and tropical medicine who help treat travelers returning from tropical and sub-tropical areas with infections. Preventive aspects of infectious diseases and infections imported by immigrants are explicitly excluded here, since they have been dealt with in other SEIMC documents. Various types of professionals (clinicians, microbiologists, and parasitologists) have helped produce this consensus document by evaluating the available evidence-based data in order to propose a series of key facts about individual aspects of the topic. The first section of the document is a summary of some of the general aspects concerning the general assessment of travelers who return home with potential infections. The main second section contains the key facts (causative agents, diagnostic procedures and therapeutic measures) associated with the major infectious syndromes affecting returned travelers [gastrointestinal syndrome (acute or persistent diarrhea); febrile syndrome with no obvious source of infection; localized cutaneous lesions; and respiratory infections]. Finally, the characteristics of special traveler subtypes, such as pregnant women and immunocompromised travelers, are described. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Perspective of Spanish medical students regarding undergraduate education in infectious diseases, bacterial resistance and antibiotic use.](https://www.ncbi.nlm.nih.gov/pubmed/29429753)\nS\u00e1nchez-Fabra, David; Dyar, Oliver J; Del Pozo, Jos\u00e9 Luis; Amiguet, Juan Antonio; Colmenero, Juan de Dios; Fari\u00f1as, Mar\u00eda Del Carmen; L\u00f3pez-Medrano, Francisco; Portilla, Joaqu\u00edn; Praena, Julia; Torre-Cisneros, Juli\u00e1n; Rodr\u00edguez-Ba\u00f1o, Jes\u00fas; Pulcini, C\u00e9line; Pa\u00f1o-Pardo, Jos\u00e9 Ram\u00f3n\n2018-02-08\nOne of the main tools to optimize antibiotics use is education of prescribers. The aim of this article is to study undergraduate education in the field of infectious diseases, antimicrobial resistance and antibiotic stewardship from the perspective of Spanish medical students. An anonymous online questionnaire was distributed among sixth grade students using different channels in Europe, within the ESGAP Student-Prepare survey. The questionnaire included 45 questions about knowledge, attitudes and perceptions about diagnosis, bacterial resistance, use of antibiotics and undergraduate training in infectious diseases. We present here the Spanish results. A total of 441 surveys were received from 21 medical schools. A total of 374 responses (84.8%) were obtained from the 8 most represented faculties, with a response rate of 28.9%. Most students felt adequately prepared to identify clinical signs of infection (418; 94.8%) and to accurately interpret laboratory tests (382; 86.6%). A total of 178 (40.4%) acknowledged being able to choose an antibiotic with confidence without consulting books or guidelines. Only 107 (24.3%) students considered that they had received sufficient training in judicious use of antibiotics. Regarding learning methods, the discussion of clinical cases, infectious diseases units rotatories and small group workshops were considered the most useful, being evaluated favorably in 76.9%, 76% and 68.8% of the cases. Medical students feel more confident in the diagnosis of infectious diseases than in antibiotic treatment. They also feel the need to receive more training in antibiotics and judicious antibiotic use. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Identification of mycobacteria to the species level by molecular methods in the Public Health Laboratory of Bogot\u00e1, Colombia].](https://www.ncbi.nlm.nih.gov/pubmed/25888362)\nHern\u00e1ndez-Toloza, Johana Esther; Rinc\u00f3n-Serrano, Mar\u00eda de Pilar; Celis-Bustos, Yamile Adriana; Aguill\u00f3n, Claudia In\u00e9s\n2016-01-01\nGlobal epidemiology of non-tuberculous mycobacteria (NTM) is unknown due to the fact that notification is not required in many countries, however the number of infection reports and outbreaks caused by NTM suggest a significant increase in the last years. Traditionally, mycobacteria identification is made through biochemical profiles which allow to differentiate M. tuberculosis from NTM, and in some cases the mycobacteria species. Nevertheless, these methods are technically cumbersome and time consuming. On the other hand, the introduction of methods based on molecular biology has improved the laboratory diagnosis of NTM. To establish the NTM frequency in positive cultures for acid-fast bacilli (AAFB) which were sent to Laboratorio de Salud P\u00fablica de Bogot\u00e1 over a 12 month period. A total of 100 positive cultures for acid-fast bacilli from public and private hospitals from Bogot\u00e1 were identified by both biochemical methods and the molecular methods PRA (PCR-restriction enzyme analysis) and multiplex-PCR. Furthermore, low prevalence mycobacteria species and non-interpretable results were confirmed by 16SrDNA sequentiation analysis. Identification using the PRA method showed NMT occurrence in 11% of cultures. In addition, this molecular methodology allowed to detect the occurrence of more than one mycobacteria in 4% of the cultures. Interestingly, a new M. kubicae pattern of PCR-restriction analysis is reported in our study. Using a mycobacteria identification algorithm, which includes the molecular method PRA, improves the diagnostic power of conventional methods and could help to advance both NTM epidemiology knowledge and mycobacteriosis control. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Group B streptococcal early-onset neonatal sepsis in the area of Barcelona (2004-2010). Analysis of missed opportunities for prevention].](https://www.ncbi.nlm.nih.gov/pubmed/25541009)\nGim\u00e9nez, Montserrat; Sanfeliu, Isabel; Sierra, Montserrat; Dopico, Eva; Juncosa, Teresa; Andreu, Antonia; Lite, Josep; Guardi\u00e0, C\u00e8lia; S\u00e1nchez, Ferran; Bosch, Jordi\n2015-01-01\nTo study the evolution of the incidence of early-onset neonatal sepsis (EOS) by Streptococcus agalactiae in the area of Barcelona and to analyze failure of compliance with the prevention protocol. A retrospective review was carried out on EOS cases in 8 Health-Care Centers in the Barcelona area between 2004 and 2010. Forty-nine newborns from 48 mothers were diagnosed with EOS. The incidence was 0.29\u2030 living newborns (0.18-0.47\u2030), with no significant differences in the fluctuations along the 7 years. The mortality rate was 8.16%. In 68.5% cases the maternal colonization studies were negative, and in 21% these studies were not performed. No risk factors were detected in 58.3% of pregnant women, and 22.9% of births were premature. In 58% of cases intra-partum antibiotic prophylaxis was not administered because it was not indicated, and in 42% due to failure to follow the protocol (3 strains were resistant to erythromycin). Resistance to clindamycin was 33.3%. The Streptococcus agalactiae serotypes more frequently isolated were iii, v, and ia. No significant changes were detected in the incidence of Streptococcus agalactiae EOS in the 7 years of the study. The increased sensitivity of screening methods with the use of molecular techniques, the performance of susceptibility testing of strains isolated from pregnant women, and the improvement of communication between Health-Care Centers, can contribute to a better implementation of the protocol, as well as to reduce the incidence of EOS. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Prevalence of anal infection due to high-risk human papillomavirus and analysis of E2 gene integrity among women with cervical abnormalities.](https://www.ncbi.nlm.nih.gov/pubmed/28069334)\nGonzalez-Losa, Mar\u00eda Del Refugio; Puerto-Sol\u00eds, Marylin; Ayora-Talavera, Guadalupe; G\u00f3mez-Carvallo, Jes\u00fas; Eu\u00e1n-L\u00f3pez, Alejandra; Cisneros-Cutz, Jos\u00e9 I; Rosado-L\u00f3pez, Ariel; Echeverr\u00eda Salazar, Jes\u00faa; Conde-Ferr\u00e1ez, Laura\n2018-04-01\nHigh-risk human papillomaviruses (HR-HPV) infection has been associated with 90% of anal cancer cases. Women with abnormal cytology are a high-risk group to develop anal neoplasia. The aim of this study is to describe the prevalence and epidemiology of HR-HPV 16, 18, 45, and 58 anal infections in women with cervical abnormalities, as well as to assess E2 gene integrity. A cross-sectional study was performed on 311 cervical and 311 anal samples from patients with abnormal cytology in two colposcopy clinics in Yucatan, Mexico. A specific PCR for oncogenes was performed in order to identify HVP 16, 18, 45 and 58. Real time PCR was used to amplify the whole HPV 16, 18, and 58 E2 gene to verify its integrity in anal samples. High risk HPV 16, 18, 58, and/or 45 were found in 41.47% (129/311) of cervical samples, and in 30.8% (96/331) of anal samples, with 18% (57/311) of the patients being positive in both samples. The same genotypes in both anatomical sites were observed in 11.25% (35/311). The E2 gene was disrupted in 82% of all tested samples. The frequency of genome disruption viral integration in anal samples by genotype was: HPV 58 (97.2%); HPV 16 (72.4%), and HPV 18 (0%). Women with cervical disease have HR-HPV anal infections, and most of them have the E2 gene disrupted, which represents a risk to develop anal cancer. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Community-acquired febrile urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria in hospitalised infants.](https://www.ncbi.nlm.nih.gov/pubmed/26976379)\nHern\u00e1ndez Marco, Roberto; Guill\u00e9n Olmos, Elena; Bret\u00f3n-Mart\u00ednez, Jos\u00e9 Rafael; Giner P\u00e9rez, Lourdes; Casado S\u00e1nchez, Benedicta; Fujkova, Julia; Salamanca Campos, Marina; Nogueira Coito, Jos\u00e9 Miguel\n2017-05-01\nExtended-spectrum beta-lactamase (ESBL) producing bacteria are infrequent pathogens of urinary tract infections in children. The objective of our study was to investigate the presence, clinically associated characteristics and risk factors for acquisition of urinary tract infection/acute pyelonephritis (UTI/APN) in hospitalised children <2years old caused by community-acquired ESBL. A case-control study in a second level community hospital in Spain, in which 537 episodes of UTI/APN were investigated in a retrospective study between November 2005 and August 2014. Cases were patients with ESBL strains. For each case, four ESBL-negative controls were selected. A questionnaire with the variables of interest was completed for every patient, and the groups were compared. ESBL-positive strains were found in 19 (3,5%) cultures. Of these 16 (84%) were Escherichia coli. Vesicoureteral reflux (VUR) of any grade was more frequent in the ESBL group (60 vs. 29%), although without statistical significance. Relapses were more frequent in the ESBL group (42% vs. 18%) (P=.029; OR=3.2; 95%CI: 1.09-9.5). The prevalence of UTI/APN due to ESBL-positive strains increased slightly from 2.7% in the period 2005-2009 to 4.4% in the period 2010-2014. ESBL UTI/APN were associated with more frequent relapses. VUR of any grade was twice more frequent in the ESBL group. Piperacillin/tazobactam, fosfomycin and meropenem showed an excellent activity. Aminoglycosides may be a therapeutic option, and in our patients gentamicin was the antibiotic most used. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Neural tube defects in Costa Rica, 1987-2012: origins and development of birth defect surveillance and folic acid fortification.](https://www.ncbi.nlm.nih.gov/pubmed/24952876)\nBarboza-Arg\u00fcello, Mar\u00eda de la Paz; Uma\u00f1a-Sol\u00eds, Lila M; Azofeifa, Alejandro; Valencia, Diana; Flores, Alina L; Rodr\u00edguez-Aguilar, Sara; Alfaro-Calvo, Thelma; Mulinare, Joseph\n2015-03-01\nOur aim was to provide a descriptive overview of how the birth defects surveillance and folic acid fortification programs were implemented in Costa Rica-through the establishment of the Registry Center for Congenital Anomalies (Centro de Registro de Enfermedades Cong\u00e9nitas-CREC), and fortification legislation mandates. We estimated the overall prevalence of neural tube defects (i.e., spina bifida, anencephaly and encephalocele) before and after fortification captured by CREC. Prevalence was calculated by dividing the total number of infants born with neural tube defects by the total number of live births in the country (1987-2012).A total of 1,170 newborns with neural tube defects were identified from 1987 to 2012 (1992-1995 data excluded); 628 were identified during the baseline pre-fortification period (1987-1991; 1996-1998); 191 during the fortification period (1999-2002); and 351 during the post-fortification time period (2003-2012). The overall prevalence of neural tube defects decreased from 9.8 per 10,000 live-births (95 % CI 9.1-10.5) for the pre-fortification period to 4.8 per 10,000 live births (95 % CI 4.3-5.3) for the post-fortification period. Results indicate a statistically significant (P < 0.05) decrease of 51 % in the prevalence of neural tube defects from the pre-fortification period to the post-fortification period. Folic acid fortification via several basic food sources has shown to be a successful public health intervention for Costa Rica. Costa Rica's experience can serve as an example for other countries seeking to develop and strengthen both their birth defects surveillance and fortification programs.\n[[Consensus statement on monitoring of HIV: pregnancy, birth, and prevention of mother-to-child transmission].](https://www.ncbi.nlm.nih.gov/pubmed/24484733)\nPolo Rodr\u00edguez, Rosa; Mu\u00f1oz Galligo, Eloy; Iribarren, Jos\u00e9 Antonio; Domingo Pedrol, Pere; Leyes Garc\u00eda, Mar\u00eda; Maiques Montesinos, Vicente; Miralles Mart\u00edn, Pilar; Noguera Julian, Antoni; Ocampo Hern\u00e1ndez, Antonio; P\u00e9res Bares, Mar\u00eda Lourdes; L\u00f3pez Rojano, Marta; Suy Franch, Anna; Vi\u00f1uela Beneitez, Mar\u00eda Carmen; Gonz\u00e1lez Tom\u00e9, Mar\u00eda Isabel\n2014-05-01\nThe main objective in the management of HIV-infected pregnant women is prevention of mother-to-child transmission; therefore, it is essential to provide universal antiretroviral treatment, regardless of CD4 count. All pregnant women must receive adequate information and undergo HIV serology testing at the first visit. We assembled a panel of experts appointed by the Secretariat of the National AIDS Plan (SPNS) and the other participating Scientific Societies, which included internal medicine physicians with expertise in the field of HIV infection, gynecologists, pediatricians and psychologists. Four panel members acted as coordinators. Scientific information was reviewed in publications and conference reports up to November 2012. In keeping with the criteria of the Infectious Diseases Society of America, 2levels of evidence were applied to support the proposed recommendations: the strength of the recommendation according to expert opinion (A, B, C), and the level of empirical evidence (I, II, III). This approach has already been used in previous documents from SPNS. The aim of this paper was to review current scientific knowledge, and, accordingly, develop a set of recommendations regarding antiretroviral therapy (ART), regarding the health of the mother, and from the perspective of minimizing mother-to-child transmission (MTCT), also taking into account the rest of the health care of pregnant women with HIV infection. We also discuss and evaluate other strategies to reduce the MTCT (elective Cesarean, child's treatment\u2026), and different aspects of the topic (ARV regimens, their toxicity, monitoring during pregnancy and postpartum, etc.). Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Predictive factors of bacterial meningitis in the patients seen in emergency departments.](https://www.ncbi.nlm.nih.gov/pubmed/26994813)\nMorales-Casado, Mar\u00eda Isabel; Juli\u00e1n-Jim\u00e9nez, Agust\u00edn; Lobato-Casado, Paula; C\u00e1mara-Mar\u00edn, Bel\u00e9n; P\u00e9rez-Matos, Julio Alberto; Mart\u00ednez-Maroto, Tamara\n2017-04-01\nTo analyse and compare predictive factors of bacterial meningitis in the patients seen in the Emergency Departments (ED) due to an episode of acute meningitis (AM). A prospective, observational study was carried out in patients aged 15 years and older seen in ED due to AM between August 2009 and November 2015. Thirty-two variables for predicting bacterial meningitis were assessed. They covered epidemiological, comorbidity, clinical and analytical factors. Multivariate logistic regression analysis was performed. The study included 154 patients. The diagnosis was bacterial meningitis in 53 (34.4%) patients. Four variables were significantly associated with bacterial aetiology: cerebrospinal fluid (CSF) lactate concentration \u226533mg/dl (odds ratio [OR] 50.84; 95% confidence interval [CI]: 21.63-119.47, P<.001), serum procalcitonin (PCT) \u22650.8ng/ml (OR 46.34; 95%CI: 19.71-108.89; P<.001), CSF glucose <60% of blood value (OR 20.82; 95%CI: 8.86-48.96; P=.001), CSF polymorphonuclears greater than 50% (OR 20.19; 95%CI: 8.31-49.09; P=.002]. The area under the curve for the model serum PCT\u22650.8ng/ml plus CSF lactate \u226533mg/dl was 0.992 (95%CI: 0.979-1; P<.001), and achieved 99% sensitivity and 98% specificity for predicting bacterial meningitis. Serum PCT with CSF lactate, CSF glucose and CSF polymorphonuclears evaluated in an initial assessment in the ED for patients with AM, achieved an excellent diagnostic usefulness for predicting bacterial meningitis. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Evaluation of an antibody avidity index method for detecting recent human immunodeficiency virus type 1 infection using an automated chemiluminescence immunoassay.](https://www.ncbi.nlm.nih.gov/pubmed/25060663)\nFern\u00e1ndez, Gema; Manzardo, Christian; Montoliu, Alexandra; Campbell, Colin; Fern\u00e1ndez, Gregorio; Casabona, Jordi; Mir\u00f3, Jos\u00e9 Maria; Matas, Lurdes; Rivaya, Bel\u00e9n; Gonz\u00e1lez, Victoria\n2015-04-01\nRecent infection testing algorithms (RITAs) are used in public health surveillance to estimate the incidence of recently acquired HIV-1 infection. Our aims were (i) to evaluate the precision of the VITROS\u00ae Anti-HIV 1+2 automated antibody avidity assay for qualitative detection of antibodies to HIV 1+2 virus; (ii) to validate the accuracy of an automated guanidine-based antibody avidity assay to discriminate between recent and long standing infections using the VITROS 3600 platform; (iii) to compare this method with BED-CEIA assay; and (iv) to evaluate the occurrence of false recent misclassifications by the VITROS antibody avidity assay in patients with a CD4 count <200 cells/\u03bcL and in patients on combination antiretroviral therapy (cART). The VITROS\u00ae antibody avidity assay is highly reproducible. The ROC curve analysis of the accuracy of this assay, optimized for sensitivity and specificity, had an AI cut off of \u22640.51, with sensitivity and specificity values of 86.67% (95% CI: 72.51-94.46) and 86.24% (95% CI: 78.00-91.84), respectively. The agreement between VITROS antibody avidity and BED-CEIA assays was good. Misclassifications of long standing infections as recent infection occurred in 8.2% of patients with CD4 <200 cell/\u03bcL and 8.7% in patients on combination antiretroviral therapy. The VITROS antibody avidity assay is a reliable serological method to detect recent HIV-1 infections and it could be incorporated into a RITA to estimate HIV incidence. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Use of procalcitonin and C-reactive protein as infection markers in febrile neutropenic patients undergoing haematopoietic stem cell transplant].](https://www.ncbi.nlm.nih.gov/pubmed/24269102)\nS\u00e1nchez-Yepes, Marina; Aznar-Oroval, Eduardo; Lorente-Alegre, Pablo; Garc\u00eda-Lozano, Tom\u00e1s; Pic\u00f3n-Roig, Isabel; P\u00e9rez-Ballestero, Pilar; Ortiz-Mu\u00f1oz, Blanca\n2014-01-01\nNeutropenia is a frequent sign in patients who are going to have a haematopoietic stem cell transplant (HSCT). Infection is an important complication in these patients, which is favoured by immunosuppression and the degree of neutropenia. This study aims to evaluate the diagnostic usefulness of procalcitonin (PCT) and C-reactive protein (CRP) in onco-haematological patients undergoing chemotherapy and HSCT to determine the origin of the fever. PCT and CRP values were measured in 30 episodes of febrile neutropenia: before starting chemotherapy, appearance of neutropenia, onset of fever, days 1, 2, 3 and 6 after the onset of fever, and when the febrile episode ended. The episodes were classified as 5 bacteraemia, 3 microbiologically documented infections, 10 clinical infections, and 12 fevers of unknown origin. The highest PCT mean values corresponded to the group of patients with bacteraemia. Statistically significant differences (P=.04) were found on the second day after the onset of fever. The cut-off point of 0.5ng/ml showed a sensitivity of 66% and a specificity of 75%. PCR results showed statistically significant differences on days 1, 2 and 3 after the onset of fever (P=.01, P=.003, and P=.002, respectively). The cut-off point of 7.5mg/L had a sensitivity of 88% and a specificity of 58%. The combination of PCT and CRP is an insufficient method to detect bacterial infections and may not replace the proper clinical and microbiological diagnosis. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Can we rely on the antiretroviral treatment as the only means for human immunodeficiency virusprevention? A Public Health perspective.](https://www.ncbi.nlm.nih.gov/pubmed/25444036)\nMozalevskis, Antons; Manzanares-Laya, Sandra; Garc\u00eda de Olalla, Patricia; Moreno, Antonio; Jacques-Avi\u00f1\u00f3, Constanza; Cayl\u00e0, Joan A\n2015-11-01\nThe evidence that supports the preventive effect of combination antiretroviral treatment (cART) in HIV sexual transmission suggested the so-called 'treatment as prevention' (TAP) strategy as a promising tool for slowing down HIV transmission. As the messages and attitudes towards condom use in the context of TAP appear to be somehow confusing, the aim here is to assess whether relying on cART alone to prevent HIV transmission can currently be recommended from the Public Health perspective. A review is made of the literature on the effects of TAP strategy on HIV transmission and the epidemiology of other sexual transmitted infections (STIs) in the cART era, and recommendations from Public Health institutions on the TAP as of February 2014. The evolution of HIV and other STIs in Barcelona from 2007 to 2012 has also been analysed. Given that the widespread use of cART has coincided with an increasing incidence of HIV and other STIs, mainly amongst men who have sex with men, a combination and diversified prevention methods should always be considered and recommended in counselling. An informed decision on whether to stop using condoms should only be made by partners within stable couples, and after receiving all the up-to-date information regarding TAP. From the public health perspective, primary prevention should be a priority; therefore relying on cART alone is not a sufficient strategy to prevent new HIV and other STIs. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Examining adherence among challenging patients in public and private HIV care in Argentina](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4553072)\nJones, Deborah; Cook, Ryan; Cecchini, Diego; Sued, Omar; Bofill, Lina; Weiss, Stephen; Waldrop-Valverde, Drenna; Lopez, Maria R; Spence, Andrew\n2015-01-01\n\u00fablica. La autoeficacia estaba asociada con mejor adherencia en los pacientes en las dos cl\u00ednicas. Los resultados indican que son necesarias intervenciones en pacientes y m\u00e9dicos para mejorar adherencia, compromiso y retenci\u00f3n en el cuidado tanto en cl\u00ednicas p\u00fablicas como privadas. PMID:25777507\n[Social Representations of Gynecologic Cancer Screening Assessment a Qualitative research on Ecuadorian women.](https://www.ncbi.nlm.nih.gov/pubmed/27384278)\nGodoy, Yolanda; Godoy, Clara; Reyes, Juan\n2016-06-01\nThe purpose of this work was to explore: knowledge, attitudes, and beliefs regarding gynecologic cancer screening on Ecuadorian women users of primary care facilities, to identify the social representations that users of health services make about these programs and their influence on the decision to undergo a screening. An exploratory and qualitative research design was held using focus groups and in-depth interviews for data collection. A narrative content analysis of the results was conducted. Women's knowledge on gynecological cancer screening was confusing. Most frequent misconceptions related to the pap smear were: the belief that it could be useful for detecting pregnancy, ovarian cysts or infections. Most of the participants stated that the pap smear procedure is a traumatic and painful experience. Regarding to mammography women said it was used for sick woman and this procedure by itself may cause cancer. El prop\u00f3sito de esta investigaci\u00f3n fue explorar los conocimientos, actitudes y creencias respecto a los programas de detecci\u00f3n del c\u00e1ncer ginecol\u00f3gico entre usuarias de centros de atenci\u00f3n primaria de salud para identificar las representaciones sociales que las usuarias de los servicios de salud elaboran acerca de estos programas y de los diferentes procedimientos que comprenden. El dise\u00f1o de la investigaci\u00f3n fue exploratorio y cualitativo, mediante grupos focales y entrevistas a profundidad, con el respectivo an\u00e1lisis narrativo e interpretativo del contenido. Se encontr\u00f3 conocimiento confuso acerca de los programas de tamizaje de c\u00e1ncer ginecol\u00f3gico y dificultades asociadas a la realizaci\u00f3n de los procedimientos. Los significados m\u00e1s frecuentes acerca de los programas fueron: el uso de la citolog\u00eda c\u00e9rvico-vaginal para detectar embarazo, quistes ov\u00e1ricos o infecciones. La mayor\u00eda de los participantes asociaba este procedimiento con una experiencia dolorosa y traum\u00e1tica. Respecto al autoexamen de mamas, lo calificaron como un masaje\n[Prevention of sexually transmitted diseases among visually impaired people: educational text validation.](https://www.ncbi.nlm.nih.gov/pubmed/27556880)\nOliveira, Giselly Oseni Barbosa; Cavalcante, Luana Duarte Wanderley; Pagliuca, Lorita Marlena Freitag; Almeida, Paulo C\u00e9sar de; Rebou\u00e7as, Cristiana Brasil de Almeida\n2016-08-18\nreformulado de acordo com as sugest\u00f5es relevantes. o texto foi validado com rela\u00e7\u00e3o ao conte\u00fado das Doen\u00e7as Sexualmente Transmiss\u00edveis. Ao total, 35 estrofes foram removidos e outros nove inclu\u00eddos, seguindo as recomenda\u00e7\u00f5es dos especialistas. educativo en el contexto de las enfermedades de trasmisi\u00f3n sexual para personas con deficiencia visual para hacerlo accesible a esa poblaci\u00f3n. un estudio de validaci\u00f3n en ambiente virtual. Recolecta de datos de mayo a septiembre de 2012 mediante la utilizaci\u00f3n de los correos electr\u00f3nicos de los sujetos, compuestos por siete especialistas en contenido en el tema, a trav\u00e9s de instrumento propio. El an\u00e1lisis fue basado en las consideraciones de los especialistas sobre los Objetivos, Estructura y Presentaci\u00f3n y Relevancia. en los bloques de Objetivos y Estructura y Presentaci\u00f3n, 77 (84,6%) y 48 (85,7%) eran totalmente adecuados o adecuados, respectivamente. En el bloque de Relevancia, los \u00edtems 3.2 - Permite transferencia y generalizaci\u00f3n del aprendizaje, y 3.5 - Muestra aspectos necesarios para informar la familia, revelaron \u00edndices de concordancia malos de 0,42 y 0,57, respectivamente. Despu\u00e9s del an\u00e1lisis, el texto fue reformulado de acuerdo con las sugestiones relevantes. el texto fue validado respecto al contenido de las enfermedades de trasmisi\u00f3n sexual. Al total, 35 estrofas fueron removidas y otros nueve incluidas, siguiendo las recomendaciones de los especialistas.\n[Labeling and defining severe and enduring anorexia nervosa: A systematic review and critical analysis.](https://www.ncbi.nlm.nih.gov/pubmed/28444828)\nBroomfield, Catherine; Stedal, Kristin; Touyz, Stephen; Rhodes, Paul\n2017-06-01\nreclutamiento de participantes cuando se investiga esta muestra, y segundo, el diagn\u00f3stico equivocado de pacientes que pueden o no tener un curso duradero de la enfermedad. La presente investigaci\u00f3n tiene el prop\u00f3sito de proporcionar una visi\u00f3n general de las etiquetas actuales y los criterios utilizados para definir los casos de AN severa y duradera, y analizar cr\u00edticamente las implicaciones de estos hallazgos. M\u00e9todo: De acuerdo con las gu\u00edas PRISMA, se realiz\u00f3 una b\u00fasqueda en la literatura utilizando cuatro bases de datos electr\u00f3nicas (PsycINFO, MEDLINE, Web of Science y Scopus) para identificar 32 art\u00edculos que cumpl\u00edan con los est\u00e1ndares estipulados por los criterios. La extracci\u00f3n de datos incluy\u00f3 el etiquetado expl\u00edcito, la definici\u00f3n o criterio utilizado para describir este subgrupo, junto con la edad del participante y el dise\u00f1o del estudio. Resultados: Se encontr\u00f3 que los t\u00e9rminos cr\u00f3nico, severo y duradero eran los adjetivos m\u00e1s com\u00fanmente utilizados cuando se refer\u00edan a este subgrupo. En t\u00e9rminos de criterios, la duraci\u00f3n de la enfermedad y el n\u00famero de intentos de tratamiento previamente fallidos fueron las caracter\u00edsticas definitorias m\u00e1s comunes dentro de la literatura. Discusi\u00f3n: Uno de los objetivos de los autores es inspirar a que se realice m\u00e1s investigaci\u00f3n en torno a cu\u00e1l ser\u00eda el etiquetado y la definici\u00f3n m\u00e1s apropiados para este subgrupo y as\u00ed facilitar un mejor abordaje y resultados para los individuos afectados. \u00a9 2017 Wiley Periodicals, Inc.\n[Meta-analysis of theory of mind in anorexia nervosa and bulimia nervosa: A specific \u0130mpairment of cognitive perspective taking in anorexia nervosa?](https://www.ncbi.nlm.nih.gov/pubmed/27425037)\nBora, Emre; K\u00f6se, Sezen\n2016-08-01\nDeficits in theory of mind (ToM), ability to infer mental states of others, can play a significant role in interpersonal difficulties and/or unawareness of illness observed in AN and other eating disorders including bulimia Nervosa (BN). Current meta-analysis aimed to summarize available evidence for deficits in ToM in AN and BN and examine the effects of number of study-level variables on observed findings. In this meta-analysis, 15 studies (22 samples with eating disorders) investigating ToM performances of 677 individuals with AN or BN and 514 healthy controls were included. AN was associated with significant deficits in ToM (d = 0.59) which were more pronounced in the acute patients (d = 0.67). Small sized deficits in ToM were observed in BN (d = 0.34) and recovered AN (d = 0.35). Both cognitive perspective-taking (ToM-PT) (d = 0.99) and decoding mental states (ToM-decoding) (d = 0.61) aspects of ToM were impaired in acute AN. ToM-decoding impairment in BN was modest. There was no evidence for significant ToM-PT deficit in BN. Several study-level variables including longer duration of illness, lower BMI, and depressive symptoms were associated with more severe deficits in ToM in AN. ToM deficits, particularly in ToM-PT, can be a specific feature of AN but not BN. ToM impairment can contribute to poor insight, treatment resistance, and social impairment in AN. \u00a9 2016 Wiley Periodicals, Inc. RESUMEN META AN\u00c1LISIS DE LA TEOR\u00cdA DE LA MENTE EN ANOREXIA NERVOSA Y BULIMIA NERVOSA: \u00bfUn deterioro de la toma de perspectiva cognitiva en Anorexia Nervosa? Las deficiencias en la teor\u00eda de la mente (ToM), la habilidad parar inferir los estados mentales de otros, pueden jugar una funci\u00f3n significativa en las dificultades interpersonales y/o falta de reconocimiento de la enfermedad observada en Anorexia Nervosa (AN) y otros trastornos de la conducta alimentaria incluyendo la Bulimia Nervosa (BN). Los meta an\u00e1lisis actuales dirigidos a resumir la\n[In vitro activity of a polyhexanide-betaine solution against high-risk clones of multidrug-resistant nosocomial pathogens.](https://www.ncbi.nlm.nih.gov/pubmed/27004429)\nL\u00f3pez-Rojas, Rafael; Fern\u00e1ndez-Cuenca, Felipe; Serrano-Rocha, Lara; Pascual, \u00c1lvaro\n2017-01-01\nTo determine the in vitro activity of a polyhexanide-betaine solution against collection strains and multidrug-resistant (MDR) nosocomial isolates, including high-risk clones. We studied of 8 ATCC and 21 MDR clinical strains of Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, including the multiresistant high-risk clones. The MICs and MBCs of a 0.1% polyhexanide-0.1% betaine solution were determined by microdilution. For each species, strains with the highest MICs were selected for further experiments. The dilution-neutralization test (PrEN 12054) was performed by incubating bacterial inocula of 10 6 CFU/mL for 1min with undiluted 0.1% polyhexanide-betaine solution. The CFUs were counted after neutralization. Growth curves and time-kill curves at concentrations of 0.25, 1, 4, and 8\u00d7MIC, were performed. MICs of recovered strains were determined when regrowth was observed in time-kill studies after 24h of incubation. Strains with reduced susceptibility were selected by serial passage on plates with increasing concentrations of polyhexanide-betaine, and MICs were determined. Polyhexanide-betaine MIC range was 0.5-8mg/L. MBCs equalled or were 1 dilution higher than MICs. The dilution-neutralization method showed total inoculum clearance of all strains. In time-kill curves, no regrowth was observed at 4\u00d7MIC, except for S. aureus (8\u00d7MIC). Increased MICs were not observed in time-kill curves, or after serial passages after exposure to polyhexanide-betaine. Polyhexanide-betaine presented bactericidal activity against all MDR clinical isolates tested, including high-risk clones, at significantly lower concentrations and time of activity than those commercially used. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nSan Mauro-Mart\u00edn, Ismael; Collado-Yurrita, Luis; Blumenfeld-Olivares, Javier Andr\u00e9s; Cuadrado-Cenzual, Mar\u00eda \u00c1ngeles; Calle-Pur\u00f3n, Mar\u00eda Elisa; Hern\u00e1ndez-Cabria, Marta; Garicano-Vilar, Elena; P\u00e9rez-Arruche, Eva; Arce-Delgado, Esperanza; CiudadCaba\u00f1as, Mar\u00eda Jos\u00e9\n2016-06-30\nIntroducci\u00f3n: la hipercolesterolemia es uno de los principales factores de riesgo en la enfermedad cardiovascular. Los esteroles vegetales se han postulado como agentes reguladores y beneficiosos para el control de esta.Objetivo: analizar el efecto de los esteroles vegetales a\u00f1adidos en una leche en la reducci\u00f3n del colesterol plasm\u00e1tico en adultos j\u00f3venes.M\u00e9todos: ensayo cl\u00ednico, controlado, aleatorizado, doble ciego y cruzado. Los esteroles (2,24 g diarios) fueron administrados en dos tomas de 350 ml de una leche comercial desnatada, durante dos periodos de 3 semanas, separados por una \"fase de lavado\" de 2 semanas, en el grupo experimental. Al grupo control se le administr\u00f3 la misma cantidad de leche desnatada, sin esteroles. Tanto al inicio como al final de cadaperiodo de intervenci\u00f3n se extrajeron muestras sangu\u00edneas. Se analizaron la composici\u00f3n corporal, h\u00e1bitos de salud y los siguientes marcadores sangu\u00edneos: perfil lip\u00eddico, hematol\u00f3gico, inflamaci\u00f3n, etc.Resultados: se incluyeron 54 personas en el estudio con una edad media de 38,8 \u00b1 7,3 a\u00f1os. La diferencia porcentual entre los marcadores basales y finales para el colesterol total, colesterol-LDL, colesterol-HDL, triglic\u00e9ridos y colesterol no-HDL fueron del 9,73%, 12,5%, 1,9%, 3,15% y 13,2%, respectivamente. Se obtuvieron diferencias estad\u00edsticamente significativas entre el grupo experimental y el grupo control, para todos los marcadores analizados excepto para los triglic\u00e9ridos.Conclusi\u00f3n: los esteroles vegetales suministrados en un alimento de consumo habitual, como la leche, pueden ser una estrategia terap\u00e9utica no farmacol\u00f3gica para el control de la hipercolesterolemia de alto inter\u00e9s sanitario.\n[['Third day intervention': an analysis of the factors associated with following the recommendations on the prescribing of antibiotics].](https://www.ncbi.nlm.nih.gov/pubmed/24813928)\nGarc\u00eda-San Miguel, Luc\u00eda; Cobo, Javier; Mart\u00ednez, Jos\u00e9 Antonio; Arnau, Josep Maria; Murillas, Javier; Pe\u00f1a, Carmen; Segura, Ferran; Gurgu\u00ed, Montserrat; G\u00e1lvez, Juan; Gim\u00e9nez, Montserrat; Gudiol, Francesc\n2014-12-01\nStewardship programs on the use of antibiotics usually include interventions based on non-compulsory recommendations for the prescribers. Factors related to the adherence to expert recommendations, and the implementation of these programmes in daily practice, are of interest. A randomized, controlled, multicentre intervention study was performed in 32 hospitalization units. Antibiotic prescriptions were evaluated by an infectious disease specialist on the third day. We describe the implementation of the intervention, the factors associated with adherence to recommendations, and the impact of the intervention. A total of 3,192 interventions were carried out. Information sources used to prepare the recommendations varied significantly between centres. A modification was recommended in 65% of cases: withdrawal (47%), change in administration route (26%), change of drugs or number of antibiotics (27%), and change in dose (5%). Simplification of treatment accounted for 75% of all recommendations. Adherence was 68%, with significant differences between hospitals, and higher when the recommendations consisted of a dose adjustment or change of route, during the first intervention period, and also when recommendations were personally commented on, in addition to writing a note in the clinical chart. We did not find any reduction in antibiotic consumption or variation in the incidence of resistant pathogens. An important proportion of antibiotic prescriptions may be susceptible to improvement, most of them towards simplification. The adherence to the intervention was high, but significant variations at different centres were observed, depending on the type of recommendation, and the study period. Those recommendations that were personally commented on were more followed more than those only written. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Contribution of microbiology in the diagnosis of tuberculosis in Castile and Le\u00f3n (Spain): Findings of the GRUMICALE 2013 study.](https://www.ncbi.nlm.nih.gov/pubmed/28087144)\nL\u00f3pez-Medrano, Ramiro; Nebreda-Mayoral, Teresa; Brezmes-Valdivieso, M F\u00e9; Garc\u00eda-de Cruz, Susana; Nogueira-Gonz\u00e1lez, Bego\u00f1a; S\u00e1nchez-Arroyo, Rafael; Tinajas-Puertas, Almudena; Guti\u00e9rrez-Zufiaurre, Nieves; Labayru-Echeverr\u00eda, Cristina; Hernando-Real, Susana; L\u00f3pez-Urrutia, Luis; Rivero-Lezcano, Octavio; Ullivarri-Francia, Bel\u00e9n; Rodr\u00edguez-Tarazona, Raquel; Antol\u00edn-Ayala, Isabel\n2018-03-01\nA retrospective study was conducted by collecting microbiological tuberculosis (TB) data in Castile and Le\u00f3n during the year 2013 in order to determine the incidence and distribution of TB, and resistance to the tuberculostatic drug, and compare them with the epidemiological data provided by the Department of Epidemiological Surveillance (SIVE). Microbiologists of the 14 hospitals of the Castile and Le\u00f3n public health network (GRUMICALE) collected epidemiological, microbiological, and management data from the Microbiology laboratories in the community during the year 2013. A single isolate of Mycobacterium tuberculosis complex (MTC) per patient was considered. The study included a total of 270 MTC isolates (an incidence rate of 11.63 cases/100,000 inhab./year). A total of 288 cases of TB (11.43 cases/100,000 inhab. year) were recovered using epidemiological data, which included 243 confirmed, 29 suspected, and 16 as probable cases. Pulmonary TB was predominant, followed a long way off by the pleural TB and the remaining locations. A total of 27,620 samples were processed for mycobacterial detection. Mycobacterial growth was observed in 3.46% of automated fluid cultures, and 50.37% were positive by direct staining of the smear. Resistance to one tuberculostatic drug, mostly to isoniazid, was observed in 16 (5.92%) isolates of Mycobacterium tuberculosis (MT). The province with greater incidence and number of isolates was Le\u00f3n (24.23 cases/100,000 inhab./year), with the highest being observed in El Bierzo health area (30.46 cases/100,000 inhab./year). An adequate collection of microbiological information is essential to determine the epidemiology of TB in our region. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reduction.](https://www.ncbi.nlm.nih.gov/pubmed/24139337)\nRamiro, Miguel A; Llibre, Josep M\n2014-11-01\nThe availability of generic lamivudine in the context of the current economic crisis has raised a new issue in some European countries: breaking up the once-daily fixed-dose antiretroviral combinations (FDAC) of efavirenz/tenofovir/emtricitabine, tenofovir/emtricitabine, or abacavir/lamivudine, in order to administer their components separately, thereby allowing the use of generic lamivudine instead of branded emtricitabine or lamivudine. The legal, ethical, and economic implications of this potential strategy are reviewed, particularly in those patients receiving a once-daily single-tablet regimen. An unfamiliar change in antiretroviral treatment from a successful patient-friendly FDAC into a more complex regimen including separately the components to allow the substitution of one (or some) of them for generic surrogates (in the absence of a generic bioequivalent FDAC) could be discriminatory because it does not guarantee access to equal excellence in healthcare to all citizens. Furthermore, it could violate the principle of non-maleficence by potentially causing harm both at the individual level (hindering adherence and favouring treatment failure and resistance), and at the community level (hampering control of disease transmission and transmission of HIV-1 resistance). Replacing a FDAC with the individual components of that combination should only be permitted when the substituting medication has the same qualitative and quantitative composition of active ingredients, pharmaceutical form, method of administration, dosage and presentation as the medication being replaced, and a randomized study has demonstrated its non-inferiority. Finally, a strict pharma-economic study supporting this change, comparing the effectiveness and the cost of a specific intervention with the best available alternative, should be undertaken before its potential implementation. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\n[Prognosis of venous thromboembolism in orthopaedic surgery or trauma patients and use of thromboprophylaxis.](https://www.ncbi.nlm.nih.gov/pubmed/29929734)\nGuti\u00e9rrez Guisado, J; Trujillo-Santos, J; Arcelus, J I; Bertoletti, L; Fernandez-Capit\u00e1n, C; Valle, R; Hernandez-Hermoso, J A; Erice Calvo-Sotelo, A; Nieto, J A; Monreal, M\n2018-06-18\nThere is scarce evidence about the prognosis of venous thromboembolism in patients undergoing orthopedic surgery and in patients suffering non-surgical trauma. We used the RIETE database (Registro Informatizado de pacientes con Enfermedad Trombo Emb\u00f3lica) to compare the prognosis of venous thromboembolism and the use of thromboprophylaxis in patients undergoing different orthopedic procedures and in trauma patients not requiring surgery. From March 2001 to March 2015, a total of 61,789 patients were enrolled in RIETE database. Of these, 943 (1.52%) developed venous thromboembolism after elective arthroplasty, 445 (0.72%) after hip fracture, 1,045 (1.69%) after non-major orthopedic surgery and 2,136 (3.46%) after non-surgical trauma. Overall, 2,283 patients (50%) initially presented with pulmonary embolism. Within the first 90 days of therapy, 30 patients (0.66%; 95% CI 0.45-0.93) died from pulmonary embolism. The rate of fatal pulmonary embolism was significantly higher after hip fracture surgery (n = 9 [2.02%]) than after elective arthroplasty (n = 5 [0.53%]), non-major orthopedic surgery (n = 5 [0.48%]) or non surgical trauma (n = 11 [0.48%]). Thromboprophylaxis was more commonly used for hip fracture (93%) or elective arthroplasty (94%) than for non-major orthopedic surgery (71%) or non-surgical trauma (32%). Major bleeding was significantly higher after hip fracture surgery (4%) than that observed after elective arthroplasty (1.6%), non-major orthopedic surgery (1.5%) or non-surgical trauma (1.4%). Thromboprophylaxis was less frequently used in lower risk procedures despite the absolute number of fatal pulmonary embolism after non-major orthopedic surgery or non-surgical trauma, exceeded that observed after high risk procedures. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights reserved.\n[Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study.](https://www.ncbi.nlm.nih.gov/pubmed/29864787)\nKraaijpoel, No\u00e9mie; van Es, Nick; Raskob, Gary E; B\u00fcller, Harry R; Carrier, Marc; Zhang, George; Lin, Min; Grosso, Michael A; Di Nisio, Marcello\n2018-06-04\nVenous thromboembolism (VTE) may be the first sign of an undiagnosed cancer. In patients with unprovoked VTE, the risk is approximately 5% in the year following VTE diagnosis. Cancer-specific screening is therefore often considered in these patients, but the optimal screening strategy remains controversial. Recently, two risk classification scores have been proposed that may help in identifying patients at high risk of occult cancer in whom extensive screening may be warranted. In the present post hoc analysis of the Hokusai-VTE study, we evaluated the performance of the Registro Informatizado de Pacientes con Enfermedad TromboEmb\u00f3lica (RIETE) and Screening for Occult Malignancy in Patients with Idiopathic Venous Thromboembolism (SOME) scores for occult cancer in patients with acute VTE. A total of 8,032 patients were included in the analysis of whom 218 (2.7%; 95% confidence interval [CI], 2.4-3.1) developed cancer between 30-day and 12-month follow-up. The c -statistics of the RIETE and SOME scores were 0.62 (95% CI, 0.57-0.66) and 0.59 (95% CI, 0.55-0.62), respectively. In patients classified as 'high risk', the cumulative incidence of cancer diagnosis during follow-up was 2.9% (95% CI, 2.1-3.9) for the RIETE score and 2.7% (95% CI, 1.9-3.7) for the SOME score, corresponding to hazard ratios of 1.8 (95% CI, 1.3-2.5) and 1.5 (95% CI, 1.04-2.2), respectively. In conclusion, the performance of both scores was poor. When used dichotomously, the scores were able to identify a group of patients with a significantly higher risk of occult cancer, although it remains unknown whether this translates into improved clinical important outcomes. Schattauer GmbH Stuttgart.\n[A case-control study on the clinical impact of ventilator associated tracheobronchitis in adult patients who did not develop ventilator associated pneumonia.](https://www.ncbi.nlm.nih.gov/pubmed/29422291)\nCant\u00f3n-Bulnes, Mar\u00eda Luisa; Gonz\u00e1lez-Garc\u00eda, Mar\u00eda Ascensi\u00f3n; Garc\u00eda-S\u00e1nchez, Manuela; Arenzana-Seisdedos, \u00c1ngel; Garnacho-Montero, Jos\u00e9\n2018-02-05\nThe main objective was to determine whether ventilator-associated tracheobronchitis (VAT) is related to increased length of ICU stay. Secondary endpoints included prolongation of hospital stay, as well as, ICU and hospital mortality. A retrospective matched case-control study. Each case was matched with a control for duration of ventilation (\u00b1 2 days until development of ventilator-associated tracheobronchitis), disease severity (Acute Physiology and Chronic Health Evaluation II) at admission \u00b1 3, diagnostic category and age \u00b110 years. Critically ill adults admitted to a polyvalent 30-beds ICU with the diagnosis of VAT in the period 2013-2016. We identified 76 cases of VAT admitted to our ICU during the study period. No adequate controls were found for 3 patients with VAT. There were no significant differences in demographic characteristics, reasons for admission and comorbidities. Patients with VAT had a longer ICU length of stay, median 22 days (14-35), compared to controls, median 15 days (8-27), p=.02. Ventilator days were also significantly increased in VAT patients, median 18 (9-28) versus 9 days (5-16), p=.03. There was no significant difference in total hospital length of stay 40 (28-61) vs. 35days (23-54), p=.32; ICU mortality (20.5 vs. 31.5% p=.13) and hospital mortality (30.1 vs. 43.8% p=.09). We performed a subanalysis of patients with microbiologically proven VAT receiving adequate antimicrobial treatment and did not observe significant differences between cases and the corresponding controls. VAT is associated with increased length of intensive care unit stay and longer duration of mechanical ventilation. This effect disappears when patients receive appropriate empirical treatment. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nCaraval\u00ed-Meza, Nuris Yohana; Jim\u00e9nez-Cruz, Arturo; Bacard\u00ed-Gasc\u00f3n, Montserrat\n2016-03-25\nAntecedentes: se ha reportado una asociaci\u00f3n entre el aumento del consumo de bebidas azucaradas y varias enfermedades metab\u00f3licas. Objetivo: evaluar el efecto del consumo de bebidas azucaradas sobre la obesidad en un periodo de 12 meses en mexicanos de 15 a 19 a\u00f1os. M\u00e9todos: el dise\u00f1o del estudio fue prospectivo, con 12 meses de seguimiento. Se midieron el peso, la talla y la circunferencia de cintura (CC), y se calcul\u00f3 el puntaje z de \u00edndice de masa corporal (IMC). Se aplic\u00f3 un cuestionario sobre consumo de 19 bebidas. Para evaluar la predicci\u00f3n del aumento de IMC y de CC como resultado del consumo de bebidas, se utiliz\u00f3 an\u00e1lisis de regresi\u00f3n log\u00edstica binomial. Resultados: al final del estudio se evalu\u00f3 al 89% (1.344). El promedio de edad fue de 15 a\u00f1os, 55% fueron mujeres. La prevalencia de sobre- peso y obesidad al final del estudio fue del 33%. Al final del estudio, un 25% de los participantes consum\u00edan m\u00e1s de 50 g de az\u00facar proveniente de las bebidas. Quienes consumieron 50 g de az\u00facar o m\u00e1s al d\u00eda presentaron mayor riesgo de aumentar la CC \u2265 2 cm (RR = 1,19, IC 95%, 1,03-1,39, p = 0,02). Quienes mantuvieron el consumo de bebidas azucaradas durante 12 meses, al compararlo con los que disminuyeron el consumo a 10 g/d\u00eda, presentaron 71% m\u00e1s probabilidades de aumentar a un puntaje de IMC \u2265 2 (RR = 1,71, IC 95%, 1,03-2,86, p = 0,039). Conclusi\u00f3n: el alto consumo de bebidas azucaradas aument\u00f3 las probabilidades de aumentar de peso y de circunferencia de cintura.\n[[Barriers to ART initiation in HIV infected subjects and with treatment indication in Spain. Why don't they start their treatment? Bridgap Study].](https://www.ncbi.nlm.nih.gov/pubmed/25577557)\nViciana-Fern\u00e1ndez, Pompeyo; Falc\u00f3, Vicen\u00e7; Casta\u00f1o, Manuel; de los Santos-Gil, Ignacio; Olalla-Sierra, Juli\u00e1n; Hernando, Asunci\u00f3n; Deig, Elisabet; Clotet, Bonaventura; Knobel, Hernando; Podzamczer, Daniel; Pedrol, Pere Domingo\n2015-01-01\nIn Spain, HIV treatment guidelines are well known and generally followed. However, in some patients there are no plans to initiate ART despite having treatment indications. The current barriers to ART initiation are presented. A cross-sectional survey including every HIV infected patient in care in 19 hospitals across Spain in 2012, with \u22651 indication to start ART according to 2011 national treatment guidelines, who had not been scheduled for ART initiation. Reasons for deferring treatment were categorized as follows (non-exclusive categories): a) The physician thinks the indication is not absolute and prefers to defer it; b) The patient does not want to start it; c) The physician thinks ART must be started, but there is some limitation to starting it, and d) The patient has undetectable viral load in absence of ART. A total of 256 patients, out of 784 originally planned, were included. The large majority (84%) were male, median age 39 years, 57% MSM, 24% heterosexuals, and 16% IDUs. Median time since HIV diagnosis was 3 years, median CD4 count, 501 cells/mm3, median viral load 4.4 log copies/ml. Main ART indications were: CD4 count <500 cells/mm(3), 48%; having an uninfected sexual partner, 28%, and hepatitis C coinfection, 23%. Barriers due to, the physician, 55%; the patient, 28%; other limitations, 23%; and undetectable viral load, 6%. The majority of subjects with ART indication were on it. The most frequent barriers among those who did not receive it were physician-related, suggesting that the relevance of the conditions that indicate ART may need reinforcing. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Phenotypic and genetic characteristics of fluoroquinolone- and methicillin-resistant Staphylococcus aureus.](https://www.ncbi.nlm.nih.gov/pubmed/28734506)\nMoreno-Flores, Antonio; Potel-Alvarellos, Carmen; Otero-Fern\u00e1ndez, Susana; \u00c1lvarez-Fern\u00e1ndez, Maximiliano\n2017-07-20\nFluoroquinolone resistance in methicillin-resistant Staphylococcus aureus (MRSA) has increased in recent years. The objective of this study was to characterise two MRSA populations, one susceptible to fluoroquinolones and other resistant identifying the clonal types and the differential characteristics of both MRSA populations. Molecular typing using PFGE, MLST, spa and SSCmec was performed on 192 MRSA strains isolated from 2009 to 2011, 49 only oxacillin-resistant (OX-R) and 143 oxacillin and levofloxacin-resistant (OX-R-LEV-R). Mutations that conferred resistance to fluoroquinolones, hypermutable phenotypes and the presence of eight microbial surface components recognising adhesive matrix molecules (MSCRAMMs) were also studied. A statistically significant increase in the OX-R-LEV-R phenotype was observed (p<0.05). The most common clone of the OX-R isolates was sequence type (ST) 8 (32.6%), followed by ST72 (26.5%) and ST5 (26.5%). In the OX-R-LEV-R phenotype, the ST5 clone was the most common (65.7%), followed by ST72 (15.4%), and ST125 (12.6%). All isolates except the ST398 clone carried the SCCmecIVc. Clones ST5, ST72, ST125, and ST30 had hypermutable phenotypes. The ST72 clone and the ST30 clone in the OX-R phenotype harboured the highest number of MSCRAMMs. ST5 and ST72 clones were the most frequent clones identified in OX-R-LEV-R phenotype. Both clones showed a hypermutable phenotype that favours their selection as the fluoroquinolone resistant clones. The genetic relationships identified indicate that OX-R-LEV-R clones have evolved from OX-R MRSA clones. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Anaerobic bacteria 150 years after their discovery by Pasteur].](https://www.ncbi.nlm.nih.gov/pubmed/23648369)\nGarc\u00eda-S\u00e1nchez, Jos\u00e9 El\u00edas; Garc\u00eda-S\u00e1nchez, Enrique; Mart\u00edn-Del-Rey, \u00c1ngel; Garc\u00eda-Merino, Enrique\n2015-02-01\nIn 2011 we celebrated the 150th anniversary of the discovery of anaerobic bacteria by Louis Pasteur. The interest of the biomedical community on such bacteria is still maintained, and is particularly focused on Clostridium difficile. In the past few years important advances in taxonomy have been made due to the genetic, technological and computing developments. Thus, a significant number of new species related to human infections have been characterised, and some already known have been reclassified. At pathogenic level some specimens of anaerobic microflora, that had not been isolated from human infections, have been now isolated in some clinical conditions. There was emergence (or re-emergence) of some species and clinical conditions. Certain anaerobic bacteria have been associated with established infectious syndromes. The virulence of certain strains has increased, and some hypotheses on their participation in certain diseases have been given. In terms of diagnosis, the routine use of MALDI-TOF has led to a shortening of time and a cost reduction in the identification, with an improvement directly related to the improvement of data bases. The application of real-time PCR has been another major progress, and the sequencing of 16srRNA gene and others is currently a reality for several laboratories. Anaerobes have increased their resistance to antimicrobial agents, and the emergence of resistance to carbapenems and metronidazole, and multi-resistance is a current reality. In this situation, linezolid could be an effective alternative for Bacteroides. Fidaxomicin is the only anti-anaerobic agent introduced in the recent years, specifically for the diarrhoea caused by C.difficile. Moreover, some mathematical models have also been proposed in relation with this species. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Characteristics of tuberculosis in the immigrant population in South Granada Health Area].](https://www.ncbi.nlm.nih.gov/pubmed/25066381)\nMorales-Garc\u00eda, Concepci\u00f3n; Parra-Ruiz, Jorge; Valero-Aguilera, Beatriz; Sanbonmatsu-G\u00e1mez, Sara; S\u00e1nchez-Mart\u00ednez, Jos\u00e9 Antonio; Hern\u00e1ndez-Quero, Jos\u00e9\n2015-03-01\nThe incidence of tuberculosis (TB) among the native population in Spain continues to decrease, resulting in a higher proportion of foreign-born cases. The aim of this study was to identify the differential TB characteristics within the immigrant population with respect to the native population in the South Granada Health Area, Spain. This was a descriptive study, including all cases of TB diagnosed during the period 2003-2010. Cases were identified through a prospective database. A logistic regression analysis was performed to determine differential characteristics. From 319 TB cases diagnosed, 247 were natives and 72 (22.6%) immigrants, and 272 were pulmonary tuberculosis. The following variables were significantly associated with immigrant TB cases: age<35 years (OR=4.75, CI: 2.72-8.31), higher percentage of cavitated chest X-ray (OR=2.26, CI: 1.20-4.20), higher percentage of smear-positive cases (OR=1.80, CI: 1.02-3.16), longer diagnostic delay in smear-positive pulmonary TB (median 32 days vs. 21 days P=.043), and lower total lethality (OR=0.12; CI: 0.01-0.89). The incidence of TB has remained constant in the South Granada Health Area due to the increase in cases among immigrants. Compared with native TB patients, immigrant patients were younger and had more advanced disease (higher percentage of smear-positive cases and higher percentage of cavitated chest X-ray) and longer diagnostic delay in smear-positive pulmonary TB, indicating poorer TB control. Strategies for earlier diagnosis of TB in immigrants are essential. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[High prevalence of asymptomatic carriers of Tropheryma whipplei in different populations from the North of Spain.](https://www.ncbi.nlm.nih.gov/pubmed/26585816)\nGarc\u00eda-\u00c1lvarez, Lara; P\u00e9rez-Matute, Patricia; Blanco, Jos\u00e9 Ram\u00f3n; Ibarra, Valvanera; Oteo, Jos\u00e9 Antonio\n2016-01-01\nTropheryma whipplei is the causative agent of Whipple disease. T. whipplei has also been detected in asymptomatic carriers with a very different prevalence. To date, in Spain, there are no data regarding the prevalence of T. whipplei in a healthy population or in HIV-positive patients, or in chronic fatigue syndrome (CFS). Therefore, the aim of this work was to assess the prevalence of T. whipplei in stools in those populations. Stools from 21 HIV-negative subjects, 65 HIV-infected, and 12 CFS patients were analysed using real time-PCR. HIV-negative and positive subjects were divided into two groups, depending on the presence/absence of metabolic syndrome (MS). Positive samples were sequenced. The prevalence of T. whipplei was 25.51% in 98 stool samples analysed. Prevalence in HIV-positive patients was significantly higher than in HIV-negative (33.8% vs. 9.09%, p=0.008). Prevalence in the control group with no associated diseases was 20%, whereas no positive samples were observed in HIV-negative patients with MS, or in those diagnosed with CFS. The prevalence observed in HIV-positive patients without MS was 30.35%, and with MS it was 55.5%. The number of positive samples varies depending on the primers used, although no statistically significant differences were observed. There is a high prevalence of asymptomatic carriers of T. whipplei among healthy and in HIV-infected people from Spain. The role of T. whipplei in HIV patients with MS is unclear, but the prevalence is higher than in other populations. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Initial experience with imported Zika virus infection in Spain.](https://www.ncbi.nlm.nih.gov/pubmed/27743683)\nD\u00edaz-Men\u00e9ndez, Marta; de la Calle-Prieto, Fernando; Montero, Dolores; Antol\u00edn, Eugenia; Vazquez, Ana; Arsuaga, Marta; Trigo, Elena; Garc\u00eda-Bujalance, Silvia; de la Calle, Mar\u00eda; S\u00e1nchez Seco, Paz; de Ory, Fernando; Arribas, Jose Ram\u00f3n\n2018-01-01\nA considerable increase of imported Zika virus (ZIKV) infection has been reported in Europe in the last year. This is the result of the large outbreak of the disease in the Americas, along with the increase in the numbers of travellers and immigrants arriving from ZIKV endemic areas. A descriptive study was conducted in the Tropical Medicine Unit of Hospital La Paz-Carlos III in Madrid on travellers returning from an endemic area for ZIKV from January to April 2016. Demographic, clinical and microbiological data were analyzed. A total of 185 patients were screened for ZIKV (59.9% women, median age of 37.7\u00b110.3 years). Main purpose of the travel was tourism to Colombia, Brazil, and M\u00e9xico. Just under three-quarters (73%) were symptomatic, mostly with fever and headache. A total of 13 patients (7% of those screened) were diagnosed with ZIKV infections, of which four of them were pregnant. All of them were symptomatic patients, the majority immigrants, and mainly from Colombia. Diagnostic tests were based on positive neutralization antibodies (8 cases, 61.6%) and a positive RT-PCR in different organic fluids (7 cases, 53.8%) The four infected pregnant women underwent a neurosonography every 3 weeks, and no alterations were detected. RT-PCR in amniotic fluid was performed in three of them, with negative results. One of the children has already been born healthy. Our cases series represents the largest cohort of imported ZIKV to Spain described until now. Clinicians must increase awareness about the progression of the ZIKV outbreak and the affected areas so that they can include Zika virus infection in their differential diagnosis for travellers from those areas. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Heterogeneous production of proteases from Brazilian clinical isolates of Pseudomonas aeruginosa.](https://www.ncbi.nlm.nih.gov/pubmed/27480954)\nGaldino, Anna Clara M; Viganor, L\u00edvia; Ziccardi, Mariangela; Nunes, Ana Paula F; Dos Santos, K\u00e1tia R N; Branquinha, Marta H; Santos, Andr\u00e9 L S\n2017-12-01\nPseudomonas aeruginosa is an important human pathogen that causes severe infections in a wide range of immunosuppressed patients. Herein, we evaluated the proteolytic profiles of 96 Brazilian clinical isolates of P. aeruginosa recovered from diverse anatomical sites. Cell-associated and extracellular proteases were evidenced by gelatin-SDS-PAGE and by the cleavage of soluble gelatin. Elastase was measured by using the peptide substrate N-succinyl-Ala-Ala-Ala-p-nitroanilide. The prevalence of elastase genes (lasA and lasB) was evaluated by PCR. Bacterial extracts were initially applied on gelatin-SDS-PAGE and the results revealed four distinct zymographic profiles as follows: profile I (composed by bands of 145, 118 and 50kDa), profile II (118 and 50kDa), profile III (145kDa) and profile IV (118kDa). All the proteolytic enzymes were inhibited by EDTA, identifying them as metalloproteases. The profile I was the most detected in both cellular (79.2%) and extracellular (84.4%) extracts. Overall, gelatinase and elastase activities measured in the spent culture media were significantly higher (around 2-fold) compared to the cellular extracts and the production level varied according to the site of bacterial isolation. For instance, tracheal secretion isolates produced elevated amount of gelatinase and elastase measured in both cellular and extracellular extracts. The prevalence of elastase genes revealed that 100% isolates were lasB-positive and 85.42% lasA-positive. Some positive/negative correlations were showed concerning the production of gelatinase, elastase, isolation site and antimicrobial susceptibility. The protease production was highly heterogeneous in Brazilian clinical isolates of P. aeruginosa, which corroborates the genomic/metabolic versatility of this pathogen. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Factors determining irregular attendance to follow-up visits among human immunodeficiency virus patients: results of the hospital survey of patients infected with human immunodeficiency virus].](https://www.ncbi.nlm.nih.gov/pubmed/25444044)\nDiaz, Asuncion; Ten, Alicia; Marcos, Henar; Guti\u00e9rrez, Gonzalo; Gonz\u00e1lez-Garc\u00eda, Juan; Moreno, Santiago; Barrios, Ana Mar\u00eda; Arponen, Sari; Portillo, \u00c1lvaro; Serrano, Regino; Garc\u00eda, Maria Teresa; P\u00e9rez, Jos\u00e9 Luis; Toledo, Javier; Royo, Maria Carmen; Gonz\u00e1lez, Gustavo; Izquierdo, Ana; Viloria, Luis Javier; L\u00f3pez, Irene; Elizalde, L\u00e1zaro; Mart\u00ednez, Eva; Castrillejo, Daniel; Aranguren, Rosa; Redondo, Caridad; Diez, Mercedes\n2015-05-01\nTo describe the occurrence of non-regular attendance to follow-up visits among HIV patients and to analyze the determining factors. One-day survey carried out annually (2002-2012) in public hospitals. Epidemiological, clinical and behavioral data are collected in all HIV-infected inpatients and outpatients receiving HIV-related care on the day of the survey. \"Non-regular attendance to a follow-up visit\" was defined as sporadic attendance to the medical appointments, according to the judgment of the attending physician. Descriptive and bivariate analyses were performed, and factors associated to non-regular attendance to follow-up visits were estimated using logistic regression. A total of 7,304 subjects were included, of whom 13.7% did not attend medical appointments regularly. Factors directly associated with non-regular attendance were: age between 25-49 years; birth in Sub-Saharan Africa or Latin-America; low educational level; being homeless or in prison; living alone or in closed institutions; being unemployed or retired; being an intravenous drug user; not using a condom at last sexual encounter, and injecting drugs in the last 30 days. Conversely, HIV diagnosis within the last year and being men who have sex with men were factors inversely associated with non-regular attendance to follow-up visits. In spite of health care beings free of charge for everyone in Spain, social factors can act as barriers to regular attendance to medical appointments, which, in turn, can endanger treatment effectiveness in some population groups. This should be taken into account when planning HIV policies in Spain. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Changes in the etiology, incidence and prognosis of acute lower respiratory track infections in human immunodeficiency virus patients.](https://www.ncbi.nlm.nih.gov/pubmed/25195179)\nPerell\u00f3, Rafael; Escoda, Ona; Cam\u00f3n, Silvia; Mir\u00f3, \u00d2scar; Casta\u00f1eda, Marta; Moreno, Asunci\u00f3n; Marcos, Maria \u00c1ngeles; Perea, Ver\u00f3nica; Alcolea, Natalia; S\u00e1nchez, Miquel; Gatell, Josep Maria; Mart\u00ednez, Esteban\n2015-04-01\nTo describe the incidence, the changes in the etiology and the prognosis of lower respiratory tract infection (LRTI) in HIV infected patients, presenting by the first time to the Emergency Department (ED), during years 2000-2010. Prospective collection of data. Data were collected on the first visit of HIV-infected patients at our ED due to a LRTI, (defined according to the criteria of the European Respiratory Society), between 1/1/2000 and 31/12/2010. A series of epidemiological and laboratory variables as well as the need for admission to the intensive care unit (ICU). LRTI etiology were also collected. The influence ofthe mentioned variables on 30-day mortality were analyzed. One hundred thirty one patients were included. LRTI represented 27% of visits to the ED by HIV-infected patients. Mean age was 39\u00b19 years. 72% of patients were males. 18% required admission to the ICU. The most frequent LRTI was pneumonia by P. jiroveci in 35 cases, bacterial penumonia in 27 and pulmonary tuberculosis in 20. LRTI incidence gradually reduced significantly over time from 6.13 \u00d7 1000 patients/year in year 2000 to 0.23 \u00d7 1000 patients/year in 2010 (p<0.05). Overall mortality was 14%. Logistic regression analysis showed that admission to ICU (p<0.004) and viral load (p<0.029) were independent variables predicting mortality. LRTI is a pathology with a decreasing incidence, probably related to the widespread utilization increased of HAART regimens. lts etiology has also been changing, but with a non negligible mortality, mostly when ICU admission was required. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Quality of the aetiological diagnosis of ventilator-associated pneumonia in Spain in the opinion of intensive care specialists and microbiologists.](https://www.ncbi.nlm.nih.gov/pubmed/27743679)\nBouza, Emilio; Mart\u00ednez-Alarc\u00f3n, Jos\u00e9; Maseda, Emilio; Palomar, Mercedes; Zaragoza, Rafael; P\u00e9rez-Granda, Mar\u00eda Jes\u00fas; Mu\u00f1oz, Patricia; Burillo, Almudena\n2017-03-01\nCurrent guidelines for the microbiological diagnosis of ventilator-associated pneumonia (VAP) are imprecise. Based on data provided by intensive care specialists (ICS) and microbiologists, this study defines the clinical practices and microbiological techniques currently used for an aetiological diagnosis of VAP and pinpoints deficiencies. Eighty hospitals in the national health network with intensive care and microbiology departments were sent two questionnaires, one for each department, in order to collect data on VAP diagnosis for the previous year. Out of the 80 hospitals, 35 (43.8%) hospitals participated. These included 673 ICU beds, 32,020 ICU admissions, 173,820 ICU days stay, and generated 27,048 lower respiratory tract specimens in the year. A third of the hospitals (35%) had a microbiology department available 24/7. Most samples (83%) were tracheal aspirates. Gram stain results were immediately reported in around half (47%) of the hospitals. Quantification was made in 75% of hospitals. Molecular techniques and direct susceptibility testing were performed in 12% and one institution, respectively. Mean turnaround time for a microbiological report was 1.7 (SD; 0.7), and 2.2 (SD; 0.6) days for a negative and positive result, respectively. Telephone/in-person information was offered by 65% of the hospitals. Most (89%) ICS considered microbiological information as very useful. No written procedures were available in half the ICUs. Both ICS and microbiologists agreed that present guidelines for the diagnosis of VAP could be much improved, and that a new set of consensus guidelines is urgently required. A need for guidelines to be more effectively implemented was also identified in order to improve outcomes in patients with VAP. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Isolation of environmental mycobacteria from soils of C\u00f3rdoba city Argentina].](https://www.ncbi.nlm.nih.gov/pubmed/12934243)\nBallarino, Guillermo J; Eseverri, M Ver\u00f3nica; Salas, Andrea V; Giayetto, V\u00edctor O; Gonz\u00e1lez, Silvia; Wolff, Lidia; Pessah, Oscar\n2002-01-01\nThe interest for the research on enviromental mycobacteria has risen over the last decades, in part, due to a significant incidence rate rise. Reports from all over the world address the soil as the major source for human contamination. In Argentina two documents report the prevalence of atypical mycobacteriosis at C\u00f3rdoba (1997), and the isolation of enviromental mycobacteria from soils of the Province of La Pampa (1999) respectively. The aim of our study was to confirm the presence of enviromental mycobacteria in soil of the city of C\u00f3rdoba. The map of the city was divided in 9 regions according to avenues and major streets distribution. A total of 120 soil samples were recollected with spatula from a 10 x 10 cm square up to 1 cm deep. Samples were kept at 4 degrees C no more than 7 days. Soil samples were homogenized with destilled water in a 1:1 proportion, and decontaminated according to Petroff's method. The cultures were made in Lowestein-Jehnsen media and incubated at 37 degrees C controlling development every 7 days for 2 months. An acid-fast-bacilli smear was made from colonies obtained. Twenty three cultures (19%) were discarded due to contamination. Twenty cultures (17%) developed acid fast bacilli (AFB). Colonies obtained were sent to the Mycobacteria Service of the Instituto Nacional de Enfermedades Infecciosas Dr. Carlos G. Malbr\u00e1n, in the city of Buenos Aires, for identification. A single isolation was identified as Mycobacterium triviale. A positive correlation was observed between the frequency of positive AFB isolation and the number of samples taken from park areas. The presence of enviromental mycobacteria in soils of C\u00f3rdoba was confirmed. Results suggest higher odds of isolation in parklands and soils where animals live. Extensive works are needed to asset the features that allow and contribute the proliferation of mycobacteria in soils.\n[[Effectiveness of human papillomavirus genotyping for detection of high-grade anal intraepithelial neoplasia compared to anal cytology].](https://www.ncbi.nlm.nih.gov/pubmed/26976378)\nPadilla-Espa\u00f1a, Laura; Repiso-Jim\u00e9nez, Juan Bosco; Fern\u00e1ndez-S\u00e1nchez, Fernando; Pereda, Teresa; Rivas-Ruiz, Francisco; Fern\u00e1ndez-Morano, Teresa; de la Torre-Lima, Javier; Palma, Ferm\u00edn; Redondo, Maximino; de Troya-Mart\u00edn, Magdalena\n2016-01-01\nThe incidence of high-grade anal intraepithelial neoplasia (HGAIN) -with an aetiological based on high-risk types of human papillomavirus- is increasing in some high-risk groups. Screening for HGAIN includes routine anal cytology and, more recently, HPV genotyping. The main objective of this study was to determine the sensitivity and specificity of anal cytology and HPV genotyping for the detection of HGAIN. This is a study to determine the correlation of cytological and microbiological findings with anal biopsy findings in a cohort of patients at high risk of developing AIN referred to the department of sexually transmitted infections of the Hospital Costa del Sol, Spain, between January 2008 and December 2014. Of the 151 patients subjected to screening, a total of 92 patients, all of them with the result of three screening test (anal cytology, genotyping and biopsy) were included in the study. Just under two-thirds (62%) of them were HIV-positive. The sensitivity and specificity of anal cytology to detect HGAIN were 52.8 and 85.7%, respectively (k: 0.328), and 78 and 62.8% to detect two or more HPV oncogenic genotypes (k: 0.417). The detection of oncogenic HPV genotypes allowed the identification of 23 new cases of HGAIN that had been underdiagnosed with anal cytology, with 14 cases containing at least three high-risk genotypes. Anal cytology did not show enough sensitivity in HGAIN screening. HPV genotyping has shown to be a useful tool to detect HGAIN cases, although it could lead to an over-diagnosis as a solitary screening procedure. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Re-emergence of measles in the province of Guadalajara, Spain. Is it time to establish new strategies for its elimination?].](https://www.ncbi.nlm.nih.gov/pubmed/24210738)\nMart\u00ednez-Ram\u00edrez, Mariela; Gonz\u00e1lez-Praetorius, Alejandro; Ory-Manch\u00f3n, Fernando de; Mart\u00ednez-Benito, Yolanda; Garc\u00eda-Rivera, M Victoria; H\u00fcbschen, Judith; Echevarr\u00eda-Mayo, Juan Emilio\n2014-10-01\nMeasles is a viral infection that was almost eradicated, but it is re-emerging in Spain and Europe in recent years. The aim of this study was to describe the microbiological, clinical and epidemiological characteristics of a measles outbreak that occurred in Guadalajara (Spain) from June to August 2012. A descriptive and retrospective study was conducted. A total of 117 samples (including serum, urine and pharyngeal swabs) from 52 patients were analyzed for measles. Measles was diagnosed in 50 patients, 41 of them by microbiological diagnosis, and 9 by epidemiological link. The patients were grouped in four community outbreaks. No imported cases were observed. Positive IgM and positive CRP were detected in 25 patients, positive CRP only in 11 and positive IgM only in 5. The genotype D4 was identified in 13 patients and the genotype A in a post-vaccine case. The age groups most affected were adults between 20-34 years of age (38%) and younger than 15 months (26%). The large majority (86%) of patients were unvaccinated (44% Roma population, 27% younger than 15 months, 11% ideological reasons), 6% had one vaccine dose. The signs/symptoms were: rash and fever, 100%, cough, 82%, and conjunctivitis 50%. Almost one-third (32%) of patients were hospitalized, and 28% had complications. It is very important to intensify the epidemiological surveillance of infections in the elimination phase. The increased incidence of measles was associated to unvaccinated pockets, presenting a challenge for Public Health Centers. These agencies should prepare strategies to obtain a higher vaccine coverage for the eradication of measles. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Indicator condition guided human immunodeficiency virus requesting in primary health care: results of a collaboration].](https://www.ncbi.nlm.nih.gov/pubmed/25769383)\nCayuelas-Redondo, Laia; Menacho-Pascual, Ignacio; Noguera-S\u00e1nchez, Pablo; Goicoa-Gago, Carmen; Pollio-Pe\u00f1a, Gern\u00f3nimo; Blanco-Delgado, Rebeca; Barba-\u00c1vila, Olga; Sequeira-Aymar, Ethel; Muns, Merc\u00e8; Clusa, Thais; Garc\u00eda, Felipe; Le\u00f3n, Agathe\n2015-12-01\nThe search of HIV infected patients guided by indicator conditions (IC) is a strategy used to increase the early detection of HIV. The objective is to analyze whether a collaboration to raise awareness of the importance of early detection of HIV in 3 primary care centers influenced the proportion of HIV serology requested. Multicenter retrospective study was conducted comparing the baseline and a post-collaboration period. The collaboration consisted of training sessions and participation in the HIDES study (years 2009-2010). Patients between 18 and 64 years old with newly diagnosed herpes zoster, seborrheic eczema, mononucleosis syndrome, and leucopenia/thrombocytopenia in 3 primary care centers in 2008 (baseline period) and 2012 (post-collaboration period). The sociodemographic variables, HIV risk conditions, requests for HIV serology, and outcomes were evaluated. A total of 1,219 ICs were included (558 in 2008 and 661 in 2012). In 2008 the number of HIV tests in patients with an IC was 3.9%, and rose to 11.8% in 2012 (P<.0001). The HIV infection rate was 2.2% (95% CI: 0.4-7.3) (n=2). It was estimated that 25 new cases (12 in 2008 and 13 in 2012) would have been diagnosed if they had performed the test on all patients with IC. Predictors of HIV request were, having an IC in 2012, a younger age, having an mononucleosis syndrome, and not being Spanish. The HIV request demand tripled, after the collaboration with primary care centers, however in 88% the test was not requested, resulting in diagnostic losses. New strategies are needed to raise awareness of the importance of early detection of HIV. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[High-risk sexual behaviour by partner type among men who have sex with men].](https://www.ncbi.nlm.nih.gov/pubmed/24246777)\nFolch, Cinta; Fern\u00e1ndez-D\u00e1vila, Percy; Ferrer, Laia; Soriano, Ra\u00fal; D\u00edez, Mercedes; Casabona, Jordi\n2014-01-01\nTo identify factors associated with high risk sexual practices among men who have sex with men (MSM) in Spain. An online survey was conducted in 2010, which included, among others, questions on HIV/STI sexual behaviours and prevention needs. Unprotected anal intercourse (UAI) with a partner of unknown or discordant HIV status in the past year was defined as a high risk sexual behaviour. Of the 13,111 participants, 49.4% had had sex with steady partners (SP) and 73.4% with non-steady partners (NSP) in the last 12months; and the prevalence of high risk UAI was 25.4% and 29.4%, respectively. Factors associated with high risk UAI with SP were: living in a city of less than 500,000 inhabitants (OR=1.42 <100,000 inhabitants), being out to no-one or only a few people (OR=1.42), and being HIV-positive with undetectable viral load among those with a high level of HIV/STI knowledge (OR=3.18). Factors associated with high risk UAI with NSP were mainly: having a higher number of sexual partners (OR=4.31 >50 partners), having used drugs for sex (OR=1.33), and at parties (OR=1.19), having a medium (OR=1.82) or low (OR=1.33) level of HIV/STI knowledge, and being HIV-positive (OR=1.56). Among MSM, the prevalence of high risk sexual practices is high with both SP and NSP. Factors associated with high risk UAI vary by type of sexual partner (e.g., having HIV with an undetectable viral load). These must be taken into account when planning strategies for primary and secondary prevention. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Pregnancy as an opportunity to diagnose human-immunodeficiency virus immigrant women in Catalonia.](https://www.ncbi.nlm.nih.gov/pubmed/27609632)\nSoriano-Arandes, Antoni; Noguera-Julian, Antoni; L\u00f3pez-Lacort, M\u00f3nica; Soler-Palac\u00edn, Pere; Mur, Antonio; M\u00e9ndez, Mar\u00eda; Mayol, Llu\u00eds; Vallmanya, Teresa; Almeda, Jes\u00fas; Carnicer-Pont, Dolors; Casabona, Jordi; Fortuny, Claudia\n2018-01-01\nMother-to-child transmission (MTCT) is relevant in the global epidemiology of human-immunodeficiency virus (HIV), as it represents the main route of infection in children. The study objectives were to determine the rate of HIV-MTCT and its epidemiological trend between the Spanish-born and immigrant population in Catalonia in the period 2000-2014. A prospective observational study of mother-child pairs exposed to HIV, treated in 12 hospitals in Catalonia in the period 2000-2014. HIV-MTCT rate was estimated using a Bayesian logistic regression model. R and WinBUGS statistical software were used. The analysis included 909 pregnant women, 1,009 pregnancies, and 1,032 children. Data on maternal origin was obtained in 79.4% of women, of whom 32.7% were immigrants, with 53.0% of these from sub-Saharan Africa. The overall HIV-MTCT rate was 1.4% (14/1,023; 95% CI; 0.8-2.3). The risk of MTCT-HIV was 10-fold lower in women with good virological control (P=.01), which was achieved by two-thirds of them. The proportion of immigrants was significantly higher in the period 2008-2014 (P<.0001), for the HIV-diagnosis (P<.0001), and antiretroviral administration (P=.02) during pregnancy, and for undetectable viral load next to delivery (P<.001). There were no differences in the rate of MTCT-HIV among Spanish-born and immigrant women (P=.6). There is a gradual increase in HIV pregnant immigrants in Catalonia. Although most immigrant women were diagnosed during pregnancy, the rate of MTCT-HIV was no different from the Spanish-born women. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[GeSIDA quality care indicators associated with mortality and hospital admission for the care of persons infected by HIV/AIDS].](https://www.ncbi.nlm.nih.gov/pubmed/27270265)\nDelgado-Mej\u00eda, Elena; Frontera-Juan, Guillem; Murillas-Angoiti, Javier; Campins-Rosell\u00f3, Antoni Abdon; Gil-Alonso, Leire; Pe\u00f1aranda-Vera, Mar\u00eda; Ribas Del Blanco, Mar\u00eda Angels; Mart\u00edn-Pena, Mar\u00eda Luisa; Riera-Jaume, Melchor\n2017-02-01\nIn 2010, the AIDS Study Group (Grupo de Estudio del SIDA [GESIDA]) developed 66 quality care indicators. The aim of this study is to determine which of these indicators are associated with mortality and hospital admission, and to perform a preliminary assessment of a prediction rule for mortality and hospital admission in patients on treatment and follow-up. A retrospective cohort study was conducted in the Hospital Universitario Son Espases (Palma de Mallorca, Spain). Eligible participants were patients with human immunodeficiency syndrome\u226518 years old who began follow-up in the Infectious Disease Section between 1 January 2000 and 31 December 2012. A descriptive analysis was performed to evaluate anthropometric variables, and a logistic regression analysis to assess the association between GESIDA indicators and mortality/admission. The mortality probability model was built using logistic regression. A total of 1,944 adults were eligible (median age: 37 years old, 78.8% male). In the multivariate analysis, the quality of care indicators associated with mortality in the follow-up patient group were the items 7, 16 and 20, and in the group of patients on treatment were 7, 16, 20, 35, and 38. The quality of care indicators associated with hospital admissions in the follow-up patients group were the same as those in the mortality analysis, plus number 31. In the treatment group the associated quality of care indicators were items 7, 16, 20, 35, 38, and 40. Some GeSIDA quality of care indicators were associated with mortality and/or hospital admissions. These indicators are associated with delayed diagnosis, regular monitoring, prevention of infections, and control of comorbidities. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Missed opportunities in the diagnosis of human immunodeficiency virus infection in the Region of Aragon. Late diagnosis importance.](https://www.ncbi.nlm.nih.gov/pubmed/29724618)\nGargallo-Bernad, C\u00e9sar; Sangr\u00f3s-Gonz\u00e1lez, Francisco Javier; Arazo-Garc\u00e9s, Piedad; Mart\u00ednez-\u00c1lvarez, Rosa; Malo-Aznar, Carmen; Gargallo-Bernad, Alicia; Ballester-Luna, Alba; Cabrero-Pascual, Luis Eduardo; Gil-Orna, Pablo; Abad\u00eda-Gallego, V\u00edctor Jos\u00e9; Torres-Pe\u00f1a, Isabel; Ordiz-Su\u00e1rez, H\u00e9ctor\n2018-04-30\nLate Diagnosis (LD) of Human Immunodeficiency Virus (HIV) infection (CD4 lymphocytes <350/\u03bcl at diagnosis of the disease), deteriorates the condition of those affected and increases the probability of transmission. The objective of the present study was to analyse the prevalence of LD, to identify missed diagnostic opportunities (MDO) and to find out which level of the health care delivery system they took place. Retrospective, observational and descriptive study of the population diagnosed with infection of HIV/AIDS in the period 2011-2015 in Aragon. MDO were identified during the 3 years prior to diagnosis of the disease in all levels of the health care delivery system as well as frequentation of consultations. The indicator conditions (IC) that generated more MDO were analysed according to the latest recommendations for early diagnosis of HIV in the health care setting. 435 newly diagnosed HIV/AIDS cases were analysed. 45.1% were diagnosed in Primary Healthcare (PH). 49.4% presented criteria of LD and 61.1% were infected through heterosexual contact. The majority of MDO (68.5%) were given in PH. The IC that generated the most MDO were seborrheic dermatitis/exanthema (19.4%) and fever of unknown origin (10.3%). However, the IC that were associated with higher LD were pneumonia acquired in the community and unjustified weight loss. In Aragon, prevalence of LD is high, the main route of infection is heterosexual and most of MDO go unnoticed in PH. The dissemination of current guidelines for requesting IC guided HIV testing and HIV screening across the preoperative period will result in an effective measure to decrease the LD. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Cooperative Cardiovascular Disease Research Network (RECAVA)].](https://www.ncbi.nlm.nih.gov/pubmed/18221692)\nGarc\u00eda-Dorado, David; Castro-Beiras, Alfonso; D\u00edez, Javier; Gabriel, Rafael; Gimeno-Blanes, Juan R; Ortiz de Land\u00e1zuri, Manuel; S\u00e1nchez, Pedro L; Fern\u00e1ndez-Avil\u00e9s, Francisco\n2008-01-01\nToday, cardiovascular disease is the principal cause of death and hospitalization in Spain, and accounts for an annual healthcare budget of more than 4000 million euros. Consequently, early diagnosis, effective prevention, and the optimum treatment of cardiovascular disease present a significant social and healthcare challenge for the country. In this context, combining all available resources to increase the efficacy and healthcare benefits of scientific research is a priority. This rationale prompted the establishment of the Spanish Cooperative Cardiovascular Disease Research Network, or RECAVA (Red Tem\u00e1tica de Investigaci\u00f3n Cooperativa en Enfermedades Cardiovasculares), 5 years ago. Since its foundation, RECAVA's activities have focused on achieving four objectives: a) to facilitate contacts between basic, clinical and epidemiological researchers; b) to promote the shared use of advanced technological facilities; c) to apply research results to clinical practice, and d) to train a new generation of translational cardiovascular researchers in Spain. At present, RECAVA consists of 41 research groups and seven shared technological facilities. RECAVA's research strategy is based on a scientific design matrix centered on the most important cardiovascular processes. The level of RECAVA's research activity is reflected in the fact that 28 co-authored articles were published in international journals during the first six months of 2007, with each involving contributions from at least two groups in the network. Finally, RECAVA also participates in the work of the Spanish National Center for Cardiovascular Research, or CNIC (Centro Nacional de Investigaci\u00f3n Cardiovascular), and some established Biomedical Research Network Centers, or CIBER (Centros de Investigaci\u00f3n Biom\u00e9dica en RED), with the aim of consolidating the development of a dynamic multidisciplinary research framework that is capable of meeting the growing challenge that cardiovascular disease will present\n[[Economic impact of nosocomial bacteraemia. A comparison of three calculation methods].](https://www.ncbi.nlm.nih.gov/pubmed/26564375)\nRiu, Marta; Chiarello, Pietro; Terradas, Roser; Sala, Maria; Castells, Xavier; Knobel, Hernando; Cots, Francesc\n2016-12-01\nThe excess cost associated with nosocomial bacteraemia (NB) is used as a measurement of the impact of these infections. However, some authors have suggested that traditional methods overestimate the incremental cost due to the presence of various types of bias. The aim of this study was to compare three assessment methods of NB incremental cost to correct biases in previous analyses. Patients who experienced an episode of NB between 2005 and 2007 were compared with patients grouped within the same All Patient Refined-Diagnosis-Related Group (APR-DRG) without NB. The causative organisms were grouped according to the Gram stain, and whether bacteraemia was caused by a single or multiple microorganisms, or by a fungus. Three assessment methods are compared: stratification by disease; econometric multivariate adjustment using a generalised linear model (GLM); and propensity score matching (PSM) was performed to control for biases in the econometric model. The analysis included 640 admissions with NB and 28,459 without NB. The observed mean cost was \u20ac24,515 for admissions with NB and \u20ac4,851.6 for controls (without NB). Mean incremental cost was estimated at \u20ac14,735 in stratified analysis. Gram positive microorganism had the lowest mean incremental cost, \u20ac10,051. In the GLM, mean incremental cost was estimated as \u20ac20,922, and adjusting with PSM, the mean incremental cost was \u20ac11,916. The three estimates showed important differences between groups of microorganisms. Using enhanced methodologies improves the adjustment in this type of study and increases the value of the results. Copyright \u00c2\u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Assessment of surveys of adolescents about smoking and the use of alcohol and cannabis in Spain].](https://www.ncbi.nlm.nih.gov/pubmed/21503559)\nVillalb\u00ed, Joan R; Suelves, Josep M; Salt\u00f3, Esteve; Cabezas, Carmen\n2011-01-01\nMonitoring health-related behaviors in adolescence requires instruments capable of providing valid data The objective of this paper is to review and assess existing information sources on smoking and alcohol and cannabis use by age and sex among adolescents in Spain. A search was carried out for studies with repeated observations over time, and their methods and characteristics reviewed. For each study, the number of surveys, their frequency and their sample size are assessed, as well as the instrument used, the available indicators, and the availability, accessibility and comparability of the information. Five sources of information providing data over extended periods of time with accessible data are identified: the National survey on drug use in secondary-school children (Encuesta estatal sobre uso de drogas en estudiantes de secundaria; ESTUDES); the Health behavior in school-aged children study (ECERSHBSC); the Monitoring system for risk factors associated with non-transmissible diseases in young people (Sistema de Vigilancia de Factores de Riesgo Asociados a Enfermedades No Transmisibles dirigido a poblacion juvenil; SIVFRENT-J); the Study of risk factors in secondary school children (Estudio de factores de riesgo en estudiantes de secundaria; FRESC); and the Monitoring study of health behaviors in adolescents (Estudio de monitorizacion de las conductas de salud de los adolescents; EMCSAT). Two of the surveys cover the whole of Spain, one is regional, and two are city-specific. All use solid methods and representative sampling techniques. In some, changes have occurred that make comparison of the evolution of some indicators difficult. Report accessibility is variable; comparability is limited for some surveys. Some provide almost no stratified data. There are valuable sources of data, but all have shortcomings. Changing the measurement instrument in a survey for comparison with others raises dilemmas as to the internal comparability of series.\n[[Changes in smoking prevalence among adolescents in Spain].](https://www.ncbi.nlm.nih.gov/pubmed/21507530)\nVillalb\u00ed, Joan R; Suelves, Josep M; Garc\u00eda-Continente, Xavier; Salt\u00f3, Esteve; Ariza, Carles; Cabezas, Carmen\n2012-01-01\nTo analyse information on adolescent use of tobacco in Spain from different school surveys. Data on daily smoking prevalence by sex at the end of compulsory education is extracted and figures are compared, analysing trends. The five representative studies on adolescents in Spain are reviewed: The National Survey on Drug Use in Secondary School Children (Encuesta estatal sobre uso de drogas en estudiantes de secundaria (ESTUDES); Survey of Health Behaviour in School-aged Children (HBSC-ECERS); Surveillance System of Risk Factors Associated With Non-Transmittable diseases in the Young Population (Sistema de Vigilancia de Factores de Riesgo Asociados a Enfermedades No Transmisibles dirigido a poblaci\u00f3n Juvenil)(SIVFRENT-J); Study of Risk Factors in Secondary School Children (Estudio de factores de riesgo en estudiantes de secundaria) (FRESC); Surveillance Study of Health Behaviour in Adolescents (Estudio de Monitorizaci\u00f3n de las Conductas de Salud de los Adolescentes) (EMCSAT). The prevalence of daily smokers varies among studies, in boys from 8.5 to 13.3% and in girls from 12.7 to 16.4%. Although some series show variations, the trend from 1993 to 2008 is downwards. With data from recent years, weighted annual declines in smoking prevalence in adolescence can be estimated to be 6.47% for boys and 6.96% for girls. There is a decreasing pattern in adolescent daily smoking prevalence in Spain from the different existing studies, which provide consistent data, although surveillance must be kept due to fluctuations. This is in agreement with tobacco sales statistics and health surveys in the adult population. However, the pace of change should be more rapid and constant. \u00a9 2010 Elsevier Espa\u00f1a, S.L. All rights reserved.\n[Prediction of higher cost of antiretroviral therapy (ART) according to clinical complexity. A validated clinical index.](https://www.ncbi.nlm.nih.gov/pubmed/26298097)\nVelasco, Cesar; P\u00e9rez, Inaki; Podzamczer, Daniel; Llibre, Josep Maria; Domingo, Pere; Gonz\u00e1lez-Garc\u00eda, Juan; Puig, Inma; Ayala, Pilar; Mart\u00edn, Mayte; Trilla, Antoni; L\u00e1zaro, Pablo; Gatell, Josep Maria\n2016-03-01\nThe financing of antiretroviral therapy (ART) is generally determined by the cost incurred in the previous year, the number of patients on treatment, and the evidence-based recommendations, but not the clinical characteristics of the population. To establish a score relating the cost of ART and patient clinical complexity in order to understand the costing differences between hospitals in the region that could be explained by the clinical complexity of their population. Retrospective analysis of patients receiving ART in a tertiary hospital between 2009 and 2011. Factors potentially associated with a higher cost of ART were assessed by bivariate and multivariate analysis. Two predictive models of \"high-cost\" were developed. The normalized estimated (adjusted for the complexity scores) costs were calculated and compared with the normalized real costs. In the Hospital Index, 631 (16.8%) of the 3758 patients receiving ART were responsible for a \"high-cost\" subgroup, defined as the highest 25% of spending on ART. Baseline variables that were significant predictors of high cost in the Clinic-B model in the multivariate analysis were: route of transmission of HIV, AIDS criteria, Spanish nationality, year of initiation of ART, CD4+ lymphocyte count nadir, and number of hospital admissions. The Clinic-B score ranged from 0 to 13, and the mean value (5.97) was lower than the overall mean value of the four hospitals (6.16). The clinical complexity of the HIV patient influences the cost of ART. The Clinic-B and Clinic-BF scores predicted patients with high cost of ART and could be used to compare and allocate costs corrected for the patient clinical complexity. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Phenotypic and genotypic characterization of vancomycin-resistant Enterococcus faecium clinical isolates from two hospitals in Mexico: First detection of VanB phenotype-vanA genotype.](https://www.ncbi.nlm.nih.gov/pubmed/26589756)\nBocanegra-Ibarias, Paola; Flores-Trevi\u00f1o, Samantha; Camacho-Ortiz, Adri\u00e1n; Morfin-Otero, Rayo; Villarreal-Trevi\u00f1o, Licet; Llaca-D\u00edaz, Jorge; Mart\u00ednez-Landeros, Erik Alan; Rodr\u00edguez-Noriega, Eduardo; Calzada-G\u00fcereca, Andr\u00e9s; Maldonado-Garza, H\u00e9ctor Jes\u00fas; Garza-Gonz\u00e1lez, Elvira\n2016-01-01\nEnterococcus faecium has emerged as a multidrug-resistant nosocomial pathogen involved in outbreaks worldwide. Our aim was to determine the antimicrobial susceptibility, biofilm production, and clonal relatedness of vancomycin-resistant E. faecium (VREF) clinical isolates from two hospitals in Mexico. Consecutive clinical isolates (n=56) were collected in two tertiary care hospitals in Mexico from 2011 to 2014. VREF isolates were characterized by phenotypic and molecular methods including pulsed-field gel electrophoresis (PFGE). VREF isolates were highly resistant to vancomycin, erythromycin, norfloxacin, high-level streptomycin, and teicoplanin, and showed lower resistance to tetracycline, nitrofurantoin and quinupristin-dalfopristin. None of the isolates were resistant to linezolid. The vanA gene was detected in all isolates. Two VanB phenotype-vanA genotype isolates, highly resistant to vancomycin and susceptible to teicoplanin, were detected. Furthermore, 17.9% of the isolates were classified as biofilm producers, and the espfm gene was found in 98.2% of the isolates. A total of 37 distinct PFGE patterns and 6 clones (25% of the isolates as clone A, 5.4% as clone B, and 3.6% each as clone C, D, E, and F) were detected. Clone A was detected in 5 different wards of the same hospital during 14 months of surveillance. The high resistance to most antimicrobial agents and the moderate cross-transmission of VREF detected accentuates the need for continuous surveillance of E. faecium in the hospital setting. This is also the first reported incidence of the E. faecium VanB phenotype-vanA genotype in the Americas. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Infective endocarditis in adult patients with congenital heart disease. Experience from a reference centre].](https://www.ncbi.nlm.nih.gov/pubmed/26860418)\nLoureiro-Amigo, Jose; Fern\u00e1ndez-Hidalgo, Nuria; Pijuan-Dom\u00e8nech, Antonia; Dos-Subir\u00e0, Laura; Subirana-Dom\u00e8nech, Teresa; Gonz\u00e0lez-Alujas, Teresa; Gonz\u00e1lez-L\u00f3pez, Juan Jos\u00e9; Tornos-Mas, Pilar; Garc\u00eda-Dorado, David; Almirante, Benito\n2016-12-01\nA growing number of patients with congenital heart disease (CHD) will reach adulthood. Infective endocarditis (IE) is a major complication in this population. The aim of this study was to describe the features of IE in adults with CHD treated in a reference centre. A retrospective review was performed on a cohort of patients over 16 years of age with CHD who presented with IE (defined by the modified Duke criteria) between 1996 and 2014. Only the first episode from each patient was considered for the descriptive analysis. IE was observed in 27 patients. The median age at diagnosis of IE was 27.7 years, and 63% were male. Comorbidity was low (median Charlson index was 0). IE was mostly community-acquired (78%). The most frequent CHD were ventricular septal defect (33%). A repair was performed in 48% of patients, and 19% received palliative treatment. Forty-one percent of patients had some type of prosthesis. A residual defect was observed in 81%. The IE was detected in the right side of 44% of the patients. The most frequent aetiological agents were viridans group streptococci (41%) and Staphylococcus epidermidis (30%). Surgery was required to treat IE in 37% of patients. There were five re-infections and three relapses. Two patients died, both as a result of recurrence. IE in adults with CHD occurred in young patients, and almost all of them carried some prosthetic material or a residual defect. The IE is frequently right-sided. Although surgical treatment was required in many cases, mortality was low, except in the case of relapses. Copyright \u00c2\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Influenza infection in the intensive care unit: Four years after the 2009 pandemic.](https://www.ncbi.nlm.nih.gov/pubmed/26025480)\nP\u00e9rez-Carrasco, Marcos; Lagunes, Leonel; Ant\u00f3n, Andr\u00e9s; Gattarello, Simone; Laborda, C\u00e9sar; Pumarola, Tom\u00e1s; Rello, Jordi\n2016-03-01\nThe role of influenza viruses in severe acute respiratory infection (SARI) in Intensive Care Units (ICU) remains unknown. The post-pandemic influenza A(H1N1)pdm09 period, in particular, has been poorly studied. To identify influenza SARI patients in ICU, to assess the usefulness of the symptoms of influenza-like illness (ILI), and to compare the features of pandemic vs. post-pandemic influenza A(H1N1) pdm09 infection. A prospective observational study with SARI patients admitted to ICU during the first three post-pandemic seasons. Patient demographics, characteristics and outcomes were recorded. An influenza epidemic period (IEP) was defined as >100 cases/100,000 inhabitants per week. One hundred sixty-three patients were diagnosed with SARI. ILI was present in 65 (39.9%) patients. Influenza infection was documented in 41 patients, 27 (41.5%) ILI patients, and 14 (14.3%) non-ILI patients, 27 of them during an IEP. Influenza A viruses were mainly responsible. Only five patients had influenza B virus infection, which were non-ILI during an IEP. SARI overall mortality was 22.1%, and 15% in influenza infection patients. Pandemic and post-pandemic influenza infection patients shared similar clinical features. During influenza epidemic periods, influenza infection screening should be considered in all SARI patients. Influenza SARI was mainly caused by subtype A(H1N1)pdm09 and A(H3N2) in post-pandemic seasons, and no differences were observed in ILI and mortality rate compared with a pandemic season. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Predictors of survival of natural killer/T-cell lymphoma, nasal type, in a non-Asian population: a single cancer centre experience](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5130333)\nV\u00e1squez, Jule; Serrano, Mariana; Lopez, Lourdes; Pacheco, Cristian; Quintana, Shirley\n2016-01-01\nBackground Natural killer/T-cell lymphoma (NKTCL), part of T-cell and NK-cell neoplasms in the World Health Organisation (WHO) classification, is an aggressive lymphoma with poor prognosis more predominantly seen in Asian and South American countries. This study evaluates the factors associated with survival among patients with newly diagnosed NKTCL in Peru. Methods Information was abstracted from medical records (MR) for all NKTCL patients >13 years of age at the Instituto Nacional de Enfermedades Neoplasicas (INEN) between 2002 and 2011. The estimate of the survival curves was performed by the Kaplan-Meier method, and the difference was computed by the log-rank test. Results Around 226 MR were reviewed, 153 met the selection criteria, the median age was 40 years (14\u201384). The median progression-free survival (PFS) was 20 months, five year PFS was 42.6%, univariable analysis (UA) showed statistical significance (p < 0.05) for male sex, non-nasal primary site, advanced clinical stages, B symptoms, poor performance status, regional nodal involvement (RNI). In the multivariate analysis the only poor prognostic factors was primary non-nasal (Hazard ratio (HR) = 2.40, 95% confidence interval (CI) = 1.43\u2013 4.02, P = 0.01). The median overall survival (OS) was 49 months, five year OS was 48.9%, UA showed statistical significance for non-nasal primary site, advanced clinical stages, B symptoms, lactate dehydrogenase (LDH) > normal, RNI and local tumour invasion. In the multivariate analysis, primary non-nasal was the only poor prognostic factor with HR = 2.57, 95% CI = 1.37\u20134.83, P = 0.03. Conclusions In Peru, OS of NKTCL is similar to other countries. This result suggests that non-nasal NKTCL is the only poor prognostic factor of OS and PFS. PMID:27994644\n[Cryptosporidiosis outbreak in a child day-care center caused by an unusual Cryptosporidium hominis subtype.](https://www.ncbi.nlm.nih.gov/pubmed/25770777)\nGo\u00f1i, Pilar; Almagro-Nievas, Diego; Cieloszyk, Joanna; L\u00f3bez, Silvia; Navarro-Mar\u00ed, Jos\u00e9 Mar\u00eda; Guti\u00e9rrez-Fern\u00e1ndez, Jos\u00e9\n2015-12-01\nThis work describes the genetic characterization of Cryptosporidium and Giardia involved in an outbreak in a nursery school in Granada, Spain, that affected seven children under the age of 4. Nucleic acids were extracted from the seven stool samples positive to Cryptosporidium or Giardia by microscopy and/or immunochromatography. The species and subtypes of Cryptosporidium were identified by PCR-RFLP and PCR of the SSUrRNA and gp60 genes, respectively. The assemblages of Giardia duodenalis isolates were characterized by PCR of the tpi gene. PCR products were sequenced and analyzed. All of the isolates were positive for Cryptosporidium hominis. Five of them belonged to subtype IaA11R2, one to subtype IbA10G2R2, and the other could not be identified. Three of these samples were positive for G. duodenalis by PCR, two belonging to the assemblage A, and the other one to assemblage B. This is the first report of Cryptosporidium hominis subtype IaA11R2 as a cause of an outbreak in Europe where subtype IbA10G2R2 is the most frequently identified. In the case of Giardia, an outbreak could not be confirmed because of the low number of positive samples and the low genetic variability of the amplified fragments for assemblage A of tpi gene. A new subtype, of Cryptosporidium hominis named IaA11R2, has been described as a cause of an outbreak in a nursery school in Granada, Spain. However an outbreak of giardiasis could not be confirmed. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Scarlet fever: A not so typical exanthematous pharyngotonsillitis (based on 171 cases).](https://www.ncbi.nlm.nih.gov/pubmed/26585817)\nGarc\u00eda-Vera, C\u00e9sar; de Dios Javierre, B\u00e1rbara; Cast\u00e1n Larraz, Beatriz; Arana Navarro, Teresa; Cenarro Guerrero, Teresa; Ruiz Pastora, Rafael; S\u00e1nchez Gimeno, Javier\n2016-01-01\nTo describe the age, signs and clinical symptoms of children with scarlet fever at the present time, and to check whether they are equivalent to those with traditional streptococcal pharyngotonsillitis. An observational, retrospective study was conducted on the clinical records of 5500 children aged from 0 to 15 years attending a primary health care center. A record was made of the percentage of the cases in which signs and symptoms appear and the Centor score was calculated. Microbiological diagnosis of the disease was made using the rapid antigen-detection test or traditional culture. A total of 171 out of 252 scarlet fever diagnoses were microbiologically verified in 158 patients. The median age was 3.8 years (interquartile range: 2.91-4.78), with the majority (57%) under the age of 4 years. There was fever in 89% of the processes (95% CI: 84-94%), with a temperature of >38\u00b0C in 73% (95% CI: 65-80%), enlarged lymph nodes in 70% (95% CI: 58-82%), absence of cough in 73% (95% CI: 65-80%), and tonsillar exudate in only 24% (95% CI: 17-31%). The Centor score (n=105) was \u22642 points in 86% (95% CI: 79-92%). The only difference regarding age is that episodes in patients under the age of 4 years old have significantly higher fever (>38\u00b0C) than the older ones (80% versus 63%. OR 3.13; 95% CI: 1.46-6.71). Scarlet fever pharyngotonsillitis differs from the traditional streptococcal pharyngotonsillitis, and its evaluation using clinical prediction rules such as Centor or McIsaac is questionable. The main diagnostic key must certainly be rash, regardless of patient age. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital.](https://www.ncbi.nlm.nih.gov/pubmed/25459191)\nCabral-Galeano, Evelyn; Ruiz-Camps, Isabel; Len-Abad, Oscar; Pou-Clav\u00e9, Leonor; Sord\u00e9-Masip, Roger; Meije-Castillo, Yolanda; Blanco-Grau, Albert; Barba-Su\u00f1ol, Pere; Monforte-Torres, Victor; Rom\u00e1n-Broto, Antonio; Pahissa-Berga, Albert; Gavald\u00e0-Santapau, Joan\n2015-05-01\nThe aim of this study was to assess the clinical usefulness of therapeutic drug monitoring (TDM) of voriconazole (VOR) in a university hospital. A retrospective review was conducted on the clinical records of 52 patients treated with VOR and on whom TDM was performed. Steady-state trough plasma VOR concentration was measured at least 5 days after starting treatment. The therapeutic range of plasma VOR concentration was defined as 1-5.5\u03bcg/mL. The most frequent underlying conditions in the study population were lung transplant (48.1%) and hematological malignancies (26.9%). At the first TDM in each patient, VOR levels were outside the therapeutic range in 16 (30.7%) cases: <1\u03bcg/mL in 10 (19.2%) and >5.5\u03bcg/mL in 6 (11.5%). Eleven patients (21.2%) experienced severe muscle weakness and had considerable difficulty walking. All these patients were receiving concomitant treatment with corticosteroids. Age younger than 30 years (p=.005) and cystic fibrosis as the underlying disease (p=.04) were factors associated with low VOR levels. Almost all patients who had VOR concentrations >1\u03bcg/mL at the first TDM had a successful outcome (96%). Plasma VOR concentrations were outside the therapeutic range at the first TDM in 30% (16/52) of patients. Age younger than 30 years and cystic fibrosis were factors associated with low VOR levels. The potential interactions between corticosteroids and VOR should be highlighted, as they could be responsible for a high rate of muscle weakness observed in our patients. Prospective trials are needed to investigate VOR TDM and corticosteroid pharmacokinetics. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Training should be the first step toward an antifungal stewardship program.](https://www.ncbi.nlm.nih.gov/pubmed/25066382)\nValerio, Maricela; Mu\u00f1oz, Patricia; Rodr\u00edguez-Gonz\u00e1lez, Carmen; Sanjurjo, Mar\u00eda; Guinea, Jes\u00fas; Bouza, Emilio\n2015-04-01\nThe frequency of use of systemic antifungal agents has increased significantly in most tertiary centers. However, antifungal stewardship has received very little attention. The objective of this article was to assess the knowledge of prescribing physicians in our institution as a first step in the development of an antifungal stewardship program. Attending physicians from the departments that prescribe most antifungals were invited to complete a questionnaire based on current guidelines on diagnosis and therapy of invasive candidiasis and invasive aspergillosis (IA). The survey was completed by 60.8% (200/329) of the physicians who were invited to participate. The physicians belonged to the following departments: medical (60%), pediatric (19%), intensive care (15.5%), and surgical (5.5%). The mean (\u00b1SD) score of correct responses was 5.16\u00b11.73. In the case of candidiasis, only 55% of the physicians clearly distinguished between colonization and infection, and 17.5% knew the local rate of fluconazole resistance. Thirty-three percent knew the accepted indications for antifungal prophylaxis, and 23% the indications for empirical therapy. However, most physicians knew which antifungals to choose when starting empirical therapy (73.5%). As for aspergillosis, most physicians (67%) could differentiate between colonization and infection, and 34.5% knew the diagnostic value of galactomannan. The radiological features of IA were well recognized by 64%, but only 31.5% were aware of the first line of treatment for IA, and 36% of the recommended duration of therapy. The usefulness of antifungal levels was known by 67%. This simple, easily completed questionnaire enabled us to identify which areas of our training strategy could be improved. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Cost-effectiveness study of the microbiological diagnosis of tuberculosis using geneXpert MTB/RIF\u00ae.](https://www.ncbi.nlm.nih.gov/pubmed/27445177)\nHerr\u00e1ez, \u00d3scar; Asencio-Egea, Mar\u00eda \u00c1ngeles; Huertas-Vaquero, Mar\u00eda; Carranza-Gonz\u00e1lez, Rafael; Castellanos-Monedero, Jes\u00fas; Franco-Huerta, Mar\u00eda; Barber\u00e1-Farr\u00e9, Jos\u00e9 Ram\u00f3n; Ten\u00edas-Burillo, Jos\u00e9 Mar\u00eda\nTo perform a cost-effectiveness analysis of a molecular biology technique for the diagnosis of tuberculosis compared to the classical diagnostic alternative. A cost-effectiveness analysis was performed to evaluate the theoretical implementation of a molecular biology method including two alternative techniques for early detection of Mycobacterium tuberculosis Complex, and resistance to rifampicin (alternative1: one determination in selected patients; alternative2: two determinations in all the patients). Both alternatives were compared with the usual procedure for microbiological diagnosis of tuberculosis (staining and microbiological culture), and was accomplished on 1,972 patients in the period in 2008-2012. The effectiveness was measured in QALYs, and the uncertainty was assessed by univariate, multivariate and probabilistic analysis of sensitivity. A value of \u20ac8,588/QALYs was obtained by the usual method. Total expenditure with the alternative1 was \u20ac8,487/QALYs, whereas with alternative2, the cost-effectiveness ratio amounted to \u20ac2,960/QALYs. Greater diagnostic efficiency was observed by applying the alternative2, reaching a 75% reduction in the number of days that a patient with tuberculosis remains without an adequate treatment, and a 70% reduction in the number of days that a patient without tuberculosis remains in hospital. The implementation of a molecular microbiological technique in the diagnosis of tuberculosis is extremely cost-effective compared to the usual method. Its introduction into the routine diagnostic procedure could lead to an improvement in quality care for patients, given that it would avoid both unnecessary hospitalisations and treatments, and reflected in economic savings to the hospital. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan.](https://www.ncbi.nlm.nih.gov/pubmed/28109551)\nRibera, Esteban; Mart\u00ednez-Sesmero, Jos\u00e9 Manuel; S\u00e1nchez-Rubio, Javier; Rubio, Rafael; Pasquau, Juan; Poveda, Jos\u00e9 Luis; P\u00e9rez-Mitru, Alejandro; Rold\u00e1n, Celia; Hern\u00e1ndez-Novoa, Beatriz\n2018-03-01\nThe objective of this study is to estimate the economic impact associated with the optimisation of triple antiretroviral treatment (ART) in patients with undetectable viral load according to the recommendations from the GeSIDA/PNS (2015) Consensus and their applicability in the Spanish clinical practice. A pharmacoeconomic model was developed based on data from a National Hospital Prescription Survey on ART (2014) and the A-I evidence recommendations for the optimisation of ART from the GeSIDA/PNS (2015) consensus. The optimisation model took into account the willingness to optimise a particular regimen and other assumptions, and the results were validated by an expert panel in HIV infection (Infectious Disease Specialists and Hospital Pharmacists). The analysis was conducted from the NHS perspective, considering the annual wholesale price and accounting for deductions stated in the RD-Law 8/2010 and the VAT. The expert panel selected six optimisation strategies, and estimated that 10,863 (13.4%) of the 80,859 patients in Spain currently on triple ART, would be candidates to optimise their ART, leading to savings of \u20ac15.9M/year (2.4% of total triple ART drug cost). The most feasible strategies (>40% of patients candidates for optimisation, n=4,556) would be optimisations to ATV/r+3TC therapy. These would produce savings between \u20ac653 and \u20ac4,797 per patient per year depending on baseline triple ART. Implementation of the main optimisation strategies recommended in the GeSIDA/PNS (2015) Consensus into Spanish clinical practice would lead to considerable savings, especially those based in dual therapy with ATV/r+3TC, thus contributing to the control of pharmaceutical expenditure and NHS sustainability. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Comparison of phenotypic tests for the detection of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa.](https://www.ncbi.nlm.nih.gov/pubmed/24908495)\nLucena, Andr\u00e9a; Dalla Costa, Libera M; Nogueira, Keite da Silva; Matos, Adriana P; Gales, Ana C; Raboni, Sonia M\n2014-12-01\nMetallo-\u03b2-lactamase (MBL)-producing gram-negative bacteria are an increasing public health concern worldwide. Screening tests for the rapid and specific identification of these pathogens are essential, and should be included among routine diagnostics in laboratories. This study aimed to determine the MBL frequency among carbapenem-resistant Pseudomonas aeruginosa isolates, and to evaluate the accuracy of different tests in screening for MBL production. From January 2001 to December 2008, a total of 142 imipenem-non-susceptible P. aeruginosa strains were isolated from distinct clinical samples from hospitalized patients. These isolates were examined by PCR, MBL E-test, double-disk synergy test (DDST), and combined disk (CD) test. The minimal inhibitory concentration (MIC; \u03bcg/mL) was determined by agar dilution, and pulsed field gel electrophoresis (PFGE) was performed on all samples. Sequencing was performed to confirm and define the MBL variant and subtype. Using PCR and DNA sequence analysis, 93 strains were confirmed positive for MBLs, 91 strains for the blaSPM-1 gene, 1 strain for the blaIMP-1 gene, and 1 strain for the blaIMP-16 gene. PFGE displayed a clonal pattern. The sensitivities, specificities, positive and negative predictive values were evaluated for all tests. The DDST assay (CAZ-MPA) was the optimal method for screening MBL production in P. aeruginosa strains. However, the results of the CD assay (IMP/EDTA) showed close agreement with those of the DDST. In addition, the CD assay allowed a more objective interpretation and did not require the use of a toxic substance. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Nosocomial infection in patients receiving a solid organ transplant or haematopoietic stem cell transplant].](https://www.ncbi.nlm.nih.gov/pubmed/24950613)\nMoreno Camacho, Asunci\u00f3n; Ruiz Camps, Isabel\n2014-01-01\nimplemented to improve the current situation. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[10 years of literature on AIDS (1983-1992): bibliometric analysis].](https://www.ncbi.nlm.nih.gov/pubmed/7654834)\nAleixandre, R; de la Cueva, A; Almero, A; Osca, J; Gim\u00e9nez, J V\n1995-01-01\nReasons for the quantitative study of the Spanish publications on AIDS are both the huge volume attained by the printed material on the subject since the first case was described in 1981 by the Center for Disease Control, and the high incidence of the cases reported on this disease. Searches have been performed on the subject through the database of the Indice M\u00e9dico Espa\u00f1ol (IME), the Indice Espa\u00f1ol de Ciencia y Technolog\u00eda (ICYT), the ISBN and Bibliograf\u00eda Espa\u00f1ola in order to retrieve all possible Spanish journal papers' and books. The references were distributed using criteria of documentary tipology, publication date, institutions involved, autonomous communities, and, finally, after its relation with the confirmed cases of AIDS. A total 2,013 items have been retrieved, 1,821 journal papers' and 192 books. More than 50% of the papers are published only by five journals, being 139 the total number of journals able to carry pertinent information. The most productive journals were Medicina Cl\u00ednica and Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. The results confirm exponential growth of the publications from 1983, the first year when a paper was published on AIDS in Spain. The grow is similar to the tend observed in other countries. Parallelism has been detected between growth in the number of publications and in the number of journals publishing on the subject, the growth in the number of journals publishing on the subject, the growth in the number of institutions which collaborate and the growing tend of reported cases in Spain. The results of the bibliometric study, showing an epidemiological growth out of comparison in the history of the scientific literature, could be useful both to information scientists, and to the research inside this scientific field.\n[Hepatitis C prevalence among the immigrant population in Spain: A systematic review and meta-analysis.](https://www.ncbi.nlm.nih.gov/pubmed/29759423)\nLazarus, Jeffrey V; Bromberg, Daniel J; Del Amo, Julia; Norgaard, Ole; Garc\u00eda-Samaniego, Javier; Casellas, Aina; Calleja, Jos\u00e9 Luis; Requena-M\u00e9ndez, Ana\n2018-05-11\nSpain, which has one of the largest immigrant populations in Europe, has committed to eliminating the hepatitis C virus (HCV). The aim of this study was to estimate the prevalence of HCV among migrant groups in Spain, a country of 46 million people, with an estimated HCV-antibody prevalence of 1.7%. Studies on HCV and migration in Spain were identified by systematically searching three databases from the first records to 30 November 2017, and consulting experts at the Ministry of Health and in the 17 Spanish autonomous communities. A meta-analysis was conducted to determine pooled HCV prevalence for the general migrant population. Prevalences were also calculated for high-risk migrant populations and populations who had undergone hospital screening, stratified by region of origin. Out of 243 studies identified, 26 met the eligibility criteria. The meta-analysis of the general migrant population found HCV antibody prevalence to be 1.6%. Migrants originating from European countries, including those at high or moderate risk for HCV, had the highest pooled prevalence (7.1%). In the general migrant population, prevalence was highest among sub-Saharan African migrants (3.1%) and lowest among Latin American migrants (0.2%). Based on the limited available data, the prevalence among the general migrant population was found to be the same as the general Spanish population. Further research is needed to more accurately determine HCV prevalence for the overall migrant population and specific migrant subpopulations with a higher risk in the country as a whole and in each of Spain's 17 autonomous communities. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Prevalence of nasal carriage of Staphylococcus aureus and Streptococcus pneumoniae in Primary Care and factors associated with colonization].](https://www.ncbi.nlm.nih.gov/pubmed/25617018)\nBoada, Albert; Almeda, Jes\u00fas; Grenzner, Elisabet; Pons-Vigu\u00e9s, Mariona; Morros, Rosa; Juv\u00e9, Rosa; Simonet, Pere J; den Heijer, Casper D J; Bol\u00edbar, Bonaventura\n2015-01-01\nTo determine (i) the prevalence of Staphylococcus aureus (S.aureus) and Streptococcus pneumoniae (S.pneumoniae) nasal carriage in Primary Health Care patients in area of Barcelona, and (ii) the factors associated with S.aureus and S.pneumoniae colonization. Multi-center cross-sectional study conducted in 2010-2011 with the participation of 27 Primary Health Care professionals. Nasopharyngeal swabs were obtained from 3,969 patients over 4 years of age who did not present with any sign of infection. S.aureus and/or S.pneumoniae carrier state. socio-demographic characteristics, health status, vaccination status, occupation, and living with children. A descriptive analysis was performed. The prevalence of carriers of S.aureus and/or S.pneumoniae was calculated and logistic regression models were adjusted by age. In children from 4 to 14 years old, the prevalence of S.aureus carriers was 35.7%, of S.pneumoniae 27.1%, and 5.8% were co-colonized. In adults older than 14 years old, the prevalence was 17.8%, 3.5%, and 0.5%, respectively. In children, S.aureus carrier state was inversely associated with S.pneumoniae carrier state; S.pneumoniae was associated with younger age, and inversely associated with S.aureus carrier state. In adults, being a carrier of S.aureus was associated with male gender, younger age, and a health-related occupation, whereas S.pneumoniae carrier state was associated with living with children under 6 years of age. The proportion of co-colonized carriers was low (1.0%). The proportion of S.aureus and S.pneumoniae carriers was higher in children than in adults. Age was the only factor associated with healthy carrier status for S.aureus and for S.pneumoniae. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Assessment of anaerobic blood cultures in pediatric oncology patients.](https://www.ncbi.nlm.nih.gov/pubmed/27221161)\nMonson\u00eds Cabedo, Manuel; Rives Sol\u00e1, Susana; Noguera-Julian, Antoni; Urrea Ayala, Mireia; Cruz Martinez, Ofelia; Gen\u00e9 Giralt, Amadeu\n2017-01-01\nThe routine use of a single aerobic bottle for blood culture in pediatric patients has become commonplace, as anaerobic bacteria are not frequently involved in clinically significant infections. The aim of this study was to assess the usefulness of routinely performing anaerobic blood cultures in pediatric oncology patients. Prospective study was conducted on pediatric (<18 years) patients affected with febrile syndrome after receiving chemotherapy for hematological or solid malignancies. Samples were inoculated into pediatric aerobic and standard anaerobic bottles (BacT/Alert automatic system). Strains were considered clinically significant, or deemed as contaminants, depending on isolation circumstances and clinical criteria. A total of 876 blood cultures from 228 patients were processed during the 21-month study period (January 2014 to September 2015). Baseline diagnosis included 143 solid tumors and 67/18 cases of leukemia/lymphoma. Bacterial growth was detected in 90 (10.2%) blood cultures for 95 different isolates, of which 62 (7.1%)/63 isolates were considered clinically significant. Among the latter, 38 (60.3%) microorganisms grew in both aerobic and anaerobic bottles, 18 (28.6%) only in aerobic bottles, and 7 (11.1%) only in anaerobic bottles. Gram-negative bacilli (33; 52.4%), mainly from the Enterobacteriaceae family, were the most frequently isolated microorganisms. Overall, only 3 out of 90 isolates (3.3%) were strict anaerobes (Propionibacterium acnes), and all of them were deemed contaminants. Strict anaerobes did not cause significant infections in febrile pediatric oncology patients, and anaerobic blood culture bottles offered no additional advantages over aerobic media. Our results suggest that routine blood cultures should be solely processed in aerobic media in this group of patients. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Staphylococcus aureus carriage in older populations in community residential care homes: Prevalence and molecular characterization of MRSA isolates.](https://www.ncbi.nlm.nih.gov/pubmed/29935797)\nGal\u00e1n-S\u00e1nchez, F\u00e1tima; P\u00e9rez-Eslava, Maria; Machuca, Jes\u00fas; Trujillo-Soto, Teresa; Arca-Suarez, Jorge; Rodr\u00edguez-Iglesias, Manuel\n2018-06-20\nThe epidemiology of S. aureus depends on conditions in specific populations. Few studies of S. aureus colonization in the older population have been performed in Spain. The aim of this study was to determine the prevalence of methicillin-resistant S. aureus (MRSA) colonization and its molecular epidemiological characteristics in an institutionalized population in community residential care homes in Cadiz, Spain. A cross-sectional epidemiological study was conducted in three residential care homes for older people. Axilla and nostril samples were tested. Identification of S. aureus and antimicrobial susceptibility testing were by MALDI-TOF and MicroScan panels. MRSA strains were subjected to SCCmec typing, multilocus sequence typing (MLST) and pulsed-field gel electrophoresis (PFGE). The presence of Panton-Valentine leukocidin (PVL) genes was determined by PCR in all S. aureus strains. A total of 293 residents were included. Fifty-one residents (17.4%) were colonized with methicillin-sensitive S. aureus (MSSA) and 11 (3.8%) with MRSA. Resistance to at least two aminoglycosides was observed in 25.4% of MSSA and 90.9% and of MRSA isolates, and resistance to levofloxacin in 80.3% of MSSA and 100% of MRSA isolates. SCCmecIV was detected in all isolates and all except one (ST-125) were ST-8. None of the S. aureus isolates were positive for PVL. A low rate of S. aureus carriage was detected and the prevalence of MRSA was very low. ST8-MRSA-IVc was the dominant clone, and only one strain belonged to ST125-MRSA-IVc. We found MRSA transmission within the residential care homes and a very high rate of quinolone resistance in MSSA and MRSA. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Prevalence of quinolone resistance mechanisms in Enterobacteriaceae producing acquired AmpC \u03b2-lactamases and/or carbapenemases in Spain.](https://www.ncbi.nlm.nih.gov/pubmed/27345951)\nMachuca, Jes\u00fas; Ag\u00fcero, Jes\u00fas; Mir\u00f3, Elisenda; Conejo, Mar\u00eda Del Carmen; Oteo, Jes\u00fas; Bou, Germ\u00e1n; Gonz\u00e1lez-L\u00f3pez, Juan Jos\u00e9; Oliver, Antonio; Navarro, Ferran; Pascual, \u00c1lvaro; Mart\u00ednez-Mart\u00ednez, Luis\n2017-10-01\nQuinolone resistance in Enterobacteriaceae species has increased over the past few years, and is significantly associated to beta-lactam resistance. The aim of this study was to evaluate the prevalence of chromosomal- and plasmid-mediated quinolone resistance in acquired AmpC \u03b2-lactamase and/or carbapenemase-producing Enterobacteriaceae isolates. The presence of chromosomal- and plasmid-mediated quinolone resistance mechanisms [mutations in the quinolone resistance determining region (QRDR) of gyrA and parC and qnr, aac(6')-Ib-cr and qepA genes] was evaluated in 289 isolates of acquired AmpC \u03b2-lactamase- and/or carbapenemase-producing Enterobacteriaceae collected between February and July 2009 in 35 Spanish hospitals. Plasmid mediated quinolone resistance (PMQR) genes were detected in 92 isolates (31.8%), qnr genes were detected in 83 isolates (28.7%), and the aac(6')-Ib-cr gene was detected in 20 isolates (7%). qnrB4 gene was the most prevalent qnr gene detected (20%), associated, in most cases, with DHA-1. Only 14.6% of isolates showed no mutations in gyrA or parC with a ciprofloxacin MIC of 0.5mg/L or higher, whereas PMQR genes were detected in 90% of such isolates. qnrB4 gene was the most prevalent PMQR gene detected, and was significantly associated with acquired AmpC \u03b2-lactamase DHA-1. PMQR determinants in association with other chromosomal-mediated quinolone resistance mechanisms, different to mutations in gyrA and parC (increased energy-dependent efflux, altered lipopolysaccharide or porin loss), could lead to ciprofloxacin MIC values that exceed breakpoints established by the main international committees to define clinical antimicrobial susceptibility breakpoints. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Deaths due to non-AIDS diseases among HIV infected patients: A 14-year study (1998-2011)].](https://www.ncbi.nlm.nih.gov/pubmed/26093959)\nL\u00f3pez, Cristina; Masi\u00e1, Mar; Padilla, Sergio; Aquilino, Ana; Bas, Cristina; Guti\u00e9rrez, F\u00e9lix\n2016-04-01\nThe objective of this study was to analyze the deaths caused by non-AIDS diseases in a cohort of HIV-infected patients treated between 1998 and 2011. Information on the causes of death was collected retrospectively, and then classified according to the deaths code (CoDe) algorithm. Patient characteristics and causes of death were compared for two periods: 1998-2004 and 2005-2011. A total of 159 out of the 1070 patients cared for in study period died, 56 (35%) due to AIDS events and 86 (54%) due to non-AIDS events (NAEs); in 17 (11%) the cause of death could not be determined. Overall, the main causes of death were infections (32%), cancer (17%), and unnatural deaths (17%). There was lower mortality from AIDS-related conditions during the second period (18.5% vs 47%; P<.001) and higher mortality from NAEs (68% vs 45%; P=.006). There was a very sharp increase in non-AIDS-defining cancers (18.5% vs 2.1%, p=001), and increased deaths from cardiovascular disease (9.2% vs 2.1%, P=.06). Patients who died in the second period were older, and had a better immunological and virological status at cohort entry and before death. They received antiretroviral therapy (ART) more often and were more often virologically suppressed before death (61.5% vs 24%; P=.001). Non-AIDS-defining cancers, unnatural deaths, and cardiovascular diseases are now major causes of death in patients with HIV. In recent years the majority of deceased patients are on ART and with virological suppression. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Lineage Analysis of Circulating Trypanosoma cruzi Parasites and Their Association with Clinical Forms of Chagas Disease in Bolivia](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2872639)\ndel Puerto, Ramona; Nishizawa, Juan Eiki; Kikuchi, Mihoko; Iihoshi, Naomi; Roca, Yelin; Avilas, Cinthia; Gianella, Alberto; Lora, Javier; Gutierrez Velarde, Freddy Udalrico; Renjel, Luis Alberto; Miura, Sachio; Higo, Hiroo; Komiya, Norihiro; Maemura, Koji; Hirayama, Kenji\n2010-01-01\nBackground The causative agent of Chagas disease, Trypanosoma cruzi, is divided into 6 Discrete Typing Units (DTU): Tc I, IIa, IIb, IIc, IId and IIe. In order to assess the relative pathogenicities of different DTUs, blood samples from three different clinical groups of chronic Chagas disease patients (indeterminate, cardiac, megacolon) from Bolivia were analyzed for their circulating parasites lineages using minicircle kinetoplast DNA polymorphism. Methods and Findings Between 2000 and 2007, patients sent to the Centro Nacional de Enfermedades Tropicales for diagnosis of Chagas from clinics and hospitals in Santa Cruz, Bolivia, were assessed by serology, cardiology and gastro-intestinal examinations. Additionally, patients who underwent colonectomies due to Chagasic magacolon at the Hospital Universitario Japon\u00e9s were also included. A total of 306 chronic Chagas patients were defined by their clinical types (81 with cardiopathy, 150 without cardiopathy, 100 with megacolon, 144 without megacolon, 164 with cardiopathy or megacolon, 73 indeterminate and 17 cases with both cardiopathy and megacolon). DNA was extracted from 10 ml of peripheral venous blood for PCR analysis. The kinetoplast minicircle DNA (kDNA) was amplified from 196 out of 306 samples (64.1%), of which 104 (53.3%) were Tc IId, 4 (2.0%) Tc I, 7 (3.6%) Tc IIb, 1 (0.5%) Tc IIe, 26 (13.3%) Tc I/IId, 1 (0.5%) Tc I/IIb/IId, 2 (1.0%) Tc IIb/d and 51 (25.9%) were unidentified. Of the 133 Tc IId samples, three different kDNA hypervariable region patterns were detected; Mn (49.6%), TPK like (48.9%) and Bug-like (1.5%). There was no significant association between Tc types and clinical manifestations of disease. Conclusions None of the identified lineages or sublineages was significantly associated with any particular clinical manifestations in the chronic Chagas patients in Bolivia. PMID:20502516\n[Adapting immunisation schedules for children undergoing chemotherapy.](https://www.ncbi.nlm.nih.gov/pubmed/27773490)\nFern\u00e1ndez-Prada, Mar\u00eda; Rodr\u00edguez-Mart\u00ednez, Mar\u00eda; Garc\u00eda-Garc\u00eda, Rebeca; Garc\u00eda-Corte, Mar\u00eda Dolores; Mart\u00ednez-Ortega, Carmen\n2018-02-01\nChildren undergoing chemotherapy for cancer have special vaccination needs after completion of the treatment. The aim of this study was to evaluate the adaptation of post-chemotherapy vaccination schedules. An observational study was performed on a retrospective cohort that included all children aged from 0 to 14 years, who completed chemotherapy in a tertiary hospital between 2009 and 2015. Inclusion and exclusion criteria were applied. Immunisation was administered in accordance with the guidelines of the Vaccine Advisory Committee of the Spanish Association of Paediatrics. Primary Care immunisation and clinical records of the Preventive Medicine and Public Health Department were reviewed. Of the 99 children who had received chemotherapy, 51 (70.6% males) were included in the study. As regards the type of tumour, 54.9% had a solid organ tumour, and 45.1% had a haematological tumour. Post-chemotherapy immunisation was administered to 70.6%. The most common vaccines received were: diphtheria-tetanus-pertussis or diphtheria-tetanus (54.9%), meningococcus C (41.2%), and seasonal influenza (39.2%). The rate of adaptation of the immunisation schedule after chemotherapy was 9.8%. The pneumococcal conjugate vaccine against 7v or 13v was administered to 21.6% of study subjects. However, only 17.6% received polysaccharide 23v. None received vaccination against hepatitis A. No statistically significant differences were observed between adherence to immunisation schedules and type of tumour (P=.066), gender (P=.304), or age (P=.342). Post-chemotherapy immunisation of children with cancer is poor. The participation of health professionals in training programs and referral of paediatric cancer patients to Vaccine Units could improve the rate of schedule adaptation and proper immunisation of this population. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Outcome after discontinuing anticoagulant therapy in women with venous thromboembolism during hormonal use.](https://www.ncbi.nlm.nih.gov/pubmed/28262237)\nBlanco-Molina, \u00c1ngeles; Trujillo-Santos, Javier; Pesavento, Raffaele; Rosa, Vladimir; Falg\u00e1, Conxita; Tolosa, Carles; Mazzolai, Lucia; Samp\u00e9riz, \u00c1ngel; Duce, Rita; Monreal, Manuel\n2017-03-01\nWhether women developing venous thromboembolism (VTE) while using hormonal therapy should be classified as having \"unprovoked\" or \"provoked\" VTE is controversial. We used the RIETE (Registro Informatizado Enfermedad TromboEmb\u00f3lica) database to compare the rate of symptomatic VTE recurrences after discontinuing anticoagulation in 3 subgroups of women aged \u226450years without cancer, pregnancy or puerperium: (1) those with hormonal therapy and no additional risk factors (hormonal users only); (2) those with unprovoked VTE; and (3) those with additional risk factors, with or without hormonal therapy. As of March 2016, 1513 women had been followed-up for at least one month after discontinuing anticoagulation. Of these, 654 (43%) were hormonal users only, 390 (26%) had unprovoked VTE and 469 (31%) had transient risk factors with or without hormonal therapy. After discontinuing anticoagulation, the rate of VTE recurrences in women with hormonal use only (2.44 per 100 patient-years; 95% CI: 1.53-3.69) was significantly lower than in those with unprovoked VTE (6.03; 95% CI: 3.97-8.77) and similar to those with transient risk factors (2.58; 95% CI: 1.50-4.13). Interestingly, the rate of VTE recurrences presenting as pulmonary embolism in women with hormonal use only (0.55 per 100 patient-years; 95% CI: 0.18-1.29) was similar to those with transient risk factors (0.46; 95% CI: 0.09-1.33) and 4-fold lower than in women with unprovoked VTE (2.23; 95% CI: 1.07-4.10). After discontinuing anticoagulation, the rate of VTE recurrences in hormonal users only was significantly lower than in women with unprovoked VTE and similar to the rate in women with additional risk factors. \u00a9 2017 Elsevier Ltd. All rights reserved.\n[An outbreak of monophasic and biphasic Salmonella Typhimurium, and Salmonella Derby associated with the consumption of dried pork sausage in Castellon (Spain).](https://www.ncbi.nlm.nih.gov/pubmed/26790900)\nArnedo-Pena, Alberto; Sabater-Vidal, Susana; Herrera-Le\u00f3n, Silvia; Bellido-Blasco, Juan B; Silvestre-Silvestre, Esther; Meseguer-Ferrer, Noemi; Yague-Mu\u00f1oz, Alberto; Gil-Fortu\u00f1o, Maria; Romeu-Garc\u00eda, Angeles; Moreno-Mu\u00f1oz, Rosario\n2016-11-01\nAn outbreak of S.Typhimurium occurred in several towns and cities in the province of Castellon (Spain) between 23 February and 27 May 2011. On April 5, the microbiology laboratory of a hospital in Castellon alerted the health authorities to the increase in S.Typhimurium isolated in fecal culture of children with gastroenteritis. The serotype and phage-type of 83 positive cases of S.Typhimurium isolated in these period included 49 monophasic/biphasic S.Typhimurium phage type 138, phage type 193, S.Derby, and 34 other S.Typhimurium phage-types. The median of age of patients was 4 years with a range of 0.6-80 years, and the 18% of patients were hospitalised. Two incident matched case-control studies were carried out; the first with S.Typhimurium phage type 138, 193, and S.Derby cases and the second with the other cases. The two studies found that the consumption of brand X dried pork sausage, purchased in a supermarket chain A, was associated with the disease (matched Odds Ratio [mOR]=13.74 95% Confidence Interval [CI] 4.84-39.06 and mOR=8.20 95% CI 2.32-28.89), respectively). S.Typhimurium phage type 193 and S.Derby were isolated in the food taken from the household of two patients and from the supermarket chain's A central warehouse. The pulsed-field gel electrophoresis study confirmed the similarity of the strains from the patients and the food. On May 25 2011, a national food alert led to the withdrawal of the food from the chain A and the outbreak ended. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Comparison of sporadic cases of Salmonella Typhimurium with other Salmonella serotypes in Castellon (Spain): case-case study.](https://www.ncbi.nlm.nih.gov/pubmed/28993063)\nArnedo-Pena, Alberto; Vivas-Fornas, Iraya; Meseguer-Ferrer, Noemi; Tirado-Balaguer, Mar\u00eda Dolores; Yag\u00fce-Mu\u00f1oz, Alberto; Herrera-Le\u00f3n, Silvia; Sabater-Vidal, Susana; Romeu-Garc\u00eda, Mar\u00eda \u00c1ngeles; Vizcaino Batll\u00e9s, Ana; Bellido-Blasco, Juan Bautista; Moreno-Mu\u00f1oz, Rosario\n2017-10-07\nSalmonella infections (SI) are common in Spain. The aim of this study was to appraise risk factors and the clinical characteristics of sporadic Salmonella Typhimurium infections compared with other sporadic salmonella serotype infections (OSI). From September 2014 to August 2015, a case-case study was carried out by the Epidemiology Division of the Public Health Centre of Castellon. Case 1 consisted of patients with sporadic S. Typhimurium infections, while case 2 comprised OSI patients, assessed according to the stool cultures analyzed by the Microbiology Laboratories of Hospital General de Castellon and Hospital de La Plana in Vila-real. Patients from detected outbreaks were not included. The salmonella serotype was identified by the National Centre of Microbiology (Madrid). The total number of SI patients reported was 327, 242 of whom were studied (74.0%). 148 patients had sporadic S. Typhimurium infection and 64 had OSI, with median ages of 4 and 8.5 years, respectively. Sporadic S. Typhimurium infection patients presented more blood in feces and diarrhea episodes. Consumption of pork meat (OR=2.22; 95% CI 1.12-4.43), cold pork meats (OR=2.49; 95% CI 1.32-4.68) and playing in the dirt (OR=3.02; 95% CI 1.55-5.88), were associated with sporadic S. Typhimurium infection. In the 0-4 year-old group, the associated factors were consumption of cold pork meats, omelets and female gender. In the 5-year-old and over group, only playing in soil was associated with sporadic S. Typhimurium infection. The consumption of pork and omelets, as well as playing in the dirt, were the main factors associated with infection. Children were most affected by sporadic S. Typhimurium infection. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Evaluation of a commercial multiplex PCR (Unyvero i60\u00ae) designed for the diagnosis of bone and joint infections using prosthetic-joint sonication.](https://www.ncbi.nlm.nih.gov/pubmed/27769681)\nPrieto-Borja, Laura; Rodriguez-Sevilla, Graciela; Au\u00f1on, Alvaro; P\u00e9rez-Jorge, Concepci\u00f3n; Sandoval, Enrique; Garcia-Ca\u00f1ete, Joaqu\u00edn; Gadea, Ignacio; Fernandez-Roblas, Ricardo; Blanco, Antonio; Esteban, Jaime\n2017-04-01\nThe development of sonication protocols over the last few years has improved the sensitivity of conventional cultures for the diagnosis of prosthetic-joint infection (PJI). However, the development of a new, specifically designed kit for the molecular diagnosis of PJI could provide a major improvement in this field. Prostheses retrieved from patients who underwent implant removal from May 2014 to May 2015 were sent for culture, and processed according to a previously defined protocol that included sonication. Furthermore, 180 microlitres of sonication fluid were used to carry out the multiplex PCR test (Unyvero i60 system \u00ae ). A comparison of the sensitivity, specificity, positive (PPV) and negative (NPV) predictive value, was performed. The study was approved by the Clinical Research Ethics Committee. The analysis included 88 prostheses from 68 patients (1.29 prostheses/patient). The type of prostheses studied were knee (n=55), total hip (n=26), partial hip (n=5), and shoulder (n=2). Twenty-nine patients were diagnosed with a PJI (15 delayed, 12 acute, and 2 haematogenous infections). In 24 cases, the result of the PCR was positive, all but 1 corresponding to patients with clinical criteria of PJI. Nine resistance mechanisms were detected from 5 samples. The Unyvero i60 system \u00ae showed slightly better results than traditional culture in terms of specificity and PPV. The Unyvero i60 system \u00ae may play a role in rapid diagnosis of PJI, due to its high specificity and PPV. However, despite these results, cultures have to be performed to detect organisms not detected by the system. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Screening for parasite infections in immigrant children from low-income countries.](https://www.ncbi.nlm.nih.gov/pubmed/27156246)\nBelhassen-Garc\u00eda, Moncef; Pardo-Lled\u00edas, Javier; P\u00e9rez Del Villar, Luis; Velasco-Tirado, Virginia; Siller Ruiz, Mar\u00eda; Cordero-S\u00e1nchez, Miguel; Vicente, Belen; Hern\u00e1ndez Egido, Sara; Mu\u00f1oz Bellido, Juan Luis; Muro, Antonio\n2017-01-01\nIn Spain, minors represent approximately 20% of the immigration flow. Many of these immigrants come from countries in the tropics and sub-tropics where intestinal parasitic infections caused by helminths and protozoa are one of the major causes of human disease. The main objective of the present work was to describe parasite infections in a group of immigrant children. A prospective evaluation was performed in 373 minors from Sub-Saharan Africa, North Africa, and Latin America. Details were collected from the medical records and physical examination. Urine, stool and peripheral blood samples were obtained for serological and routine laboratory tests. Direct and indirect parasitological tests were also performed. At least 1 parasitic disease was diagnosed in 176 (47.1%) immigrant children, while 77 (20.6%) minors were infected with two or more parasites. The number of parasites was highest in children from Sub-Saharan Africa compared with the rest of the areas of origin (p<.001), and in children from urban areas compared with those from rural areas (OR 1.27 [1.059-1.552], p=.011). The most frequent causes of multiple parasite infection were filariasis plus strongyloidiasis and filariasis plus schistosomiasis. Intestinal parasite infection was diagnosed in 38 cases (13.8%). Logistic regression analysis revealed that for each month of stay, the probability of a positive finding in the stool sample decreased by 0.02% [\u03b2=-0.020, (p=.07)]. The high infection rates of parasite diseases in immigrant children point to the need for screening protocols for certain infectious diseases in these children according to their country of origin and their length of residence in Spain. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Validation and verfication of microbiology methods].](https://www.ncbi.nlm.nih.gov/pubmed/24958671)\nCamar\u00f3-Sala, Mar\u00eda Luisa; Mart\u00ednez-Garc\u00eda, Rosana; Olmos-Mart\u00ednez, Piedad; Catal\u00e1-Cuenca, Vicente; Ocete-Moch\u00f3n, Mar\u00eda Dolores; Gimeno-Cardona, Concepci\u00f3n\n2015-01-01\nClinical microbiologists should ensure, to the maximum level allowed by the scientific and technical development, the reliability of the results. This implies that, in addition to meeting the technical criteria to ensure their validity, they must be performed with a number of conditions that allows comparable results to be obtained, regardless of the laboratory that performs the test. In this sense, the use of recognized and accepted reference methodsis the most effective tool for these guarantees. The activities related to verification and validation of analytical methods has become very important, as there is continuous development, as well as updating techniques and increasingly complex analytical equipment, and an interest of professionals to ensure quality processes and results. The definitions of validation and verification are described, along with the different types of validation/verification, and the types of methods, and the level of validation necessary depending on the degree of standardization. The situations in which validation/verification is mandatory and/or recommended is discussed, including those particularly related to validation in Microbiology. It stresses the importance of promoting the use of reference strains as controls in Microbiology and the use of standard controls, as well as the importance of participation in External Quality Assessment programs to demonstrate technical competence. The emphasis is on how to calculate some of the parameters required for validation/verification, such as the accuracy and precision. The development of these concepts can be found in the microbiological process SEIMC number 48: \u00abValidation and verification of microbiological methods\u00bb www.seimc.org/protocols/microbiology. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Epidemiology of measles in vaccinated people, Spain 2003-2014.](https://www.ncbi.nlm.nih.gov/pubmed/27262819)\nRisco-Risco, Carlos; Masa-Calles, Josefa; L\u00f3pez-Perea, Noem\u00ed; Echevarr\u00eda, Juan Emilio; Rodr\u00edguez-Caravaca, Gil\n2017-11-01\nDuring the final phase of measles elimination rigorous investigation of each individual case becomes fundamental to confirm or discard cases, particularly among vaccinated people, since they experience a milder disease, and laboratory diagnosis is more complex. Our study focused in the epidemiology of measles in vaccinated people. Longitudinal study on measles cases in two dose vaccinated people in Spain from 2003 to 2014. We confirmed 138 measles cases (90 of them, laboratory confirmed) in people with two doses of vaccine. The median of time from last vaccination to rash onset showed a lineal trend (P<.001), in parallel with the number of doses of vaccine received (0, 1, 2 doses). Among confirmed cases, the hospitalization risk decreased inversely proportional to the number of administered vaccine doses (linear trend, P<.001). Only in 23.9% of confirmed cases and 50% of discarded cases the guidelines about sample taking were fulfilled. 50% of samples in two dose vaccinated people were taken without fulfilling time delay criteria. 16.7% (36/215) of discarded cases with a negative IgM result did correspond to samples taken early (first 72h after rash) and could represent false negatives. Our results highlight the importance of fulfilling properly the guidelines for laboratory diagnosis in order to confirm or discard every measles case, especially in two dose vaccinated people. When a negative IgM result is obtained in early samples a new IgM test should be practiced, as well as a PCR test, in order to avoid infra-detection of cases. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Postural instability and gait are associated with severity and prognosis of Parkinson disease.](https://www.ncbi.nlm.nih.gov/pubmed/27178702)\nvan der Heeden, Jorine F; Marinus, Johan; Martinez-Martin, Pablo; Rodriguez-Blazquez, Carmen; Geraedts, Victor J; van Hilten, Jacobus J\n2016-06-14\nDifferences in disease progression in Parkinson disease (PD) have variously been attributed to 2 motor subtypes: tremor-dominant (TD) and postural instability and gait difficulty (PIGD)-dominant (PG). We evaluated the role of these phenotypic variants in severity and progression of nondopaminergic manifestations of PD and motor complications. Linear mixed models were applied to data from the Profiling Parkinson's disease (PROPARK) cohort (n = 396) to evaluate the effect of motor subtype on severity and progression of cognitive impairment (Scales for Outcomes in Parkinson's disease [SCOPA]-Cognition [SCOPA-COG]), depression (Hospital Anxiety and Depression Scale [HADS]), autonomic dysfunction (SCOPA-Autonomic [SCOPA-AUT]), excessive daytime sleepiness, psychotic symptoms (SCOPA-Psychiatric Complications [SCOPA-PC]), and motor complications. In first analyses, subtype as determined by the commonly used ratio of tremor over PIGD score was entered as a factor, whereas in second analyses separate tremor and PIGD scores were used. Results were verified in an independent cohort (Estudio Longitudinal de Pacientes con Enfermedad de Parkinson [ELEP]; n = 365). The first analyses showed that PG subtype patients had worse SCOPA-COG, HADS, SCOPA-AUT, SCOPA-PC, and motor complications scores, and exhibited faster progression on the SCOPA-COG. The second analyses showed that only higher PIGD scores were associated with worse scores for these variables; tremor score was not associated with severity or progression of any symptom. Analyses in the independent cohort yielded similar results. In contrast to PIGD, which consistently was associated with greater severity of nondopaminergic symptoms, there was no evidence of a benign effect of tremor. Our findings do not support the use of the TD subtype as a prognostic trait in PD. The results showed that severity of PIGD is a useful indicator of severity and prognosis in PD by itself. \u00a9 2016 American Academy of Neurology.\n[Paediatric invasive pneumococcal disease on the island of Gran Canaria: 16-year prospective study (2001-2016).](https://www.ncbi.nlm.nih.gov/pubmed/29179982)\nSantana Hern\u00e1ndez, Milagrosa; Aguiar-Santana, Ione Ahedey; Artiles Campelo, Fernando; Colino Gil, Elena\n2017-11-24\nTo calculate the incidence of invasive pneumococcal disease (IPD) in the paediatric population of Gran Canaria (Spain), its clinical and epidemiological characteristics, serotype distribution, antibiotic resistance, and variations in these variables before and after the introduction of the PCV13 vaccine. Prospective hospital-based study including all patients (190) aged 0-14 years admitted with confirmed IPD between January 2001-May 2010 (152 cases) and June 2010-December 2016 (38 cases). Patients were divided into 3 age groups (<2 years; 2-5 years; and >5 years). Clinical symptoms were mutually-exclusively classified as meningitis, bacteraemic pneumonia, pleural effusion (PE), empyema or bacteraemia without a focus. Most cases occurred in boys (59.47%), during autumn-winter (65.79%), in children aged <2 years (55.79%) and with mean age increasing from the pre-PCV13 to the post-PCV13 period (2.5 vs 3.1 years). Incidence between periods reduced by 66.4% (p<0.001): from 13.1/100,000 to 4.4/100,000. PEs (3.9% vs 18.4%, p<0.005) and empyemas (1.5% vs 16.7%, p=NS) increased in the post-PCV13 period whereas all other symptoms decreased, although this was not statistically significant. Vaccine serotypes (77% vs 40.6%, p=0.000), particularly serotypes 19A (23.9% vs 12.5%) and 14 (14.2% vs 9.4%), as well as erythromycin resistance (57.2% vs 7.9%, p=0.000) decreased in the post-PCV13 period. IPD incidence, vaccine serotypes and erythromycin resistance decreased in the post-PCV13 period whereas PEs increased. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Trends and determinants factors of Chlamydia trachomatis genital infection in young people under 25 years. Catalonia 2007-2014].](https://www.ncbi.nlm.nih.gov/pubmed/26706394)\nL\u00f3pez-Corbeto, Evelin; Gonz\u00e1lez, Victoria; Bascunyana, Elisabeth; Humet, Victoria; Casabona, Jordi\n2016-10-01\nChlamydia trachomatis (chlamydia) infection is the most common bacterial sexually transmitted diseases (STD). However, the prevalence among young people is unknown in our country. In 2007, the monitoring of the prevalence and behaviours related to acquiring it began in Catalonia in young people \u226425years. To determine and monitor the prevalence and determining factors of chlamydia among a young sexually active population \u226425years, treated in sexual and reproductive health care centras (CT/NG-ASSIR) and in prisons (CT/NG-Prisons). An analysis was performed on 6 cross-sectional data studies in two sentinel populations of young people from the period 2007-2014. Behavioural indicators were recorded and urine specimens were collected for analysis by PCR. The prevalence and trends are described, and the variables associated with infection were evaluated using multivariate logistic regression analysis. The mean prevalence for CT/NG-ASSIR was 7.4%, with an upward trend (P=.174), and an increase of 46.5%. CT/NG-Prisons had a mean 8.0%, with an upward trend (P=.282), and an increase of 31.6%. Age and foreign origin are presented as risk factors in both populations. The concurrent sexual partners added to CT/NG-ASSIR and the time spent in prison to CT/NG-Prisons. The results underscore the need for a more efficient approach to control activities related to chlamydia infection in Catalonia. Policies need to be strengthened to promote safer sexual behaviours and active case finding by opportunistic screening in less than 25year-old. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Identification of a new variant of Chlamydia trachomatis in Mexico.](https://www.ncbi.nlm.nih.gov/pubmed/29636285)\nEscobedo-Guerra, Marcos R; Katoku-Herrera, Mitzuko; Lopez-Hurtado, Marcela; Villagrana-Zesati, Jesus Roberto; de Haro-Cruz, Mar\u00eda de J; Guerra-Infante, Fernando M\n2018-04-07\nChlamydia trachomatis is one of the main etiological agents of sexually transmitted infections worldwide. In 2006, a Swedish variant of C. trachomatis (Swedish-nvCT), which has a deletion of 377bp in the plasmid, was reported. In Latin America, Swedish-nvCT infections have not been reported. We investigated the presence of Swedish-nvCT in women with infertility in Mexico. Swedish-nvCT was searched in 69C. trachomatis positive samples from 2339 endocervical specimens. We designed PCR primers to identify the deletion in the plasmid in the ORF1, and the presence of a repeated 44bp in the ORF3. The sample with the deletion was genotyped with the genes of the major outer membrane protein A (ompA) and the polymorphic membrane protein (pmpH). The deletion was detected in one of the 69 samples positive C. trachomatis of 2339 endocervical exudates. The nucleotide sequence analysis of the ompA shows a high degree of similarity with the Swedish nvCT (98%), however the variant found belongs to serovar D. The nucleotide sequence of the pmpH gene associates to the variant found in the genitourinary pathotype of the Swedish-nvCT but in different clusters. Our results revealed the presence of a new variant of C. trachomatis in Mexican patients. This variant found in Mexico belongs to serovar D based on the in silico analysis of the ompA and pmpH genes and differs to the Swedish-nvCT (serovars E). For these variants of C. trachomatis that have been found it is necessary to carry out a more detailed analysis, although the role of this mutation has not been demonstrated in the pathogenesis. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nMart\u00ednez Carri\u00f3n, Jos\u00e9 Miguel; C\u00e1mara, Antonio D; P\u00e9rez-Castroviejo, Pedro Mar\u00eda\n2016-12-12\nObjetivo: analizar la geograf\u00eda del estado nutricional en Espa\u00f1a y su evoluci\u00f3n entre mediados del siglo xixy comienzos del siglo xx, etapa previa a la transici\u00f3n nutricional con alta prevalencia de malnutrici\u00f3n.M\u00e9todos: se utilizan datos antropom\u00e9tricos agregados (promedios provinciales de estatura) del reclutamiento militar en 1858 y 1913, as\u00ed como promedios provinciales de estatura y peso procedentes de una revisi\u00f3n realizada entre 119.571 soldados en 1903-1906. Con estos datos se elaboran cartograf\u00eda y estad\u00edsticos descriptivos.Resultados: los par\u00e1metros antropom\u00e9tricos de los espa\u00f1oles se situaban entre los valores de complexi\u00f3n m\u00e1s bajos de Europa antes de la transici\u00f3n nutricional. Entre 1858 y 1913, la altura media creci\u00f3 solo 1,43 cm. En ese periodo hubo cambios significativos en la geograf\u00eda antropom\u00e9trica marcados por la configuraci\u00f3n de una polaridad nutricional a las puertas de la I Guerra Mundial: las provincias del centro y del sur de pa\u00eds exhiben mayor incidencia de la malnutrici\u00f3n cr\u00f3nica que las provincias del arco Noreste, que disfrutan de ventaja relativa en t\u00e9rminos nutricionales.Conclusi\u00f3n:las desigualdades territoriales que configuraron una geograf\u00eda polarizada del estado nutricional en Espa\u00f1a pueden asociarse en parte a los cambios ambientales del periodo, caracterizados por el inicio de la modernizaci\u00f3n y la industrializaci\u00f3n y, asimismo, por la privaci\u00f3n derivada de las crisis agrarias, las enfermedades y el relativo atraso tecnol\u00f3gico. Se destaca la relevancia de la historia antropom\u00e9trica para el estudio de los niveles de vida en poblaciones del pasado y del proceso de transici\u00f3n nutricional.\n[Jovenes con Discapacidades y Enfermedades Cronicas: Una Guia Introductoria para Joyenes y Padres. Revisiones de CYDLINE (Youth with Disabilities and Chronic Illnesses: An Introductory Guide for Youth and Parents. CYDLINE Reviews). Parents. CYDLINE Reviews.](https://eric.ed.gov/?q=GRANADA&pg=5&id=ED345428) [ERIC Educational Resources Information Center](http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced)\nMinnesota Univ., Minneapolis. National Center for Youth with Disabilities.\nThis bibliography covers a wide range of issues related to the needs of adolescents and young adults with chronic illnesses and disabilities and their families. For each item in the bibliography, information provided includes author, title, source, date, and abstract. Price information is given when available. Materials include books, audiotapes,\u2026\n[Determinacion del error sistematico del momentum de muones producidos por interacciones neutrino-nucleon en el detector MINER$$\\](https://www.osti.gov/servlets/purl/1362136) [DOE Office of Scientific and Technical Information (OSTI.GOV)](http://www.osti.gov/search)\nDiaz Bautista, Gonzalo A.\nestudio de un tipo especco de interaccion denominado corriente cargada, cuyas partculas de estado nal incluye hadrones y, principalmente, muones. La precision en los resultados de secciones de choque esta sujeta a que la energa y el momentum estos muones sean, a su vez, correctamente caracterizados, incluyendo sus incertidumbres sistematicas. El objetivo de este trabajo de tesis es precisamente presentar la metodologa usada para medir las energas de los muones producidos por interacciones de neutrinos y sus correspondientes incertidumbres asociadas a dicha medicion.\u00ab less\n[Annual Activity Density of groundbeetles (Coleoptera: Carabidae) of a Celtis ehrenbergiana (Rosales: Celtidaceae) Forest of Buenos Aires Province, Argentina](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5634045)\nCastro, Adela V.; Porrini, Dar\u00edo P.; Cicchino, Armando C.\n2014-01-01\nAbstract The aim of this study was to describe the annual activity cycle, the sex ratio, and the relationship between the weather variables and activity density of the 16 most abundant carabid species of a typical southeastern region of Pampasia, Argentina. The study focused on the southernmost Celtis ehrenbergiana (Klotzsch) Liebmann ( = C. tala Guillies ex Planch) native forest of the region, from March 2008 to March 2009, a period during which there was a marked draught associated with the La Ni\u00f1a phenomenon. Forty-five pitfall traps were emptied once every 2 wk, and the occurrence of larvae, tenerals, and subtenerals was recorded. Photoperiod, temperature, and precipitations explained 35% of the total variation in the catch. Total carabid activity was high in early autumn and late spring. Eight species reached their maximum activity in spring, five in winter, two in summer, and one in autumn. Possible reproductive strategies, the influence of different variables involved in the life cycles of the species, and the sex ratio and their limitations are discussed. RESUMEN El objetivo de este trabajo fue describir la proporci\u00f3n de sexos, el ciclo de actividad annual, la relaci\u00f3n entre las variables meteorol\u00f3gicas y la actividad de las 16 especies m\u00e1s frecuentes de car\u00e1bidos de una regi\u00f3n t\u00edpica del sudeste de la Pampasia, Argentina. El trabajo se enfoc\u00f3 en el talar, C. ehrenbergiana (Klotzsch) Liebmann ( = C. tala Guillies ex Planch), m\u00e1s austral de la regi\u00f3n, durante marzo 2008-marzo 2009, per\u00edodo marcado por una sequ\u00eda asociada con el fen\u00f3meno La Ni\u00f1a. Se utilizaron 45 trampas \u201cpitfall\u201d recambiadas quincenalmente. Se registr\u00f3 la presencia de larvas, tenerales y subtenerales. El fotoper\u00edodo, la temperatura y las precipitaciones explicaron el 35% de la variaci\u00f3n en el n\u00famero de total de individuos. La actividad total de los car\u00e1bidos fue alta en oto\u00f1o temprano y primavera tard\u00eda. Ocho especies alcanzaron el pico de m\n[Experiences and coping with the altered body image in digestive stoma patients.](https://www.ncbi.nlm.nih.gov/pubmed/27982309)\nHueso-Montoro, C\u00e9sar; Bonill-de-Las-Nieves, Candela; Celdr\u00e1n-Ma\u00f1as, Miriam; Hern\u00e1ndez-Zambrano, Sandra Milena; Amezcua-Mart\u00ednez, Manuel; Morales-Asencio, Jos\u00e9 Miguel\n2016-12-08\n\u00e9 a resigna\u00e7\u00e3o e a rejei\u00e7\u00e3o. As experi\u00eancias pr\u00e9vias de outros familiares, a possibilidade de reconstru\u00e7\u00e3o do estoma ou o tipo de doen\u00e7a s\u00e3o fatores condicionantes. o enfrentamento diante da not\u00edcia do estoma est\u00e1 condicionado pelo tipo de doen\u00e7a. Apesar disso, observa-se que a maioria dos informantes tende a normalizar o processo. A enfermagem tem papel fundamental na implementa\u00e7\u00e3o de interven\u00e7\u00f5es cognitivas-comportamentais e outros recursos destinados \u00e0 promo\u00e7\u00e3o da autonomia dos pacientes em tudo relacionado ao cuidado do estoma. describir el afrontamiento de personas ostomizadas ante la noticia de la realizaci\u00f3n de la ostom\u00eda, as\u00ed como analizar el significado y la vivencia ante su nueva realidad corporal. estudio cualitativo fenomenol\u00f3gico mediante entrevistas semiestructuradas a 21 personas ostomizadas. Se realiz\u00f3 an\u00e1lisis mediante comparaci\u00f3n constante de datos, incorporaci\u00f3n progresiva de sujetos y triangulaci\u00f3n entre investigadores y enfermeras expertas en estomaterapia. Se emple\u00f3 el programa Atlas.ti. emergen dos categor\u00edas centrales: \"Afrontamiento ante la noticia de que van a ser ostomizados\" y \"Significado y vivencia de la nueva realidad corporal\". La respuesta de los informantes es variable, percibi\u00e9ndose situaciones que van desde la aceptaci\u00f3n natural de su proceso hasta la resignaci\u00f3n y el rechazo. Las experiencias previas de otros familiares, la posibilidad de reconstrucci\u00f3n del estoma o el tipo de enfermedad, son factores condicionantes. el afrontamiento ante la noticia del estoma est\u00e1 condicionado por el tipo de enfermedad, aunque la normalizaci\u00f3n del proceso es la tendencia observada en la mayor\u00eda de los informantes. Enfermer\u00eda tiene un papel fundamental en la puesta en marcha de intervenciones cognitivos-conductuales y otros recursos destinados a la promoci\u00f3n de la autonom\u00eda de los pacientes en todo lo relacionado con el cuidado del estoma.\n[Reliability and construct validity of the Instrument to Measure the Impact of Valve Heart Disease on the Patient's Daily Life.](https://www.ncbi.nlm.nih.gov/pubmed/27992024)\nAnjos, Daniela Brianne Martins Dos; Rodrigues, Roberta Cunha Matheus; Padilha, K\u00e1tia Melissa; Pedrosa, Rafaela Batista Dos Santos; Gallani, Maria Cec\u00edlia Bueno Jayme\n2016-12-19\n\u00e9dio de 9,9 minutos e com 110% de respostas, respectivamente. Constatados efeitos teto e ch\u00e3o para todos os dom\u00ednios, principalmente efeito ch\u00e3o. A confiabilidade foi testada por meio do teste-teste de repeti\u00e7\u00e3o, obtendo-se evid\u00eancias de estabilidade temporal da medida. Foram constatadas correla\u00e7\u00f5es negativas significantes de moderada a forte magnitude entre o escore da quest\u00e3o gen\u00e9rica sobre o impacto da doen\u00e7a e os escores do IDCV, o que aponta para validade de construto convergente do instrumento. o Instrumento para Mensura\u00e7\u00e3o do Impacto da Doen\u00e7a no Cotidiano do Valvopata apresentou evid\u00eancias de confiabilidade e validade quando aplicado em pacientes com valvopatia. evaluar la viabilidad, aceptabilidad y los efectos techo y suelo, estimar la confiabilidad y verificar la validez de constructo convergente del Instrumento para Medir el Impacto en lo Cotidiano (IDCV) del sujeto con valvulopat\u00edas mitral y/o a\u00f3rtica. los datos fueron obtenidos de 86 pacientes con valvulopat\u00edas por medio de tres etapas: una entrevista presencial para caracterizaci\u00f3n sociodemogr\u00e1fica y cl\u00ednica y las otras dos realizadas por medio de contacto telef\u00f3nico para las aplicaciones del instrumento (test y test de repetici\u00f3n). en cuanto a la viabilidad y aceptabilidad, el instrumento fue aplicado con un tiempo promedio de 9,9 minutos y con 110% de respuestas, respectivamente. Fueron constatados los efectos techo y suelo para todos los dominios, principalmente el efecto suelo. La confiabilidad fue comprobada por medio del test de repetici\u00f3n, obteni\u00e9ndose evidencias de estabilidad temporal de la medida. Fueron constatadas correlaciones negativas significativas de moderada a fuerte magnitud entre el puntaje de la pregunta gen\u00e9rica sobre el impacto de la enfermedad y los puntajes del IDCV, lo que apunta para la validez de constructo convergente del instrumento. el instrumento para medir el impacto de la valvulopat\u00eda en lo cotidiano del sujeto, present\u00f3 evidencias de\n[Manual de Adiestramiento sobre Terapia de Rehidratacion Oral y Control de las Enfermedades Diarreicas (Oral Rehydration Therapy and the Control of Diarrheal Diseases). Training for Development. Peace Corps Information Collection & Exchange Training Manual No. T-53.](http://files.eric.ed.gov/fulltext/ED307490.pdf) [ERIC Educational Resources Information Center](http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced)\nClark, Mari; And Others\nThis Spanish-language manual was developed to train Peace Corps volunteers and other community health workers in Spanish-speaking countries in oral rehydration therapy (ORT) and the control of diarrheal diseases. Using a competency-based format, the manual contains three training modules (organized in seven sessions) that focus on interrelated\u2026\n[Mortality trends for tuberculosis in European Union countries, 2000-2010.](https://www.ncbi.nlm.nih.gov/pubmed/28733107)\nAl-Rahamneh, Moad J; Al-Rahamneh, Anas; Guill\u00e9n-Grima, Francisco; Arnedo-Pena, Alberto; Aguinaga-Ontoso, In\u00e9s\nThe objective of this study was to update and analyze tuberculosis (TB) mortality data in the European Union between 2000 and 2010 separately for men and women and try to detect if there have been any changes in trends in each country and the association with the economic situation and inequalities. Data were extracted for tuberculosis deaths in 2000-2010 for 29 European Union countries and for Switzerland, via the World Health Organization (WHO) European detailed mortality database (DMDB), using the Mortality tabulation list 1 (MTL1) codes for men and women separately for one age group (20-85+). We estimated age-standardised mortality rates, and analyzed data using the Joinpoint Regression Program for men and women separately in the European Union overall and by individual country for each year. Between 2000 and 2010, there were 68,771 recorded tuberculosis deaths in the European Union and the mortality rates were higher for men than women in the entire study zone. Overall, TB mortality rates declined linearly for both genders, but more in women than in men (from 5.43/100,000 in 2000 to 2.59/100,000 in 2010 in men and from 1.37/100,000 in 2000 to 0.51/100,000 in 2010 in women). There was decline in both genders for the entire study period, with a significant Estimated Annual Percentage Change (EAPC) of -8.1 for women and -7 for men when alpha<0.05 and with a 95% confidence interval (CI). A higher tuberculosis mortality was associated with lower economic resources and greater inequalities. TB mortality rates in the European Union decreased overall in 2000-2010 for both genders. Men have higher TB mortality rates than women in all countries. Our findings were consistent with the downward TB mortality trend in many other countries worldwide. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Influence of baseline MELD score in the efficacy of treatment of hepatitis C with simeprevir and sofosbuvir.](https://www.ncbi.nlm.nih.gov/pubmed/28641865)\nMoreno-Planas, Jos\u00e9 Mar\u00eda; Larrubia-Marfil, Juan Ram\u00f3n; S\u00e1nchez-Ruano, Juan Jos\u00e9; Morillas-Ari\u00f1o, Julia; Pat\u00f3n-Arenas, Roberto; S\u00e1iz-Chumillas, Rosa Mar\u00eda; T\u00e9bar-Romero, Emilia; Lucendo-Villar\u00edn, Alfredo; Gancedo-Bringas, Pilar; Solera-Mu\u00f1oz, Mario; Vicente-Guti\u00e9rrez, Mar\u00eda Del Mar; Mart\u00ednez-Alfaro, Elisa\n2018-05-01\nThere are few published studies on predictors of response to treatment with sofosbuvir and simeprevir in HCV patients. The objective of the study was to analyse possible predictors of response to simeprevir (SMV) and sofosbuvir (SOF) in patients infected with hepatitis C genotypes 1 or 4. Prospective observational cohort study in 12 hospitals. The primary efficacy endpoint was SVR rate 12 weeks after end of treatment (SVR12). 204 patients (62.3% male, mean age 55 years) were included: 186 (91.2%) genotype 1 (60.3% 1b 25% 1a) and 18 (8.8%) genotype 4. 132 (64.7%) cirrhotic (87.9% Child A), 33 (16.2%) F3, 31 (15.2%) F2, 8 (3.9%) F0-1. 80.8% MELD<10. 93 (45.6%) naive. Ribavirin was added in 68 (33.3%). Mean baseline viral load 2,151,549 IU/ml (SD: 2,391,840). Treatment duration 12 weeks in 93.1%. 4 discontinued therapy: suicide, psychotic attack, hyperbilirubinaemia and liver cancer recurrence. 190 (93.1%) achieved SVR12. There were no differences in SVR12 depending on the genotype, treatment duration, ribavirin use, prior therapy, viral load (VL) or baseline platelets. In univariate analysis, undetectable VL at 4 weeks (p=0.042), absence of cirrhosis (p=0.021), baseline albumin \u2265 4g/dl (p=0.001) and MELD<10 (p<0.0001) were associated with higher SVR12. In multivariate analysis, only baseline MELD score <10 patients had higher SVR12 (p<0.001). The combination of simeprevir and sofosbuvir in patients infected with genotype 1 and 4 hepatitis C is highly effective. It is a safe therapy, especially in patients without ribavirin. This combination was more effective in patients with a MELD score below 10. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Bibliometric study of Actas Dermo-sifiliogr\u00e1ficas (1984-2003) III. Analysis of bibliographic impact factors].](https://www.ncbi.nlm.nih.gov/pubmed/16476300)\nMiralles, Julia; Ramos, Jos\u00e9 M; Ballester, Rosa; Belinch\u00f3n, Isabel; Sevila, Amparo; Morag\u00f3n, Manuel\n2005-11-01\nTo quantify the impact factor of the journal Actas Dermo-Sifiliogr\u00e1ficas (AD) from 1986 to 1990 and from 1999 to 2003 and to identify the journal's citation pattern in those years. Citations obtained by AD in the periods from 1985-1990 and 1998-2003 for articles published from 1984 to 1989 and from 1997 to 2002 were collected using Science Citation Index Expanded (SCI). The number of times AD was cited doubled during the second period, increasing from 38 (period from 1985-1990) to 76 (period from 1998-2003). Considering the number of citations, AD's impact factor increased from 0.016 in 1986 to 0.040 in 2003. In both periods, citations corresponding to AD articles were included in a wide range of source journals, mainly dermatological publications abroad. The most referred journals in the second period were the Dutch publication Journal of the European Academy of Dermatology and Venereology (13 citations) and the Journal of the American Academy of Dermatology (12 citations). Unlike the period from 1985 to 1990 when no Spanish journal cited AD, four Spanish publications mentioned AD in the second period: Revista cl\u00ednica espa\u00f1ola (6 citations), Archivos de bronconeumolog\u00eda (4 citations), Medicina cl\u00ednica (3 citations) and the journal Enfermedades infecciosas y microbiolog\u00eda cl\u00ednica (1 citation). Citations mainly corresponded to articles published by Spanish authors (63.2 % in the 1985-1990 period and 81.6 % in the period from 1998 to 2003). Self-citation increased from 10.5 % (first period) to 31.6 % (second period). The impact factor of AD is low and not comparable to other publications included in the Dermatology and Venereal Diseases field from SCI. Our results confirm the low citation rate of AD by source journals in this repertory. However, the increase of this rate in recent years seems to indicate a higher Spanish presence in SCI due to an increasing number of publications corresponding to Spanish authors in international journals and the inclusion of\n[Cost-Effectiveness Analysis of Breast Cancer Control Interventions in Peru](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3859673)\nZelle, Sten G.; Vidaurre, Tatiana; Abugattas, Julio E.; Manrique, Javier E.; Sarria, Gustavo; Jeronimo, Jos\u00e9; Seinfeld, Janice N.; Lauer, Jeremy A.; Sepulveda, Cecilia R.; Venegas, Diego; Baltussen, Rob\n2013-01-01\nObjectives In Peru, a country with constrained health resources, breast cancer control is characterized by late stage treatment and poor survival. To support breast cancer control in Peru, this study aims to determine the cost-effectiveness of different breast cancer control interventions relevant for the Peruvian context. Methods We performed a cost-effectiveness analysis (CEA) according to WHO-CHOICE guidelines, from a healthcare perspective. Different screening, early detection, palliative, and treatment interventions were evaluated using mathematical modeling. Effectiveness estimates were based on observational studies, modeling, and on information from Instituto Nacional de Enfermedades Neopl\u00e1sicas (INEN). Resource utilizations and unit costs were based on estimates from INEN and observational studies. Cost-effectiveness estimates are in 2012 United States dollars (US$) per disability adjusted life year (DALY) averted. Results The current breast cancer program in Peru ($8,426 per DALY averted) could be improved through implementing triennial or biennial screening strategies. These strategies seem the most cost-effective in Peru, particularly when mobile mammography is applied (from $4,125 per DALY averted), or when both CBE screening and mammography screening are combined (from $4,239 per DALY averted). Triennially, these interventions costs between $63 million and $72 million per year. Late stage treatment, trastuzumab therapy and annual screening strategies are the least cost-effective. Conclusions Our analysis suggests that breast cancer control in Peru should be oriented towards early detection through combining fixed and mobile mammography screening (age 45-69) triennially. However, a phased introduction of triennial CBE screening (age 40-69) with upfront FNA in non-urban settings, and both CBE (age 40-49) and fixed mammography screening (age 50-69) in urban settings, seems a more feasible option and is also cost-effective. The implementation of this\n[Identifying priorities to improve paediatric in-hospital antimicrobial use by cross-sectional evaluation of prevalence and appropriateness of prescription.](https://www.ncbi.nlm.nih.gov/pubmed/28284685)\nGoycochea-Valdivia, Walter Alfredo; Moreno-Ramos, Francisco; Pa\u00f1o-Pardo, Jos\u00e9 Ram\u00f3n; Aracil-Santos, Francisco Javier; Baquero-Artigao, Fernando; Del Rosal-Rabes, Teresa; Mellado-Pe\u00f1a, Mar\u00eda Jos\u00e9; Escosa-Garc\u00eda, Luis\n2017-11-01\n\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Clinical, epidemiological and treatment failure data among HIV-1 non-B-infected patients in the Spanish AIDS Research Network Cohort.](https://www.ncbi.nlm.nih.gov/pubmed/26364856)\nTorrecilla Garc\u00eda, Esther; Yebra Sanz, Gonzalo; Ll\u00e1cer-Delicado, Teresa; Rubio Garc\u00eda, Rafael; Gonz\u00e1lez-Garc\u00eda, Juan; Garc\u00eda Garc\u00eda, Federico; L\u00f3pez-Aldeguer, Jos\u00e9; Asensi \u00c1lvarez, V\u00edctor; Holgu\u00edn Fern\u00e1ndez, \u00c1frica\n2016-01-01\nThe prevalence of HIV-1 non-B variants is increasing in Spain, showing a higher number of transmitted drug resistance mutations (TDR) since 2002. This study presents the features of non-B-infected patients enrolled in the cohort of antiretroviral treatment (ART) na\u00efve HIV-infected patients included in the Research Network on HIV/AIDS (CoRIS). The study includes a selected group of HIV-1 non-B-infected subjects from 670 subjects with pol sequences collected from 2004 to 2008 in the CoRIS cohort. Epidemiological-clinical-virological data were analyzed since cohort entry until October 2011, considering the presence or absence of treatment failure (TF). Eighty two non-B infected subjects with known HIV-1 variants were selected from 2004 to 2008 in the CoRIS cohort, being mainly female, immigrants, infected by recombinant viruses, and by heterosexual route. They had an intermediate TDR rate (9.4%), a high rate of TF (25.6%), of losses to follow-up (35%), of coinfections (32.9%), and baseline CD4+ counts \u2265350cells/mm(3) (61.8%). Non-B subjects with TF showed higher rates of heterosexual infection (85.7% vs. 69.5%, p<0.05), tuberculosis (30.8% vs. 9.1%, p=0.10) and hepatitis C (23.8% vs. 13.9%, p=0.34) coinfections and lower rates of syphilis (0% vs. 21.9%, p<0.05), and had more frequently received first-line ART including protease inhibitors (PIs) than patients without TF (70% vs. 30%, p<0.05). Interestingly, infection with non-B variants reduced the risk of TDR to nucleoside reverse transcriptase inhibitors and increased the risk to PIs. HIV-1 non-B-infected patients in Spain had a particular epidemiological and clinical profile that should be considered during their clinical management. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Prevalence and concordance of high-risk papillomavirus infection in male sexual partners of women diagnosed with high grade cervical lesions.](https://www.ncbi.nlm.nih.gov/pubmed/27004428)\nL\u00f3pez Diez, Elena; P\u00e9rez, Sonia; I\u00f1arrea, Amparo; de la Orden, Angel; Castro, M\u00e1ximo; Almuster, Sheila; Tortolero, Leonardo; Rodr\u00edguez, Moises; Montero, Ruben; Ojea, Antonio\n2017-05-01\nLittle is known about the characteristics of high-risk papillomavirus (HR-HPV) infection in men. The aims of this cross-sectional study were: (a) to investigate HR-HPV prevalence and genotype distribution in men, sexual partners of women presenting with high-grade cervical intraepithelial neoplasia (HG-CIN), according to epidemiological characteristics, and (b) to assess type-specific concordance between partners. A total of 125 men were recruited within the first 6 months after HG-CIN diagnosis of their partner. Samples from the coronal sulcus, glans penis shaft, and scrotum were tested with linear array HPV genotyping assay (Roche Diagnostics, Mannheim, Germany). Type-specific concordance within 120 couples was studied. Epidemiological factors were evaluated by multivariate logistic regression analysis. SPSS 19 (IBM, Chicago, USA). The prevalence of HR-HPV infection in males was 50.4% (63/125). HPV16/53/52/51/66/31 were the most frequent genotypes (24/10.4/9.6/8.8/8/7.2%, respectively). Current smoking was associated with an increased risk for HR-HPV infection in men (38.2% (21/55) vs 60% (42/70), OR 2.4, p=0.025). Among 60 infected couples, 62% shared at least one genotype: 41.7% couples were concordantly HPV16 positive and 18.3% were HPV16 negative (kappa value: 0.21). The proportion of women with the same genotype as their male partner was higher than the proportion of men sharing the same genotype as their female partner: 58.7% (37/63) vs 30.8% (37/120), p<0.0001. Sexual partners of women with HG-CIN are a significant reservoir and vector of HPV infection, a fact that could contribute to making viral clearance more difficult to achieve in their partners after treatment of their HG-CIN lesions. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Characteristics of HIV infected individuals traveling abroad. Results from the +REDIVI Collaborative Network.](https://www.ncbi.nlm.nih.gov/pubmed/26021187)\nP\u00e9rez-Molina, Jose A; Martinez-Perez, Angela; Serre, Nuria; Trevi\u00f1o, Bego\u00f1a; Ruiz-Giard\u00edn, Jos\u00e9 Manuel; Torr\u00fas, Diego; Goikoetxea, Josune; Echevarr\u00eda, Esteban Mart\u00edn; Malmierca, Eduardo; Rojo, Gerardo; Calabuig, Eva; Gutierrez, Bel\u00e9n; Norman, Francesca; Lopez-Velez, Rogelio\n2016-02-01\nThe improvement in the prognosis of HIV infection, coupled with the increase in international travel and migration, has led to a rising number of HIV infected travelers. The objective of this study was to describe the epidemiological and clinical features of returning travelers, according to their HIV status. An observational prospective study was conducted including travelers and immigrants who traveled to visit friends and relatives (VFRs) registered in the +REDIVI collaborative network (January-2009; October-2014). +REDIVI is a national network that registers information regarding infections imported by travelers and immigrants at 21 different centers using a standardized protocol. A total of 3464 travellers were identified: 72 were HIV+ (2.1%) and 3.392 HIV- (98%). HIV+ vs. HIV- travelers were often older (40.5y vs. 34.2y P=.001), VFRs (79.1% vs. 44.4%; P<.001), and consulted less for pre-travel advice (27% vs. 37%; P=.078). The main destinations for both groups were sub-Saharan Africa and Latin America. The most frequent reasons for consultation after travel were fever, request for a health examination, gastrointestinal complaints, and abnormal laboratory tests (mainly eosinophilia and anemia), which differed between groups. The most frequent diagnoses in HIV+ travelers were malaria (38.8%), newly diagnosed HIV infection (25%), and intestinal parasites (19.4%), while for HIV- travelers the main diagnoses were \"healthy\" (17.9%), malaria (14%), and intestinal parasites (17.3%). The typical profile of an HIV+ traveler in +REDIVI was that of a VFR traveler who did not seek pre-travel advice and made high-risk trips. This may increase the chance of acquiring travel-related infections which may pose a special risk for HIV-infected travelers. The post-travel visit was a good opportunity for HIV infection screening. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nDe Arriba Mu\u00f1oz, Antonio; L\u00f3pez \u00dabeda, Marta; Rueda Caballero, Carmen; Labarta Aizp\u00fan, Jos\u00e9 Ignacio; Ferr\u00e1ndez Long\u00e1s, \u00c1ngel\n2016-07-19\nIntroducci\u00f3n: saber diagnosticar y tratar la obesidad se ha convertido en el mayor reto del siglo XXI, debido al aumento de su prevalencia.Objetivos: determinar los valores de normalidad de per\u00edmetro abdominal (PA) e \u00edndice de masa corporal (IMC) seg\u00fan edad y sexo en poblaci\u00f3n espa\u00f1ola sana.M\u00e9todos: estudio longitudinal observacional realizado entre 1980 y 2014. Se incluyeron 165 ni\u00f1os y 169 ni\u00f1as reci\u00e9n nacidas, recogiendo datos de forma anual hasta los 18 a\u00f1os (74 varones y 92 mujeres), y posteriormente a los 28 a\u00f1os (42 varones y 45 mujeres). Se realiz\u00f3 medici\u00f3n de peso, longitud/talla y per\u00edmetro abdominal. Se calcularon los percentiles (P3, P10, P25, P50, P75, P90, P97) de IMC y PA seg\u00fan edad y sexo.Resultados: se presentan datos evolutivos de IMC y PA durante la infancia, destacando c\u00f3mo aumentan los valores entre los 18 y 28 a\u00f1os de los percentiles superiores al p50, sobre todo en mujeres. Existe una correlaci\u00f3n positiva en relaci\u00f3n al PA entre el valor obtenido a los 3 a\u00f1os con el valor de los 18 a\u00f1os y de los 28 a\u00f1os tanto en varones (r = 0,722 y r = 0,605, p = 0,000, respectivamente) como en mujeres(r = 0,922, r = 0,857, p = 0,000, respectivamente). Y entre los 18 y 28 a\u00f1os (r = 0,731, p = 0,000 para varones y r = 0,961, p = 0,000 para mujeres).Conclusi\u00f3n: se presentan valores de normalidad de PA e IMC seg\u00fan edad y sexo, que podr\u00e1n utilizarse como herramienta de referencia para identificar a personas con riesgo de desarrollar enfermedades cardiovasculares o diabetes.\n[The threat of disease increases as species move toward extinction.](https://www.ncbi.nlm.nih.gov/pubmed/24033873)\nHeard, Matthew J; Smith, Katherine F; Ripp, Kelsey; Berger, Melanie; Chen, Jane; Dittmeier, Justin; Goter, Maggie; McGarvey, Stephen T; Ryan, Elizabeth\n2013-12-01\nAt local scales, infectious disease is a common driver of population declines, but globally it is an infrequent contributor to species extinction and endangerment. For species at risk of extinction from disease important questions remain unanswered, including when does disease become a threat to species and does it co-occur, predictably, with other threats? Using newly compiled data from the International Union for Conservation of Nature (IUCN) Red List, we examined the relative role and co-occurrence of threats associated with amphibians, birds, and mammals at 6 levels of extinction risk (i.e., Red List status categories: least concern, near threatened, vulnerable, endangered, critically endangered, and extinct in the wild/extinct). We tested the null hypothesis that the proportion of species threatened by disease is the same in all 6 Red List status categories. Our approach revealed a new method for determining when disease most frequently threatens species at risk of extinction. The proportion of species threatened by disease varied significantly between IUCN status categories and linearly increased for amphibians, birds, and all species combined as these taxa move from move from least concern to critically endangered. Disease was infrequently the single contributing threat. However, when a species was negatively affected by a major threat other than disease (e.g., invasive species, land-use change) that species was more likely to be simultaneously threatened by disease than species that had no other threats. Potential drivers of these trends include ecological factors, clustering of phylogenetically related species in Red List status categories, discovery bias among species at greater risk of extinction, and availability of data. We echo earlier calls for baseline data on the presence of parasites and pathogens in species when they show the first signs of extinction risk and arguably before. La Amenaza de Enfermedades Incrementa a Medida que las Especies se\n[Rectal pre-treatment with ozonized oxygen (O3) aggravates clinic status in septic rats treated with amoxicillin/clavulanate.](https://www.ncbi.nlm.nih.gov/pubmed/25459192)\nMart\u00edn-Barrasa, Jos\u00e9 L; M\u00e9ndez Cordovez, Charl\u00edn; Espinosa de los Monteros y Zayas, Antonio; Juste de Santa Ana, M Candelaria; Clavo Varas, Bernardino; Herr\u00e1ez Thomas, Pedro; Bordes Benitez, Ana; Montoya-Alonso, Jos\u00e9 Alberto; Garc\u00eda-Bello, Miguel; Artiles Campelo, Fernando; Tejedor-Junco, M Teresa\n2015-01-01\nDespite the advanced antibiotic therapies, sepsis continues being a clinical entity with high morbidity and mortality. The ozone/oxygen mixture (O3/O2) has been reported to exhibit positive effects on immunity. The aim of our study was to analyze whether (O3/O2) combined with amoxicillin/clavulanate has any influence on the morbidity and mortality of septic rats. We used 48 Sprague-Dawley rats randomly allocated to 6 groups (n=8): healthy (C), septic (I), healthy+ozone therapy (O3), septic+amoxicillin/clavulanate (AMC), septic+amoxicillin/clavulanate+ozone therapy (AMC/O3) and septic+ozone therapy (I/O3). O3/O2 was administered rectally at increasing O3 concentrations during 10 days prior to the onset of sepsis model (intraperitoneally injection of fecal material) or saline administration in healthy control rats. Later (post-inoculation), 3 days per week, O3 was also administered. Vital signs were recorded, and microbiological, hematological and histopathological studies were performed. The number of surviving animal/total was higher in AMC (8/8) than in AMC/O3 (4/8) p=0.077. The percentage of surviving animals with pneumonia was higher in AMC/O3 than in AMC (100% vs 37.5%). In dead animals, AMC/O3 rats had a significantly higher percentage of lesions: Cardiac lesions, pulmonary hemorrhages and pleuritis (100%) and serositis/peritonitis (75%). Only Escherichia coli (2 different biotypes) was isolated from blood and/or peritoneal fluid from all infected groups. A significant decrease in the percentage of band neutrophils from the surviviors belonging to AMC/O3vs AMC was observed (p<0.05). Rectal pre-treatment with O3/O2 aggravates clinic status in septic rats treated with amoxicillin/clavulanate. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis.](https://www.ncbi.nlm.nih.gov/pubmed/26992301)\nBaumann Kreuziger, Lisa; Cote, Lauren; Verhamme, Peter; Greenberg, Steven; Caprini, Joseph; Mu\u00f1oz, Francisco Jos\u00e9; Valle, Reina; Monreal Bosch, Manuel\n2015-07-01\nFew studies have investigated the treatment and the outcomes of patients with catheter-related thrombosis (CRT). The RIETE registry (Registro Informatizado de Enfermedad TromboEmb\u00f3lica [Computerized Registry of Patients with Venous Thromboembolism]) is a prospective international registry of consecutive patients with objectively confirmed venous thromboembolism (VTE). We analyzed the characteristics, treatment, and outcomes of patients with CRT. Of 558 patients with CRT, 45 (8%) presented with a pulmonary embolism (PE) concomitantly. More patients had central line-associated thrombosis compared with port systems, but catheter type did not influence the risk of presenting with a PE. Patients with only CRT were more often prescribed low-molecular-weight heparin for the duration of their anticoagulant treatment compared with patients presenting with concomitant PE. VTE recurrences and major bleeding events occurred frequently during treatment with anticoagulation (7 per 100 patient-years and 8.9 per 100 patient years, respectively). The rates of fatal PE recurrences (1.85 per 100 patient-years) and fatal bleeding (2.32 per 100 patient-years) were similar. Patients with an additional transient risk factor for VTE had the lowest risk for VTE recurrences (odds ratio [OR], 0.07; 90% confidence interval [CI], 0.01-0.45) compared with patients with CRT and no additional transient risk factors. PE at presentation increased the risk of recurrent thrombosis by 2.4 times. Renal insufficiency was also an independent predictor of recurrent thrombosis (OR, 3.93; 90% CI, 2.0-7.7). The odds of recurrent thrombosis was decreased by 77% in patients who received anticoagulation therapy for >90 days compared with patients with a shorter treatment (OR, 0.23; 90% CI, 0.1-0.56). Concomitant PE occurs less frequently in CRT than lower extremity deep venous thrombosis, but it is associated with a worse outcome. CRT occurs in high-risk patients, and duration of anticoagulation must be\n[Prevalence of relevant NS5A resistance-associated substitutions to elbasvir in genotype 1a hepatitis C virus patients in Spain.](https://www.ncbi.nlm.nih.gov/pubmed/28521955)\nPalladino, Claudia; Esteban-Cartelle, Beatriz; Mate-Cano, Irene; S\u00e1nchez-Carrillo, Marta; Resino, Salvador; Briz, Ver\u00f3nica\n2018-05-01\nResistance-associated substitutions (RASs) to the new HCV NS5A inhibitor elbasvir may limit its efficacy and lead to virological failure in HCV-GT1a-infected patients. There are no data outside clinical trials evaluating their prevalence and impact in grazoprevir/elbasvir in GT1a-infected patients in Spain. A multicentre cross-sectional study of 632 initial patients was conducted. In 13 of these patients, the sample could not be amplified or a consensus sequence by Sanger sequencing could not be performed. Ultimately, 617 HCV-G1a-infected individuals treated at 84 Spanish hospitals from the 17 autonomous communities plus the 2 autonomous cities of Spain were analysed. HCV population sequencing was used to identify RAS to elbasvir and the mutational pattern and drug sensitivity were confirmed by geno2pheno[HCV]. Viruses bearing RASs to elbasvir were present in 6.2% of HCV-G1a infected patients. The most common RASs were the Y93C/H/N and Q30E/H/R (2.4% and 2.3%, respectively). Only 3.4% of the identified RASs to elbasvir conferred reduced susceptibility to elbasvir by geno2pheno[HCV], which exclusively identified the positions Q30H/R (n=7) and Y93C/H/N (n=8) as single mutations and Q30H+Y93H (n=4) and Q30R+Y93H (n=2) as double mutations as the major RASs to elbasvir. A lower prevalence of RASs to elbasvir was observed in our HCV-G1a Spanish cohort than reported previously in clinical trials evaluating patients from the USA. This information may be essential to guide the implementation of grazoprevir/elbasvir in Spain and to manage G1a-infected patients. Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.](https://www.ncbi.nlm.nih.gov/pubmed/26321131)\nBerenguer, Juan; Rivero, Antonio; Blasco, Antonio Javier; Arribas, Jos\u00e9 Ram\u00f3n; Boix, Vicente; Clotet, Bonaventura; Domingo, Pere; Gonz\u00e1lez-Garc\u00eda, Juan; Knobel, Hernando; L\u00e1zaro, Pablo; L\u00f3pez, Juan Carlos; Llibre, Josep M; Lozano, Fernando; Mir\u00f3, Jos\u00e9 M; Podzamczer, Daniel; Tuset, Montserrat; Gatell, Josep M\n2016-01-01\nGESIDA and the AIDS National Plan panel of experts suggest a preferred (PR), alternative (AR) and other regimens (OR) for antiretroviral treatment (ART) as initial therapy in HIV-infected patients for 2015. The objective of this study is to evaluate the costs and the effectiveness of initiating treatment with these regimens. Economic assessment of costs and effectiveness (cost/effectiveness) based on decision tree analyses. Effectiveness was defined as the probability of reporting a viral load <50 copies/mL at week 48, in an intention-to-treat analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART and its consequences (adverse effects, changes of ART regimen, and drug resistance studies) during the first 48 weeks. The payer perspective (National Health System) was applied, only taking into account differential direct costs: ART (official prices), management of adverse effects, studies of resistance, and HLA B*5701 testing. The setting is Spain and the costs correspond to those of 2015. A deterministic sensitivity analysis was conducted, building three scenarios for each regimen: base case, most favourable and least favourable. In the base case scenario, the cost of initiating treatment ranges from 4663 Euros for 3TC+LPV/r (OR) to 10,902 Euros for TDF/FTC+RAL (PR). The effectiveness varies from 0.66 for ABC/3TC+ATV/r (AR) and ABC/3TC+LPV/r (OR), to 0.89 for TDF/FTC+DTG (PR) and TDF/FTC/EVG/COBI (AR). The efficiency, in terms of cost/effectiveness, ranges from 5280 to 12,836 Euros per responder at 48 weeks, for 3TC+LPV/r (OR) and RAL+DRV/r (OR), respectively. The most efficient regimen was 3TC+LPV/r (OR). Among the PR and AR, the most efficient regimen was TDF/FTC/RPV (AR). Among the PR regimes, the most efficient was ABC/3TC+DTG. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.](https://www.ncbi.nlm.nih.gov/pubmed/25175171)\nBlasco, Antonio Javier; Llibre, Josep M; Berenguer, Juan; Gonz\u00e1lez-Garc\u00eda, Juan; Knobel, Hernando; Lozano, Fernando; Podzamczer, Daniel; Pulido, Federico; Rivero, Antonio; Tuset, Montserrat; L\u00e1zaro, Pablo; Gatell, Josep M\n2015-03-01\nGESIDA and the National AIDS Plan panel of experts suggest preferred (PR) and alternative (AR) regimens of antiretroviral treatment (ART) as initial therapy in HIV-infected patients for 2014. The objective of this study is to evaluate the costs and the efficiency of initiating treatment with these regimens. An economic assessment was made of costs and efficiency (cost/efficacy) based on decision tree analyses. Efficacy was defined as the probability of reporting a viral load <50 copies/mL at week 48, in an intention-to-treat analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART and its consequences (adverse effects, changes of ART regimen, and drug resistance studies) during the first 48 weeks. The payer perspective (National Health System) was applied by considering only differential direct costs: ART (official prices), management of adverse effects, studies of resistance, and HLA B*5701 testing. The setting is Spain and costs correspond to those of 2014. A sensitivity deterministic analysis was conducted, building three scenarios for each regimen: base case, most favourable and least favourable. In the base case scenario, the cost of initiating treatment ranges from 5133 Euros for ABC/3TC+EFV to 11,949 Euros for TDF/FTC+RAL. The efficacy varies between 0.66 for ABC/3TC+LPV/r and ABC/3TC+ATV/r, and 0.89 for TDF/FTC/EVG/COBI. Efficiency, in terms of cost/efficacy, ranges from 7546 to 13,802 Euros per responder at 48 weeks, for ABC/3TC+EFV and TDF/FTC+RAL respectively. Considering ART official prices, the most efficient regimen was ABC/3TC+EFV (AR), followed by the non-nucleoside containing PR (TDF/FTC/RPV and TDF/FTC/EFV). The sensitivity analysis confirms the robustness of these findings. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Comunicaci\u00f3n de pareja y VIH en mujeres en desventaja social](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2779544)\nRosina Cianelli, A.; Lilian Ferrer, L.; Margarita Bernales, S.; Natalia Villegas, R.\n2009-01-01\nIntroducci\u00f3n La epidemia de VIH y SIDA se ha diseminado r\u00e1pidamente a nivel mundial tendiendo a la feminizaci\u00f3n, pauperizaci\u00f3n y heterosexualizaci\u00f3n. La comunicaci\u00f3n de pareja en torno el VIH es descrita como uno de los factores protectores en la adquisici\u00f3n de esta enfermedad, favoreciendo la adopci\u00f3n de conductas sexuales seguras tales como la negociaci\u00f3n de pareja y la utilizaci\u00f3n de preservativo, consider\u00f3ndose como un pilar fundamental en la incorporaci\u00f3n de medidas de autocuidado en la sexualidad femenina. Objetivo Determinar el nivel de comunicaci\u00f3n de pareja en torno al VIH en mujeres chilenas en desventaja social. Metodolog\u00eda Cuatrocientas noventa y seis mujeres contestaron la entrevista inicial de la investigaci\u00f3n \u201cTesting an HIV/AIDS Prevention Intervention for Chilean Women\u201d (RO1 TW 006977 PI Cianelli). Se utiliz\u00f3 la escala \u201cHealth protective sexual communication scale (HPC)\u201d (0\u201310 puntos). Se realiz\u00f3 un an\u00e1lisis descriptivo utilizando el programa SPSS 16.0. Resultados El promedio del nivel de comunicaci\u00f3n de pareja fue de 3,26 \u00b1 2,7 puntos con la pareja principal, de 2,52 \u00b1 2,48 puntos con una segunda pareja y de 0 puntos con una tercera pareja. Los temas de menor comunicaci\u00f3n entre las parejas fueron el uso de preservativo y la realizaci\u00f3n del test para VIH antes de tener relaciones sexuales. Conclusi\u00f3n Las mujeres de la muestra presentan bajos niveles de comunicaci\u00f3n de pareja en relaci\u00f3n a VIH con todas sus parejas sexuales. Son necesarias estrategias que potencien este t\u00f3pico dentro de las intervenciones de prevenci\u00f3n de VIH y SIDA de manera de fortalecer la adopci\u00f3n de conductas de autocuidado en torno al tema. PMID:19936328\n[Detecci\u00f3n de Treponema pallidum subespecie pallidum para el diagn\u00f3stico de s\u00edfilis cong\u00e9nita mediante reacci\u00f3n en cadena de la polimerasa anidada.](https://www.ncbi.nlm.nih.gov/pubmed/29676865)\nPinilla, Gladys; Campos, Lesly; Dur\u00e1n, Andrea; Navarrete, Jeannette; Mu\u00f1oz, Liliana\n2018-03-15\nIntroducci\u00f3n. La s\u00edfilis es una enfermedad producida por Treponema pallidum subespecie pallidum cuya incidencia mundial es de 12 millones de casos por a\u00f1o, aproximadamente; de estos, m\u00e1s de dos millones se presentan en mujeres gestantes, siendo la s\u00edfilis cong\u00e9nita la complicaci\u00f3n m\u00e1s grave de esta infecci\u00f3n en el embarazo.Objetivo. Detectar la presencia de T. pallidum subespecie pallidum en muestras cl\u00ednicas para el diagn\u00f3stico de s\u00edfilis cong\u00e9nita mediante reacci\u00f3n en cadena de la polimerasa (PCR) anidada y determinar su concordancia con las pruebas serol\u00f3gicas.Materiales y m\u00e9todos. Mediante PCR convencional y anidada, se amplificaron tres genes diana (polA, 16S ADNr y TpN47) y se confirmaron los productos de amplificaci\u00f3n de los genes TpN47 y polA por secuenciaci\u00f3n. Las pruebas serol\u00f3gicas empleadas fueron la VDRL (Venereal Disease Research Laboratory), la de reagina plasm\u00e1tica r\u00e1pida (Rapid Plasma Reagin, RPR) y la de aglutinaci\u00f3n de part\u00edculas para Treponema pallidum (Treponema pallidum Particle Agglutination Assay, TPPA).Resultados. La sensibilidad para la PCR convencional fue de 52 pg y, para la PCR anidada, de 0,52 pg. La especificidad con los iniciadores TpN47 y polA fue de 100 %; los resultados de la secuenciaci\u00f3n mostraron una identidad de 97 % con T. pallidum. En 70 % de las muestras, los resultados de las pruebas serol\u00f3gicas y la PCR anidada concordaron.Conclusi\u00f3n. El gen TpN47 result\u00f3 ser el mejor blanco molecular para la identificaci\u00f3n de T. pallidum. La PCR anidada se presenta como una alternativa de diagn\u00f3stico molecular promisoria para el diagn\u00f3stico de s\u00edfilis cong\u00e9nita.\n[Comparative study of bacterial translocation control with nitric oxide donors and COX2 inhibitor.](https://www.ncbi.nlm.nih.gov/pubmed/26832645)\nGarc\u00eda-Cenador, Mar\u00eda Bego\u00f1a; Lorenzo-G\u00f3mez, Mar\u00eda Fernanda; Garc\u00eda-Moro, Mar\u00eda; Garc\u00eda-Garc\u00eda, Mar\u00eda Inmaculada; S\u00e1nchez-Conde, Mar\u00eda Pilar; Garc\u00eda-Criado, Francisco Javier; Garc\u00eda-S\u00e1nchez, Enrique; Lozano-S\u00e1nchez, Francisco; Garc\u00eda-S\u00e1nchez, Jos\u00e9 El\u00edas\n2016-10-01\nEspa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.](https://www.ncbi.nlm.nih.gov/pubmed/28532596)\nRivero, Antonio; P\u00e9rez-Molina, Jos\u00e9 Antonio; Blasco, Antonio Javier; Arribas, Jos\u00e9 Ram\u00f3n; Asensi, V\u00edctor; Crespo, Manuel; Domingo, Pere; Iribarren, Jos\u00e9 Antonio; L\u00e1zaro, Pablo; L\u00f3pez-Aldeguer, Jos\u00e9; Lozano, Fernando; Mart\u00ednez, Esteban; Moreno, Santiago; Palacios, Rosario; Pineda, Juan Antonio; Pulido, Federico; Rubio, Rafael; Santos, Jes\u00fas; de la Torre, Javier; Tuset, Montserrat; Gatell, Josep M\n2018-05-01\nGESIDA and the Spanish National AIDS Plan panel of experts have recommended preferred (PR), alternative (AR) and other regimens (OR) for antiretroviral therapy (ART) as initial therapy in HIV-infected patients for 2017. The objective of this study was to evaluate the costs and the efficiency of initiating treatment with PR and AR. Economic assessment of costs and efficiency (cost-efficacy) based on decision tree analyses. Efficacy was defined as the probability of reporting a viral load <50copies/mL at week 48, in an intention-to-treat analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART and its consequences (adverse effects, changes of ART regimen and drug resistance studies) during the first 48 weeks. The payer perspective (National Health System) was applied considering only differential direct costs: ART (official prices), management of adverse effects, resistance studies and HLA B*5701 screening. The setting was Spain and the costs correspond to those of 2017. A deterministic sensitivity analysis was conducted, building three scenarios for each regimen: base case, most favourable and least favourable. In the base case scenario, the cost of initiating treatment ranged from 6882 euro for TFV/FTC/RPV (AR) to 10,904 euros for TFV/FTC+RAL (PR). The efficacy varied from 0.82 for TFV/FTC+DRV/p (AR) to 0.92 for TAF/FTC/EVG/COBI (PR). The efficiency, in terms of cost-efficacy, ranged from 7923 to 12,765 euros per responder at 48 weeks, for ABC/3TC/DTG (PR) and TFV/FTC+RAL (PR), respectively. Considering ART official prices, the most efficient regimen was ABC/3TC/DTG (PR), followed by TFV/FTC/RPV (AR) and TAF/FTC/EVG/COBI (PR). Copyright \u00a9 2017 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Trends in hospital admissions, re-admissions, and in-hospital mortality among HIV-infected patients between 1993 and 2013: Impact of hepatitis C co-infection.](https://www.ncbi.nlm.nih.gov/pubmed/27609631)\nMeijide, H\u00e9ctor; Mena, \u00c1lvaro; Rodr\u00edguez-Osorio, Iria; P\u00e9rtega, Sonia; Castro-Iglesias, \u00c1ngeles; Rodr\u00edguez-Mart\u00ednez, Guillermo; Pedreira, Jos\u00e9; Poveda, Eva\n2017-01-01\nNew patterns in epidemiological characteristics of people living with HIV infection (PLWH) and the introduction of Highly Active Antiretroviral Therapy (HAART) have changed the profile of hospital admissions in this population. The aim of this study was to evaluate trends in hospital admissions, re-admissions, and mortality rates in HIV patients and to analyze the role of HCV co-infection. A retrospective cohort study conducted on all hospital admissions of HIV patients between 1993 and 2013. The study time was divided in two periods (1993-2002 and 2003-2013) to be compared by conducting a comparative cross-sectional analysis. A total of 22,901 patient-years were included in the analysis, with 6917 hospital admissions, corresponding to 1937 subjects (75% male, mean age 36\u00b111 years, 37% HIV/HCV co-infected patients). The median length of hospital stay was 8 days (5-16), and the 30-day hospital re-admission rate was 20.1%. A significant decrease in hospital admissions related with infectious and psychiatric diseases was observed in the last period (2003-2013), but there was an increase in those related with malignancies, cardiovascular, gastrointestinal, and chronic respiratory diseases. In-hospital mortality remained high (6.8% in the first period vs. 6.3% in the second one), with a progressive increase of non-AIDS-defining illness deaths (37.9% vs. 68.3%, P<.001). The admission rate significantly dropped after 1996 (4.9% yearly), but it was less pronounced in HCV co-infected patients (1.7% yearly). Hospital admissions due to infectious and psychiatric disorders have decreased, with a significant increase in non-AIDS-defining malignancies, cardiovascular, and chronic respiratory diseases. In-hospital mortality is currently still high, but mainly because of non-AIDS-defining illnesses. HCV co-infection increased the hospital stay and re-admissions during the study period. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y\n[Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.](https://www.ncbi.nlm.nih.gov/pubmed/27459919)\nRivero, Antonio; P\u00e9rez-Molina, Jos\u00e9 Antonio; Blasco, Antonio Javier; Arribas, Jos\u00e9 Ram\u00f3n; Crespo, Manuel; Domingo, Pere; Estrada, Vicente; Iribarren, Jos\u00e9 Antonio; Knobel, Hernando; L\u00e1zaro, Pablo; L\u00f3pez-Aldeguer, Jos\u00e9; Lozano, Fernando; Moreno, Santiago; Palacios, Rosario; Pineda, Juan Antonio; Pulido, Federico; Rubio, Rafael; de la Torre, Javier; Tuset, Montserrat; Gatell, Josep M\n2017-02-01\nGESIDA and the AIDS National Plan panel of experts suggest preferred (PR), alternative (AR), and other regimens (OR) for antiretroviral treatment (ART) as initial therapy in HIV-infected patients for the year 2016. The objective of this study is to evaluate the costs and the efficacy of initiating treatment with these regimens. Economic assessment of costs and efficiency (cost/efficacy) based on decision tree analyses. Efficacy was defined as the probability of reporting a viral load <50copies/mL at week 48 in an intention-to-treat analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART and its consequences (adverse effects, changes of ART regimen, and drug resistance studies) during the first 48 weeks. The payer perspective (National Health System) was applied, only taking into account differential direct costs: ART (official prices), management of adverse effects, studies of resistance, and HLA B*5701 testing. The setting is Spain and the costs correspond to those of 2016. A sensitivity deterministic analysis was conducted, building three scenarios for each regimen: base case, most favourable, and least favourable. In the base case scenario, the cost of initiating treatment ranges from 4663 Euros for 3TC+LPV/r (OR) to 10,894 Euros for TDF/FTC+RAL (PR). The efficacy varies from 0.66 for ABC/3TC+ATV/r (AR) and ABC/3TC+LPV/r (OR), to 0.89 for TDF/FTC+DTG (PR) and TDF/FTC/EVG/COBI (AR). The efficiency, in terms of cost/efficacy, ranges from 5280 to 12,836 Euros per responder at 48 weeks, for 3TC+LPV/r (OR), and RAL+DRV/r (OR), respectively. Despite the overall most efficient regimen being 3TC+LPV/r (OR), among the PR and AR, the most efficient regimen was ABC/3TC/DTG (PR). Among the AR regimes, the most efficient was TDF/FTC/RPV. Copyright \u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5056330)\nCastaneda, Carlos A; Mittendorf, Elizabeth; Casavilca, Sandro; Wu, Yun; Castillo, Miluska; Arboleda, Patricia; Nunez, Teresa; Guerra, Henry; Barrionuevo, Carlos; Dolores-Cerna, Ketty; Belmar-Lopez, Carolina; Abugattas, Julio; Calderon, Gabriela; De La Cruz, Miguel; Cotrina, Manuel; Dunstan, Jorge; Gomez, Henry L; Vidaurre, Tatiana\n2016-01-01\nAIM To determine influence of neoadjuvant-chemotherapy (NAC) over tumor-infiltrating-lymphocytes (TIL) in triple-negative-breast-cancer (TNBC). METHODS TILs were evaluated in 98 TNBC cases who came to Instituto Nacional de Enfermedades Neoplasicas from 2005 to 2010. Immunohistochemistry staining for CD3, CD4, CD8 and FOXP3 was performed in tissue microarrays (TMA) sections. Evaluation of H/E in full-face and immunohistochemistry in TMA sections was performed in pre and post-NAC samples. STATA software was used and P value < 0.05 was considered statistically significant. RESULTS Higher TIL evaluated in full-face sections from pre-NAC tumors was associated to pathologic-complete-response (pCR) (P = 0.0251) and outcome (P = 0.0334). TIL evaluated in TMA sections showed low level of agreement with full-face sections (ICC = 0.017-0.20) and was not associated to pCR or outcome. TIL in post-NAC samples were not associated to response or outcome. Post-NAC lesions with pCR had similar TIL levels than those without pCR (P = 0.6331). NAC produced a TIL decrease in full-face sections (P < 0.0001). Percentage of TIL subpopulations was correlated with their absolute counts. Higher counts of CD3, CD4, CD8 and FOXP3 in pre-NAC samples had longer disease-free-survival (DFS). Higher counts of CD3 in pre-NAC samples had longer overall-survival. Higher ratio of CD8/CD4 counts in pre-NAC was associated with pCR. Higher ratio of CD4/FOXP3 counts in pre-NAC was associated with longer DFS. Higher counts of CD4 in post-NAC samples were associated with pCR. CONCLUSION TIL in pre-NAC full-face sections in TNBC are correlated to longer survival. TIL in full-face differ from TMA sections, absolute count and percentage analysis of TIL subpopulation closely related. PMID:27777881\n[Acinetobacter baumannii in critically ill patients: Molecular epidemiology, clinical features and predictors of mortality.](https://www.ncbi.nlm.nih.gov/pubmed/26821549)\nGarnacho-Montero, Jos\u00e9; Guti\u00e9rrez-Pizarraya, Antonio; D\u00edaz-Mart\u00edn, Ana; Cisneros-Herreros, Jos\u00e9 Miguel; Cano, Mar\u00eda Eugenia; Gato, Eva; Ruiz de Alegr\u00eda, Carlos; Fern\u00e1ndez-Cuenca, Felipe; Vila, Jordi; Mart\u00ednez-Mart\u00ednez, Luis; Tom\u00e1s-Carmona, M Del Mar; Pascual, \u00c1lvaro; Bou, Germ\u00e1n; Pach\u00f3n-Diaz, Jer\u00f3nimo; Rodr\u00edguez-Ba\u00f1o, Jes\u00fas\n2016-11-01\nThe main aim of this study was to assess changes in the epidemiology and clinical presentation of Acinetobacter baumannii over a 10-year period, as well as risk factors of mortality in infected patients. Prospective, multicentre, hospital-based cohort studies including critically ill patients with A. baumannii isolated from any clinical sample were included. These were divided into a first period (\"2000 study\") (one month), and a second period (\"2010 study\") (two months). Molecular typing was performed by REP-PCR, PFGE and MSLT. The primary endpoint was 30-day mortality. In 2000 and 2010, 103 and 108 patients were included, and the incidence of A. baumannii colonization/infection in the ICU decreased in 2010 (1.23 vs. 4.35 cases/1000 patient-days; p<0.0001). No differences were found in the colonization rates (44.3 vs. 38.6%) or infected patients (55.7 vs. 61.4%) in both periods. Overall, 30-day mortality was similar in both periods (29.1 vs. 27.8%). The rate of pneumonia increased from 46.2 in 2000 to 64.8% in 2010 (p<0.001). Performing MSLT, 18 different sequence types (ST) were identified (18 in 2000, 8 in 2010), but ST2 and ST79 were the predominant clones. ST2 isolates in the ICU increased from 53.4% in the year 2000 to 73.8% in 2010 (p=0.002). In patients with A. baumannii infection, the multivariate analysis identified appropriate antimicrobial therapy and ST79 clonal group as protective factors for mortality. At 10 years of the first analysis, some variations have been observed in the epidemiology of A. baumannii in the ICU, with no changes in mortality. Epidemic ST79 clone seems to be associated with a better prognosis and adequate treatment is crucial in terms of survival. Copyright \u00a9 2015 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nFerrer G\u00f3mez, Mercedes; Garc\u00eda Zafra, Mar\u00eda Victoria; Cuenca S\u00e1nchez, Juan Ram\u00f3n; S\u00e1nchez Romera, Juan Francisco; Aranda Garc\u00eda, Ana; Rausell Rausell, V\u00edctor Jos\u00e9; Hern\u00e1ndez Mart\u00ednez, Antonio Miguel\n2016-09-20\nIntroducci\u00f3n: en Murcia, y hasta 2010, la administraci\u00f3n de la nutrici\u00f3n enteral domiciliaria (NED) dictaba cumplir la regulaci\u00f3n marcada en cuanto a los facultativos con competencias para su prescripci\u00f3n.Objetivos: examinar aspectos esenciales de este recurso en el periodo 2007-2010, caracter\u00edsticas de la muestra y evoluci\u00f3n del coste, as\u00ed como perspectivas de futuro.M\u00e9todos: estudio del perfil de la poblaci\u00f3n NED en un \u00e1rea de salud espec\u00edfica. Selecci\u00f3n de recetas facturadas de productos NED en el conjunto de la Regi\u00f3n, clasificaci\u00f3n por tipos y an\u00e1lisis de la evoluci\u00f3n en importe y en envases para el periodo 2007-2010.Resultados: respecto al perfil de la muestra del \u00c1rea I de Salud de la Regi\u00f3n, la patolog\u00eda, v\u00eda de administraci\u00f3n y tipo de nutrici\u00f3n m\u00e1s frecuentes resultaron, respectivamente, la enfermedad neurol\u00f3gica, la v\u00eda oral y la nutrici\u00f3n no espec\u00edfica. Por otro lado, el gasto sanitario en productos dietoter\u00e1picos, en el Servicio Murciano de Salud, aument\u00f3 alrededor del 50% entre los a\u00f1os 2007 y 2010. Tanto en envases como en importe, Murcia se sit\u00faa por encima de la media nacional.Conclusiones: el perfil de la muestra no coincide con trabajos publicados en otras regiones. Este dato, junto a la posici\u00f3n de Murcia en gasto dietoter\u00e1pico, y su evidente tendencia al alza en los a\u00f1os analizados, hace evidente la necesidad de medidas que mejoren la calidad de la NED en la Regi\u00f3n de Murcia y, en caso de ser posible, conseguir alcanzar valores nacionales en relaci\u00f3n con el consumo medio y el gasto.\nHiguera Pulgar, Isabel; Bret\u00f3n Lesmes, Irene; Carrascal Fabi\u00e1n, Mar\u00eda Luisa; Prieto Garc\u00eda, Alicia; Mench\u00e9n Viso, Luis; Nogales Rinc\u00f3n, \u00d3scar; Iglesias Hern\u00e1ndez, Natalia Covadonga; Issasa Rodr\u00edguez, Leire; Garc\u00eda Peris, Pilar\n2016-07-19\nIntroducci\u00f3n: la esofagitis eosinof\u00edlica (EEo) es una enfermedad inmunoal\u00e9rgica cr\u00f3nica emergente en adultos. Surge como respuesta disfuncional frente a los ant\u00edgenos de los alimentos y se caracteriza por s\u00edntomas recurrentes de disfunci\u00f3n esof\u00e1gica e inflamaci\u00f3n. El tratamiento farmacol\u00f3gico y diet\u00e9tico se basa en su patog\u00e9nesis y debe ser individualizado. Uno de los posibles abordajes diet\u00e9ticos se basa en la eliminaci\u00f3n emp\u00edrica de alimentos que con mayor frecuencia causan EEo.Objetivo: evaluar la ingesta diet\u00e9tica de los pacientes con EEo que siguen la dieta de exclusi\u00f3n de los seis grupos de alimentos (DESGA) y conocer sus posibles carencias nutricionales.M\u00e9todos: estudio transversal descriptivo en un grupo de pacientes con EEo que inici\u00f3 tratamiento con DESGA durante el periodo de marzo de 2013 hasta marzo de 2015. Se evalu\u00f3 la ingesta mediante registro de 72 horas. Se compararon los resultados con las referencias para poblaci\u00f3n adulta sana espa\u00f1ola (23). Para el an\u00e1lisis estad\u00edstico se usaron los test de Mann-Whitney, Krhuskall-Wallis y Chi-cuadrado. Significaci\u00f3n p < 0,05.Resultados: se incluyeron en el estudio 14 pacientes. En algunos de ellos, la ingesta diet\u00e9tica siguiendo DESGA fue deficitaria en energ\u00eda, prote\u00ednas y fibra. Tampoco consiguieron cubrir las ingestas de micronutrientes de calcio, zinc, magnesio, \u00e1cido f\u00f3lico, niacina y vitaminas B2 y D, teniendo en cuenta edad y sexo, el 60% de la muestra.Conclusiones: el abordaje terap\u00e9utico mediante DESGA, teniendo en cuenta las caracter\u00edsticas de la dieta, debe acompa\u00f1arse de una evaluaci\u00f3n peri\u00f3dica del estado nutricional, que incluya micronutrientes y una pauta de suplementaci\u00f3n espec\u00edfica.\n[[Pertussis in fully vaccinated infants and children. Are new vaccination strategies required?].](https://www.ncbi.nlm.nih.gov/pubmed/23725786)\nMoraga-Llop, Fernando A; Mendoza-Palomar, Nat\u00e0lia; Muntaner-Alonso, Antoni; Codina-Grau, Gemma; F\u00e0bregas-Martori, Anna; Campins-Mart\u00ed, Magda\n2014-04-01\nTo analyse the vaccination status of children diagnosed with pertussis and to compare the clinical manifestations of fully vaccinated with unvaccinated, or incompletely-vaccinated, children. The clinical histories and vaccination cards of patients under 16years of age seen in the Emergency Room of the University Hospital Vall d'Hebron, Barcelona (Spain), for pertussis confirmed by a microbiological study were reviewed. The study period lasted from January 1, 2009 to December 31, 2011. Two hundred and twelve cases were studied: 35 in 2009, 28 in 2010 and 149 in 2011. RT-PCR was positive in 210 patients, and 73 had a positive culture. Infants under 6months of age account for 36.8% of all cases. Forty-four patients (21.5%) were not vaccinated. Forty-four (21.5%) children were between 2 and 5months of age and had received 1-2vaccine doses. One hundred and seventeen (57%) children were fully vaccinated; 76.9% (90cases) had received the last dose less than 4years ago. When clinical manifestations of the fully vaccinated patients were compared with those of the non-vaccinated or incompletely-vaccinated children, only cyanosis was found with a higher frequency in the latter group (P<.001). The age-adjusted probability of hospitalisation was significantly associated with non-vaccination (P=.001). The case mortality rate among inpatients was 1.3%. The number of pertussis cases seen in our centre has risen significantly in the last year. More than half (57%) of the patients were fully vaccinated, and 76.9% had received the last dose in the previous 4years. Other vaccination strategies, such as vaccination of adolescents, adults, and pregnant women, as well as a cocoon strategy are required to protect infants under 6months of age. More effective vaccines need to be developed. Copyright \u00a9 2012 Elsevier Espa\u00f1a, S.L. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\nAlvarez Padilla, Facundo Nicol\u00e1s; Schiavoni, Emiliano Nestor; Bustos, Mario Eduardo Francisco\n2018-04-20\nINTRODUCCIONEl derrame pleural neopl\u00e1sico (DPN) implica una enfermedad oncol\u00f3gica avanzada. La biopsia pleural por cirug\u00eda tor\u00e1cica endosc\u00f3pica permite el diagn\u00f3stico en m\u00e1s del 90% de los casos y la instrumentaci\u00f3n del espacio pleural complicado, mejorando los resultados de la t\u00e9cnica.MATERIAL Y METODOSe realiz\u00f3 un an\u00e1lisis retrospectivo de pacientes con DPN operados para la realizaci\u00f3n de una pleurodesis qu\u00edmica con talco. Se formaron dos grupos, uno con derrame pleural neopl\u00e1sico complicado (DPNC) y otro con derrame pleural neopl\u00e1sico no complicado (DPNNC). En el grupo con DPNC se realiz\u00f3 \"maniobras de liberaci\u00f3n - expansi\u00f3n\". Se compararon las variables entre ambos grupos para el an\u00e1lisis pertinente.RESULTADOSSe analizaron 28 pacientes con DPN tratados con pleurodesis qu\u00edmica por cirug\u00eda tor\u00e1cica endosc\u00f3pica. La edad promedio fue de 62,64 a\u00f1os. El compromiso pleural por patolog\u00eda mamaria fue la forma m\u00e1s frecuente (46,4%). No se hubo diferencia en cuanto a complicaciones (p= 0,31) y riesgo de defunci\u00f3n a los 30 d\u00edas (p=1,09) con el manejo agresivo del espacio pleural. La demora en la indicaci\u00f3n de pleurodesis se relacion\u00f3 con un mayor \u00edndice de complicaciones (p=0,002) y mayor probabilidad de defunci\u00f3n dentro de los 30 d\u00edas (p=0,008). La mayor\u00eda de pacientes se reinsert\u00f3 a sus tareas diarias, con buena tolerancia a la disnea luego del procedimiento. CONCLUSIONEn los pacientes con DPNC, las \"maniobras de liberaci\u00f3n - expansi\u00f3n pulmonar\" descriptas, aumentar\u00edan las chances de mejorar los resultados con bajo riesgo. La pleurodesis qu\u00edmica temprana mejora la calidad de vida de los pacientes portadores de un DPN.\n[DVT Management and Outcome Trends, 2001 to 2014.](https://www.ncbi.nlm.nih.gov/pubmed/27071810)\nMorillo, Raquel; Jim\u00e9nez, David; Aibar, Miguel \u00c1ngel; Mastroiacovo, Daniela; Wells, Philip S; Samp\u00e9riz, \u00c1ngel; Saraiva de Sousa, Marta; Muriel, Alfonso; Yusen, Roger D; Monreal, Manuel\n2016-08-01\nA comprehensive evaluation of temporal trends in the treatment of patients who have DVT may assist with identification of modifiable factors that contribute to short-term outcomes. We assessed temporal trends in length of hospital stay and use of pharmacological and interventional therapies among 26,695 adults with DVT enrolled in the Registro Informatizado de la Enfermedad TromboEmb\u00f3lica registry between 2001 and 2014. We also examined temporal trends in risk-adjusted rates of all-cause, pulmonary embolism-related, and bleeding-related death to 30 days after diagnosis. The mean length of hospital stay decreased from 9.0 days in 2001 to 2005 to 7.6 days in 2010 to 2014 (P < .01). For initial DVT treatment, the use of low-molecular-weight heparin decreased from 98% to 90% (P < .01). Direct oral anticoagulants use increased from 0.5% in 2010 to 13.4% in 2014 (P < .001). Risk-adjusted rates of 30-day all-cause mortality decreased from 3.9% in 2001 to 2005 to 2.7% in 2010 to 2014 (adjusted rate ratio per year, 0.84; 95% CI, 0.74-0.96; P < .01). VTE-related mortality showed a nonstatistically significant downward trend (adjusted rate ratio per year, 0.70; 95% CI, 0.44-1.10; P = .13), whereas 30-day bleeding-related mortality significantly decreased from 0.5% in 2001 to 2005 to 0.1% in 2010-2014 (adjusted rate ratio per year, 0.55; 95% CI, 0.40-0.77; P < .01). This international registry-based temporal analysis identified reductions in length of stay for adults hospitalized for DVT. The study also found a decreasing trend in adjusted rates of all-cause and bleeding-related mortality. Copyright \u00a9 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.\n[Comparative evaluation of the identification of rapidly growing non-tuberculous mycobacteria by mass spectrometry (MALDI-TOF MS), GenoType Mycobacterium CM/AS assay and partial sequencing of the rpo\u03b2 gene with phylogenetic analysis as a reference method.](https://www.ncbi.nlm.nih.gov/pubmed/29871765)\nCosta-Alcalde, Jos\u00e9 Javier; Barbeito-Casti\u00f1eiras, Gema; Gonz\u00e1lez-Alba, Jos\u00e9 Mar\u00eda; Aguilera, Antonio; Gal\u00e1n, Juan Carlos; P\u00e9rez-Del-Molino, Mar\u00eda Luisa\n2018-06-02\nThe American Thoracic Society and the Infectious Diseases Society of America recommend that clinically significant non-tuberculous mycobacteria (NTM) should be identified to the species level in order to determine their clinical significance. The aim of this study was to evaluate identification of rapidly growing NTM (RGM) isolated from clinical samples by using MALDI-TOF MS and a commercial molecular system. The results were compared with identification using a reference method. We included 46 clinical isolates of RGM and identified them using the commercial molecular system GenoType \u00ae CM/AS (Hain, Lifescience, Germany), MALDI-TOF MS (Bruker) and, as reference method, partial rpo\u03b2 gene sequencing followed by BLAST and phylogenetic analysis with the 1093 sequences available in the GeneBank. The degree of agreement between GenoType \u00ae and MALDI-TOF MS and the reference method, partial rpo\u03b2 sequencing, was 27/43 (62.8%) and 38/43 cases (88.3%) respectively. For all the samples correctly classified by GenoType \u00ae , we obtained the same result with MALDI-TOF MS (27/27). However, MALDI-TOF MS also correctly identified 68.75% (11/16) of the samples that GenoType \u00ae had misclassified (p=0.005). MALDI-TOF MS classified significantly better than GenoType \u00ae . When a MALDI-TOF MS score >1.85 was achieved, MALDI-TOF MS and partial rpo\u03b2 gene sequencing were equivalent. GenoType \u00ae was not able to distinguish between species belonging to the M. fortuitum complex. MALDI-TOF MS methodology is simple, rapid and associated with lower consumable costs than GenoType \u00ae . The partial rpo\u03b2 sequencing methods with BLAST and phylogenetic analysis were not able to identify some RGM unequivocally. Therefore, sequencing of additional regions would be indicated in these cases. Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[El uso de la neuromodulaci\u00f3n para el tratamiento del temblor](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4138824)\nBendersky, Dami\u00e1n; Ajler, Pablo; Yampolsky, Claudio\n2014-01-01\nIntroducci\u00f3n: El temblor puede ser un desorden incapacitante y el tratamiento de primera l\u00ednea para estos pacientes es farmacol\u00f3gico. Sin embargo, este tratamiento puede llevar a una reducci\u00f3n satisfactoria del temblor en s\u00f3lo el 50% de los pacientes con temblor esencial. La talamotom\u00eda era el tratamiento de elecci\u00f3n para el temblor refractario al tratamiento m\u00e9dico hasta que comenz\u00f3 a utilizarse la estimulaci\u00f3n cerebral profunda (ECP) del n\u00facleo ventral intermedio (Vim) del t\u00e1lamo. En la actualidad, raramente se realiza la talamotom\u00eda. M\u00e9todos: Este art\u00edculo es una revisi\u00f3n no sistem\u00e1tica de las indicaciones, resultados, par\u00e1metros de programaci\u00f3n y t\u00e9cnica quir\u00fargica de la ECP del Vim para el tratamiento del temblor. Resultados: Aunque los resultados cl\u00ednicos son similares usando la talamotom\u00eda o la ECP del Vim, la primera causa m\u00e1s efectos adversos que la \u00faltima. Adem\u00e1s, la ECP puede ser usada bilateralmente, mientras que la talamotom\u00eda tiene un alto riesgo de causar disartria cuando se realiza de ambos lados. La ECP del Vim logr\u00f3 una adecuada mejor\u00eda del temblor en varias series de pacientes con temblor causado por temblor esencial, enfermedad de Parkinson o esclerosis m\u00faltiple. Adem\u00e1s del Vim, hay otros blancos que est\u00e1n siendo usados por varios autores, tales como la zona incerta y las radiaciones prelemniscales. Conclusi\u00f3n: La ECP del Vim es un tratamiento \u00fatil para el temblor incapacitante refractario al tratamiento m\u00e9dico. Es esencial realizar una precisa selecci\u00f3n de pacientes, as\u00ed como utilizar una t\u00e9cnica quir\u00fargica correcta. A\u00fan se desconoce el mejor blanco estereot\u00e1ctico para el temblor, aunque el Vim es el m\u00e1s usado. PMID:25165613\n[Cost-effectiveness analysis of breast cancer control interventions in Peru.](https://www.ncbi.nlm.nih.gov/pubmed/24349314)\nZelle, Sten G; Vidaurre, Tatiana; Abugattas, Julio E; Manrique, Javier E; Sarria, Gustavo; Jeronimo, Jos\u00e9; Seinfeld, Janice N; Lauer, Jeremy A; Sepulveda, Cecilia R; Venegas, Diego; Baltussen, Rob\n2013-01-01\nIn Peru, a country with constrained health resources, breast cancer control is characterized by late stage treatment and poor survival. To support breast cancer control in Peru, this study aims to determine the cost-effectiveness of different breast cancer control interventions relevant for the Peruvian context. We performed a cost-effectiveness analysis (CEA) according to WHO-CHOICE guidelines, from a healthcare perspective. Different screening, early detection, palliative, and treatment interventions were evaluated using mathematical modeling. Effectiveness estimates were based on observational studies, modeling, and on information from Instituto Nacional de Enfermedades Neopl\u00e1sicas (INEN). Resource utilizations and unit costs were based on estimates from INEN and observational studies. Cost-effectiveness estimates are in 2012 United States dollars (US$) per disability adjusted life year (DALY) averted. The current breast cancer program in Peru ($8,426 per DALY averted) could be improved through implementing triennial or biennial screening strategies. These strategies seem the most cost-effective in Peru, particularly when mobile mammography is applied (from $4,125 per DALY averted), or when both CBE screening and mammography screening are combined (from $4,239 per DALY averted). Triennially, these interventions costs between $63 million and $72 million per year. Late stage treatment, trastuzumab therapy and annual screening strategies are the least cost-effective. Our analysis suggests that breast cancer control in Peru should be oriented towards early detection through combining fixed and mobile mammography screening (age 45-69) triennially. However, a phased introduction of triennial CBE screening (age 40-69) with upfront FNA in non-urban settings, and both CBE (age 40-49) and fixed mammography screening (age 50-69) in urban settings, seems a more feasible option and is also cost-effective. The implementation of this intervention is only meaningful if\n[Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.](https://www.ncbi.nlm.nih.gov/pubmed/29884455)\nP\u00e9rez-Molina, Jos\u00e9 Antonio; Mart\u00ednez, Esteban; Blasco, Antonio Javier; Arribas, Jos\u00e9 Ram\u00f3n; Domingo, Pere; Iribarren, Jos\u00e9 Antonio; Knobel, Hernando; L\u00e1zaro, Pablo; L\u00f3pez-Aldeguer, Jos\u00e9; Lozano, Fernando; Mari\u00f1o, Ana; Mir\u00f3, Jos\u00e9 M; Moreno, Santiago; Negredo, Eugenia; Pulido, Federico; Rubio, Rafael; Santos, Jes\u00fas; de la Torre, Javier; Tuset, Montserrat; von Wichmann, Miguel A; Gatell, Josep M\n2018-06-05\nThe GESIDA/National AIDS Plan expert panel recommended preferred regimens (PR), alternative regimens (AR) and other regimens (OR) for antiretroviral treatment (ART) as initial therapy in HIV-infected patients for 2018. The objective of this study was to evaluate the costs and the efficiency of initiating treatment with PR and AR. Economic assessment of costs and efficiency (cost-effectiveness) based on decision tree analyses. Effectiveness was defined as the probability of reporting a viral load <50copies/mL at week 48, in an intention-to-treat analysis. Cost of initiating treatment with an ART regimen was defined as the costs of ART and its consequences (adverse effects, changes of ART regimen, and drug-resistance studies) over the first 48 weeks. The payer perspective (National Health System) was applied considering only differential direct costs: ART (official prices), management of adverse effects, studies of resistance, and HLA B*5701 testing. The setting was Spain and the costs correspond to those of 2018. A deterministic sensitivity analysis was conducted, building three scenarios for each regimen: base case, most favourable and least favourable. In the base-case scenario, the cost of initiating treatment ranges from 6788 euros for TAF/FTC/RPV (AR) to 10,649 euros for TAF/FTC+RAL (PR). The effectiveness varies from 0.82 for TAF/FTC+DRV/r (AR) to 0.91 for TAF/FTC+DTG (PR). The efficiency, in terms of cost-effectiveness, ranges from 7814 to 12,412 euros per responder at 48 weeks, for ABC/3TC/DTG (PR) and TAF/FTC+RAL (PR), respectively. Considering ART official prices, the most efficient regimen was ABC/3TC/DTG (PR), followed by TAF/FTC/RPV (AR) and TAF/FTC/EVG/COBI (AR). Copyright \u00a9 2018 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.\n[[Treatment of type 2 diabetes mellitus in patients with chronic kidney disease. Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal cr\u00f3nica].](https://www.ncbi.nlm.nih.gov/pubmed/24268912)\nG\u00f3mez-Huelgas, Ricardo; Mart\u00ednez-Castelao, Alberto; Artola, Sara; G\u00f3rriz, Jos\u00e9 Luis; Men\u00e9ndez, Edelmiro\n2014-01-21\nChronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) are highly prevalent chronic diseases, which represent an important public health problem and require a multidisciplinary management. T2DM is the main cause of CKD and it also causes a significant comorbidity with regard to non-diabetic nephropathy. Patients with diabetes and kidney disease represent a special risk group as they have higher morbi-mortality as well as higher risk of hypoglycemia than diabetic individuals with a normal kidney function. Treatment of T2DM in patients with CKD is controversial because of the scarcity of available evidence. The current consensus report aims to ease the appropriate selection and dosage of antidiabetic treatments as well as the establishment of safety objectives of glycemic control in patients with CKD. Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L. All rights reserved.\nG\u00f3mez, Luis Alberto; Montoya, Gladis; Rivera, Hern\u00e1n Mauricio; Hern\u00e1ndez, Juan Carlos\n2017-04-01\nIntroducci\u00f3n. El virus del Zika (ZIKV) es un flavivirus con envoltura, transmitido a los seres humanos principalmente por el vector Aedes aegypti. La infecci\u00f3n por ZIKV se ha asociado con un gran neurotropismo y con efectos neurop\u00e1ticos, como el s\u00edndrome de Guillain-Barr\u00e9 en el adulto y la microcefalia fetal y posnatal, as\u00ed como con un s\u00edndrome de infecci\u00f3n cong\u00e9nita similar al producido por el virus de la rub\u00e9ola (RV).Objetivo. Comparar las estructuras moleculares de la prote\u00edna de envoltura E del virus del Zika (E-ZIKV) y de la E1 del virus de la rub\u00e9ola (E1-RV), y plantear posibles implicaciones en el neurotropismo y en las alteraciones del sistema nervioso asociadas con el ZIKV.Materiales y m\u00e9todos. La secuencia de amino\u00e1cidos de la prote\u00edna E-ZIKV (PDB: 5iZ7) se aline\u00f3 con la de la glucoprete\u00edna E1 del virus de la rub\u00e9ola (PDB: 4ADG). Los elementos de la estructura secundaria se determinaron usando los programas Vector NTI Advance\u00ae, DSSP y POSA, as\u00ed como herramientas de gesti\u00f3n de datos (AlignX\u00ae). Uno de los criterios principales de comparaci\u00f3n y alineaci\u00f3n fue la asignaci\u00f3n de residuos estructuralmente equivalentes, con m\u00e1s de 70 % de identidad.Resultados. La organizaci\u00f3n estructural de la prote\u00edna E-ZIKV (PDB: 5iZ7) fue similar a la de E1-RV (PDB: 4ADG) (70 a 80 % de identidad), y se observ\u00f3 una correspondencia con la estructura definida para las glucoprote\u00ednas de fusi\u00f3n de membrana de clase II de los virus con envoltura. E-ZIKV y E1-RV exhibieron elementos estructurales de fusi\u00f3n muy conservados en la regi\u00f3n distal del dominio II, asociados con la uni\u00f3n a los receptores celulares de entrada del virus de la rub\u00e9ola (glucoprote\u00edna de mielina del oligodendrocito, Myelin Oligodendrocyte Glycoprotein, MOG), y con los receptores celulares Axl del ZIKV y de otros flavivirus.Conclusi\u00f3n. La comparaci\u00f3n de las prote\u00ednas E-ZIKV y E1-RV es un paso necesario hacia la definici\u00f3n de otros factores moleculares determinantes del\n[The experience of bedaquiline implementation at a decentralised clinic in South Africa.](https://www.ncbi.nlm.nih.gov/pubmed/27695682)\nCariem, R; Cox, V; de Azevedo, V; Hughes, J; Mohr, E; Dur\u00e1n, L Trivi\u00f1o; Ndjeka, N; Furin, J\n2016-09-01\nMultidrug-resistant tuberculosis (MDR-TB) is a serious public health problem, but the new drugs bedaquiline (BDQ) and delamanid offer hope to improve outcomes and minimise toxicity. In Khayelitsha, South Africa, patients are routinely started on BDQ in the out-patient setting. This report from the field describes BDQ use in the out-patient setting at the Nolungile Clinic. The clinic staff overall report a positive experience using the drug. Challenges have been based largely on the logistics of drug supply and delivery. BDQ can be started successfully in the out-patient setting, and can be a positive experience for both patients and providers. La tuberculose multir\u00e9sistante (TB-MDR) est un probl\u00e8me de sant\u00e9 publique grave, mais les nouveaux m\u00e9dicaments que sont la b\u00e9daquiline (BDQ) et le d\u00e9lamanide apportent un espoir d'am\u00e9liorer les r\u00e9sultats tout en r\u00e9duisant la toxicit\u00e9. A Khayelitsha, Afrique du Sud, les patients d\u00e9marrent leur traitement par BDQ en consultation externe en routine. Ce rapport du terrain d\u00e9crit l'utilisation de la BDQ \u00e0 la consultation externe du dispensaire Nolungile. Dans l'ensemble, le personnel du centre de sant\u00e9 exprime une exp\u00e9rience positive du m\u00e9dicament. Les d\u00e9fis ont surtout \u00e9t\u00e9 li\u00e9s \u00e0 la logistique de l'approvisionnement et de la distribution du m\u00e9dicament. La BDQ peut \u00eatre mise en route avec succ\u00e8s dans le cadre d'une consultation externe et peut constituer une exp\u00e9rience positive pour les patients et les prestataires de soins. La tuberculosis multirresistente (TB-MDR) representa un grave problema de salud p\u00fablica, pero la utilizaci\u00f3n de nuevos medicamentos como la bedaquilina (BDQ) y el delamanid ofrece perspectivas de mejores desenlaces terap\u00e9uticos y disminuci\u00f3n de la toxicidad asociada. En Khayelitsha, Sur\u00e1frica, se inicia de manera sistem\u00e1tica el tratamiento ambulatorio con BDQ. En el presente informe del terreno, se describe la utilizaci\u00f3n de BDQ en tratamiento antituberculoso ambulatorio en el\n[Nursing interventions in monitoring the adolescent with Cystic Fibrosis: a literature review.](https://www.ncbi.nlm.nih.gov/pubmed/27982311)\nReisinho, Maria da Concei\u00e7\u00e3o Marinho Sousa Ribeiro Oliveira; Gomes, B\u00e1rbara Pereira\n2016-12-08\npadres/otras personas significantes, ya que tanto el adolescente como la familia deben asumir la responsabilidad por el autocuidado. Los profesionales de salud deben ser capaces de identificar las necesidades especiales de los pacientes con enfermedades cr\u00f3nicas y sus familias, visando alcanzar una mejor comprensi\u00f3n y adaptaci\u00f3n al proceso de transici\u00f3n entre la salud y la enfermedad.\n[[An analysis of Spanish biomedical journals by the impact factor].](https://www.ncbi.nlm.nih.gov/pubmed/1630206)\nBa\u00f1os, J E; Casanovas, L; Guardiola, E; Bosch, F\n1992-06-13\nOne of the most frequently used parameters for evaluating scientific publications is that of impact factor (IF) published in the Science Citation Index-Journal Citation Reports (SCI-JCR) which evaluates the number of citations a journal receives on behalf of other journals. The present study analyzed the Spanish biomedical journals included in the SCI-JCR by the IF. The IF were obtained from the SCI-JCR (1980-89). The journals were evaluated by the IF and the weighted impact factor (WIF) calculated according to WIF = (IF/MIF) x 100 in which MIF = maximum IF of the considered area. Nine Spanish biomedical journals were included in the SCI-JCR, four being basic sciences (Histology and Histopathology, Inmunolog\u00eda, Methods and Findings in Experimental and Clinical Pharmacology, Revista Espa\u00f1ola de Fisiolog\u00eda) and five clinical journals (Allergologia et Immunopathologia, Medicina Cl\u00ednica, Nefrolog\u00eda, Revista Espa\u00f1ola de las Enfermedades del Aparato Digestivo, Revista Cl\u00ednica Espa\u00f1ola). Their IF were much lower than the most important journals in each area with the mean (+/- standard deviation) being 0.21 +/- 0.22 (range 0.016-0.627). The mean WIF was 2.88 +/- 4.07 (0.16-12.82). The journals of basic sciences had higher IF and WIF than the clinical journals (p less than 0.05). Only the four journals of basic sciences were included in the SCI. Four journals, those of basic sciences, are preferentially or exclusively published in English and other five are published in Spanish. The differences in IF among these groups were not significant (p = 0.06) while those of WIF were significant (p less than 0.05). The number of Spanish biomedical journals in the SCI-JCR has risen from 1 in 1980 to 9 in 1989 with IF which have evolved variably. In mind of impact factor, the contribution of Spanish journals is low, with that of biomedical sciences being higher than that of clinical journals. Language and inclusion in the Science Citation Index may explain, at least in part\n[[Etiology and clinical course of urinary tract infections in infants less than 3 months-old].](https://www.ncbi.nlm.nih.gov/pubmed/25542336)\nHern\u00e1ndez-Bou, Susanna; Trenchs Sainz de la Maza, Victoria; Alarc\u00f3n Gamarra, Marcela; Camacho D\u00edaz, Juan A; Gen\u00e9 Giralt, Amadeu; Luaces Cubells, Carles\n2015-10-01\nInfants less than 3 months of age with urinary tract infection are usually hospitalized. Recent studies show that a less aggressive management for those patients aged \u2265 29 days may be feasible. To determine the complication rate in infants<3 months of age with urinary tract infection, and to identify the causative agents and their antibiotic susceptibility. A retrospective study was conducted on infants<3 months of age with positive urinalysis results, together with a positive urine culture from a catheterized specimen and seen in the Emergency Department from 2007 to 2012. Demographics, clinical and microbiology (microorganism isolated and antibiotic susceptibility) data were collected. The complications rate (bacteremia, bacterial meningitis, renal abscess, surgical intervention, Intensive Care Unit admission, or death) were calculated for the overall sample and for different age groups (<29, 29-60, and 61-90 days). A total of 460 patients are included; 137 (29.8%)<29, 166 (36.1%) 29-60, and 157 (34.1%) 61-90 days of age. Twenty four (5.4%; 95% CI: 3.6-7.8) had bacteremia; 15 (10.9%; 95% CI: 6.7-17.3) were<29 days; 8 (4.9%; 95% CI: 2.5-9.4) were 29-60 days, and one (0.7%; 95% CI: 0.1-3.7) was 61-90 days of age (P<.001). One neonate (0.8%; 95% CI: 0.1-4.1) had bacterial meningitis, and 2, renal abscess. Escherichia coli was the common pathogen identified (87.2%) in the urine culture, with a susceptibility to amoxicillin-clavulanate, gentamicin, and cefixime of 89.2, 97.0, and 96.0%, respectively. Complications are low in infants<3 months of age with UTI, especially in those \u2265 29 days of age. The identification of patients at very low risk for complications would allow a less aggressive management. Escherichia coli antibiotic susceptibility remains stable, but continuing careful surveillance is essential to optimize empirical antibiotic treatment. Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl", "language": null, "image": null, "pagetype": null, "links": ["#", "//www.science.gov/", "//www.science.gov/about.html", "//www.science.gov/STEM_Opportunities.html", "//www.science.gov/members/", "#", "#", "#", "#", "#", "#", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4469391", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4114320", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/28693021", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3325789", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/29684901", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29775036", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://adsabs.harvard.edu/abs/2008MsT..........1R", "http://adsabs.harvard.edu/abstract_service.html", "https://www.ncbi.nlm.nih.gov/pubmed/10089785", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/20381210", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/2389103", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/19898592", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/9198479", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24100819", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27759985", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6018019", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/9646562", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3627816", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/18053472", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5799940", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "http://www.dtic.mil/docs/citations/ADA345647", "http://www.dtic.mil/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/11138239", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29165933", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29177379", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://www.dtic.mil/docs/citations/ADA195304", "http://www.dtic.mil/", "https://www.niddk.nih.gov/-/media/Files/Health-Information/HF_Factsheet_Bladder_Control_Problems_UI_EN_SP_RF508_FINAL_508.pdf?la=en", "http://medlineplus.gov/", "http://www.dtic.mil/docs/citations/ADA434804", "http://www.dtic.mil/", "http://www.dtic.mil/docs/citations/ADA629410", "http://www.dtic.mil/", "http://patients.gi.org/topics/biliary-tract-disorders-gallbladder-disorders-and-gallstone-pancreatitis/", "http://medlineplus.gov/", "http://www.dtic.mil/docs/citations/ADA317354", "http://www.dtic.mil/", "https://www.niddk.nih.gov/-/media/Files/Health-Information/HF_Factsheet_Prediabetes_EN_SP_RF508_FINAL_508.pdf?la=en", "http://medlineplus.gov/", "http://www.dtic.mil/docs/citations/ADA476452", "http://www.dtic.mil/", "http://www.dtic.mil/docs/citations/ADA158674", "http://www.dtic.mil/", "http://www.dtic.mil/docs/citations/ADA567639", "http://www.dtic.mil/", "http://www.dtic.mil/docs/citations/ADA223527", "http://www.dtic.mil/", "https://www.ncbi.nlm.nih.gov/pubmed/27238779", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/20404354", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28737879", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29902150", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://eric.ed.gov/?q=cultura&pg=4&id=EJ116172", "http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced", "https://www.ncbi.nlm.nih.gov/pubmed/27571647", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3484016", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/27571646", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://adsabs.harvard.edu/abs/2002BAAA...45...26C", "http://adsabs.harvard.edu/abstract_service.html", "https://www.ncbi.nlm.nih.gov/pubmed/27513487", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/21804831", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3144548", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2248176", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/27901221", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://adsabs.harvard.edu/abs/1998BAAA...42Q..51C", "http://adsabs.harvard.edu/abstract_service.html", "https://www.ncbi.nlm.nih.gov/pubmed/23518639", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25958373", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.fs.usda.gov/treesearch/pubs/39130", "http://www.fs.usda.gov/treesearch/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Polymyalgia-Rheumatica", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/HIV-Rheumatic-Diseases", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Living-Well-with-Rheumatic-Disease/Neck-Pain", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Health-Care-Team/What-is-a-Rheumatologist", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Living-Well-with-Rheumatic-Disease/Genetics-and-Rheumatic-Disease", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Living-Well-with-Rheumatic-Disease/Pregnancy-Rheumatic-Disease", "http://medlineplus.gov/", "https://www.rheumatology.org/Directories/Find-a-Rheumatologist", "http://medlineplus.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Juvenile-Arthritis", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Gout", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Dermatomyositis-Juvenile", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Living-Well-with-Rheumatic-Disease/The-Immune-System-Its-Link-to-Rheumatic-Disease", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/HCV-Rheumatic-Diseases", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Osteonecrosis", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Antinuclear-Antibodies-ANA", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/NSAIDs", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Living-Well-with-Rheumatic-Disease/Sex-Arthritis", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Osteonecrosis-of-the-Jaw-ONJ", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/Joint-Injection-Aspiration", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Giant-Cell-Arteritis", "http://medlineplus.gov/", "https://www.rheumatology.org/", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Carpal-Tunnel-Syndrome", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Metabolic-Myopathies", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Spinal-Stenosis", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Sjogrens-Syndrome", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Granulomatosis-with-Polyangitis-Wegners", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Calcium-Pyrophosphate-Deposition-CPPD", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Cryopyrin-Associated-Autoinflammatory-Syndrome-CAPS-Juvenile", "http://medlineplus.gov/", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Tendinitis-Bursitis", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Vasculitis", "http://medlineplus.gov/", "https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Periodic-Fever-Aphthous-Stomatitis-Pharyngitis-Adenitis-Syndrome-Juvenile", "http://medlineplus.gov/", "https://www.ncbi.nlm.nih.gov/pubmed/27269214", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://espanol.epa.gov/espanol/los-incendios-y-su-salud", "http://www.epa.gov/pesticides/search.htm", "https://espanol.epa.gov/control-de-plagas/informacion-general-sobre-los-mosquitos", "http://www.epa.gov/pesticides/search.htm", "https://www.cdc.gov/ncbddd/actearly/pdf/parents_pdfs/IntellectualDisability.pdf", "http://medlineplus.gov/", "https://kidshealth.org/en/parents/sickle-cell-anemia.html", "http://medlineplus.gov/", "https://www.paho.org/hq/index.php?option=com_topics&view=article&id=343&Itemid=40931&lang=en", "http://medlineplus.gov/", "https://espanol.epa.gov/seguridad-laboral-al-usar-pesticidas", "http://www.epa.gov/pesticides/search.htm", "https://www.ncbi.nlm.nih.gov/pubmed/21129580", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25643679", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://kidshealth.org/en/parents/tay-sachs.html", "http://medlineplus.gov/", "https://nei.nih.gov/glaucoma/", "http://medlineplus.gov/", "http://www.dtic.mil/docs/citations/ADA550563", "http://www.dtic.mil/", "http://www.dtic.mil/docs/citations/ADP011068", "http://www.dtic.mil/", "https://www.ncbi.nlm.nih.gov/pubmed/26970258", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://www.dtic.mil/docs/citations/ADA188340", "http://www.dtic.mil/", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3635533", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/27598377", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/29430232", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28236498", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5803716", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/27508909", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://adsabs.harvard.edu/abs/2011RMxAC..39..100L", "http://adsabs.harvard.edu/abstract_service.html", "http://www.dtic.mil/docs/citations/ADA584895", "http://www.dtic.mil/", "https://www.ncbi.nlm.nih.gov/pubmed/28000469", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27571654", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://files.eric.ed.gov/fulltext/ED469408.pdf", "http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced", "http://adsabs.harvard.edu/abs/2002BAAA...45...76F", "http://adsabs.harvard.edu/abstract_service.html", "https://www.ncbi.nlm.nih.gov/pubmed/27571678", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27533266", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/10605257", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.cancer.gov/about-nci/organization/cgh/blog/2016/diplomacy", "http://www.cancer.gov", "http://adsabs.harvard.edu/abs/1996BAAA...40...44A", "http://adsabs.harvard.edu/abstract_service.html", "https://www.ncbi.nlm.nih.gov/pubmed/29412895", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26211840", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27509012", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27269215", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3987255", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/26993436", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27759964", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25583331", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29206827", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/19418838", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25704893", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25772329", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25976750", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://files.eric.ed.gov/fulltext/ED118646.pdf", "http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced", "https://www.ncbi.nlm.nih.gov/pubmed/25028899", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29902137", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4351992", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/29902139", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27238773", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29520084", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29775038", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24746402", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28737863", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29469793", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3711750", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/28700843", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28094065", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://adsabs.harvard.edu/abs/1999BAAA...43...22S", "http://adsabs.harvard.edu/abstract_service.html", "http://www.jstor.org/stable/1592132", "http://pubs.er.usgs.gov/pubs/index.jsp?view=adv", "https://www.ncbi.nlm.nih.gov/pubmed/29775033", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4979598", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2799936", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/27238774", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26933750", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4176920", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/25703209", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/23453224", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/18053474", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26706393", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24533971", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27112976", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25504134", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26611100", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27474211", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28238505", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/28032856", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25541008", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27156244", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24953385", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26980233", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26976381", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28986845", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/7494924", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/10722428", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://adsabs.harvard.edu/abs/1996BAAA...40Q..28A", "http://adsabs.harvard.edu/abstract_service.html", "https://www.ncbi.nlm.nih.gov/pubmed/29107401", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26741190", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28000480", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28372875", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24468627", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27236235", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25444049", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27056581", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/11818987", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24315300", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/24182418", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=265515", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/25795150", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26804792", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29414972", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25444359", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28215487", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29295754", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27016136", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26341042", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/16243113", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25444041", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26869070", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28427796", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26994814", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24913991", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26279208", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25541012", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27495382", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26832999", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/29426791", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25979598", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24656967", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25500299", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26851978", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/21395817", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28693028", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/16536934", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2832313", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/20212916", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27866752", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29887216", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24844192", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24889543", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29510860", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27353835", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/10856132", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26481661", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29759422", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24986715", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/29239557", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/17692213", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28108122", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26920587", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26474708", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24529681", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25858681", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26474709", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25976754", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29198784", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28818481", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24211134", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25444048", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.osti.gov/biblio/20942922-lekking-behavior-anastrepha-fraterculus-diptera-tephritidae", "http://www.osti.gov/search", "https://www.ncbi.nlm.nih.gov/pubmed/24081891", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.fs.usda.gov/treesearch/pubs/22732", "http://www.fs.usda.gov/treesearch/", "https://www.ncbi.nlm.nih.gov/pubmed/27508903", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/8116809", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29033026", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25475657", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/19409668", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26139304", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28888401", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27571669", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/23850188", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29217096", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25124488", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28126326", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27712849", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29703463", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25749416", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28017477", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29709795", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25303781", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26827134", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25746206", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5834313", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/24698008", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27445176", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/11112115", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/8922569", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27238783", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://adsabs.harvard.edu/abs/2010PhDT.......232G", "http://adsabs.harvard.edu/abstract_service.html", "https://www.ncbi.nlm.nih.gov/pubmed/11111133", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26169070", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27269219", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28245938", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25023372", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24661995", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27571657", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25533742", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26100217", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24200033", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27068257", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26409726", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28818482", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27592463", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3448309", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/24332711", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3101880", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/26304641", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27508918", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28146181", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27533264", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/9466769", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/19736814", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4623613", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5047372", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/27238781", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29902136", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4286892", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/25735714", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/19241668", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25648468", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4556424", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/25487603", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26409725", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26232121", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25543161", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24054042", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/22432093", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24880651", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24953252", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26900002", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28291670", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26055287", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25124489", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/17288909", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/8540716", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3198801", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/25600217", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27269220", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26139303", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25728853", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/20011236", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24447919", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29187293", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26021186", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25176009", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28237435", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/24144785", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26048720", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25475656", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24908497", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24656969", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5783560", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/25824991", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25937455", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25735715", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24054972", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2792930", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/29420514", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26706392", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/19254641", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27238782", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28000481", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4576453", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/28025247", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/19260945", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28399216", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/24913994", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24461249", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25533744", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/23582193", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27513511", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24447922", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29110928", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25444360", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25487604", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25124487", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26778796", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/21932709", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26530224", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26971249", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27513500", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24616542", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24210519", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27859887", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25510595", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2843427", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5860754", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/25553717", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24054971", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/21163243", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25595690", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25027695", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26778797", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27916290", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26860417", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26049175", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27769682", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28087145", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29275076", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4539153", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/28396090", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29429753", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25888362", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25541009", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28069334", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26976379", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/24952876", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24484733", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26994813", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25060663", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24269102", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25444036", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4553072", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/27384278", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27556880", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28444828", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27425037", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27004429", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27513506", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24813928", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28087144", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24139337", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29929734", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29864787", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29422291", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27238784", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/25577557", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28734506", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/23648369", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25066381", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26585816", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27743683", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27480954", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25444044", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25195179", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27743679", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/12934243", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26976378", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24210738", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25769383", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24246777", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27609632", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27270265", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29724618", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/18221692", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26564375", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/21503559", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/21507530", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26298097", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26589756", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26860418", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26025480", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5130333", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/25770777", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26585817", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25459191", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25066382", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27445177", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28109551", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24908495", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24950613", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/7654834", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29759423", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25617018", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27221161", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29935797", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/27345951", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26093959", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2872639", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/27773490", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28262237", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26790900", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28993063", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27769681", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27156246", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24958671", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27262819", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27178702", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29179982", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26706394", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29636285", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28000483", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://eric.ed.gov/?q=GRANADA&pg=5&id=ED345428", "http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced", "https://www.osti.gov/servlets/purl/1362136", "http://www.osti.gov/search", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5634045", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/27982309", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/27992024", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "http://files.eric.ed.gov/fulltext/ED307490.pdf", "http://www.eric.ed.gov/ERICWebPortal/search/extended.jsp?_pageLabel=advanced", "https://www.ncbi.nlm.nih.gov/pubmed/28733107", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28641865", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/16476300", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3859673", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/28284685", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26364856", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27004428", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26021187", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27571663", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24033873", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25459192", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26992301", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28521955", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26321131", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25175171", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2779544", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/29676865", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/26832645", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "#", "https://www.ncbi.nlm.nih.gov/pubmed/28532596", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27609631", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27459919", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5056330", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/26821549", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27759966", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27571662", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/23725786", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29902147", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27071810", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29871765", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4138824", "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pmc", "https://www.ncbi.nlm.nih.gov/pubmed/24349314", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/29884455", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/24268912", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/28527274", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27695682", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/27982311", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/1630206", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "https://www.ncbi.nlm.nih.gov/pubmed/25542336", "https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed", "#", "#", "#", "#", "#", "#", "http://www.science.gov/disclaimer.html", null, "http://www.science.gov", "http://worldwidescience.org"]}